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Abstract
Charcot Marie Tooth disease (CMT) and distal hereditary motor neuropathy (dHMN)
are two heterogeneous and clinically overlapping diseases of the peripheral nervous
system. Pathogenic mutations in various proteins including the small heat shock protein
27 (Hsp27, HSPB1) are associated with CMT and dHMN; however the molecular
mechanisms underlying disease progression are not understood. Hsp27 is a ubiquitously
expressed and highly conserved molecular chaperone that is involved in cytoprotective
functions including protein homeostasis (proteostasis), redox modulation, inhibition of
apoptosis, stabilisation of the cytoskeleton, and axonal transport. The mechanisms by
which Hsp27 impacts these processes are largely unknown, as are the effects of diseaserelated mutations on the molecular structure and function of the protein. In an effort to
better understand the roles of Hsp27 mutations in the development of CMT and dHMN,
this thesis explores the effects of disease-causing mutations on the in vitro structure and
chaperone activity of Hsp27, investigates the roles of Hsp27 in neuronal differentiation,
mitochondrial maintenance and transport, and determines the interactome of Hsp27 and
two disease-causing Hsp27 mutants in motor neuron-like cells.
Hsp27 is a dynamic protein, consisting of a conserved α-crystallin domain that contains
a single disulfide bond-forming cysteine residue (C137), and flexible N- and C-terminal
extensions. Hsp27 forms dynamic oligomers that undergo constant subunit exchange,
and the oligomeric distribution of the protein influences its ability to inhibit protein
aggregation through its chaperone function as well as its interactions with cellular
proteins. In the work presented in Chapters 3 and 4, a set of recombinant isoforms of
human Hsp27 were expressed and purified; Hsp27WT, and the disease-causing mutants
Hsp27P39L, Hsp27G84R, Hsp27R127W, Hsp27S135F, Hsp27R136W, Hsp27R140G,

and

Hsp27T151I. Biophysical techniques and in vitro aggregation assays were utilised to
examine the effects of mutations, and the influence of redox status on the structure and
chaperone function of the protein. Bulk-Förster resonance energy transfer experiments
demonstrated that each of the mutants was capable of subunit exchange with Hsp27WT,
although exchange was slower than between Hsp27WT homo-oligomers. The reduced
iii

rate of subunit exchange is accompanied by an increased oligomer size for each of the
disease-mutants examined (with the exception of Hsp27T151I, which appeared to form
smaller oligomers) as determined via analytical size exclusion chromatography and
dynamic light scattering. This indicates an increased affinity between subunits to form
oligomers in the mutant isoforms, which may be explained by a partial loss of structure
of the mutant isoforms, as indicated by an increased solvent exposure of tryptophan
residues, and an increase in exposed hydrophobicity compared to Hsp27WT, as
determined by intrinsic tryptophan fluorescence and bis-ANS binding, respectively.
The single cysteine residue in Hsp27 mediates the formation of disulfide-bonded
dimers, the building block of larger oligomers in vitro. The presence of this disulfide
bond in the reducing environment of the cell was confirmed. The disease-causing
mutant isoforms of Hsp27 each had a weakened disulfide bond in comparison to the
WT protein. These structural and subunit exchange alterations may also affect the
ability of mutated Hsp27 to interact with other proteins. Indeed, the two diseaseassociated mutants with the slowest exchange-rate were also the least effective at
inhibiting the aggregation of two model client proteins α-lactalbumin and citrate
synthase. The in vitro chaperone activity of Hsp27 in preventing the aggregation of
different model client proteins was, however, highly variable and did not correlate with
the location of a mutation, the presence or absence of reducing agents, nor the mode of
aggregation of the client protein.
Disease mutations in Hsp27 are thought to influence the axonal transport of
mitochondria and affect mitochondrial membrane potential, however the role that
Hsp27 plays in these processes is unknown. The work presented in Chapter 5 provides
evidence that Hsp27 interacts with β-actin in NSC-34 cells, and that endogenous Hsp27
is present in branch points and growth cones of neurite extensions in differentiating SHSY5Y cells. Knockdown of Hsp27 in SH-SY5Y cells was found to slow the rate of
neurite outgrowth and promote disorganisation of neurite branching during
differentiation, increase the rate of axonal mitochondrial transport, and to alter the
morphology of mitochondria. This suggests that the disease mechanism underlying
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Hsp27 mutation may be linked to disruptions in cytoskeleton dynamics, axonal
maintenance and transport, and mitochondrial function.
Until the work presented in Chapter 6, the cellular interactome of Hsp27 in the context
of motor neurons was unknown. Proteomic analysis of binding partners isolated via coimmunoprecipitation of Myc-tagged Hsp27 isoforms from motor neuron-like NSC-34
cells supported previous evidence that Hsp27 is involved in proteostasis, cytoskeleton
dynamics, redox homeostasis, inhibition of apoptosis, and mitochondrial energetics and
morphology. The R136W and T151I disease-causing mutations in Hsp27 cause a
distinct shift in the interactome of the protein compared to Hsp27WT, indicating that the
structural alterations introduced by mutations may drastically alter the intracellular
activity of the protein.
The results presented in this thesis reveal that disease-causing mutations in Hsp27 cause
alterations to the structure-dynamics of the protein, and that these differences cause
complex changes in the functional interactions made by Hsp27 mutants. This suggests
that development of CMT or dHMN may result from different functional interactions
depending on the nature of the mutation. The diverse interactions of Hsp27 in NSC-34
cells indicates that disease-causing mutations may impact multiple cellular processes.
Therefore, future work should involve further exploration of the interactions made by
Hsp27, in motor neurons, and how alterations resulting from mutation lead to their
disease pathogenesis. Such work may provide a basis for the development of
therapeutics for the treatment of CMT and dHMN.
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Chapter 1

Chapter 1: Introduction

1

Chapter 1

1 Introduction
The nervous system consists of the central nervous system (CNS) and the peripheral
nervous system (PNS). The CNS consists of the brain and spinal cord, while the PNS
transmits signals between the CNS and muscles and organs. Bundles of neurons
surrounded by connective tissue form nerves, which can be motor, sensory or mixed (a
nerve containing both motor and sensory neurons). Peripheral sensory neurons have an
axon that extends from the cell body to the CNS, and another that extends into the
periphery, and are responsible for conducting signals from the periphery to the CNS.
Peripheral motor neurons carry signals from the CNS to the periphery. Motor
neuropathies can affect both the upper motor neurons of the CNS and the lower motor
neurons of the PNS, (such as amyotrophic lateral sclerosis), or may be confined to only
the CNS (such as primary lateral sclerosis) or the PNS such as distal hereditary motor
neuropathy (dHMN). Charcot-Marie-Tooth disease (CMT) is another neuropathy of the
PNS, however it affects both motor and sensory nerves.

1.1 Charcot Marie Tooth disease and distal hereditary neuropathy
1.1.1

Onset, symptoms, and diagnosis of CMT and dHMN

Charcot-Marie-Tooth disease (CMT; sometimes referred to as hereditary motor sensory
neuropathy), and distal hereditary motor neuropathy (dHMN, sometimes referred to as
spinal muscular atrophy) were first described in 1886 (Marie and Charcot, 1886, Tooth,
1886). CMT and dHMN are a group of genetically heterogeneous and clinically
overlapping disorders that affect the peripheral nervous system (P Drew et al., 2011).
Disease onset is generally between childhood and early adulthood and progresses over
decades, with earlier onset correlating with higher disease severity, although neither
CMT nor dHMN usually affect lifespan. Both CMT and dHMN are polyneuropathies in
that multiple nerves in each limb are affected. Nerves are affected in a symmetrical
length-dependent, distal to proximal pattern; the feet are affected first, with the loss of
muscle stretch reflexes, the development of contractures causing pes cavus and hammer
toes, as well as muscle weakness, fatigue and wasting, which may progress up the leg to
the knee and lower thigh area (Gemignani et al., 1999, Ramchandren, 2017, Laurá et
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al., 2019). The hands and arms are affected after onset in the lower limbs
(Ramchandren, 2017, Laurá et al., 2019). In CMT, sensory deficits develop in a similar
pattern, and result in decreased pain, vibration and touch sensations and loss of
proprioception. Overall, wasting and weakness of the limbs, as well as sensory
decreases, result in difficulties running and walking, weakness of the ankles and
steppage gait, muscle cramps, bone deformities, impaired balance and difficulties in
hand manipulation and reflexes (Johnson et al., 2014). While pain sensations are
decreased in CMT, both CMT and dHMN can also cause both nociceptive and
neuropathic pain for more than 80% of patients, further impacting quality of life
(Ribiere et al., 2012, Laurà et al., 2014, Azevedo et al., 2021). Some forms of CMT and
dHMN can cause other symptoms such as the development of restless leg syndrome
(Gemignani et al., 1999).
CMT is broadly classified as either demyelinating or axonal (classifications are
discussed further in section 1.1.4). Clinical diagnosis of CMT uses nerve conduction
velocity (NCV) of the ulnar or medial nerve, with a significantly slowed NCV of less
than 38 m/s characteristic of demyelinating, and a slightly reduced NCV but more than
38 m/s paired with reduced muscle action potential characteristic of the axonal type
(Dyck and Lambert, 1968). Nerve conduction velocity between 25 – 45 m/s may be
indicative of an intermediate type (Vallat et al., 2013).
The symptoms of classical dHMN are similar to CMT with symmetrical, length
dependent neuropathy, however, it presents as a purely motor neuronal disease. In some
cases, dHMN can also present with features including predominantly upper limb (Gross
et al., 1998), lower limb or non-length dependent onset (Peeters et al., 2013), pyramidal
features (De Jonghe et al., 2002), and paralysis of the vocal cords (Young and Harper,
1980) or diaphragm (Bertini et al., 1989, Puls et al., 2005).
1.1.2

Treatment of CMT and dHMN

The mechanisms underlying disease progression in CMT and dHMN are not fully
understood, and as such no curative treatments have been developed. Instead, treatments
are focussed on managing symptoms and include physiotherapy and occupational
therapy, surgery, and orthopaedic devices such as braces and orthotics (Lindeman et al.,
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1999, Ramdharry et al., 2017, Moinuddin, 2021, Ramdharry et al., 2021, Wielen and
Van Gelder, 2021). Pain management can also be using nonsteroidal anti-inflammatory
drugs (Hernandez et al., 2020), however neuropathic pain does not respond as well to
pharmacological treatment and is better managed with physical therapy (Jeong et al.,
2013). These aid in maintaining range of motion and reducing pain in an effort to
improve the quality of life of patients.
1.1.3

Prevalence of CMT and dHMN

Charcot-Marie-Tooth disease and dHMN make up the most common inherited
neurological disorders. The most cited statistic for the prevalence of CMT is one in
2500 people (or 40 in 100 000). This statistic originated from a study in an isolated
Norwegian population of 725 000 (Skre, 1974). The prevalence of CMT and dHMN,
however, is geographically variable (Martyn and Hughes, 1997), and ranges between
1.5 and 82.3 cases per 100 000 in certain geographic populations (Table 1.1).
Table 1.1: Prevalence of CMT and dHMN in different geographical locations.
Prevalence
Location
(/100 000)
Source
1.5
Leal et al. (2009)
Costa Rica
22.5
Vaeth et al. (2017)
Denmark
3181*
Kandil et al. (2012)
Egypt
11.8
Foley et al. (2012)
England (Newcastle upon Tyne)
12
Guðmundsson et al. (2010)
Iceland
10.5
Lefter et al. (2017)
Ireland
17.5
Morocutti et al. (2002)
Italy (Molise)
9.4
Mostacciuolo et al. (1991)
Italy (Padua and Rovigo)
10.8
Kurihara et al. (2002)
Japan (Sakaiminato)
8
Radhakrishnan et al. (1987)
Libya
10
Osuntokun et al. (1987)
Nigeria
82.3
Braathen et al. (2011)
Norway (Eastern Akershus County)
54
Skre (1974)
Norway (Western)
9.7
Mladenovic et al. (2011)
Serbia (Belgrade)
28
Combarros et al. (1987)
Spain (Cantabria)
30.1
Lousa et al. (2018)
Spain (Gran Canaria)
20.1
Holmberg (1993)
Sweden (Norrbotten and Vasterbotten)
19**
Hagberg and Westerberg (1983)
Sweden (Northern)
16
Nicolaou et al. (2010)
Turkey (Cyprus)
18.1
MacMillan and Harper (1994)
Wales (Glamorgan)
*Peripheral neuropathies not limited to CMT/dHMN, **Study of children aged 2 – 15 years.

1.1.4

Causes and classification

CMT and dHMN are heterogeneous and clinically overlapping diseases, with the major
difference being the involvement of sensory neurons in CMT (although motor neuron4
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related symptoms are usually significantly more pronounced), while dHMN is purely
associated with motor neurons (Züchner and Vance, 2006a). CMT is classified into two
main types: CMT1 (also referred to as demyelinating; characterised by reduced nerveconduction velocities and myelin abnormalities), and CMT2 (alternatively known as
axonal or non-demyelinating, characterised by chronic axonal de- and re-generation),
and there are various intermediate forms (Table 1.2), although few clinical symptoms
can differentiate CMT1 and CMT2 (Bienfait et al., 2006). These classifications are
further divided into various subtypes according to the genetic source of the disease
(Skre, 1974, Pareyson and Marchesi, 2009, Reilly and Shy, 2009) (Table 1.2, Table
1.3).
Table 1.2: Classification and inheritance patterns of CMT and dHMN. AD and AR indicate
autosomal dominant and autosomal recessive patterns of inheritance, respectively.
Classification
CMT1
CMT2

Type
Demyelinating, most
common form
Axonal

Inheritance
AD

Subtypes
CMT1A – F

AD/AR

CMT2A – E, I – L, O
– P, Z

CMT3

Demyelinating, early
onset version of CMT1
CMT4
Demyelinating, early
AR
CMT4A, B1, B2, C –
onset
F, H, J
CMTX1
Intermediate forms
X-linked
DI-CMT
Dominant intermediate
AD
DI-CMTB - D
dHMN1 – 8, J
Purely motor
AD/AR
dHMN2A – D, 5A –
neuropathies,
B, 7A - B
overlapping features
and genetic causes with
CMT subtypes
Irobi et al. (2004a), Irobi et al. (2006), Pareyson and Marchesi (2009), Scherer (2006), Skre (1974)

Since duplication of the PMP22 gene was identified as the first genetic cause of CMT
(Lupski et al., 1991, Raeymaekers et al., 1991), over 70 CMT-causative genes have
been identified, and more than 30 that cause dHMN, with overlap between the two
groups. However, up to 84.8% of dHMN patients lack a genetic characterisation
(Dierick et al., 2008). The products of the identified peripheral neuropathy-causing
genes are involved in a wide array of cellular processes including cell growth,
differentiation and survival, modulation of the cytoskeleton, axonal transport, and
maintenance of mitochondrial morphology and function (Table 1.3). One of these genes
(HSPB1) encodes the small heat shock protein (sHsp) Hsp27, which is known to
5
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interact with many of these pathways (discussed in following sections). Thus far, the
pathogenic mechanisms underlying CMT and dHMN pathogenesis are not understood.
Identifying the pathogenic mechanisms underlying mutations in Hsp27 would give
insight into the molecular processes disrupted in these patients. As Hsp27 performs
many and varied functions involving potential interactions with other proteins linked to
CMT and dHMN, these insights may extend beyond those linked just to Hsp27
mutations, thus providing a basis from which to develop therapeutics for these diseases.
Table 1.3: Genes carrying CMT and/or dHMN-causing mutations, and the function of
their expression products in relation to cellular functions.

Gene

Cell growth,
differentiation
and gene
expression
Cytoskeleton

AARS1

tRNA synthesis

Transport

Other

tRNA synthesis
Apoptosis
regulation

AIFM12
ARHGEF103

Mitochondria

Neural
morphogenesis

ATP1A14

Cation transport
Copper levels and
transport

ATP7A5
BAG36

Anti-apoptotic

Co-chaperone

BSCL27

Lipid droplet
biogenesis

CNTNAP18

Myelination,
neuronal signalling

COA79

Respiratory chain
assembly

COX6A110

Electron transport

DCTN111

Cell division

Microtubuleassociated transport

DCTN212

Cell division

Microtubuleassociated transport
Amino acid
degradation, ATP
production

DHTKD113

DNAH1012

Microtubule force
production

Co-chaperone,
protein degradation

DNAJB214
DNM215

Microtubule
associated motor
protein

Actin/tubulin
organisation

Endocytosis
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Gene

Cell growth,
differentiation
and gene
expression
Cytoskeleton

DNMT116

DNA methylation

Mitochondria

Membranecytoskeleton
interactions

DRP217

Other

Myelination
Microtubuleassociated transport

DYNC1H118
EGR219

Transport

Transcription
factor

FGD420

Actin organisation

FIG421

Actin organisation Vesicle transport

GARS22

Protein synthesis

GDAP123

Differentiation

Vesicle formation

Fission

GJB124

Gap junction
formation,
myelination

GNB425

Transmembrane
signalling

HARS26

tRNA synthesis

HINT127

Transcription
modulation

Axon guidance
Pro-apoptosis

HK128

Glucose
metabolism

HSPB129

Inhibition of
apoptosis, and
oxidative damage,
mitochondrial
maintenance

Axon formation

Stabilisation

Molecular
chaperone

Molecular
chaperone (muscle
specific)

Inhibits actin
polymerisation

HSPB330

Signalling,
proteasomal
degradation

HSPB831

Respiration

Molecular
chaperone

DNA helicase and
IGHMBP232 translation
activity
Actin
polymerisation/

INF233

depolymerisation
Intercellular
junctions

JPH134
KARS14
KIF1B35

tRNA synthesis
Microtubuleassociated transport
(vesicles and
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Gene

Cell growth,
differentiation
and gene
expression
Cytoskeleton

Transport

Mitochondria

Other

Apoptosis

Protein trafficking,
lysosomal
degradation

mitochondria)
KIF5A36

Axon formation

Neurofilament
transport

Microtubuleassociated transport

LITAF37

LMNA38

Nuclear envelope
scaffolding

LRSAM139

Cell adhesion,
endocytic cargo
sorting

LRIG312

Morphogenesis in
development

MARS40

tRNA synthesis

MCM3AP41

DNA replication

MED2542

Transcription
activation

MFN243

Morphology

MME44
MORC245

Endopeptidase
Transcription
repression,
differentiation

Lipogenesis
Mitochondrial
membrane –
function unknown

MPV1746
MPZ47

Myelination

MT-ATP658

ATP synthesis

MTMR249

Tyrosine
phosphatase

Vesicle trafficking

MYO1A12

Actin binding

Motor protein
Lysosomal
degradation

NAGLU50
NDRG151

Cell growth,
differentiation

Lipid trafficking

NEFH52

Axoskeleton
protein

NEFL53

Axoskeleton
protein

PMP2256

Hormone responses

Glucose
metabolism,
aerobic respiration

PDK354

PLEKHG555

Pro-apoptotic

Neuronal
differentiation
Myelination
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Gene
PRPS157

Cell growth,
differentiation
and gene
expression
Cytoskeleton

Transport

Mitochondria

Nucleotide
synthesis
Myelin
maintenance

PRX58
PTRH259

tRNA hydrolysis

Apoptosis control
Vesicle transport,
Microtubuleassociated
endosome transport

RAB7A60

SBF161

Cell growth,
differentiation

SBF262

Cell growth,
differentiation
ATP synthesis,
oxidoreductase

SCO263
SETX11

DNA helicase

SGPL164

Cell migration,
differentiation

Anti-apoptotic
Myelination, axonglial cell
interactions

SH3TC265
Retrograde
mitochondrial
transport

SIGMAR166 Cell proliferation
SLC25A4667
SPG1168

Other

Signalling receptor,
prevents oxidative
cell death
Fission

Gene expression

Axonal
maintenance

Protein trafficking
Sphingolipid
synthesis

SPTLC169
SURF170

ATP synthesis
Neurofilament light
ubiquitination

TRIM271
TRPV472

Proteasomal
degradation
Apoptosis

VCP73

Cell division and
proliferation

WARS74

tRNA synthesis,
stress-response
gene expression

YARS40

Translation

Calcium channel
Proteasomal
degradation

Reorganisation

1: McLaughlin et al. (2012), 2: Rinaldi et al. (2012), 3: Stendel et al. (2007), 4: Lassuthova et al. (2018),
5: Kennerson et al. (2010), 6: Shy et al. (2018), 7: Choi et al. (2013), 8:Freed et al. (2019), 9: Yoshimura
et al. (2019), 10: Tamiya et al. (2014), 11: Høyer et al. (2014), 12: Braathen et al. (2016), 13: Xu et al.
(2012), 14: Lupo et al. (2016), 15: Fabrizi et al. (2007), 16: Klein et al. (2011), 17: Brennan et al.
(2015), 18: Weedon et al. (2011), 19: Warner et al. (1998), 20: Delague et al. (2007), 21: Menezes et al.
(2014), 22: Antonellis et al. (2003), 23: Senderek et al. (2003a), 24: Bergoffen et al. (1993), 25: Soong et
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Gene

Cell growth,
differentiation
and gene
expression
Cytoskeleton

Transport

Mitochondria

Other

al. (2013), 26: Safka Brozkova et al. (2015), 27: Zhao et al. (2014), 28: Gabrikova et al. (2013), 29:
Evgrafov et al. (2004), 30: Nam et al. (2018), 31: Nakhro et al. (2013b), 32: Cottenie et al. (2014), 33:
Boyer et al. (2011), 34: Kanwal and Perveen (2019), 35: Zhao et al. (2001), 36: Crimella et al. (2012),
37: Street et al. (2003), 38: De Sandre‐Giovannoli et al. (2002), 39: Guernsey et al. (2010), 40: Hyun et
al. (2014), 41: Ylikallio et al. (2017), 42: Leal et al. (2009), 43: Züchner et al. (2004), 44: Higuchi et al.
(2016), 45: Sevilla et al. (2015), 46: Baumann et al. (2019), 47: De Jonghe et al. (1999), 48: Pitceathly et
al. (2012), 49: Kim et al. (2002), 50: Tétreault et al. (2015), 51: Gabrikova et al. (2013), 52: Nam et al.
(2017), 53: Mersiyanova et al. (2000), 54: Kennerson et al. (2013), 55: Kim et al. (2013), 56: Valentijn
et al. (1992), 57: Kim et al. (2007), 58: Kabzińska et al. (2006), 59: Alazami et al. (2015), 60:
Verhoeven et al. (2003), 61: Nakhro et al. (2013a), 62: Senderek et al. (2003b), 63: Rebelo et al. (2018),
64: Atkinson et al. (2017), 65: Colomer et al. (2006), 66: Li et al. (2015), 67: Li et al. (2018), 68:
Montecchiani et al. (2015), 69: Ramdharry et al. (2017), 70: Echaniz-Laguna et al. (2013), 71: Ylikallio
et al. (2013), 72: Landouré et al. (2010), 73: Gonzalez et al. (2014), 74: Tsai et al. (2017).

1.2 Proteostasis and the molecular chaperones
Maintenance of a stable proteome is essential to cellular function and is achieved via the
protein homeostasis (proteostasis) network. Proteostasis encompasses the processes that
balance the synthesis, folding, trafficking and degradation of proteins to maintain the
proteome in a functional state and is facilitated by a network of hundreds of proteins
(Balch et al., 2008, Morimoto, 2008). This balance can be impacted by a number of
factors, including protein mutations (either inherited or the result of errors during
protein synthesis), protein mis- or unfolding, or other protein modifications induced by
cellular stress (Stadtman, 1992, Ben-Zvi et al., 2009). Protein misfolding may occur
during the initial synthesis and folding of a protein, as a result of inherent mutations in
the protein, or changes in physicochemical conditions, such as redox state (Uehara et
al., 2006, Merksamer et al., 2008), pH (Dill, 1990, Zhou et al., 2019), temperature
(Privalov, 1990, Pace et al., 1996, Graziano et al., 1997), or molecular crowding (Chi et
al., 2003). Protein misfolding can lead to protein aggregation, an often irreversible
process which may result in the accumulation of cytotoxic protein species (Chi et al.,
2003). Conversely, protein aggregation may act as a protective mechanism with affects
in yeast cell studies such as protection of the cell from oxidative stress (Carija et al.,
2017), and can sometimes be a reversible process that aids in cell regulation (Saad et al.,
2017). All cells (and organisms) have various control pathways in place that act to
maintain proteostasis, and therefore reduce the accumulation of damaged, dysfunctional
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Chapter 1

and/or toxic proteins (Stadtman, 1992, Ron and Walter, 2007, Medicherla and
Goldberg, 2008, Morimoto, 2008). The loss of proteostasis, and accumulation of nonfunctional and toxic protein aggregates is implicated in various diseases ranging from
neurodegenerative disorders to cancer (Morimoto, 2008, Sweeney et al., 2017, Hipp et
al., 2019).
The heat shock proteins (Hsps) are molecular chaperones and are an important part of
the proteostasis network and are the cell’s major defence against protein misfolding and
aggregation. Molecular chaperones consist of proteins that aid in the assembly of
proteins into their correct conformation, but do not remain as part of the final functional
assembly (Ellis and Van der Vies, 1991). Many molecular chaperones are part of the
heat shock response, due to their upregulated expression in response to stress, but many
constitutively expressed chaperones also aid in proteostasis under non-stress conditions
(Shemesh et al., 2021). The molecular chaperones interact with polypeptides such that
exposed hydrophobic regions are protected from incorrect interactions that lead to
protein aggregation (Ellis and Van der Vies, 1991, Ellis, 1994, Ehrnsperger et al., 1997,
reviewed in Arhar et al., 2021). The molecular chaperones can be divided into six major
classes based on their molecular weights: the Hsp40s, the Hsp60s (chaperonins), Hsp70,
Hsp90, the Hsp100s and the sHsps. The molecular chaperones can also be classified
based on the mechanism of their chaperone action as either (i) holdase chaperones,
which interact with, and prevent aggregation of proteins in a non-native conformation
but play no active part in their folding, and (ii) foldase chaperones, which actively assist
in the folding or refolding of proteins to their native conformation in an ATP-dependent
manner.
1.2.1

The small heat shock proteins

The sHsps are ATP-independent molecular chaperones ranging between 12 and 43 kDa,
and are defined by a conserved α-crystallin domain (αCD) flanked by variable N- and
C-terminal domains (Ingolia and Craig, 1982, Wistow, 1985, de Jong et al., 1998). The
sHsps, which are expressed in all phyla of life, act to maintain cell viability and are
some of the most upregulated proteins under conditions of cellular stress. There are 10
human sHsps, although it should be noted that only a selection of these (such as Hsp27,
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αB-crystallin and Hsp22) are “true” sHsps in that they are directly involved in the
cellular stress-response via heat shock factor 1 (Hsf1) driven, stress-induced expression.
Among other cytoprotective functions, the defining function of the sHsps is their
chaperone activity: the ability to interact with proteins to prevent their aggregation and
thus maintain proteostasis (Jakob et al., 1993, Treweek et al., 2015). The sHsps are
classed as holdase chaperones, and the traditional model of action dictates that they bind
and stabilise client proteins in their non-native conformation, preventing inappropriate
interactions that can lead to protein aggregation (Ellis and Van der Vies, 1991, Sharma
et al., 1997, van Montfort et al., 2001). This activity is mediated via interactions
between the sHsp and exposed hydrophobic residues on partially folded or misfolded
protein intermediates. The αCD is essential to the chaperone activity of the sHsps
(Sharma et al., 1997, Ghosh et al., 2005, Muchowski and Wacker, 2005), and
hydrophobic portions of the N- and C- termini have also been demonstrated to be
important in interactions between the sHsps and particular client proteins (Giese and
Vierling, 2002, Lelj-Garolla and Mauk, 2005, Cox et al., 2018). Upon interaction with
the sHsps, the client protein is then typically held in a high molecular mass chaperoneclient complex, often referred to as a reservoir of intermediates (Ehrnsperger et al.,
1997, Giese and Vierling, 2002, Shashidharamurthy et al., 2005, Ikeda et al., 2009,
Aquilina et al., 2013, Jovcevski et al., 2015). It has been demonstrated in vitro that the
bound client proteins retain the potential for correct refolding (Ehrnsperger et al., 1997)
since they can be folded back to their native conformation via the action of ATPdependent foldase chaperones, such as Hsp70 (Ehrnsperger et al., 1997, Friedrich et al.,
2004). The foldases, upon recognising a non-native protein, provide a protected
environment in which the protein can fold to its native state (reviewed in Gething and
Sambrook (1992), Hartl et al. (1992), Szabo et al. (1994), Hartl et al. (2011), and Arhar
et al., (2019)). Thus, in vitro, the presence of ATP and foldases such as Hsp70 allows
reactivation of proteins in complex with sHsps (Stege et al., 1994, Ehrnsperger et al.,
1997, Lee et al., 1997, Lee and Vierling, 2000, Wang and Spector, 2000). Recent work,
however, has demonstrated that Hsp27 prevents the fibrillar aggregation of α-synuclein
(α-syn) via transient interactions that protect the protein from aberrant interactions,
rather than a holdase type mechanism (Cox et al., 2016), indicating that the sHsps may
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interact with client proteins via different molecular mechanisms, depending on the
properties of the specific protein. This is likely considering the highly dynamic nature
of the sHsps imparted by flexibility in the N- and C-terminal regions, formation of
polydisperse homo- and heterooligomers, subunit exchange, and post translational
modifications such as phosphorylation (these subjects are discussed in further detail in
reference to Hsp27 in the following sections).
If client proteins in complex with the sHsps cannot be refolded, they may be targeted
for degradation. The sHsps are involved in the delivery of misfolded proteins to be
degraded either via the ubiquitin-proteasome pathway (Parcellier et al., 2003b,
Medicherla and Goldberg, 2008, Singh et al., 2010, Ahner et al., 2013, Carra et al.,
2013), or by lysosomal proteolysis (Kaarniranta et al., 2009, Crippa et al., 2010a,
Crippa et al., 2010b, Carra et al., 2013).
1.2.1.1 The sHsps and neurodegeneration

The sHsps are considered to be protective against various types of neurodegeneration,
mainly via their chaperone activity (Outeiro et al., 2006, Crippa et al., 2010a, Kourtis et
al., 2012, Leak, 2014, Zhu and Reiser, 2018, Muranova et al., 2019, Webster et al.,
2019). As could be anticipated, mutations in various human sHsps are associated with
neuropathies and cataract. For example, mutations in HSPB3 cause dHMN type 2C
(Kolb et al., 2010) and axonal CMT (Nam et al., 2018), mutations in HSPB4 cause
cataract (Litt et al., 1998, Cobb and Petrash, 2000, Mackay et al., 2003, Graw et al.,
2006, Gu et al., 2008, Richter et al., 2008b, Reis et al., 2013), mutations in HSPB5
cause myopathy (Vicart et al., 1998b, Fu and Liang, 2003, Sacconi et al., 2012, Brodehl
et al., 2017), and mutations in HSPB8 cause dHMN type 2A and CMT2L (Irobi et al.,
2004b, Tang et al., 2005b, Echaniz‐Laguna et al., 2017) as well as rimmed-vacuolar
myopathy (Al-Tahan et al., 2019, Nicolau et al., 2020). At least 38 mutations have been
identified in the HSPB1 gene (encoding Hsp27) which are associated with CMT disease
type 2F, and/or dHMN type II (Table 1.4), which are the focus of this thesis.
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1.3 The small heat shock protein Hsp27
1.3.1

Structure and oligomerisation of Hsp27

Hsp27 is constitutively and ubiquitously expressed, and its levels are dramatically
upregulated during periods of cellular stress (Kelley and Schlesinger, 1978). Hsp27
contains the conserved β-sheet-rich αCD characteristic of the sHsps (residues 88 – 175)
(Li and Spector, 1974), flanked by flexible N- and C-terminal extensions (residues 1 –
87 and 176 – 205 respectively) (Ingolia and Craig, 1982, de Jong et al., 1998). Like
some other sHsps, Hsp27 forms large oligomers in solution (up to ~600 kDa) in
equilibrium with smaller oligomers, including dimers, which facilitate dynamic subunit
exchange (Jovcevski et al., 2015, Mymrikov et al., 2016) (Figure 1.1). Hsp27 contains
three phosphorylatable serine residues in the N-terminal region (S15, 78 and 82).
Phosphorylation of these serines under cellular stress conditions (by mitogen-activated
protein kinase-activated protein kinase 2; MAPKAP-K2) and phosphomimicking (by
replacement of phospho-serines with negatively charged aspartic or glutamic acid
residues) induces the dissociation of Hsp27 oligomers into predominantly dimers
(Shashidharamurthy et al., 2005, Jovcevski et al., 2015) (Figure 1.1), likely as a result
of the introduction of negative charge that repels Hsp27 monomers from one another.
This dissociation of Hsp27 results in an increase in exposed hydrophobicity and a
resultant increase in efficacy to prevent the stress-induced aggregation of some proteins
(Thériault et al., 2004, Jovcevski et al., 2015). Thus, these data support a model in
which the dimer is the more chaperone-active species of the protein (Baranova et al.,
2011). However, other studies have found that larger oligomers, or the nonphosphorylated isoforms of Hsp27 are the more chaperone-active species (Rogalla et
al., 1999, Lelj-Garolla and Mauk, 2005). Taken together, this suggests that factors such
as the aggregating protein, and differences in the cellular or experimental environment
influence the chaperone activity of Hsp27 in its various isoforms.
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Figure 1.1: Hsp27 exists in a dynamic equilibrium of oligomeric states. Under normal
physiological conditions, Hsp27 exists in an equilibrium between dimers/small oligomers and larger
oligomers. Upon cellular stress, Hsp27 expression is upregulated, and the protein can be phosphorylated
on up to three serine residues (S19, S78 and S82), a process that drives dissociation of larger oligomers
into smaller oligomers, including dimers. Images were rendered using the POLYVIEW-3D web interface
(Porollo and Meller, 2007), using the Hsp27 core-domain dimeric structure (protein data bank (PDB):
4MJH; (Hochberg and Benesch, 2014)), and the oligomeric structures are represented by the biological
assembly of Hsp27 core-domain hexameric structures (PDB:3Q9P; (Baranova et al. 2011)).

1.3.2

Cytoprotective functions of Hsp27

Hsp27 has been shown to modulate many cellular pathways through its interactions
with various proteins. While these Hsp27 protein-protein interactions are complex and
diverse, the overarching theme is one of cytoprotection. The roles of Hsp27 in the cell
can be divided into three main categories; (i) its role in the proteostasis network in
preventing protein aggregation and facilitating ubiquitin-proteasome mediated protein
degradation, (ii) its inhibitory interactions with proteins involved in cell death pathways,
and (iii) its interactions with the cytoskeleton, and subsequently cell growth and
differentiation.
1.3.2.1 Proteostasis

Hsp27 has been shown to have molecular chaperone activity in preventing the
aggregation of a variety of aggregation-prone client proteins in vitro (Jakob et al., 1993,
Rogalla et al., 1999, Aquilina et al., 2013, Yerbury et al., 2013, Hochberg et al., 2014,
Mymrikov et al., 2016). Hsp27 can bind and hold protein intermediates in a foldingcompetent state which can be (re)folded to their native state by ATP-dependent
chaperones such as Hsp70. Hsp27 has been demonstrated to interact with Hsp70 and
allow the proper folding of protein intermediates in vitro (Ehrnsperger et al., 1997,
Bryantsev et al., 2007, Ecroyd and Carver, 2008, Rauch et al., 2017, Żwirowski et al.,
2017), and these results are correlated by findings that expression of Hsp27 in fibroblast
cells enhances protein refolding after heat shock, but that this effect is diminished by
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negative regulation of Hsp70 by overexpression of Bcl-2-associated athanogene 1
(Bag1; Bryantsev et al. (2007)).
Despite the presence of many molecules that prevent misfolding and aggregation of
proteins, aggregates can still form, and underlie several neurodegenerative diseases
(Chen and Brown, 2007, Morimoto, 2008). There are, however, mechanisms in place to
prevent damage caused by the formation of protein aggregates, such as the degradation
of aggregated proteins by autophagy (reviewed in Kopito (2000)), or by the ubiquitin
proteasome (Glickman and Ciechanover, 2002), and Hsp27 is involved in both of these
processes. Hsp27 overexpression in rat kidney cells has been demonstrated to induce
autophagy, while knock-down of Hsp27 by small interfering RNA (siRNA) inhibited
hydrogen peroxide-induced autophagy (Matsumoto, 2015). In Hsp27 knockout HeLa
cells, autophagosome formation is impaired, but can be rescued on re-expression of
Hsp27 (Haidar et al., 2019). Hsp27 interacts with Hsp70, sequestosome 1
(SQSTM1/p62) (Haidar et al., 2019), as well as with the Hsp70 co-chaperone Bag3
(Rauch et al. 2017). Each of these proteins is involved in formation of the chaperoneassisted selective autophagy (CASA) complex, along with the co-chaperone STIP1
homology and U-Box containing protein 1, to facilitate the degradation of substrate
proteins by autophagy (Gamerdinger et al., 2011). It should be noted that the interaction
between Hsp27 and Bag3 is relatively weak in comparison to the interaction of Bag3
with some other sHsps, e.g. Hsp22 (HSPB8), and was found via experiments using
purified protein (Rauch et al. 2017), while another study using over-expression of Bag3
and Hsp27 in human embryonic kidney (HEK) cells found no interaction between the
two proteins (Morelli et al., 2017). Mutant versions of Hsp27 display decreased
interactions with SQSTM1/p62, leading to autophagy deficits, which were reflected in
patient derived motor neurons (Haidar et al., 2019). Hsp27 also interacts with high
mobility group box 1 (HMGB1) (Tang et al., 2011), a DNA-binding protein involved in
transcription, DNA repair and other nuclear functions (Miao et al., (2020), reviewed by
Bustin (1999)), mitochondrial maintenance (Tang et al. 2011) as well as regulation of
autophagy in response to oxidative stress (Tang et al., 2010). The interactions of Hsp27
with Hsp70/Bag3, SQSTM1 and/or HMGB1 implicate it in the delivery of misfolded
proteins to the aggresome for degradation.
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Hsp27 is also involved in facilitating removal of misfolded proteins via ubiquitinproteasome mediated degradation (Parcellier et al., 2003a, Medicherla and Goldberg,
2008). The ubiquitin-proteasome mediated degradation of proteins is the major disposal
method for misfolded proteins in cells (Glickman and Ciechanover, 2002). It involves
the tagging of a short-lived, damaged or misfolded protein with at least four ubiquitin
molecules (Weissman, 2001). The protein is then recognised and degraded by the
catalytic proteasome complex, releasing ubiquitin and amino acids for recycling.
Various enzymes are involved in both the ubiquitin tagging of a protein and its
subsequent degradation (reviewed in Ciechanover (1998) and Pohl and Dikic (2019)).
Hsp27 acts as a delivery molecule to the proteasome by binding ubiquitinated proteins
destined for degradation, and then interacting with the proteasome machinery, thereby
facilitating degradation of the ubiquitinated protein (Parcellier et al. 2003) and
preventing the potential formation of toxic protein aggregates.
1.3.2.2 Interaction with cell death pathways and mediation of oxidative cell stress

Hsp27 is also involved in other cellular pathways, including the inhibition of apoptosis
(Bruey et al., 2000, Charette and Landry, 2000, Charette et al., 2000) and resistance to
oxidative cell stress (Préville et al., 1999, Rogalla et al., 1999). Apoptosis can be
induced via the intrinsic or the extrinsic pathways; Hsp27 is involved in the suppression
of both pathways (Concannon et al., 2003, Tan et al., 2009) through interaction with
various signalling molecules including; phosphatidyl inositol-3 kinase (Havasi et al.,
2008); cytochrome-c (Cyt-c) (Bruey et al., 2000, Pandey et al., 2000); caspase-3
(Pandey et al. 2000); and death domain-associated protein-6 of the caspase-independent
extrinsic pathway (Charette and Landry 2000, Charette et al. 2000). These interactions
result in the inhibition of Cyt-c release from mitochondria, as well as the inhibition of
intrinsic and extrinsic signalling pathways, altogether leading to the prevention of
apoptotic cell death.
Several roles have also been proposed for Hsp27 in mediating reactive oxygen species
(ROS)-induced cellular damage. Cellular exposure to ROS can induce either apoptotic
cell death, or necrosis. The former is generally the result of exposure to low-moderate
levels of ROS, which lead to a depletion of the intracellular antioxidant, glutathione.
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The glutathione ascorbate pathway is responsible for the conversion of ROS to water in
the cell (Préville et al. 1999), and high glutathione levels reduce ROS-induced apoptosis
(Wedi et al., 1999). A lack of glutathione, on the other hand, triggers the mitochondrial
apoptosis pathway (Schnelldorfer et al., 2000), and glutathione dysregulation has been
linked to neurodegenerative diseases such as ALS (Weiduschat et al., 2014),
Alzheimer’s disease (Adams et al., 1991, Akkaya et al., 2017), Freidrich’s ataxia
(Bulteau et al., 2012), Huntington’s disease (Ribeiro et al., 2012), and Parkinson’s
disease

(Merad-Boudia

et

al.,

1998)(Bjørklund

et

al.,

2021).

Glutathione

supplementation is even being investigated as a potential treatment for Alzheimer’s
disease (Pocernich and Butterfield, 2012, Mandal et al., 2019) and ALS (Kim, 2021).
Expression of Hsp27 has been shown to decrease ROS-induced cytotoxicity in cells
exposed to tumour necrosis factor α (TNFα, Mehlen et al. (1995)) doxorubicin,
daunorubicin, vincristine, sodium arsenite and actinomycin D (Huot et al., 1991), and
oxidative stressors such as iron (Arrigo, 2005), hydrogen peroxide and menadione
(Mehlen et al., 1993, Mehlen et al., 1995a). Using five L929 cell clones that expressed
different levels of Hsp27 (between 0.22 and 0.88 ng/µg of total protein) Mehlen et al.
(1995a) found that this protective effect is proportional to the expression levels of
Hsp27 and associated with a reduced intracellular ROS concentration, and increased
glutathione levels (Mehlen et al., 1996). The cytoprotective function of Hsp27 in
response to TNFα treatment of HeLa, L929 and NIH-3T3-ras cells is also associated
with an apparent initial increase (after 2 h) in Hsp27 oligomer size up to approximately
a 30mer, followed by a decrease (after 4 h) to a maximum of approximately a 10mer,
alongside an increase in phosphorylation (Mehlen et al., 1995a, Mehlen et al., 1997b).
These findings, however, were based on size exclusion chromatography analysis of cell
lysates, and do not take into account possible size changes resulting from altered
binding interactions. Furthermore, Rogalla et al. (1999) found that expression of wild
type Hsp27 in L929 and 13.S.1.24 cells conferred resistance to oxidative stress, while a
triple phosphomimic of Hsp27 did not. These studies suggest that the large,
unphosphorylated oligomers of Hsp27 are responsible for this increase in cell survival
in response to ROS exposure, and that the subsequent phosphorylation of Hsp27
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decreases this activity, and may “activate” the chaperone function of Hsp27, allowing a
reduction in toxicity caused by oxidised proteins resulting from the presence of ROS.
In cells, Hsp27 increases the activity of glucose 6-phosphate dehydrogenase in the
pentose phosphate pathway (Préville et al., 1999, Cosentino et al., 2011, Arrigo, 2013)
and glutathione-ascorbate pathways. The pentose phosphate pathway maintains
NADPH levels in the cell, which in turn maintains reduced glutathione levels and a
reduced intracellular environment. This compares with a model in which Hsf1 (the
transcription factor responsible for the stress-induction of Hsp27) knock-out mice
display lowered expression of Hsp27. This correlated with a decrease in glucose 6phosphate dehydrogenase activity, and a decrease in the ratio of reduced to oxidised
glutathione (Yan et al., 2002), although further investigation would be necessary to
determine whether the effect is a direct result of lowered Hsp27 expression levels, or is
related to altered expression of other proteins under the control of Hsf1. Furthermore,
Hsp27 is suggested to increase the activity of glutathione reductase (responsible for
maintaining glutathione in its reduced state) and glutathione transferase (which
catalyses interactions between reduced glutathione and its substrates) (Préville et al.
1999). These interactions result in an increase in glutathione levels, an increase in the
ratio of reduced to oxidised glutathione (Baek et al., 2000), and a concomitant decrease
in intracellular reactive oxygen species, thereby reducing damage to macromolecules
and promoting cell survival (Mehlen et al., 1995a, Mehlen et al., 1995b, Mehlen et al.,
1996, Mehlen et al., 1997a, Rogalla et al., 1999, Paul and Arrigo, 2000, Arrigo, 2001).
Further to its interactions with the pathways specific to oxidative stress-resistance,
Hsp27 has been proposed to act as a cellular “redox sensor” via its chaperone function
and hence its ability to bind to destabilised proteins. This is particularly relevant in cells
exposed to high levels of ROS, which leads to a decrease in ATP (which prevents ATPdependent apoptosis singalling), alongside the oxidation of proteins and other
macromolecules in the cell, eventually resulting in cell death by necrosis. Arrigo (2001)
suggests that Hsp27 may bind to oxidised proteins and assist in trafficking them to the
20S proteasome for degradation, thereby reducing the accumulation of toxic oxidised
protein aggregates.
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Interestingly, the sHsps have generally low cysteine content compared to the proteome
in which they exist (Kriehuber et al., 2010), and Hsp27 is unique among the sHsps in
containing a single cysteine residue in the dimer interface of its αCD, which is thought
to modulate the activity of Hsp27 in response to the redox-status of the cell (Chalova et
al., 2014). This cysteine residue is capable of forming a disulfide bond with that of an
adjacent monomer in vitro, and thereby stabilises the dimeric subunit of Hsp27
(Hochberg et al., 2014). Rajagopal et al. (2015) characterised the structure of the
oxidised αCD of Hsp27, and determined that formation of the C137-C137 disulfide
bond resulted in a change in the curvature of the αCD, along with an increased exposure
of hydrophobicity, suggesting an increased ability of Hsp27 to interact with exposed
hydrophobic regions on proteins damaged by oxidative stress. In both the reduced and
oxidised forms of Hsp27, the C137 sidechains are exposed, suggesting that the protein
may act as a ROS scavenger (Rajagopal et al., 2015). A C137A mutant isoform of
Hsp27 expressed in HeLa cells was found to greatly increase cell sensitivity to
hydrogen peroxide-induced oxidative stress compared to cells expressing the wild-type
protein or N-terminal mutant isoforms (Arrigo et al. 2005). A similar decrease in cell
viability was observed with various C-terminal domain mutant isoforms, highlighting
the importance of the disulfide-forming ability of the protein, and suggesting a
simultaneous role for the C-terminal region in minimising cellular damage from
oxidative stress. Taken together, these findings suggest that the cytoprotection provided
by Hsp27 in response to oxidative stress is multifold; it acts as a redox sensor in the
cell, directly influences cellular glutathione levels, and, via its chaperone action, it
prevents oxidative damage to proteins, and promotes cellular survival via its inhibition
of apoptosis pathways.
1.3.2.3 Interaction with the cytoskeleton

Hsp27 has been shown to interact with various components of the cytoskeleton,
including actin (Mounier and Arrigo, 2002, Graceffa, 2011), tubulin (Williams et al.,
2005), and neurofilament proteins (Zhai et al., 2007). Actin is a major component of the
cytoskeleton. An early response to cell stress is the loss of cytoskeletal organisation due,
at least in part, to dissociation of oligomeric actin (Contaxis et al., 1977, Mounier and
Arrigo, 2002, Pan et al., 2019). Hsp27 modulates actin dynamics (Miron et al., 1991,
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Mounier and Arrigo, 2002), and has been shown to act as an actin-capping protein in
non-neuronal cells (Graceffa, 2011). Studies by Williams et al. (2005) demonstrated
that Hsp27 associates with both actin and tubulin during neurite growth. It has been
suggested that Hsp27 plays an important role in the initiation, extension, and pattern of
neurite growth via interactions with actin and tubulin, and that these interactions are
influenced by the phosphorylation state of Hsp27 (Williams et al., 2005, Williams and
Mearow, 2011). Furthermore, overexpression of Hsp27 in laminin-stimulated adult
dorsal root ganglion neurons results in an increase in neurite tree length and complexity,
while down-regulation of endogenous Hsp27 results in decreases in both of these
parameters (Williams et al., 2006).
Hsp27 also interacts with neurofilaments (Perng et al., 1999) which are essential for the
growth and maintenance of axons. Neurofilaments provide structural support and
control of axon diameter, and are essential in the transmission of electrical impulses.
Disruption of the neurofilament network, and aggregation of neurofilaments in cellbodies and proximal axons, are associated with neuronal disorders (reviewed in
Lariviere and Julien (2004)).

1.4 CMT and dHMN-causing mutations in Hsp27
Currently, 34 distinct naturally-occurring mutations in Hsp27 have been identified as
causative of CMT2F, dHMNII or other related intermediate neuropathies (Table 1.4),
most with an autosomal dominant inheritance pattern (Züchner and Vance, 2006b,
Züchner and Vance, 2006a). The exceptions are S86L and L99M, which display
autosomal recessive inheritance (Houlden et al., 2008, Scarlato et al., 2015). A further
29 mutations have been identified in patients with neuropathies where disease aetiology
could not be established (DiVincenzo et al., 2014, Antoniadi et al., 2015). Elucidation
of the pathological mechanisms by which mutations in Hsp27 cause these diseases is
particularly challenging given that Hsp27 is involved in such a wide range of cellular
functions (see section 1.3.2). Moreover, the precise molecular mechanisms by which
Hsp27 interacts with other proteins and cellular pathways are not well understood.
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The disease-related mutations in Hsp27 occur in all three domains of the protein (Table
1.4, Figure 1.2,

Figure 1.3). Many of the mutations target residues that are well

conserved between the 10 human sHSPs, and, interestingly, many of the other sHsps
have disease-associated mutations at these conserved residues (Table 1.4). Examination
of the relationship between the site of mutation in the Hsp27 sequence and age at
disease onset in affected patients (Figure 1.4) shows that, in general, mutations in the Nterminal region of the protein lead to late onset of disease (in the 4th decade of life or
later), with the exception of the E41K mutation which leads to disease onset in the first
decade (Capponi et al., 2011). It is not known why the E41K mutation leads to earlier
onset, although it has been shown to exhibit an increased sensitivity to heat-induced
aggregation, and a slightly lower chaperone activity in comparison to other the other Nterminal mutations (Muranova et al., 2015). Mutations in the C-terminal region
distinctly correlate with an earlier age of disease onset (up to the 2nd decade), with the
exception of the S187L mutation, in which disease onset appears to be particularly late.
The reason for the late onset of disease caused by the S187L mutation is not understood,
however, this mutation has been shown to have a less pronounced effect on
neurofilament phosphorylation induced by other disease-causing Hsp27 mutations
(Echaniz‐Laguna et al., 2017). Mutations in the αCD result in a varied age of disease
onset, ranging between 9 and 70 years of age. It is possible that mutations in different
regions of the protein will have different effects on Hsp27 function, relating to the
specific roles and interactions that these regions have in the wild type protein (i.e.
oligomer formation, interaction with different client proteins). These changes may
manifest as hyperactivity, aggregation of the chaperone itself, or loss of activity, all
leading to altered interaction(s) with one or more biological pathways. These concepts
are explored in more detail in the following sections.

22

Chapter 1

Figure 1.2: The human small heat shock proteins are highly conserved. Sequence alignment
of Hsp27 (1) with the other nine (2 – 10 as indicated to the left) human sHsps, using the ClustalW
multiple sequence alignment tool (Larkin et al., 2007). Residues are coloured according to their
properties, as per the EMBL classifications; small and hydrophobic residues are coloured red ( ), acidic
residues are coloured blue ( ), basic residues are coloured yellow ( ), and residues containing hydroxyl,
sulfhydryl or amine groups and glycine are coloured green ( ). Sites of disease-causing mutations in
Hsp27 are indicated by “˅” above the corresponding residue.
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Figure 1.3: Disease-related mutations occur in all regions of the Hsp27 protein. A:The
amino acid sequence of Hsp27. Sites of disease-causing mutations in Hsp27 are indicated by “˅” above
the corresponding residue. Structural features are indicated below each section: The N-terminal region,
αCD, and C-terminal region are coloured green, blue and magenta, respectively, with flexible regions
indicated by a broken line. The three phosphorylatable serines (S15, 78 and 82), the WDPF motif, the
disulfide-forming cysteine, and the IXI motif are marked as yellow boxes, and α-helical regions and βsheets are indicated. B: The 3D solution-state NMR structure of the oxidised Hsp27 αCD dimer (residues
79 – 176), PDB 2N3J, (Rajagopal et al. 2015). The dimer interface is indicated by a dotted line, and
structural domains (where present) are indicated as per the alignment in (A), rendered using the
POLYVIEW-3D web interface (Porollo and Meller 2007).
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Table 1.4: Properties of disease-related mutations in Hsp27. The domain and structural features
(where known) in which the mutation occurs, key motifs adjacent to the mutation, the basic chemical
properties of the wild-type and mutant (replacement) amino acid residues and conservation of the amino
acids in other human sHsps are given. Mutations with an “fs” refer to frameshift mutations.
Disease
Adjacent key
Amino acid property
Conserved
Mutation
association Domain residues/regions
change
in HSPB#:
dHMN
N
MAPKAP Kinase 2 Rigid, cyclic to positive 2, 8
P7R1,2
recognition sequence
dHMN
N
MAPKAP Kinase 2 Rigid, cyclic to polar
2, 8
P7S3
recognition sequence
Peripheral N
Phosphoserine 15
Polar to positive
2**, 6 – 8
S15R4
neuropathy
CMT
N
Phosphoserine 15
Hydrophobic to
V16I5
hydrophobic
ALS
N
Positive to hydrophobic
R27L6
CMT
N
Positive to rigid, cyclic
R27P5
dHMN
N
Small, uncharged to
2, 4 – 6, 8
G34R7
positive
Unspecified, N
Rigid, cyclic to
2, 8
P39L3,4,5,7,8,9,10
CMT2F
hydrophobic
dHMN
N
Negative to positive
2, 6
E41K7
CMT
N
Small, uncharged to polar
G48S5
dHMN
N
Small, uncharged to
8
G53D3
negative
dHMN
N
Hydrophobic to
8
L58Afs3
hydrophobic
CMT
N
Rigid, cyclic to polar
P60S5
dHMN
N
Hydrophobic to positive
A61Rfs3
CMT
N
Phosphoserines 78 & Polar to polar
S83N5
82, N – αCD border,
α-helix
CMT
N
Phosphoserines 78 & Small, uncharged to
2, 4, 5, 7, 8,
G84R6,8,11,12,13
‡
82, N – αCD border, positive
α-helix
N
N – αCD border, α- Polar to hydrophobic
S86L†,14
helix
CMT
αCD
α-helix
Negative to polar
D93N5
unspecified αCD, β3
Hydrophobic to
2 – 6, 9
L99M†,8
hydrophobic
CMT
αCD
Polar to polar
N102S5
CMT2F
Premature STOP in αCD, β5
4, 5, 9
K123*10
dHMN
αCD, β5
Positive to hydrophobic 2 – 6a, 10
R127L15
Positive to hydrophobic 2 – 6a, 10
R127W3,4,10,16,17,18, CMT2F/dH αCD, β5
19,20
MN
dHMN/ALS
Polar to positive
4, 5f, 8
Q128R3
Other
αCD, β5
Negative to negative
2 – 6d, 10
D129E21
5,10,19
CMT2F
αCD,
C137
Polar to hydrophobic,
2 – 5g, 8
S135C
β6/7
sulfur-containing
C137
Polar to hydrophobic
2 – 5, 8
S135F3,4,8,20,22,23,24 CMT2F/dH αCD,
MNII
β6/7
CMT2F
αCD,
C137
Polar to polar
S135Y25
β6/7
CMT2F/dH αCD,
C137
Positive to hydrophobic 2 – 6c
R136L5,7,26,27
MN
β6/7
CMT
αCD,
C137
Positive to polar
2 – 6e
R136Q5
β6/7
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αCD,
C137
Positive to hydrophobic 2 – 6e
β6/7
CMT2F
αCD,
C137
Polar, neutral to
3, 8
T139A5
β6/7
hydrophobic
CMT2F
αCD,
C137
Polar, neutral to polar,
3, 8
T139M5,28
β6/7
neutral
dHMN/CMT αCD,
C137
Positive to small
2 – 6b,h
R140G1,8,10,29
2F
β6/7
uncharged
dHMN
αCD,
C137
Positive to polar
5, 7, 8
K141Q6,10,30
β6/7
dHMN/CMT αCD,
Between β7 & β8
Polar to hydrophobic
7, 9
T151I3,10,18,20
2F
CMT
αCD,
Between β7 & β8
Polar to polar
7, 9
T151P5
unspecified Premature STOP between β8 and 9
S158fs7,31
CMT2F
αCD, β9, αCD-C border
Polar to hydrophobic
4, 5, 7i
T164A32
α-helix
dHMN
α-helix
M169Cfs25
CMT2F
α-helix
Polar to polar
P170T33
CMT2F
Premature STOP at αCD-C border
Q175fs3,34
dHMN
C, IXI/V IXI/V
Polar to hydrophobic
5
T180I1,7,35
CMT2F
C
IXI/V
Polar to hydrophobic
P182A10
dHMN
C
IXI/V
Rigid, cyclic to
4, 5, 8, 10
P182L18,20
hydrophobic
dHMN
C
IXI/V
Rigid, cyclic to
4, 5, 8, 10
P182S36
hydrophobic
CMT2F
Premature STOP
E186*33
dHMN
C
Polar to hydrophobic
10
S187L3,5
CMT2F
C
Positive to hydrophobic
R188W7
CMT
C
Polar to positive
Q190H5
CMT
C
Hydrophobic to polar
A204T5
1. Luigetti et al. (2016), 2. Fortunato et al. (2017), 3. Echaniz‐Laguna et al. (2017), 4. Antoniadi et al.
(2015), 5. DiVincenzo et al. (2014), 6. Maeda et al. (2014), 7. Capponi et al. (2011), 8. Houlden et al.
(2008), 9. Yavarna et al. (2015), 10. Tanabe et al. (2018), 11. Manganelli et al. (2014), 12. James et al.
(2008), 13. Fischer et al. (2012), 14. Scarlato et al. (2015), 15. Høyer et al. (2014), 16. Solla et al.
(2010), 17. Tang et al. (2005a), 18. Dierick et al. (2008), 19. Benedetti et al. (2010), 20. Evgrafov et al.
(2004), 21. Lewis-Smith et al. (2016), 22. Kim et al. (2015), 23. Phadke et al. (2015), 24. Oberstadt et al.
(2016), 25. Ylikallio et al. (2015), 26. Stancanelli et al. (2015), 27. Gaeta et al. (2012), 28. Amornvit et
al. (2017), 29. Ghodasara et al. (2018), 30. Ikeda et al. (2009), 31. Mandich et al. (2010), 32. Lin et al.
(2011), 33. Katz et al. (2020), 34. Rossor et al. (2012), 35. Luigetti et al. (2010), 36. Kijima et al.
(2005). a. R107L mutation in HSPB5 causes cataract (Ma et al., 2016), b. R120G mutation in HspB5
causes myopathy (Vicart et al., 1998a, Berry et al., 2001), c. R116C/R116H cause mutations in HspB4
cause cataract (Richter et al., 2008a), d. D109H in HspB5 causes myofibrillar myopathy (Fichna et al.,
2017), e. R116C mutation in HspB4 causes cataract (Litt et al., 1998), f. G108H mutation in HSPB5
causes cataract, g. S115Pfs mutation in HSPB5 causes cataract, h. R116P in HSPB3 causes dHMN, i.
mutation in HSPB7 †Homozygous mutation, ‡HSPB2, HSPB4 (Carver et al., 1996), HSPB5 (Voorter et
al., 1989, Smith et al., 1992, Ito et al., 1997), HSPB6 (Fan et al., 2004, Edwards et al., 2012), HSPB8
(Shemetov et al., 2008) and HSPB10 (Rosales et al., 2007) contain N-terminal phosphoserines but not at
this exact position. “Unspecified” disease association refers to mutations in which the reporting article
does not specify the exact neuropathy caused by the mutation.
R136W20

CMT2F
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Figure 1.4: Domain positions of disease-causing mutations in Hsp27 and age of disease
onset. Using data compiled from original publications, a correlation can be seen between the position of
a mutation in the Hsp27 sequence and the age of disease onset. Marked in green are mutations occurring
in the N-terminal region, in blue are those in the αCD, and in magenta are those in the C-terminal region.
Squares indicate patients diagnosed with the DHMNII phenotype, circles are those diagnosed with
CMT2F, and triangles indicate patients with an intermediate phenotype or one that does not fit the
diagnosis of either, due to the presence of other symptoms. Data compiled from: Luigetti et al. (2016),
Capponi et al. (2011), Houlden et al. (2008), James et al. (2008), Ylikallio et al. (2015), Solla et al. (2010), Tang et
al. (2005), Dierick et al. (2008), Benedetti et al. (2010), Lewis-Smith et al. (2016), Kim et al. (2015), Phadke et al.
(2015), Oberstadt et al. (2016), Stancanelli et al. (2015), Evgrafov et al. (2004), Ikeda et al. (2009), Maeda et al.
(2014), Mandich et al. (2010), Lin et al. (2011), Rossor et al. (2012), Luigetti et al. (2010), Kijima et al. (2005).

1.4.1

Mutations in the N-terminal region

Mutations in the N-terminal region may interfere with phosphorylation, and therefore
oligomerisation of Hsp27, as well as with Hsp27-client protein interactions. All of the
mutations

occurring

in

the

N-terminal

region

result

in

a

change

in

charge/hydrophobicity at the site of mutation (with the exception of the L58 frameshift),
mostly via introduction of a positive charge at sites that normally have a net negative or
zero charge (Table 1.4). These changes may interfere with the secondary structure of the
protein, and therefore with interactions between the N-terminal region and other
proteins (e.g. client proteins, or MAPKAP-K2 which phosphorylates Hsp27 at S15, 78
and 82). Interestingly, mutation of the highly conserved G84 to an R introduces a
positive charge adjacent to two of the phosphoserine residues (S78 and S82). The
addition of a positive charge at this site may either (i) inhibit phosphorylation of these
residues by MAPKAP-K2, or (ii) affect the dissociation of oligomers usually associated
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with the introduction of negatively charged phosphate groups at these phosphorylation
sites. Indeed, analysis of three N-terminal disease-associated mutations (G34R, P39L
and E41K) demonstrated that phosphorylation-induced oligomer dissociation was
decreased or abolished, and that the N-terminal region is less susceptible to
chymotrypsinolysis (Muranova et al., 2015). These mutant isoforms were also
associated with larger oligomeric size, increased oligomeric stability and lower
chaperone activity. Together, this suggests that mutations in the N-terminal extension of
Hsp27 decrease exposure of this region potentially altering the interactions of Hsp27
with client proteins (Muranova et al., 2015). The G84R mutation shows asymmetrical
and unusually late onset disease compared to other Hsp27 disease mutations (James et
al., 2008). Similarly, the P7R and P7S mutations are adjacent to the MAPKAP-K2
recognition sequence at S15 and may interfere with phosphorylation at this site.
Additionally, mutations in the N-terminal region may interfere with the ability of Hsp27
to inhibit apoptosis, as it has been shown that residues 51 – 88 are essential to the
interaction of Hsp27 and Cyt-c (Bruey et al. 2000).
1.4.2

Mutations in the αCD

Mutations in the highly conserved αCD are the most studied of the disease-causing
Hsp27 mutations, partly due to the importance of this domain in the chaperone activity
of the sHsps (Sharma et al. 1997, Muchowski et al. 1999, Ghosh et al. 2005), as well as
the ability to obtain crystal structures of the core domain and therefore deduce the
structural effects of mutation. Mutations in the αCD may interfere with interactions
between β-strands 6/7 of two αCD monomers, which facilitate dimer formation (Figure
1.3, Figure 1.5). Several structural factors are predicted to be involved in the dimer
interactions along the β-strands 6/7, including the high proportion of positively charged
and polar amino acids (and the absence of any negatively charged groups), the
formation of hydrogen bonds between residues on adjacent monomers, and the presence
of an intermolecular disulfide bond between the C137 residues of the two monomers.
Furthermore, the interactions between β-strands 6/7 are dynamic, especially in response
to the redox state of Hsp27 (Rajagopal et al., 2015, Alderson et al., 2019). Oxidation of
the adjacent C137 residues changes the curvature of β-strands 6/7, thereby altering the
orientation of surrounding residues, and increasing exposed hydrophobicity (Rajagopal
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et al. 2015) (Figure 1.5), while reduction increases the proportion of monomers in the
polydisperse population, and increases disorder in β-strands 6/7 of these monomers
(Alderson et al. 2019a). In some cases, monomerisation of Hsp27 has been found to
increase its chaperone activity, as well as its self-association into amorphous aggregates,
perhaps by increasing the availability of regions of the ACD, and/or by acting as a pool
of smaller species that may be more chaperone active (Alderson et al. (2019b),
Almeida-Souza, (2010). It is likely that mutations within β-strands 6/7 will also alter the
assembly of Hsp27 dimers, and hence, Hsp27 activity.

Figure 1.5: Redox status alters the dimer interface of Hsp27. 3D structures of the interface

between antiparallel β-strands 6/7 of an Hsp27 dimer in its A: oxidised state (PDB 2N3J (Rajagopal et al.
2015)), and B: reduced state (PDB 4MJH, (Hochberg et al. 2014)). The two C137 residues are coloured
yellow, while residues at sites of disease-causing mutations are coloured red. Structures were rendered
using the Polyview3D web interface (Porollo and Meller 2007).

Mutations within β-strands 6/7 (S135C, S135F, R136L R136W, R140G and K141Q),
and the R127W mutation positioned close to this region (Figure 1.3, Figure 1.5), all
replace positively charged residues (with the exception of the polar S135), with
hydrophobic ones. The positive charge in this region of αA- and αB-crystallin is critical
to the maintenance of structural and functional integrity of these sHsps (Bera et al.,
2002). For example, replacement of R116 in αA-crystallin (HSPB4) or R120 in αBcrystallin (HSPB5) (which correspond to R140 in Hsp27) with a non-positively charged
amino acid results in changes to the oligomeric structure and the chaperone ability of
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these proteins, whereas mutating it to another positively charged residue does not result
in such dramatic changes (Bera et al. 2002). Introduction of a positive charge at H124
of Hsp27 (either by protonation or substitution with a positively charged amino acid) is
shown to reduce the stability of the Hsp27 dimer interface, and increase the oligomeric
size of the protein (Clouser and Klevit, 2017). Interestingly, naturally-occurring
mutations to R116 (in αA-crystallin) and R120 (in αB-crystallin), as well as the
corresponding positively charged K141 in Hsp22 (HSPB8), to hydrophobic, noncharged, or negatively-charged residues all cause disease: cataract (Cobb and Petrash,
2000), desmin-related myopathy (Vicart et al., 1998a), and CMT2/dHMNII (Evgrafov
et al., 2004, Tang et al., 2004, Fontaine et al., 2006), respectively. The R116C and
R120G mutations in αA- and αB-crystallin cause significant changes to the secondary
and tertiary structures of the proteins, decreasing chaperone activity, increasing
aggregate size and reducing interactions with apoptotic pathways (Andley et al., 2002,
Bera and Abraham, 2002, Treweek et al., 2005). These findings all support the premise
that the positively charged amino acids in this region of the protein are critical to the
structure and function of sHsps. Changes in the oligomeric distribution of Hsp27 have
also been observed in the K141Q (Ikeda et al., 2009), R127W, S135F and R136W
(Almeida-Souza et al., 2010) mutants.
The single cysteine residue of Hsp27 (C137) resides in the monomer-monomer interface
and forms a disulfide bond that strengthens the dimer interaction (Hochberg et al.
2014). Mutations in this region (R127W and S135F) have been shown to increase the
proportion of monomer relative to dimer in the larger Hsp27 oligomers; this is likely
due to interruption of the disulfide bond and/or interruption of hydrogen-bonding
between adjacent monomers (Almeida-Souza et al. 2010). It has been suggested that the
presence of monomeric (rather than dimeric) subunits in sHsp oligomers increases
exposure of surfaces otherwise involved in dimer contacts, thereby increasing
interactions with substrates (Benesch et al., 2008). Stable expression of some of the
αCD mutants of Hsp27 in cells results in hyperactive chaperone ability (R127W,
S135F), and/or higher thermotolerance to heat-shock (R127W, S135F, R136W)
compared to cells expressing wild type Hsp27 (Hsp27WT) (Almeida-Souza et al. 2010).
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Expression of the Hsp27S135F mutation in Neuro-2a cells, COS fibroblast-like cells, or
HEK293T cells results in a reduction in viability and altered neurofilament assembly
compared to cells transfected with Hsp27WT (Evgrafov et al., 2004). The R127W,
S135F and R136W mutants also show increased binding to tubulin and microtubules,
resulting in an over-stabilisation of the microtubule network in HEK293T and COS
cells (Almeida-Souza et al., 2011), while S135F and P182L result in a decrease in
tubulin acetylation (which is important in axonal transport) in the peripheral neurons of
mice expressing mutant Hsp27 (d'Ydewalle et al., 2011).
If the widely accepted theory that smaller subunits of the sHsps are the chaperone-active
form holds true, then, taken together, these findings suggest that mutations in the αCD
disrupt dimerisation, and lead to hyperactivity of Hsp27 (by promoting formation of
monomers), resulting in inappropriate sequestration of proteins into Hsp27-client
complexes. The consequences of these aberrant interactions may include the prevention
of client proteins from performing their normal cellular activities and/or a reduction in
the amount of ‘free’ Hsp27 available to perform certain cellular functions. Hence, a
possible ‘toxic gain-of-function’ mechanism of pathogenesis has been proposed for the
αCD mutants (Houlden et al. 2008, d'Ydewalle et al. 2011), although further work is
necessary to confirm and characterise this. As this is a relatively new area of study, with
the first motor neuropathy-causing mutation in Hsp27 being reported in 2004 (Evgrafov
et al. 2004), and more being discovered each year, it is yet to be determined whether
other mutations in this region result in increased monomerisation and hyperactivity.
It may be, at least in part, that the high degree of variability in the age of disease onset
of patients carrying mutations in the αCD is a result of mutations in this region affecting
Hsp27 activity via different mechanisms, or at least to different degrees. For example,
mutations near the β4/β8 groove (L109 – K114 and S154 – L157) (Hochberg et al.
2014) such as L99M, R127L/W, T151I, S158fs and T164A, may inhibit binding of the
C-terminal IXI/V motif, preventing formation of higher order oligomers. This β4/β8
groove is also suggested to facilitate interactions with Bag3 (via binding of the Bag3
IXI motif) and hence Hsp70 (Rauch et al., 2017, Alderson et al., 2019), and so may
interrupt Bag3-associated autophagy or Hsp70-associated refolding of Hsp27 client
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proteins.
1.4.3

Mutations in the C-terminal region

Mutations in the C-terminal region of Hsp27 (T180I, P182L, P182S, and R188W)
appear to be associated with more severe, early onset neuropathies compared to those
that occur within the N-terminal or αCD (Dierick et al., 2008) (Figure 1.4). The Cterminal region of Hsp27 is thought to be involved in interactions between Hsp27 and
client proteins as well as in dimer-dimer interactions, whereby the IXI/V motif
(residues 181 – 183) of a dimeric subunit, can bind to a groove formed by the β4 and
β8 strands in an adjacent αCD (Laganowsky et al., 2010, Hilton et al., 2013, Hochberg
and Benesch, 2014). This facilitates association of Hsp27 into higher order oligomers.
Furthermore, the flexible C-terminal extension is thought to be critical to the solubility
of Hsp27, and the complexes it forms with client proteins (Lelj-Garolla and Mauk
2012).
Two mutations of the central proline residue (i.e. P182L and P182S) of the IXI/V
motif (Evgrafov et al., 2004, Kijima et al., 2005), as well as one directly adjacent to it
(T180I) (Luigetti et al., 2010, Capponi et al., 2011, Luigetti et al., 2016) cause early
onset dHMN. Unlike some of the αCD mutants of Hsp27, compared to Hsp27WT,
expression of the Hsp27P182L results in decreased cellular thermotolerance, and no
difference in the ability to facilitate the intracellular refolding of luciferase (AlmeidaSouza et al. 2010). Interestingly, frameshift or premature STOP mutations before the
C-terminal region (S158fs, M169fs and Q175X) seem to be less severe (with regards
to the age at disease onset) than mutations occurring within the C-terminal region, with
the exception of the C-terminal S187L mutation, which has a late age of disease onset
(Figure 1.4). Due to the importance of the C-terminal region in the solubility of Hsp27,
it may be that point mutations in this region render the mutant isoforms insoluble and
therefore unable to properly interact with the normal cellular clients of Hsp27. Taken
together, these findings suggest that, in the case of C-terminal point mutations of
Hsp27, the disease-causing mechanism is related to loss of function due to insolubility.
This is in contrast to the toxic gain-of-function (due to monomerisation) mechanism
proposed for disease-causing mutations in the N-terminal and αCD of the protein.
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Meanwhile, frameshift or premature STOP mutations show intermediate onset. This
may be the result of massive destabilisation of the frameshift mutant Hsp27 leading to
its degradation. This would result in an overall reduced expression of the wild type
protein due to the heterozygous mode of inheritance. As such, the activity of Hsp27
would be decreased by lowered expression, but the molecular mechanisms underlying
its interactions with other proteins would remain unaltered.
Mutations in the IXI/V motif may also inhibit the formation of large oligomers
(preventing binding of the motif to the β4/β8 groove), thereby affecting the function of
Hsp27. Additionally, if there is a legitimate intracellular interaction between Hsp27 and
Bag3 that is the result of competitive binding between the IXI/V motifs of Bag3 and
Hsp27 itself, as suggested by Rauch et al. (2017) and Alderson et al. (2019), then
mutation of the IXI/V motif in Hsp27 may increase interactions between Hsp27 and
Bag3, with downstream effects on autophagy and Hsp70 interactions.
Sakamoto et al. (2002) found R188 of Hsp27 to be a site of methylglyoxal modification
to form argpyrimidine. The disease-causing R188L mutation of Hsp27 may prevent this
modification, and thereby affect its oligomerisation. Sakamoto et al. (2002) suggest that
inhibition of methylglyoxal modification by mutation of R188 may decrease the ability
of Hsp27 to repress Cyt-c-mediated apoptosis, such that HEK293T cells transfected
with an R188G mutant of Hsp27 (such that methylglyoxal modification was prevented)
were more sensitive to campthothecin or etoposide-induced apoptosis, compared to
control or Hsp27WT-transfected cells. Furthermore, in a cell-free system using extracts
from these cells and addition of dATP and Cyt-c, Sakamoto et al. (2002) confirmed that
only extracts from Hsp27WT-transfected cells showed a decreased caspase activation.
1.4.4

Why do mutations in Hsp27 lead to motor neuropathies?

It is clear from the discussion above that further biophysical and biochemical analyses
of differences between disease-associated mutant forms of Hsp27 and Hsp27WT are
required in order to determine the mechanism of disease pathogenesis. Furthermore,
while much progress has been made into understanding the many roles of Hsp27 in the
cell, most of the interactions and the mechanisms underlying them remain unknown.
This makes it difficult to pinpoint the overall mechanism(s) by which Hsp27 mutations
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cause disease. Pathways that are likely to be involved are discussed in the following
sections.
Interestingly, while Hsp27 is expressed in virtually every tissue type in the human
body, to date, mutations in Hsp27 are only directly associated with CMT and dHMN.
Thus, it appears that motor neurons are particularly susceptible to mutations in Hsp27
compared to other cell types. At this point one can only speculate on various
possibilities of why this is the case (summarised in Figure 1.6). While considerable
research has been conducted on the in vitro chaperone activity of Hsp27WT, little work
has been done with respect to the relative chaperone abilities of the disease-related
mutants of Hsp27. The work that has been completed in this area by different groups
has focussed on different Hsp27 mutants and used different “model systems” to test
activity (Evgrafov et al., 2004, Ackerley et al., 2006, Fontaine et al., 2006, Zhai et al.,
2007, Almeida-Souza et al., 2010, Almeida-Souza et al., 2011). It is therefore
necessary to develop a comprehensive, relevant and consistent array of in vitro and
cell-based assays to address the effect disease-related mutations have on Hsp27 with
regards to its chaperone role in proteostasis, maintenance of the cytoskeleton,
protection from oxidation, and inhibition of cell death.
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Figure 1.6. Proposed mechanisms by which mutations in Hsp27 may interfere with various cellular pathways leading to motor neuropathies.As Hsp27 is involved in the
control of various cellular processes, and its molecular mechanisms are dynamic, various modes of pathogenesis are possible. These interactions are discussed in detail in the following sections.
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1.4.4.1 Interactions with other sHsps

It is possible that in cells other than motor neurons, expression of other sHsps with
similar and/or overlapping functions to Hsp27 is sufficient to compensate for any
deficits in Hsp27 function, hence the progression of disease affecting only motor
neurons. In fact, the constitutive expression of Hsp27 in the motor neurons of rat spinal
cords is high, yet is undetectable in neurons of the entorhinal cortex, hippocampus, or
substantia nigra or glial cells, as determined by immunohistochemistry (Chen and
Brown 2007). Furthermore, expression of Hsp27 in these motor neurons is substantially
higher than that of other Hsps (Chen and Brown, 2007). Hsp20 (HspB6) and αBcrystallin both form hetero-oligomers with Hsp27 (Bukach et al., 2009, Aquilina et al.,
2013, Heirbaut et al., 2016). Hsp22 has been shown to interact with Hsp27 via yeast
two-hybrid screening of a human heart cDNA library (Benndorf et al., 2001), and by
FRET analysis of COS-7 cells expressing fluorescently tagged Hsp22 and Hsp27 (Sun
et al., 2004). Interestingly, mutations in Hsp22 also cause CMT2 and dHMNII
pathogenesis (Irobi et al., 2004b, Tang et al., 2004, Fontaine et al., 2006). Quantum
Förster resonance energy transfer experiments in COS-7 cells (Fontaine et al. 2006) and
co-immunoprecipitation experiments (Irobi et al. 2004) have shown that the Hsp22
mutants (especially K141N) show increased interaction with Hsp27WT (compared to
Hsp22WT) and the Hsp27S135F mutant shows increased interaction with Hsp22WT
(compared to Hsp27WT).
1.4.4.2 Interactions with the cytoskeleton and axonal transport

An alternate explanation as to why motor neurons may be particularly susceptible to
mutations in Hsp27 is due to the role of this sHsp in the polymerisation and stabilisation
of the cytoskeleton. Cytoskeletal organisation, axonal transport, and the roles of sHsps
in these processes are all linked to peripheral neurodegeneration; this important
relationship is highlighted by the fact that separate, distinct mutations in sHsps,
neurofilament proteins, and axonal transport proteins all lead to the same disease
phenotype. Furthermore, deregulation of axonal transport is linked to a number of other
neurodegenerative diseases, indicating that disruption of cellular homeostasis leads to
altered axonal transport (both anterograde and retrograde), downstream interruption to
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various cellular processes that rely on axonal transport, and eventually to
neurodegeneration (reviewed in Perlson et al. (2010)).
Disruption of Hsp27 function may affect the formation and maintenance of the long
axons that are characteristic of peripheral nerves (Williams et al. 2005). In both the
demyelinating and non-demyelinating forms of CMT, disruption of axonal structure
and/or transport is common (Suter and Scherer, 2003). As the phosphorylation and
oligomerisation state of Hsp27 has been suggested to be essential in controlling Hsp27actin interactions (Guay et al., 1997, Graceffa, 2011, Williams and Mearow, 2011),
mutations that affect these properties (especially those in the N-terminal and αCD) may
alter these interactions. It has been proposed that smaller subunits of Hsp27 (e.g.
dimers) interact with actin (Graceffa 2011). If this is the case, mutations in the αCD that
increase monomerisation of Hsp27 may increase the strength of these interactions
resulting in a gain-of-toxic-function mechanism of pathogenesis. Conversely, mutations
that increase the oligomeric size of Hsp27 may abolish or decrease these interactions,
leading to a loss-of-function mechanism of pathogenesis.
Hsp27 plays a role in neurofilament assembly and in preventing filament aggregation,
both of which are essential to the maintenance of peripheral nerves, axonal integrity,
and axonal transport (Guay et al. 1997, Perng et al. 1999, Nefadova et al. 2017).
Mutations in neurofilament light protein are also associated with CMT2F or dHMNII
(Mersiyanova et al., 2000, Evgrafov et al., 2004, Fontaine et al., 2006), implicating a
link between neurofilament formation and disease pathogenesis. In cells transfected
with Hsp27S135F and neurofilament light, neurofilaments showed a greater proportion of
non-filamentous assembly compared to cells expressing Hsp27WT (Evgrafov et al. 2004,
Zhai et al. 2007). As neurofilaments are specific to nerve cells, this may explain why
these mutations do not result in altered phenotypes in other cell types. Other shorter
neuronal cells may be less affected by alterations to neurofilament dynamics, such that
effects may be slow enough not to cause a detectable disease phenotype, as opposed to
the long, highly polarised motor neurons affected by the length-dependent progression
of CMT and dHMN.
In addition to possible interruptions to axon-formation and maintenance via direct
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interactions with cytoskeletal elements, disease mutations in both Hsp22 and αBcrystallin have been found to correlate with the formation of cytoplasmic and
perinuclear protein aggregates, which disrupt axonal transport and can lead to cell death
(Der Perng et al., 2004, Evgrafov et al., 2004, Irobi et al., 2012). Similarly, the P182L
mutation in Hsp27 has been shown to form aggregates with other intracellular proteins
including the nerofilament middle-chain subunit and dynactin 1 (Ackerley et al. 2005),
providing another mechanism by which axons could be disrupted, leading to disease
pathogenesis. Mutations in dynamin 2 (Züchner et al. 2005) and dynactin 1 (Puls et al.,
2003), both of which are involved in axonal transport, have also been implicated in the
pathogenesis of CMT and other peripheral neuropathies. Specifically, the S135F and
P182L mutations of Hsp27 result in a decrease in tubulin acetylation (which is
important in axonal transport) in the peripheral neurons of mice expressing these mutant
isoforms of Hsp27 (d'Ydewalle et al. 2011). The S135F and P182L mutations of Hsp27
also reduce tubulin acetylation and mitochondrial transport in patient-derived induced
pluripotent stem cells (Kim et al., 2016). As mitochondria are essential to cell survival,
interruptions to mitochondrial function or transport are likely to have deleterious
effects. This is likely involved in the pathogenesis of CMT type 2; mutations in
mitofusin 2 are the most common cause of CMT2, and are found to result in alterations
to axonal transport of mitochondria (Baloh et al., 2007).
Axonal transport of Hsp27 itself could also be altered by mutations in the protein. The
P182L mutation was found to lead to differences in the localisation of Hsp27 in
transfected cells, with much less of the sHsp protein appearing in neurites and cellular
processes compared to Hsp27WT (Ackerley et al. 2006). This reduction in transportation
may be linked to decreased solubility of the P182L mutant compared to Hsp27WT, and
disruption and aggregation of neurofilaments (Ackerley et al. 2006).
1.4.4.3 Interactions with other cell types

While Hsp27 mutations cause CMT2 (the non-demyelinating class of CMT), some
slight alterations in myelination have been observed in the peripheral nerves of patients
with Hsp27T180I mutation-related dHMN (Luigetti et al. 2010). This suggests that
changes in Hsp27 function in the Schwann cells responsible for myelination may cause
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differences in the myelination of nerve cells, interrupting axonal function in neurons,
and leading to their degeneration. The importance of Hsp27 in the Schwann cell-axon
relationship is highlighted by increased expression of Hsp27 in the Schwann cell
columns that are associated with regeneration of axons in injured nerves (Hirata et al.,
2003). It is suggested that Hsp27 upregulation in these Schwann cell columns is linked
to the organisation of intermediate filaments in the production of neurites due to its
known interactions with cytoskeletal proteins (Hirata et al. 2003). In addition, the
regulation of cell-shape and gene expression involved in Schwann cell myelination is
influenced by Hsp27 phosphorylation (Fragoso et al., 2003). Therefore, mutations that
affect the phosphorylation state of Hsp27 may impact on the myelination of peripheral
nerves. Interestingly, disruption to aggresomes and autophagy in Schwann cells are
suggested to be involved in the pathogenesis of CMT1 (demyelinating) (Fortun et al.,
2003). This may indicate that mutations in Hsp27 interfere with its interactions with
Bag3, Hsp70 and/or HMGB1, affecting autophagic clearance of cytosolic components
in Schwann cells, and thereby cause downstream disruption to axon function, with a less
severe effect on myelination than demyelinating forms of CMT.
1.4.4.4 Interactions with mitochondria

Interestingly, many of the proposed roles of Hsp27 in cells are linked to the transport,
maintenance and function of mitochondria. Recently, it has been established that
misfolded cytosolic proteins are transported into the mitochondrial intermembrane
space in yeast cells, and that this influx of misfolded proteins increases both under cell
stress conditions and in the presence of defective Hsp70 (Ruan et al. 2017). These
misfolded proteins are then degraded in mitochondria, in a manner separate to
proteasomal degradation, as specific blocking of mitochondrial import machinery
slowed the degradation of these proteins, while blocking of the proteasome had no
effect. As Hsp27 interacts with aggregation-prone misfolded proteins, is an interacting
partner of Hsp70, and is involved in the regulation of mitochondrial autophagy (Narumi
et al. 2015; Tang et al. 2011), mitochondrial degradation of misfolded proteins provides
a direct link to the molecular chaperone activity of Hsp27. Interestingly, Hsp22, an
interacting partner of both Hsp27 and Hsp70, and another protein in which mutations
cause CMT, is involved with the mitochondrial unfolded protein response (Morrow and
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Tanguay, 2015). In fibroblasts taken from dHMN patients carrying a mutation in Hsp22,
mitochondrial membrane potential was reduced, and these cells showed a higher
number of intracellular aggregates (Irobi et al. 2012). Furthermore, Hsp27 expression is
regulated by HMGB1 (Tang et al. 2011), a DNA-binding protein involved in the
maintenance of mitochondrial morphology and function, and notably with regulation of
autophagy (Kang et al., 2011a, Kang et al., 2011b, Tang et al., 2011). Tang et al. (2011)
found that HMGB1 knockout mouse embryonic fibroblasts express less Hsp27, but not
Hsf1 (the transcription factor mainly responsible for stress-induced synthesis of Hsps),
than cells expressing HMGB1. Cells lacking HMGB1, and with subsequently low
Hsp27 expression, showed mitochondrial fragmentation, decreased mitochondrial
membrane potential, decreased mitophagy, and increased apoptosis under cell stress
(Tang et al. 2011) therefore it was suggested that these changes may relate to the role of
Hsp27 in stabilising the cytoskeleton, and thus mitochondrial transport.
Mitochondrial transport in motor neurons occurs via both anterograde and retrograde
axonal transport, and is essential in the growth, maintenance and function of these cells.
Many of the genes in which CMT and dHMN-causing mutations have been identified
are axonal transport-related genes (such as dynein, dynactin and Rab7; Table 1.3). The
overexpression of the Hsp27R136W mutant results in severe axonopathy, defective
neurofilament cytoskeleton, and the accumulation of mitochondria along axons
(Srivastava et al., 2012). The retrograde axonal transport of mitochondria in primary
mouse motor neurons expressing three Hsp27 mutations (P39L, S135F, and R140G) is
significantly impaired relative to cells expressing the wild type protein, while
anterograde transport is unaffected (Kalmar et al., 2017). However, mitochondrial
transport in cortical cell cultures was not affected by the expression of the P182L Hsp27
isoform (Ackerley et al. 2017), suggesting that different Hsp27 mutations may
differentially affect mitochondrial transport. Furthermore, mitochondrial function is also
impaired in cells expressing theP39L, S135F and R140G Hsp27 isoforms, such that
mitochondrial membrane potential and complex 1 activity are decreased, and
mitochondria are more sensitive to stressors (Kalmar et al., 2017). The involvement of
Hsp27 with cytoskeletal-based cellular transport may affect the movement of
mitochondria down the length of motor neuron axons, and this failure to deliver
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mitochondria to the correct location may lead to energy deprivation and these effects
may be exacerbated by interactions with proteins that maintain mitochondrial
morphology and function.
The involvement of Hsp27 in inhibiting apoptosis is tightly linked to mitochondria
through interactions with the mitochondrial membrane, binding of Cyt-c and inhibition
of apoptosome formation (Bruey et al. 2000). Interestingly though, mitochondrial
activity is linked to another cytoprotective pathway in which Hsp27 plays a role:
conversion of reactive oxygen species, (a by-product of mitochondrial oxidative
phosphorylation), to water in order to prevent oxidative cell death.
Mitofusion 2, another gene identified in which mutations cause CMT and dHMN
(Kijima et al. 2005), is a mitochondrial GTPase involved in mitochondrial fusion. While
the molecular mechanism of disease underlying any of the CMT-causing mutations is
unknown, it has been suggested that mutation in mitofusion 2 may disrupt
mitochondrial morphology and transport (reviewed in Cartoni and Martinou (2009)).
Furthermore, mutations in various cytoskeletal, and transport-related proteins cause
CMT and/or dHMN, including the mitochondrial transport motor protein KIF1Bβ
(Nangaku et al., 1994). Taken together, these findings link CMT pathogenesis to the
function and transport of mitochondria, suggesting that mutations in Hsp27 may affect
mitochondrial transport, morphology and/or function. In fact, myopathy-causing
mutations in the closely related sHsp, αB-crystallin, lead to impaired mitochondrial
function (Maloyan et al., 2005), and many other motor and sensory neuropathies have
been linked to mitochondrial dysfunction, such as optic neuropathies (Carelli et al.,
2002, Carelli et al., 2004, Giordano et al., 2010), peripheral neuropathies (Srinivasan et
al., 2000, Flatters and Bennett, 2006), and amyotrophic lateral sclerosis (Wong et al.,
1995, Manfredi and Xu, 2005, Cozzolino and Carrì, 2012).

1.5 Conclusions
Normal Hsp27 function is critical in various cellular pathways, and this has hampered
identification of the precise mechanism(s) by which mutations in this chaperone protein
leads to CMT2 and dHMNII. Furthermore, mutations in different regions of the protein
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appear to have drastically different effects on the oligomeric structure and activity of
Hsp27, such that several mechanisms of pathogenesis may exist. Likely effects of
disease-mutations on Hsp27 include disruptions to its role in proteostasis, its ability to
inhibit oxidation-induced or apoptotic cell death, and/or its pivotal role in modulating
cytoskeletal elements. Determining the pathways affected by disease-related mutations
in Hsp27 will help us better understand the pathogenesis of CMT and dHMN caused by
various other genetic mutations and provide a basis for future work aimed at developing
therapeutics for these neuropathies. Possible therapeutics may aim to inhibit expression
or activity of Hsp27 in patients with a toxic gain-of-function mutation, while patients
with loss-of-function mutations may benefit from therapeutics that aim to upregulate
Hsp27 expression. Alternatively, as the majority of disease-related mutations in Hsp27
follow heterozygous inheritance, therapeutics that selectively target the mutant protein
and allow expression of the recessive wild type gene may be beneficial. Overall,
downregulation of Hsp27 may carry some risk since impaired expression of Hsp27 (due
to a mutation in the Hsp27 heat shock element promotor region) has been linked to
amyotrophic lateral sclerosis (Dierick et al. 2007). Thus, downregulation of Hsp27 may
need to be paired with upregulation of other sHsps (such as Hsp22) as a possible
treatment strategy. A potential therapeutic has already been suggested that targets the
role of Hsp27 in cellular transport: the use of histone deacetylase 6 (Hdac6) inhibitors
(Benoy et al., 2017). Hdac6 inhibitors counteract the effect of Hsp27 mutation on
tubulin acetylation in patient derived induced pluripotent stem cells (Kim et al., 2016),
restore mitochondrial movement disrupted by mutant Hsp27 expression in mouse motor
neurons (Kalmar et al., 2017), and rescue Hsp27 mutant-induced defects in drosophila
(Kang et al., 2020).
Investigations into the disease mechanisms of Hsp27 mutations should be directed at
identifying the structural and functional differences between the mutant proteins and
Hsp27WT. These investigations should focus both on widely applicable and relevant
model experiments in vitro as well as physiologically relevant studies in neuronal and
support cells (e.g. Schwann and glial cells). Investigation of disease-causing mutations
in Hsp27 will not only provide insight into the molecular mechanisms underlying
disease pathogenesis, but also into the mechanisms underlying the many cytoprotective
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functions of Hsp27 and the sHsps in general.

1.6 Aims
The molecular mechanisms underlying the disease progression of CMT and dHMN
caused by mutations in Hsp27 are unknown. Furthermore, the detailed mechanism of
action of Hsp27, and the cellular pathways in which it is involved are poorly
understood. Further work is required to elucidate these mechanisms, and how they
contribute to the onset of disease. Therefore, the aims of this project were to:
1. Generate and characterise a set of recombinant Hsp27 isoforms with which to
compare the effect of disease-causing mutations on the biophysical and
biochemical properties, and activity of Hsp27,
2. Assess the effect of redox status on the structure and activity of Hsp27WT and
disease-causing mutant isoforms,
3. Determine whether Hsp27WT is involved in the growth and differentiation of
neuronal cells, and/or the axonal transport of mitochondria,
4. Determine the effect of disease-causing mutations (Hsp27P39L, Hsp27R136W,
Hsp27R140G, and Hsp27T151I) on the intracellular localisation of Hsp27, and
5. Identify the interacting partners of Hsp27WT and two disease-causing mutants
(Hsp27R136W and Hsp27T151I) in motor neuron-like NSC-34 cells.
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Chapter 2: General materials and
methods
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2 General materials and methods
The general materials and methods used in this research are presented in this chapter.
Methods specific to the results chapters are presented therein.

2.1

Materials

All materials and reagents were of molecular grade and, unless otherwise stated,
purchased from either Sigma-Aldrich (St. Lois, MO, USA) or Amresco (Solon, OH,
USA).
2.1.1

Buffers

All buffers were pH adjusted using a Eutech Instruments 510 pH meter (Thermo-Fisher
Scientific, Waltham, MA, USA) and filtered prior to use with a 0.22 μM membrane
(Millipore, Billerica, MA, USA). Commonly used buffers in this project were phosphate
buffer (PB; 50 mM, pH 7.4 unless otherwise stated), phosphate buffered saline (PBS;
NaCl (137 mM), KCl (2.7 mM), Na2HPO4 (10 mM), KH2PO4 (2 mM), pH 7.4 unless
otherwise stated). The compositions of all other buffers used are given in the relevant
methods sections.
2.1.2

Plasmid Constructs

Plasmid constructs used in each chapter are listed in the relevant methods section of the
results chapters.
2.1.3

Antibodies

Antibodies used in this study for various techniques are listed in Table 2.1.
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Table 2.1: Antibodies used in this study. The antibodies used, their clonality (monoclonal (M), or
polyclonal (P)) and the dilution factor relevant to each technique (immunoblotting (IB),
immunohistochemistry (IHC), and immunoprecipitation (IP)) are given.
IB

IHC
IP
Dilution factor (1/)
250
200
see 4.2.3
200
1 250
1 250
-

Clonality
Mouse (G3.1) anti-Hsp27 (ab2790)1
M
5 000
Mouse anti-α Tubulin (ab184613)1
M
5 000
Mouse anti-C-Myc (9E10)2
M
CLASP2 (F-3)4
M
1500
Mouse anti-SLK (38)4
M
1500
Rabbit anti-Myc (ab152146)1
P
Mouse IgG Isotype Control (ab37355)1
P
Rabbit IgG Isotype Control (ab37415)1
P
Goat anti-Rabbit IgG – Peroxidase 2’2
P
5 000
Rabbit anti-Mouse IgG (whole molecule) P
5 000
Peroxidase 2’3
Goat anti-Mouse IgG H&L (Dylight 550) 2’
P
250
(ab96872)1
Goat anti-rabbit IgG H&L (Dylight 650) 2’
P
250
(ab96886)1
1
Purchased from Abcam, (Cambridge, UK), 2purchased from Thermo-Fisher Scientific, 3purchased from
Sigma-Aldrich, 4purchased from Santa Cruz Biotechnology (Dallas, TX, USA).

2.2 General Methods
2.2.1

Protein analyses

2.2.1.1 Extraction of cellular proteins
2.2.1.1.1

Denaturing SDS-extraction

Proteins were extracted from cells for various analyses throughout this project. Cells
(both bacterial and mammalian) destined for SDS-PAGE/immunoblotting were washed
twice with PBS, resuspended in SDS-extraction buffer (500 mM Tris-HCl, pH 6.8, with
2% (w/v) SDS) and incubated at 95°C for 5 min. Lysates were then cleared of insoluble
debris by centrifugation (20 000 × g, 10 min, room temperature, RT).
2.2.1.1.2

Non-denaturing extraction

In cases where denaturation of proteins on extraction was not desired, washed cells were
resuspended in lysis buffer (5 mM EDTA and 0.5% (v/v) Triton X-100 in PBS, pH 7.4,
supplemented with 1 × Halt™ Protease and Phosphatase Inhibitor Cocktail (ThermoFisher Scientific)). These cells were then incubated on ice for 30 min, with brief
vortexing every 5 min. Lysates were cleared by centrifugation (20 000 × g, 10 min,
4°C).
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2.2.1.2 Protein determination

Where required, the total protein concentration of extracts or purified protein was
quantified using the Pierce™ BCA (bicinchoninic acid) Protein assay kit (ThermoFisher Scientific), as per the manufacturer’s instructions, in 96-well plates. Briefly, BSA
in 50 mM PB was used as a concentration standard in these assays (serially diluted from
2 mg/mL). Cell extracts were diluted 1 in 5 or 1 in 10 in 50 mM PB as required. BCA
reagent was added to all wells containing standards or unknowns, and plates were
incubated at 37°C for 30 min. The optical density at 562 nm was then read using a
SpectraMax Plus384 absorbance microplate reader (Molecular Devices, CA, USA), and
a standard curve generated from which protein concentrations were calculated.
Alternatively, protein concentration was determined using a Nanodrop 2000c
spectrophotometer (Thermo-Fisher Scientific) and calculated using specific A280 values
and molecular weights (Table 2.2).
Table 2.2: Protein extinction coefficients and molecular weights used in this study.
A280 (1 mg/mL)
Molecular weight (Da)
α-lactalbunin (α-lac)1,a
2.09
14 200
α-synuclein (α-syn)2
0.35
41 500
Bovine serum albumin (BSA)3
0.66
66 410
Citrate synthase (CS)4
1.78
48 969
Creatine phosphokinase (CPK)5
0.88
80 000
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)6
0.91
35 606
Green fluorescent protein (GFP)7,b
0.08
27 000
Hsp258
1.87
23 014
Hsp279
1.65
22 783
Insulin6
0.97
5 734
Lysozyme6
2.64
14 300
Rhodanese10
1.75
35 600
Superoxide dismutase 1 (SOD1)11, c
0.39
15 975
1
2
3
4
5
Pace et al. (1995), Bousset et al. (2013), Peters Jr (1995), Singh et al. (1970), Vasak et al. (1979),
6
Gill and Von Hippel (1989), 7Heim and Tsien (1996), 8Ehrnsperger et al. (1999), 9Hayes et al. (2009),
10
Ogata and Volini (1990), 11Seetharaman et al. (2010). aKindly donated by Dr. Tracey Berg (University of
Wollongong, Australia). bKindly donated by Ms. Caitlin Johnston (University of Wollongong, Australia),
c
Kindly donated by Dr. Luke McAlary (University of Wollongong, Australia).

2.2.1.3 Protein electrophoresis
2.2.1.3.1

SDS-polyacrylamide gel electrophoresis (SDS-PAGE)

SDS-PAGE was performed using either precast 10- or 12-well Any kD MiniPROTEAN TGX Stain-Free Protein Gels (Bio-Rad, Hercules, CA, USA), or 12% (v/v)
polyacrylamide gels made in-house via standard techniques (Weber and Osborn, 1969).
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Samples for SDS-PAGE were first mixed with SDS sample buffer to give a final
concentration of 70 mM Tris-HCl, 30% (v/v) glycerol, 2% (v/v) SDS and 0.01% (w/v)
bromophenol blue with or without β-mercaptoethanol (BME; 2.5% (v/v)) as indicated.
Samples were heated at 95°C for 5 min before being loaded onto polyacrylamide gels,
with Bio-Rad dual colour protein standards, and electrophoresed at 150 V for ~ 1 h (or
until the loading dye front reached the end of the gel) using a Mini-Protean tetra cell gel
apparatus system (Bio-Rad) as per the manufacturer’s instructions. Gels were either (i)
stained with Coomassie-blue stain (12% (w/v) Coomassie brilliant blue, 40% (v/v)
methanol and 10% (v/v) acetic acid) then de-stained (in 40% (v/v) methanol and 10%
(v/v) acetic acid), or (ii) transferred to membranes for immunoblotting.
2.2.1.3.2

Immunoblotting (IB)

Following SDS-PAGE, stain-free gels used for immunoblot analysis were imaged using
a Criterion Stain Free™ Gel Imaging System (Bio-Rad), then blotted onto
polyvinylidene fluoride (PVDF) membrane (Bio-Rad) using transfer buffer (25 mM
Tris- HCl, 192 mM glycine, 20% (v/v) methanol, 0.03% SDS, pH 7.6) at 100 V for 1 h
(Towbin et al., 1979) using a Mini-protean tetra cell gel apparatus system (Bio-Rad).
Stain-free images were then taken of the membranes, and total lane densitometry was
determined using Image Lab™ Software (Bio-Rad) as a control for protein loading.
Membranes were blocked for 1 h at RT or overnight (4°C) in 5% (w/v) skim milk
powder in tris buffered saline (TBS; 100 mM Tris HCl, 150 mM NaCl, pH 7.5), rinsed
four times in TBS-T (TBS containing 0.05% Tween- 20) and then incubated with
primary antibody diluted in TBS-T with 5% (w/v) skim milk powder as outlined in
Table 2.1. Membranes were incubated with rocking for 2 h at RT or overnight at 4°C.
Blots were washed four times in TBS-T, then incubated with appropriate secondary
antibody in TBS-T diluted as per Table 2.1, with rocking for 1 h at RT or overnight at
4°C. The labelled proteins were detected using either SuperSignal® West Pico
Chemiluminescent Substrate or SuperSignal® West Dura Extended Duration
Chemiluminescent Substrate (as per manufacturer’s instructions, Thermo-Fisher
Scientific). The resulting chemiluminescent signal was detected using an Amersham
Gel Imager 600 (GE Healthcare, Chicago, IL, USA), with exposure times between one
sec and 10 min, or by exposure (5 sec – 10 min) to Amersham Hyperfilm ECL (GE
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Healthcare) and developed using standard techniques. Where appropriate, detected
bands were analysed by densitometry using ImageJ, and normalised to the total lane
densitometry from stain-free images of the blotted membranes.
2.2.1.4 Förster resonance energy transfer (FRET)

Each of the Hsp27 isoforms and Hsp25 were labelled with CF®647 Succinimidyl Ester
Dye (Biotium, Fremont, CA, USA), and Hsp27WT was also labelled with Alexa Fluor™
488 NHS Ester (Succinimidyl Ester) (Thermo-Fisher Scientific), as per the
manufacturer’s instructions, with a 10:1 dye:protein molar ratio. Labelled proteins were
dialysed into 50 mM PB (pH 7.4) using Slide-A-Lyzer Dialysis Cassettes (0.1 – 0.5 mL,
10 K molecular weight cut off; Thermo-Fisher Scientific), and the labelled protein
concentration was calculated such that:
𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶 = �𝐴𝐴280 − (𝐴𝐴𝑚𝑚𝑚𝑚𝑚𝑚 × 𝐶𝐶𝐶𝐶)� ÷ (𝜀𝜀 × 𝑙𝑙)

Where A280 is the absorbance of the protein at 280 nm, Amax is the absorbance
maximum of the dye (490 and 650 nm for Alexa Fluor 488 and CF647, respectively),
CF is the absorption correction factor for each dye at 280 nm (0.1 and 0.03 for Alexa
Fluor 488, and CF647, respectively), l is the pathlength of the spectrophotometer, and ɛ
is the molar extinction coefficient of the protein.
Each labelled protein was then diluted to 25 µM and incubated 37°C for 1 h to allow
subunit exchange, before being placed on ice. Equimolar ratios of 488-labelled
Hsp27WT and each of the 647-labelled Hsp27 isoforms, Hsp25, or SOD1 as a negative
control were then added to a black, clear-bottomed 384-microwell plate (Greiner Bio
One, Kremsmünster, Austria) and FRET monitored for 90 min at 37°C by measuring
the levels of fluorescence with a 490/650 nm excitation/emission filter set using a
POLARstar Optima plate reader (BMG Lab Technologies). The ratio of fluorescence
intensity at each time-point to time 0 was then calculated, with an increase over time
indicating subunit exchange.
2.2.2

Agarose gel electrophoresis of DNA

DNA samples were mixed with DNA loading buffer (glycerol (5% (v/v), bromophenol
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blue (0.05% (w/v)) for separation by electrophoresis using either 1.0 or 1.2% (w/v)
agarose (TopVision, Thermo-Fisher Scientific) gels (Tris-acetate-EDTA (TAE buffer;
Tris base (40 mM), acetic acid (20 mM) EDTA (1 mM), pH 8.0) with GelRed® Nucleic
Acid Gel Stain (Biotium,). Electrophoresis was performed in a MiniSub® Cell GT
electrophoresis tank (Bio-Rad) in TAE buffer, at 85 V until the bromophenol blue dye
front had migrated to the end of the gel. Hyperladder I (200 – 10037 bp) and/or
Hyperladder II (50 – 2000 bp) (Bioline, Smeaton Grange, NSW, AU) were used as
molecular mass markers.
2.2.3

Bacterial culture

All bacterial culture was carried out under sterile conditions. E. coli was grown in
Luria-Bertani medium (LB; 1% (w/v) tryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast
extract, pH 7.4) supplemented as required with agar (1.5% (w/v)) and appropriate
antibiotics (100 µg/mL ampicillin or 50 µg/mL kanamycin sulfate). All cultures were
grown at 37°C, with shaking of liquid media. E. coli DH5α was used for all cloning and
plasmid DNA glycerol stocks, while E. coli BL21(DE3) was used for protein
expression.
2.2.3.1 Transformation of E. coli with plasmid DNA

Chemically competent E. coli stocks for transformation were prepared by inoculating a
5 mL non-selective starter culture of LB with a single colony of either BL21 or DH5α
from a streaked non-selective LB agar plate. The culture was grown overnight, then
used to inoculate 100 mL of LB, and grown to an optical density at 600 nm (OD600) of
approximately 0.6, determined using an Ultraspec 10 cell density meter (GE
Healthcare). Cells were then centrifuged (5 000 × g, 5 min, RT), resuspended in 10 mL
ice-cold CaCl2 (100 mM), and incubated on ice for 30 min. Cells were then centrifuged
(4 000 × g, 5 min, 2°C), and resuspended in ice-cold CaCl2 (100 mM), containing
glycerol (15% (v/v)). Competent cells were then aliquoted into pre-chilled tubes, snapfrozen in liquid nitrogen, and stored at -80°C until use.
Transformations were performed by adding approximately 100 ng of plasmid DNA to
100 µL of competent BL21 or DH5α E. coli cells and incubating on ice for 30 min.
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Cells were then heat shocked at 42°C for 30 s, then placed on ice before adding 700 µL
of non-selective resuscitating media. LB was used for prepared plasmid DNA, and
super optimal broth with catabolite repression (SOC) media (LB containing KCl (2.5
mM), MgCl2 (10 mM), MgSO4 (10 mM) and glucose (20 mM)) was used for ligations.
Transformed cells were then grown for 1 h (37°C with shaking), spread onto prewarmed selective LB agar, and grown overnight.
2.2.3.2 Plasmid DNA preparation and storage

For transformations and/or cloning plasmid minipreps were performed with the
QIAprep Spin Miniprep Kit (Qiagen, Hilden, Germany). For transfections, either the
QIAGEN Plasmid Midi Kit (Qiagen) or PureYield Plasmid Midiprep System (Promega,
Madison, WI, USA) were used. Polymerase chain reaction (PCR) or gel cleanups were
performed using the Isolate II PCR and Gel Kit (Bioline).
E. coli DH5α stocks were created for all plasmid constructs for long term storage, and
E. coli BL21 stocks were created for all bacterial expression plasmid constructs.
Constructs were transformed into E. coli DH5α and grown overnight on agar. These
were then streaked onto fresh agar and grown overnight. Single colonies were then used
to inoculate an overnight LB culture, which was then mixed with sterile glycerol at a
1:1 ratio and stored at -80°C.
2.2.3.3 Expression of recombinant proteins

Recombinant proteins were overexpressed in E. coli BL21(DE3) containing the
appropriate vector for each protein. Glycerol stocks were streaked onto LB agar plates
supplemented with appropriate antibiotics and grown overnight at 37°C. Single colonies
from these plates were then streaked onto new plates and again grown overnight. A
single colony was then used to inoculate a 100 mL LB-glucose (LB supplemented with
glucose (55.5 mM) to supress leaky expression in the pET plasmid system (Novy and
Morris, 2001)) overnight starter culture. The starter culture was then split into 1 L flasks
of LB-glucose and grown to an OD600 of approximately 0.6. Protein overexpression was
then induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG; 250 μM),
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and the culture incubated for a further 4 h. Samples of culture were taken before and
after addition of IPTG and analysed by SDS-PAGE to confirm protein expression.
2.2.4

Aggregation assays to determine the relative chaperone activity of Hsp27
isoforms

The relative chaperone ability of Hsp27WT and the disease-related mutant isoforms was
assessed using in vitro aggregation assays, in which the target proteins underwent
reduction or heat-induced amorphous aggregation, or amyloid-like fibrillar aggregation.
The aggregation of target proteins was spectroscopically monitored using the increase in
light scatter (at 340 - 360 nm; amorphous aggregation) or the increase in ThT
fluorescence (ex/em: 440/490 nm; fibrillar aggregation) using either a FLUOstar
OPTIMA or Polarstar OPTIMA plate reader (BMG Lab Technologies) at 37°C (unless
otherwise stated). Assays were performed in duplicate in 384-well clear polystyrene Fbottom microplates (Greiner Bio One), with each well containing a total of 30 µL of
sample. Plates were sealed with sealing film. Assays were performed under both
reducing and non-reducing conditions, by the inclusion (or not) of 20 mM dithiothreitol
(DTT). Negative protein controls (i.e. non-chaperone proteins, as specified) were used
at concentrations equivalent to the highest chaperone concentration for each assay, and
each Hsp27 isoform was also monitored at the highest tested concentration in the
absence of the target protein to ensure no aggregation of the chaperone. After addition
of reagents, plates were centrifuged to remove any air-bubbles (20 000 × g, 5 min, 4°C)
before measurements. All assays were repeated at least three times (as indicated).
At the end of each assay, traces representing absorbance or ThT fluorescence were fit to
a plateau followed by one phase association model (with the exception of α-syn, which
was fit using the one phase association model which does not define a lag phase) using
GraphPad (GraphPad Software, La Jolla CA, USA), such that the lag phase and overall
increase in aggregation were determined using the resulting X0, Y0 and plateau values
(Figure 2.1). In cases where the data did not fit the model well (i.e. 95% confidence
intervals were very wide for the data, and dependency of the parameter was ≥ 0.99 as
defined by GraphPad), these parameters were not used. This generally occurred when
there was no significant increase in fluorescence (i.e. aggregation was inhibited, and
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there was no Y0 or plateau), and as such X0 was deemed to be greater than the time
limit of the assay. In these cases the plateau value was replaced with the end-point
fluorescence or absorbance value (taken as the average of the last five data points in a
given sample). The lag phase is defined by X0, and the difference in the length of the
lag phase between the aggregating protein (client) alone and in the presence of
chaperone is defined by:
∆𝐿𝐿𝐿𝐿𝐿𝐿 = 𝑋𝑋0𝐶𝐶ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − 𝑋𝑋0𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶𝐶

As such, if the lag phase was increased in the presence of a chaperone, ∆Lag is a
positive value, if there was no change ∆Lag is equal to zero, and if the lag phase was
decreased, ∆Lag is a negative value. The overall change in light scatter or fluorescence
was also calculated for each individual sample such that:
∆𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 − 𝑌𝑌0

and the difference in aggregation between the target sample and the target in presence of
Hsp27 was defined by:
∆𝐴𝐴𝐴𝐴𝐴𝐴 = ∆𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐶𝐶ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − ∆𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇

As such, if the Hsp27 inhibited aggregation of the target protein, then ∆Agg is a
negative value; if ∆Agg is a positive value, this indicates that the presence of the Hsp27
lead to an increase in aggregation. Note that in the example given here, fluorescence is
used as the indicator of aggregation, but the same parameters were also applied in cases
where absorbance was used to track amorphous aggregation, with the substitution of
∆Fluo with ∆Abs.
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Figure 2.1: An illustration of the curve-fitting and parameters used to analyse the
chaperone activity of Hsp27WT and the disease-causing mutant isoforms. Data from each
sample was fitted with a plateau followed by one-phase association curve using GraphPad. The resulting
Y0, X0 and plateau values were used to define the starting fluorescence, end of the lag phase, and endpoint fluorescence increase for each sample. Note that ThT fluorescence is used here, but the same
parameters were also applied in cases where absorbance was used to monitor aggregation.

Methods specific to individual aggregation assays are described in the relevant chapters.
2.2.5

Mammalian cell culture

All cell lines were routinely tested for mycoplasma, and the genetic identity of each cell
line was confirmed by STR profiling. Human-derived neuroblastoma-like SH-SY5Y
(American Type Culture Collection, Manassas, VA, USA), mouse-derived motor
neuron-like NSC-34 cells (kindly donated by Dr. Justin Yerbury (University of
Wollongong, Australia)), and human-derived HeLa cells (kindly donated by Prof. Mark
Wilson, University of Wollongong, Australia) were each cultured in 10% media
(Dulbecco’s modified eagle medium with nutrient mixture F-12 (DMEM-F12;
Invitrogen, Carlsbad, CA, USA), containing 2 mM glutathione (Invitrogen), and 10%
(v/v) Gibco heat-inactivated foetal bovine serum (Thermo-Fisher Scientific)). Cells
were incubated in sterile Corning® cell culture flasks (Sigma-Aldrich) at 37°C in 95%
humidified atmosphere containing 5% (v/v) CO2 and were passaged every two to four
days when cell confluence reached 70 – 80%. SH-SY5Y and NSC-34 cells were lifted
for passage using 0.05% trypsin-EDTA (Invitrogen), while HeLa cells were lifted using
a cell scraper. All cells were washed with 1% (v/v) foetal bovine serum (FBS) DMEMF12 before being transferred into a new flask, with fresh media. Where appropriate,
cells were lifted and counted using a haemocytometer to determine their concentration
prior to seeding into Greiner CELLSTAR® 96, 24 or 6-well flat-bottom plates (Greiner
Bio One), or Ibidi 8-well µ-slides (Ibidi, Martinsried, Germany).
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2.2.5.1 Transfections

Plasmid DNA for transfections was purified from E. coli DH5α (containing the plasmid
of interest) by midiprep (as per the manufacturer’s instructions) under sterile conditions.
The concentration of DNA was determined using the absorbance at 260 nm, and purity
of DNA as the 260/280 nm absorbance ratio using the Nanodrop spectrophotometer.
DNA yields of ≥ 200 ng/μL with 260/280 ratios of ~ 1.8 were considered pure and used
for transfections. As SH-SY5Y and NSC-34 cells are difficult to transfect, routine
transfections were performed using the Lipofectamine 3000 System (Thermo-Fisher
Scientific), with a ratio of 1.5 µL Lipofectamine 3000 and 2 µL P3000 reagent per 1 µg
of plasmid DNA, with 1 µg DNA per mL of cell culture volume (ratios optimised as per
the manufacturer’s instructions). All transfection components were prepared in serum
free DMEM-F12, and added drop-wise, to cells, plated 24 h prior, in fresh 10% (v/v)
FBS DMEM-F12. Transfected cells were then incubated at 37°C for 48 h prior to
treatment or analysis unless otherwise stated.
2.2.5.2 Differentiation

Plates were pre-coated with MaxGel™ Human ECM Mixture (Sigma-Aldrich), diluted
1:100 in SFM, as per the manufacturer’s “Thin-coat plating method”. SH-SY5Y or
NSC-34 cells were then seeded into plates (either coated 96-well plates or 8-well µslides) at low confluency (5 000 cells/cm2 growth area) to promote differentiation and
allow analyses of single cells and their outgrowths. After 16 h, the media was replaced
with 1% (v/v) FBS DMEM-F12 supplemented with 10 µM retinoic acid. Cells were
then incubated for 2 – 7 days (as specified in relevant sections), with fresh media and
retinoic acid added every 48 h by half-volume media changes (to preserve delicate cell
morphology).
2.2.5.3 Microscopy

Various fluorophore-conjugated antibodies, fluorescent stains, and fluorescent proteins
were used throughout this study (Table 2.1). Successful transfections or staining was
confirmed by epifluorescence on a Leica DMi8 fluorescence microscope run via Leica
Application Suite (LAS)-X software, (Leica Microsystems, Wetzlar, Germany). Images
were collected either by confocal microscopy using either a Leica TCS SP5 confocal
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microscope, controlled by the Leica Application Suite – Advanced Fluorescence (LASAF) software (Version 3), or a Leica TCS SP8 confocal microscope controlled by LASX, or by epifluorescence using an Incucyte Zoom System (Essen BioScience, Ann
Arbor, MI, USA). To minimise any bleed-through where fluorophores produced
spectral overlap, all confocal microscopy images were acquired using sequential
scanning between frames, with detectors set to eliminate spectral overlap between
fluorophores (Table 2.1). Confocal microscope scan speed was set to 400 Hz, and image
resolution was set to 1024 × 1024 px unless otherwise stated, and laser power was kept
constant for all samples within each independent experiment, and never exceeded 25%
intensity.
2.2.6

Image analysis

Image analyses was performed using either the Fiji bundled distribution of ImageJ
(Schindelin et al., 2012), CellProfiler 3.0 Open-Source software (Carpenter et al.,
2006), or IncuCyte Zoom Image Analysis Software (Essen Bioscience) as stated in the
relevant sections.
Table 2.3: Fluorophores and microscope settings used in this study
Fluorophore
tGFP

Ex/Em
(nm)
482/502

Dylight 488
DyLight 550
Dylight 650

493/518
562/576
654/673

DAPI
MitoTracker™ Red CMXRos

358/461
579/599

Microscope
SP5
Incucyte
DMi8
SP8
SP5
SP5
SP8
SP8
SP5
SP8

Excitation
laser (nm)
Argon 488
488
561
633
638
405
552
552

Detector
range
499 - 536
495 - 540
610 - 644
655 - 699
650 - 700
410 - 480
565 - 611
560 - 624

Filter cube
Green
FITC
-

2.3 Data analysis
Unless otherwise stated, all curve-fitting and statistical data analysis was performed
using GraphPad Prism V. 5 for Windows. Specific analyses are stated where relevant.
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3 Purification and characterisation of recombinant Hsp27
disease-causing mutants
3.1

Introduction

Hsp27 is one of the most studied of the human sHsps, yet our understanding of the roles
and interactions of Hsp27 is complicated by its ubiquitous distribution, and interactions
with diverse molecular pathways such as proteostasis, apoptosis, cytoskeletal
maintenance and oxidative stress mitigation. The discovery of disease-causing
mutations in Hsp27 provides an opportunity both to clarify the functions and molecular
mechanisms of Hsp27, and to elucidate the molecular mechanisms underlying disease
pathology in patients with Hsp27 mutations. To date, over 30 disease-causing mutations
in Hsp27 have been reported (see section 1.4), but our understanding of the molecular
mechanisms underlying disease is complicated by the dynamic nature of the protein,
and a lack of understanding of the exact mechanisms underlying the structure and
function of Hsp27. Disease-associated mutations occur in each structural domain of
Hsp27, and may affect its oligomeric state, its rate of subunit exchange, and its
interactions with aggregation-prone client proteins. An understanding of how mutations
in different regions of the protein affect its structure and chaperone function would
provide perspective as to the molecular mechanisms that underly Hsp27 mutationcaused disease pathogenesis.
3.1.1

Aims

The aims of the work described in this chapter were:
1. to produce a set of purified, recombinant Hsp27 isoforms that includes wild type
and disease-associated mutant forms that encompass each structural domain of
the protein, and/or are in or adjacent to motifs known to be important for Hsp27
function,
2. to establish the oligomeric states and subunit exchange behaviours of these
Hsp27 isoforms using SEC and bulk FRET, respectively, and
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3. to analyse the chaperone activity of these Hsp27 isoforms against the
aggregation of two model client proteins, α-lactalbumin (α-lac) and citrate
synthase (CS).

3.2 Materials and methods
3.2.1

Plasmid constructs

The pET3a(+)-Hsp27WT plasmid construct for the inducible expression of recombinant
Hsp27WT (HSPB1; GenBank BT019888.1), consisted of the protein-coding sequence
inserted into the BamHI and NdeI restriction sites of pET3a(+). The disease-related
mutant isoforms (Hsp27P39L, Hsp27G84R, Hsp27R127W, Hsp27S135F, Hsp27R136W,
Hsp27R140G, Hsp27T151I, Hsp27P182L and Hsp27P182S), and a cysteine-free Hsp27
(Hsp27C137S) isoform were synthesised by site-directed mutagenesis of the pET3a(+)Hsp27WT plasmid by GenScript (Piscataway, NJ, USA) to produce plasmids referred to
hereafter as pET3a(+)-Hsp27X, where “X” refers to the specific isoform of Hsp27.
3.2.2

Extraction and purification of Hsp27WT and the disease-causing mutant
isoforms

3.2.2.1 Extraction

Recombinant Hsp27 proteins expressed in E. coli (2.2.3.2) were extracted as previously
described (Horwitz et al., 1998), with minor modifications. Briefly, cell pellets were
resuspended in 18 mL of ice-cold lysis buffer (50 mM Tris-base, 100 mM NaCl, 1 ×
Roche cOmplete™ Protease Inhibitor Cocktail (Sigma-Aldrich), 17.5 μM lysozyme, pH
8.0). After 20 min incubation on ice with gentle agitation, deoxycholic acid was added
(to 3.4 mM final concentration) and the mixture incubated at 37°C for 30 min with
shaking, before being placed on ice. Deoxyribonuclease I (DNaseI; to 210 nM final
concentration) was added, and the mixture was incubated for 20 min on ice, with
rocking, before centrifugation (10 min, maximum speed, swinging bucket rotor, 4°C).
The soluble fraction was collected and subjected to high speed centrifugation (30 min,
100 000 × g, 4°C) then the supernatant collected, and DTT (10 mM), polyethylenimine
(PEI; 0.25% (w/v)), and ethylenediaminetetraacetic acid (EDTA; to 1.5 mM final
concentration) added and the sample stirred for 20 min at RT. The mixture was then
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centrifuged (30 min, 100 000 × g, 4°C), and the supernatant collected for subsequent
purification.
3.2.2.2 Purification

Extracted proteins were purified via anion exchange chromatography and subsequent
size exclusion chromatography (SEC). Where necessary, an additional ion-exchange
chromatography clean-up step was added. All chromatography was performed using an
AKTA Prime Plus FPLC (GE Healthcare) with an in-line UV detector to monitor the
elution of proteins at 280 nm.
3.2.2.2.1

Purification step 1: Anion exchange chromatography

Anion exchange chromatography was performed using a HiPrep DEAE FF 16/10
column (GE Healthcare) pre-equilibrated with buffer A (20 mM Tris-HCl, 1 mM
EDTA, 3 mM sodium azide (NaN3), pH 8.5) before loading 5 mL aliquots of protein
extract. Protein was eluted at a flow rate of 1 mL/min by manually increasing the NaCl
concentration from 0 to 250 mM in 40 mM steps while monitoring elution. Elution was
performed manually as each different mutation resulted in changes to the elution profile
due to changes to the isoelectric point. Fractions were collected and analysed by SDSPAGE, and those determined to contain Hsp27 were pooled and concentrated using an
Amicon Stirred Cell with a 10 kDa molecular weight cut-off membrane (Merck,
Burlington, MA, USA).
3.2.2.2.2

Purification step 2: SEC

Hsp27 isoforms were further purified by SEC, performed using a Hiprep 26/60
Sephacryl S-300 High Resolution column (GE Healthcare) following a method adapted
from Horwitz et al. (1998). The column was equilibrated with 50 mM PB (pH 7.4)
containing 3 mM NaN3, before 2 – 5 mL aliquots of protein concentrate were loaded
onto the column. Protein was eluted in PB at a flow rate of 1 mL/min and collected in
10 mL fractions. Eluted samples were analysed by SDS-PAGE and those containing
pure Hsp27 were pooled, concentrated, and the resulting protein aliquots were stored at
-80°C.
3.2.2.2.3

Purification step 3: Anion exchange clean-up

The disease-associated Hsp27G84R mutant isoform was not sufficiently pure following
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SEC, so was further purified using a HiScreen™ Capto™ Q ImpRes anion exchange
column (GE Healthcare) pre-equilibrated with ion-exchange buffer A. Samples were
eluted with a gradient from 0 to 60 mM NaCl over 50 mL (10 column volumes) using
buffer A supplemented with 2M NaCl at a maximum flow rate of 1 mL/min. Fractions
containing protein were collected, analysed by SDS-PAGE, and those containing
purified Hsp27G84R were pooled, dialysed into PB to remove excess NaCl, concentrated,
and aliquots were stored at -80°C.
3.2.2.2.4

Protein determination of Hsp27 isoforms

The concentration of each Hsp27X aliquot was determined by BCA assay (as some
isoforms carried mutations that either introduced or deleted aromatic residues that affect
A280) after thawing and centrifugation (20 000 × g, 4°C), as the Hsp27G84R and
Hsp27R140G isoforms were found to precipitate during storage. Freeze-thawing was
therefore avoided, and aliquots were used within 48 h of thawing.
3.2.3

Analytical SEC

To establish the oligomeric state of recombinant Hsp27WT, and the disease-associated
mutants, 200 μL of purified protein (at 10 and 45 μM) was subjected to analytical size
exclusion chromatography using a Superdex 200 10/300 GL (GE Healthcare), preequilibrated with 50 mM PB containing 100 mM NaCl, pH 7.4. Samples were run at 0.5
mL/min and protein elution was monitored using an in-line UV-detector. The column
was calibrated with standards from Bio-Rad (Hercules, CA, USA) that included bovine
thyroglobulin (670 kDa), bovine γ-globulin (158 kDa), chicken ovalbumin (44 kDa) and
horse myoglobin (17 kDa). A calibration curve generated from the Log10(MW) and
elution volumes of standards was used to calculate the molecular mass of the
recombinant Hsp27 samples.
3.2.4

FRET analysis of subunit exchange between Hsp27WT and mutant isoforms

Bulk FRET was used to determine the relative amount of subunit exchange between
Hsp27WT (488-labelled) and the disease-associated mutant isoforms or Hsp27C137S (647
labelled) as described in section 2.2.1.3.3.
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3.2.5

Aggregation assays to determine the relative chaperone ability of diseasecausing mutant isoforms of Hsp27

Aggregation assays were carried out as described in section 2.2.4. Specific details of the
assays presented in this chapter are outlined below.
3.2.5.1 Heat-induced amorphous aggregation assays
3.2.5.1.1

CS

The amorphous aggregation of CS (15 µM) was performed in PBS, pH 7.4, at 42°C.
Hsp27WT or the mutant isoforms were added at molar ratios of 0.25:1 and 0.5:1
(CS:Hsp27X) and recombinant SOD1 was used as a negative control. Aggregation was
monitored for 4 h.
3.2.5.2 Reduction-induced amorphous aggregation assays
3.2.5.2.1

α-Lac

The reduction-induced aggregation of α-lac (100 μM) was performed in 50 mM PB
containing 5 mM EDTA and 100 mM NaCl, pH 7.0. The Hsp27WT or mutant isoforms
were added at molar ratios between 2:1 and 32:1 (α-lac:Hsp27X), and CPK was used as
a negative control at 2:1 (α-lac:CPK). Aggregation was initiated by addition of 20 mM
DTT and monitored every three min for ~21 h.

3.3 Results
3.3.1

Expression and purification of recombinant Hsp27 isoforms

Eleven isoforms of Hsp27, including Hsp27WT, were chosen for expression, purification
and structure-function analysis. These included an isoform with the cysteine replaced
by a serine (to disable disulfide bond formation; Hsp27C137S), two CMT-causing
mutations in the N-terminal domain (Hsp27P39L, Hsp27G84R), one CMT and dHMNcausing mutation in the αCD β5 strand (Hsp27R127W), three disease-causing mutations in
the αCD β6/7 strand (Hsp27S135F (CMT and dHMN), Hsp27R136W (CMT), Hsp27R140G
(CMT and dHMN)), one CMT and dHMN-causing mutation in the αCD β7 – β8 strand
junction (Hsp27T151I), and two dHMN-causing mutations in the IXI/V motif of the Cterminal region (Hsp27P182L and Hsp27P182S). Each of these isoforms was successfully
expressed in E. coli, as indicated by a high density band at ~25 kDa by SDS-PAGE in
each of the induced samples compared to non-induced (e.g. Hsp27WT; Figure 3.1).
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However, upon protein extraction for purification, it was evident that the P182L and
P182S isoforms were not extracted as soluble protein. Test expressions at 20 and 24°C
were performed, but no soluble Hsp27P182L/P182S proteins could be extracted under either
condition (Figure 3.1). SDS-PAGE analysis of extracts indicated that the majority of
Hsp27P182L/S was present in the insoluble fraction after cell lysis (Figure 3.1, lane i1),
such that the final soluble protein extract contained no Hsp27 detectable by SDS-PAGE
(Figure 3.1). Therefore, further purification of these isoforms was not pursued.

Figure 3.1: Recombinant Hsp27 isoforms are highly expressed in IPTG-induced E. coli
cells transformed with Hsp27 expression constructs. SDS-PAGE analysis of total protein from E.
coli transformed with the expression construct for Hsp27WT or Hsp27P182S: non-induced (NI) and IPTGinduced (I). Hsp27WT was expressed at 37°C, while Hsp27P182S was expressed at 20°C. E. coli expressing
Hsp27P182S was extracted as described (3.2.2.1), and samples of the soluble fractions (s1, s2, s3) were
taken after each of the three centrifugation steps, and the insoluble pellets (i1, i2, i3) were resuspended in
8 M guanidinium-HCl (volume equal to the removed supernatant) to solubilise the protein. Equal volumes
of each soluble (s) and insoluble (i) fraction were loaded onto the gel. The mass of molecular markers is
shown on the left.

Initial purification of the Hsp27 isoforms by anion exchange chromatography resulted
in varied elution profiles in relation to the NaCl concentration at which the protein
eluted from the column. Hsp27WT eluted between 0.15 and 0.18 M NaCl, with the main
peak eluting at approximately 0.16 M; Hsp27P39L eluted between ~0.14 and 0.35 M with
a peak at 0.18 M; Hsp27R127W eluted between 0.19 and 0.26 M with a peak at 0.22 M;
Hsp27S135F eluted between 0.16 and 0.26 M with a peak at 0.19 M, Hsp27R136W eluted in
a narrow peak between 0.19 and 0.2 M; Hsp27R140G eluted between 0.22 and 0.40 M,
with peaks at 0.22 and 0.32 M; Hsp27T151I eluted between 0.17 and 0.26 M with a peak
at 0.19 M; Hsp27C137S eluted between 0.05 and 0.08 M; Hsp27G84R eluted across most of
the salt steps, so purity after the initial anion exchange step was low (Figure 3.2).
The wide elution profile of the Hsp27G84R isoform eluting from the anion exchange
column (Figure 3.2A, C) resulted in a high amount of contaminating protein, much of
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which remained after SEC (Figure 3.2B, D). Hence, this isoform was further purified by
cation exchange chromatography (Figure 3.2E, F), which substantially increased the
purity of the sample. Following purification, each preparation of recombinant Hsp27
protein showed very high purity (>93% when analysed by SDS-PAGE, Figure 3.3,
Table 3.1). Yields for each isoform were high (> 10 mg/L expression culture), except
for the Hsp27G84R and Hsp27R140G isoforms. The lower yield for Hsp27G84R is explained
by protein loss during purification, including the extra purification step (Figure 3.2),
while some Hsp27R140G was lost due to precipitation throughout the purification process.
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Figure 3.2: Purification of Hsp27G84R. A: DEAE anion-exchange A280 chromatogram (

) of
protein extracts from E. coli expressing Hsp27G84R. Extract was diluted in equilibration buffer, loaded
onto the column and eluted by manually increasing NaCl concentration (
) in steps as peaks
(numbered) eluted. Conductivity (mS/cm) is shown (
, on the right y-axis). B: HiPrep 26/60 Sephacryl
) of Hsp27G84R.
S-300 High Resolution column (S300) size exclusion purification A280 chromatogram (
Concentrated protein samples from the DEAE purification were loaded onto the column (pre-equilibrated
with 50 mM PB) and eluted in the same buffer. Peaks analysed by SDS-PAGE are numbered. C: SDSPAGE analysis of the DEAE-eluted fractions shown in A. The original protein extract (load sample) is
shown (L), numbers (above) correspond to the peak numbers shown in A, and the positions of molecular
weight (kDa) markers are shown to the left. Samples containing Hsp27 (peaks 1 – 3) were pooled,
concentrated and further purified by SEC. D: SDS-PAGE analysis of Hsp27G84R S300 fractions shown in
B. The original pooled DEAE-Hsp27 (from C; load sample) is shown (L), numbers (above) correspond to
the peak numbers shown in B, and the positions of molecular weight (kDa) markers are shown to the left.
) of Hsp27G84R. Protein eluted from the
E: Capto-Q anion-exchange clean-up A280 chromatogram (
S300 SEC was loaded onto the column and eluted by a gradient increase in NaCl concentration (
).
Conductivity (mS/cm) is shown
(
, on the right y-axis). F: SDS-PAGE analysis of the eluted
Capto-Q fractions. A sample of the original concentrated S300 protein (from D; load sample) is shown
(L), numbers (above) correspond to the peak numbers shown in E, the positions of molecular weight
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(kDa) markers are shown to the left, and the box indicates the collected purified sample.

Figure 3.3: Hsp27WT, the disease associated mutant isoforms, and Hsp27C137S were
successfully purified. SDS-PAGE analysis of final purified samples (0.5 mg/mL) of each Hsp27
isoform (as indicated). Units on the left indicate molecular weight (kDa).

Table 3.1: Hsp27 expression and purification purity and yield for each isoform. Final purity
was calculated by densitometry of the gel shown in Figure 3.3, and typical yield was calculated per L of
original induced expression culture.

3.3.2

Final purity (%)

Yield (mg/L culture)

WT

98.3

14.32

P39L

94.2

22.11

G84R

95.4

7.90

R127W

93.1

19.38

S135F

94.6

29.85

R136W

97.3

31.81

R140G

93.8

5.12

T151I

99.8

41.69

C137S

98.2

11.63

Disease-causing mutations in Hsp27 alter its oligomeric state and capacity
for subunit exchange in solution

3.3.2.1 The oligomeric size of Hsp27 disease mutant isoforms

Each of the Hsp27 isoforms was analysed by SEC to determine the size and
polydispersity of the oligomeric complexes formed by each of the proteins (Figure 3.4).
When analysed at a concentration of 45 µM, Hsp27WT eluted as a broad peak, with an
average molecular weight of 588 kDa, and a tail with an average molecular weight of 71
kDa (Figure 3.4, Table 3.2). At 45 µM all but one mutation (Hsp27T151I) resulted in an
apparent increase in the size of the larger oligomers compared to Hsp27WT, indicated by
a decrease in the elution volume of the first peak (Figure 3.4). A second peak eluting at
~14 mL was also evident for the Hsp27R140G, Hsp27T151I, Hsp27S135F, and Hsp27G84R
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isoforms, indicating the presence of smaller oligomers (Figure 3.4). Hsp27WT
displayed a concentration-dependent dissociation of oligomers when analysed at 10 µM,
with the appearance of a distinct peak corresponding to an average molecular weight of
64.4 kDa, while the average size of the peak corresponding to larger oligomers shifted
to 399 kDa (Figure 3.4, Table 3.2). When the protein was analysed at a lower
concentration (10 µM), dissociation of larger oligomers to form dimers and trimers
occurred for each isoform, with Hsp27G84R, Hsp27S135F, Hsp27R140G and Hsp27T151I
predominantly existing as smaller complexes (Figure 3.4, Table 3.2).

Figure 3.4: Disease-causing mutations alter the oligomeric size and distribution of Hsp27.
Each of the purified recombinant Hsp27 isoforms was analysed by SEC at 45 µM (left) and 10 µM (right)
to determine oligomeric size and distribution. Protein (200 µL) was loaded onto an S200 column, and
eluted in PBS, pH 7.4 at a flow rate of 1 mL/min. Resulting A280 chromatograms (normalised to the
highest A280 value) are shown. Dotted lines indicate the elution volumes of molecular weight standards
(670, 158, 44, and 17 kDa, as indicated above).
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Table 3.2: Oligomeric size distributions of Hsp27WT and disease-associated mutations.The
molecular weights of protein peaks were calculated using the elution profiles of Hsp27 isoforms and a
standard curve constructed from the elution volumes of molecular weight standards.*indicates a
molecular weight inferred outside of the exclusion limit of the S200 column used, **indicates a molecular
weight inferred outside of the size standards used.
45 µM

10 µM

Small oligomers
(kDa)

Large oligomers
(kDa)

Small oligomers
(kDa)

Large oligomers
(kDa)

WT

71.0

588

64.4

399.0

P39L

61.9

1052.846**

55.1

1073.3**

G84R

66.9

742.1**

61.9

423.0

R127W

56.2

1278.0*

61.9

936.8**

S135F

73.7

700.5**

60.8

399.0

R136W

61.9

1841.4*

56.2

757.0**

R140G

65.6

786.8**

60.8

-

T151I

61.9

335.1

65.6

-

3.3.2.2 Subunit exchange of Hsp27 disease mutant isoforms with Hsp27WT

To determine whether disease-causing mutations in Hsp27 affect subunit exchange,
bulk FRET was used to determine the rate of exchange between Hsp27WT and each of
the mutant isoforms (Figure 3.5). The SOD1 negative control showed no subunit
exchange with Hsp27WT (Figure 3.5). Results indicate that each of the mutants is
capable of exchange with Hsp27WT. Interestingly, each mutant has a slower exchange
rate with Hsp27WT oligomers than Hsp27WT has with itself; however, there are no
statistically significant differences between the samples as a result of the high variance
in the WT samples (Figure 3.5B).
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Figure 3.5. FRET analysis of Hsp27 subunit exchange. Mutations in Hsp27 affect subunit
exchange. Bulk FRET was used to analyse the subunit exchange between Hsp27WT (488-labelled) and
Hsp27WT, Hsp27P39L, Hsp27G84R, Hsp27R127W, Hsp27C137S , Hsp27S135F, Hsp27R136W, Hsp27R140G or
Hsp27T151I (647-labelled) at equimolar ratios (30 µM total concentration) in PBS. SOD1 (647-labelled)
with Hsp27WT was included as a negative control. F(t)/F(0) values obtained over a 30 min period for A:
), Hsp27G84R ( ), or Hsp27R127W (
), B: Hsp27WT and Hsp27C137S (
),
Hsp27WT and Hsp27P39L (
S135F
R136W
WT
R140G
(
), or Hsp27
( ), and C: Hsp27 and Hsp27
(
) or Hsp27T151I ( ). In A –
Hsp27
C the Hsp27WT/Hsp27WT ( ) and Hsp27WT/SOD1 ( ) traces are included.; smooth lines indicate a
one-phase association (exponential) curve fit. D: The subunit exchange rate constant (K) values obtained
from each curve. Data represent the mean of three independent biological replicates ±SEM, analysis by
one-way ANOVA indicated no significant statistical difference between samples.

3.3.2.3 Molecular chaperone activity of Hsp27 disease-causing mutants

To assess the effects of disease-associated mutations on the molecular chaperone
activity, each of the Hsp27 mutant isoforms was analysed against the aggregation of CS,
and α-lac, two models of protein aggregation widely used in assessing chaperone
activity. Incubation of CS at 42°C resulted in an increase in light scatter, indicative of
the formation of amorphous aggregates (Figure 3.6A). This increase in light scatter was
unchanged by the addition of the non-chaperone control protein, SOD1 (Figure 3.6A).
As expected, incubation of Hsp27WT or the disease-associated mutant isoforms in the
absence of CS did not result in any increase in light scatter. When CS was incubated in
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the presence of Hsp27WT the light scatter increased compared to when CS was
incubated alone (Figure 3.6A).
The change in light scatter for CS alone had a lag-phase of 0.32 ± 0.01 h. At a molar
ratio of 1:0.5 or 1:1 (Hsp27:CPK) the lag phase was increased by the addition of
Hsp27WT by 0.18 ± 0.18 h and 0.02 ± 0.01 h (respectively). The lag phases in the
presence of each of the Hsp27 isoforms were highly variable between the two molar
ratios tested, with no clear pattern. Interestingly, Hsp27R127W and Hsp27S135F
significantly (F(7, 24) = 5.949, p < 0.05) increased the lag-phase from that of CS alone
by 0.59 ± 0.14 h and 0.60 ± 0.17 h compared to Hsp27WT at the 1:1 (Hsp27:CS) molar
ratio (Figure 3.6B). None of the other mutant isoforms significantly changed the lag
phase in comparison to Hsp27WT, at either molar ratio (Figure 3.6B).
The overall aggregation of CS was increased in the presence of Hsp27WT, and
Hsp27T151I at both molar ratios, and in the presence of Hsp27R136W at a 1:0.5
(Hsp27:CS) molar ratio; however, the latter was due to high variability between
replicates (Figure 3.6C). At a 1:1 molar ratio, CS aggregation was significantly (F(7,
24) = 5.949, p < 0.0001) lower in the presence of Hsp27P39L, Hsp27R127W, Hsp27S135F,
Hsp27R136W and Hsp27R140G compared to Hsp27WT.
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Figure 3.6: Disease-causing mutations affect the chaperone activity of Hsp27 against the
heat-induced amorphous aggregation of CS. CS (30 µM) was incubated at 42°C in PBS, pH 7.4 in
the absence or presence of Hsp27 isoforms or the non-chaperone control protein SOD1. Formation of
amorphous aggregates was monitored by the change in light scatter over time at 340 nm. A: A
) or SOD1
representative trace of the aggregation of CS in the absence (
) or presence of Hsp27WT (
(
) at a 1:0.5 or 1:1 molar ratio of Hsp27/SOD1:CS, respectively. The negative control of Hsp27WT in
the absence of α-syn (
) is also shown. The overall change in the length of the lag phase (∆Lag; B) or
aggregation (∆Agg; C) between CS alone and CS in the presence of Hsp27WT ( ), Hsp27P39L ( ),
Hsp27G84R ( ), Hsp27R127W ( ), Hsp27S135F ( ), Hsp27R136W ( ), Hsp27R140G ( ) or Hsp27T151I ( ) at
molar ratios between 1:0.5 and 1:1 (Hsp27:CS) are shown. The red line represents the mean ± SEM
(shaded) complete inhibition of CS aggregation determined as ∆AggCS (equal to 0) - ∆FCS. Traces in A
show a representative replicate; error bars are ±SEM of duplicates. B and C show the means ± SEM of
four independent replicates, with individual data points overlayed. Statistically significant differences
determined by a one-way ANOVA followed by a Dunnett’s multiple comparison post-hoc test comparing
each isoform to Hsp27WT is indicated; *denotes p <0.05, *** denotes p < 0.0001.

Incubation of α-lac with DTT resulted in an increase in light scatter, indicative of the
formation of amorphous aggregates (Figure 3.6A). This increase in light scatter was
unchanged by the addition of the non-chaperone control protein, CPK (Figure 3.7A). As
expected, incubation of Hsp27WT or the disease-associated mutant isoforms in the
absence of α-lac did not result in any increase in light scatter. When α-lac was incubated
in the presence of Hsp27WT the light scatter decreased compared to when α-lac was
incubated alone (Figure 3.7A).
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The change in light scatter for α-lac alone had a lag phase of 0.60 ± 0.23 h under the
conditions of this assay (Figure 3.7A). At a 1:2 molar ratio (Hsp27: α-lac), Hsp27WT
increased this lag phase by 4.9 ± 0.85 h (Figure 3.7A). At molar ratios between 1:2 and
1:32 (Hsp27:α-lac) all isoforms increased the lag phase with the exception of
Hsp27R140G and Hsp27S135F (Figure 3.7B). At a molar ratio of 1:2 (Hsp27:α-lac), the
R127W (p < 0.05), R140G (p < 0.01) and T151I (p < 0.01) isoforms were significantly
less effective than Hsp27WT in increasing the lag phase (as determined by a one-way
ANOVA and Dunnett’s multiple comparisons test). Similarly at a molar ratio of 1:16
(Hsp27:α-lac), Hsp27R127W (p < 0.01) and Hsp27R140G (p < 0.001) were significantly less
effective in increasing the lag phase. The lag phases in presence of each of the Hsp27
isoforms showed a concentration dependent decrease (Figure 3.7A).
The overall aggregation of α-lac was decreased in the presence of all Hsp27 isoforms at
the highest molar ratio tested (1:2, Hsp27:α-lac). At a 1:2 molar ratio of Hsp27: α-lac,
Hsp27R140G was significantly less effective in decreasing the aggregation of α-lac than
Hsp27WT (p < 0.001). At molar ratios lower than 1:2 (Hsp27: α-lac), the Hsp27P39L and
Hsp27G84R isoforms did not inhibit the aggregation of α-lac, and both were significantly
less effective than Hsp27WT at a 1:4 molar ratio (p < 0.01 and 0.05, respectively). In
fact, the P39L and G84R isoforms promoted aggregation as demonstrated by the
increase in ∆Agg (Figure 3.7C). A similar trend was seen for Hsp27WT at molar ratios
lower than 1:16 (Hsp27:α-lac, Figure 3.7C).
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Figure 3.7: Disease-causing mutations affect the chaperone activity of Hsp27 against the
reduction-induced amorphous aggregation of α-lac. α-Lac (100 µM) was incubated at 37°C in 50
mM PB (supplemented with 5 mM EDTA, 100 mM NaCl, pH 7.4, with 20 mM DTT added to initiate
aggregation) in the absence or presence of the Hsp27 isoforms or the non-chaperone control protein
SOD1. Formation of amorphous aggregates was monitored by the change in light scatter over time at 340
nm. A: A representative trace of the aggregation of α-lac in the absence (
) or presence of Hsp27WT (
) or CPK ( ) at a 1:0.5 or 1:1 molar ratio of Hsp27/CPK: α-lac, respectively. The negative control
) is also shown. The overall change in the length of the lag phase
of Hsp27WT in the absence of α-syn (
(∆Lag; B) or aggregation (∆Agg; C) between α-lac alone and α-lac in the presence of Hsp27WT ( ),
Hsp27P39L ( ), Hsp27G84R ( ), Hsp27R127W ( ), Hsp27S135F ( ), Hsp27R136W ( ), Hsp27R140G ( ) or
Hsp27T151I ( ) at molar ratios between 1:2 and 1:32 (Hsp27: α-lac) are shown. The red line represents the
complete inhibition of α-lac aggregation determined as ∆Aggα-lac (equal to 0) - ∆Fα-lac ±SEM. Traces in A
and B show a representative replicate; error bars are ±SEM of duplicates. B and C show the means of
four independent replicates ±SEM, with individual data points overlayed. Statistically significant
differences determined by a one-way ANOVA followed by a Dunnett’s multiple comparison post-hoc test
comparing each isoform to Hsp27WT is indicated; *denotes p <0.05, *** denotes p < 0.0001.

3.4 Discussion
The molecular mechanism(s) underlying disease pathogenesis associated with Hsp27
mutations is unknown, but mutations are likely to affect the structure, oligomeric
distribution, and chaperone activity of the sHsp. Hence, a set of recombinant diseaseassociated isoforms of Hsp27 was generated, and the oligomeric distribution, ability to
undergo subunit exchange, and chaperone activity of each isoform was investigated.
The two mutations occurring at the P182 residue both resulted in an inability to obtain
soluble protein in the bacterial overexpression system used in this work; the protein
precipitated on expression and could not be extracted in its native state. P182 is the
central residue of the IXI/V motif in Hsp27 – a motif that is heavily involved in
interactions between Hsp27 subunits to form oligomers (Pasta et al., 2004, Alderson et
al., 2017, Alderson et al., 2019). Interestingly, the P182 disease-causing mutations
result in very early onset of disease in patients (see Chapter 1; Figure 1.3). Chalova et
al. (2014) found that overexpression of P182 mutants resulted in sequestration of the
protein into inclusion bodies, and resorted to urea denaturation with urea and
subsequent refolding of the protein to obtain a soluble fraction. It has been shown,
however, that urea-denatured and refolded chaperone proteins have altered structural
and functional characteristics. For example, Saha and Das (2007) compared the
structure and chaperone activity of bovine α-crystallin purified in its native state to
samples that had been urea-denatured and refolded. They found that the refolded protein
had a smaller oligomeric size, increased exposure of hydrophobic regions, and increased
74

Chapter 3

chaperone activity than non-denatured α-crystallin. Similarly, refolding of αA- and αBcrystallin following denaturation with urea is shown to result in loss of the dimeric
substructure of these proteins, and increased client protein affinity due to increased
exposure of hydrophobic surfaces (Aquilina et al., 2003, Benesch et al., 2008).
Furthermore, when stably expressed in human SH-SY5Y cells, the Hsp27P182L mutant
forms intracellular aggregates, disrupts cytoskeletal organisation and interferes with the
redox state of cells (Holmgren et al., 2013). Taken together, these results suggest that
mutations in the IXI/V motif of Hsp27 result in reduced solubility of the protein, which
may contribute to the early onset of disease associated with these mutations. Hence,
solubilisation and refolding of the insoluble P182L/S was not performed, and these
isoforms were excluded from further analyses.
The other nine Hsp27 mutant isoforms were readily expressed and purified using the
bacterial overexpression and purification procedures outlined previously (Horwitz et al.,
1998); however, the G84R mutation eluted across a broad range of NaCl concentrations
during DEAE anion-exchange chromatography. The G84R mutation results in the
largest shift in isoelectric point (pI) from 5.98 for Hsp27WT to 6.22 (theoretical pI values
calculated using the ExPasy ProtParam tool (Gasteiger et al., 2005)). Additionally, the
broad elution from the DEAE column may have resulted from altered interactions with
contaminating E. coli proteins present in the original extract. This was overcome, by
using an additional step of ion exchange chromatography purification which resulted in
a similar yield and level of purity to the other Hsp27 isoforms, as determined by SDSPAGE. Overall, this procedure resulted in recombinant proteins of high purity and
reasonable yields, which enabled their subsequent biophysical and biochemical
characterisation.
We have shown previously that the oligomeric size of Hsp27WT is concentration
dependent, and that at ~10 µM the oligomeric equilibrium shifts toward the formation
of small oligomers and dimers (Jovcevski et al., 2015). Interestingly, Hsp27G84R was the
mutation that altered the oligomeric distribution of the protein the least compared to the
other mutant isoforms. Hsp27G84R displayed a similar elution profile to Hsp27WT at 45
µM, and a similar level of dissociation into smaller oligomers on dilution to 10 µM. The
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Hsp27P39L, Hsp27R127W and Hsp27R136W isoforms were also similar to Hsp27WT in terms
of oligomeric distribution at high and low concentrations. However, each of these
mutations resulted in an overall shift towards larger oligomers at the higher
concentration, and a higher proportion of larger oligomers following dilution. These
results suggest a higher affinity between subunits of these isoforms than Hsp27WT alone.
In contrast, the Hsp27S135F, Hsp27R140G and Hsp27T151I mutations resulted in a shift to
smaller oligomers than Hsp27WT, with Hsp27S135F and Hsp27R140G having a distinct
population of smaller oligomers at the high concentration, along with a population of
larger oligomers.
Unlike any of the other isoforms, Hsp27T151I did not form distinct populations of larger
and smaller oligomers, instead eluting as one broad peak. This peak shifted towards a
smaller oligomeric size on dilution, but even then, no distinct “small” or “large”
populations were evident (although the maximum oligomeric size was decreased overall
in comparison to Hsp27WT). The Hsp27T151I mutation is close to the β4 – β8 groove with
which the IXI/V motif is known to interact to facilitate the formation of larger order
oligomers in the sHsps (Hilton et al., 2013). The unique shift in oligomeric size
distribution caused by the Hsp27T151I mutation may be indicative of a disruption to this
interaction site, which lowers the propensity of Hsp27 to associate into large oligomers.
The dynamic nature of oligomer formation and subunit exchange is characteristic of
Hsp27 and the other sHsps (Jakob et al., 1993, Bukach et al., 2009). Exchange of Hsp27
subunits can occur between multiple Hsp27 monomers and/or dimers, or between
Hsp27 and other sHsps, such as Hsp22 or αB-crystallin. The majority of the diseasecausing mutations in Hsp27 identified to date are inherited in an autosomal dominant
pattern, and thus exist in heterozygosity with Hsp27WT. Hence, the capacity of each of
the disease-causing isoforms to subunit exchange with Hsp27WT was analysed by bulk
FRET. Interestingly, while each of the mutants was capable of subunit exchange with
Hsp27WT, exchange was slower than between Hsp27WT homo-oligomers. The reduced
rate of subunit exchange is in accord with increased oligomer size for each of the
disease-mutants examined (with the exception of Hsp27T151I) since this too reflects an
increased affinity between subunits within large oligomers.
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This reduced rate of subunit exchange may also affect the ability of mutated Hsp27 to
undergo subunit exchange with other sHsps, as well as the ability to interact with client
proteins in the cell. Previous studies have suggested that an increased rate of subunit
exchange (e.g. due to heat shock at 40°C) also increases chaperone activity of the sHsps
through exposure of hydrophobic regions on release of subunits, and stabilisation of
client proteins upon re-incorporation into larger oligomers (Lelj-Garolla and Mauk,
2012). Indeed, Hsp27P39L and Hsp27G84R displayed the lowest rate of subunit exchange
with Hsp27WT, accompanied by the least efficient chaperone activity against the
aggregation of CS and α-lac. All of the Hsp27 isoforms examined were able to inhibit
the reduction-induced aggregation of α-lac in a concentration-dependent manner, with
activity increasing with concentration. However, there was no clear pattern in the ability
of the Hsp27 isoforms to inhibit the heat-induced aggregation of CS at the molar ratios
tested in this work. Taken together, these results suggest a correlation between the rate
of subunit exchange and chaperone activity, however they also highlight the variability
in activity observed in these in vitro aggregation assays.
Overall, these data show that mutations in the N-terminal region of Hsp27 both slow the
subunit-exchange of the sHsp and reduce its capacity to inhibit the stress-induced
aggregation of CS and α-lac. However, since it was found that the disease-associated
mutations have variable effects on the oligomeric distribution, subunit exchange and
chaperone activity of the sHsp, these results suggest that they may lead to disease
through distinct molecular mechanisms. Thus, further characterisation is required in
order to elucidate the mechanisms underlying disease pathology.

77

Chapter 4

Chapter 4: The influence of
disease-causing mutations and
disulfide interactions on the
structure and function of Hsp27

78

Chapter 4

4 The influence of disease-associated mutations and disulfide
interactions on the structure and function of Hsp27
4.1
4.1.1

Introduction
Hsp27 and the intracellular redox environment

The intracellular environment is highly sensitive to changes in the redox state. There are
three main redox-coupling systems (each consisting of a reduced and oxidised form)
that control the intracellular redox state: NADPH, thioredoxin (the reduction of which
also involves NADPH), and glutathione. Glutathione is the most abundant cellular nonprotein thiol, and is the most important of the redox-responsive couples, with
concentrations of its reduced and oxidised forms (GSH and GSSG respectively) directly
reflecting the overall redox state of a cell or cellular compartment (Hwang et al., 1992,
Schafer and Buettner, 2001). Glutathione concentration in the cytosol ranges between 1
– 11 mM (Hwang et al., 1992, Schafer and Buettner, 2001), but is generally higher in
the mitochondria and endoplasmic reticulum (Schafer and Buettner, 2001).
Various studies have described a cytoprotective effect of Hsp27 expression in cells
exposed to oxidative stress, and various interactions have been suggested which may
facilitate this protective action, including maintaining intracellular levels of GSH (Huot
et al., 1991, Mehlen et al., 1995, Huot et al., 1996, Wang et al., 1996, Mehlen et al.,
1997, Park et al., 1998, Préville et al., 1999, Baek et al., 2000; see section 1.3.2.2).
Thus far, however, the molecular mechanisms by which Hsp27 may act to mitigate
oxidative stress-induced damage remain to be established. It is known that Hsp27 can
form an intermolecular disulfide bond via C137 at the monomer-monomer interface of a
dimer in vitro (Baranova et al., 2011), and it has been suggested that Hsp27 acts as a
redox-sensor within the cell by way of this single cysteine residue (Alderson et al.,
2019b, Arrigo 2001). It is relatively rare however, for a cytosolic protein (such as
Hsp27) to exist in disulfide-bonded state, as under normal conditions, the GSH:GSSG
ratio in the cell favours reduction (Kosower and Kosower, 1978, Gilbert, 1990, Rietsch
and Beckwith, 1998, Cumming et al., 2004, Østergaard et al., 2004). Yet some cysteinecontaining proteins are more prone to oxidation of cysteine due to interactions of other
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neighbouring amino acids which alter the pKa value of the protein (Rietsch and
Beckwith, 1998). Thus it is possible that Hsp27 belongs to this relatively rare group of
redox-sensitive proteins, and that many of its suggested roles in mitigating oxidative
stress are via a cysteine/disulfide-related mechanism. Moreover, disease-causing
mutations in Hsp27 may alter the propensity of the protein to form disulfide-bonds (by
increasing or decreasing its propensity to become reduced), which would subsequently
affect its activity in response to changes in the intracellular redox state.
To date, it is yet to be established whether Hsp27 does in fact form disulfide-bonded
dimers in cells, or if this phenomenon is an artefact of the extraction of the protein from
the cell lysate. It has been previously reported that a population of disulfide-bonded
Hsp27 exists in CHO cells (Pasupuleti et al., 2010), however these results were obtained
using a cell lysis method that would not prevent the formation of dimers on extraction.
Similarly, Almeida-Souza et al. (2010) reported the presence of intracellular disulfidebonded Hsp27 dimer in SH-SY5Y cells, but the method used for extraction again did
not prevent oxidation after cell lysis.
In addition to the roles of Hsp27 in directly interacting with redox pathways, it is likely
that it also protects the cell against oxidative stress via its molecular chaperoning of
other proteins. Alterations to the secondary, tertiary and quaternary structure of Hsp27,
as well as exposed hydrophobicity and ionic interactions may affect its interactions with
other proteins (Das and Surewicz, 1995, Reddy et al., 2006). The oligomer size of
Hsp27 is known to affect its chaperone activity (Shashidharamurthy et al., 2005, Hayes
et al., 2009, Jovcevski et al., 2015), and it is likely that alterations to the disulfide bond
may affect oligomer formation, and hence chaperone activity.
Previous work on Hsp27 analysing the chaperone activity of various isoforms of the
protein have reported disparate findings. Some studies have concluded that the smaller
oligomers and dimers of Hsp27 that result from phosphorylation or phosphomimicking
of the protein are the chaperone-active form (e.g. against the amorphous aggregation of
insulin and BSA (Hayes et al., 2009, Jovcevski et al., 2015), the fibril formation of κcasein (Jovcevski et al., 2015), or the heat-induced aggregation of CS (Alderson et al.,
2019b). On the other hand, others suggest that the larger non-phosphorylated oligomers
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are the active species (e.g. against the thermal denaturation of CS (Rogalla et al., 1999),
or the reduction-induced aggregation of insulin (Lelj-Garolla and Mauk, 2005)).
Similarly, the disease-associated mutant isoforms of Hsp27 display varying chaperone
activity. Increased activity of the Hsp27 disease-causing mutant isoforms Hsp27R127W
and Hsp27S135F against the reduction-induced aggregation of insulin has been reported
(Weeks et al., 2018). Activity of Hsp27P182S and Hsp27R188W against the reductioninduced aggregation of lysozyme or heat-induced aggregation of subfragment S1 of
skeletal muscle myosin and malate dehydrogenase was decreased (Chalova et al.,
2014b), as was the activity of Hsp27G34R, Hsp27P39L, and Hsp27E41K against the
aggregation of lysozyme, malate dehydrogenase and insulin (Muranova et al., 2015),
and the activity of Hsp27R127W, Hsp27S135F, and Hsp27R136W against the aggregation of
the myosin S1 fragment and lysozyme. Furthermore, the chaperone activity of
Hsp27T164A and Hsp27T180I against the aggregation of lysozyme, subfragment S1 of
skeletal muscle myosin and malate dehydrogenase was no different to the wild type
protein (Chalova et al., 2014b).The chaperone activity of Hsp27WT is also affected by
the redox state, with its chaperone activity against either malate dehydrogenase or the
isolated S1 fragment of rabbit myosin decreasing slightly (although not statistically
significantly) with oxidation (Chalova et al., 2014a). Differences in these findings are
likely the result of various factors, including the client protein used to assess chaperone
activity, the concentration of chaperone and aggregating protein, and the buffer
conditions (such as pH, osmolality, and redox potential) under which activity was
determined.
Almeida-Souza et al. (2010) conducted chaperone assays using heat-shocked SH-SY5Y
cells stably expressing Hsp27 isoforms and luciferase, in which thermotolerance was the
reporter of chaperone activity. They found that expression of the Hsp27R127W or
Hsp27S135F mutants increased thermotolerance of the SH-SY5Y cells compared to
expression of Hsp27WT, while Hsp27P182L decreased thermotolerance, and Hsp27R136W
and Hsp27T151I had no effect. Taken together, these finding suggest that different
disease-causing mutations in Hsp27 may cause disease via various mechanisms, and
that differences in activity may depend on the specific mutation, their relative impact on
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the formation of disulfide-bonded dimers, as well as variations in the intracellular
environment in which they are expressed.
4.1.2

Aims

The specific aims of the work described in this chapter were to:
1. Establish the presence of the disulfide-bonded dimer of Hsp27 in cells.
2. Determine whether the proportion of disulfide-bonded dimeric Hsp27 varies
depending on the redox status of the cell.
3. Analyse the effect(s) of disease-causing mutations on the strength of the
disulfide bond in Hsp27 using purified recombinant forms of the proteins.
4. Assess the effect(s) of disease-causing mutation and redox-state on the structure
and chaperone function of Hsp27.

4.2 Materials and methods
4.2.1

Detection of intracellular disulfide-bonded Hsp27

It is known that in solution, Hsp27 forms disulfide-bonded dimers. To determine
whether these dimers also exist in the reducing intracellular environment, proteins were
extracted from HeLa, SH-SY5Y, and human fibroblast cells (the latter kindly donated
by Monique Bax, University of Wollongong, Australia). All steps were performed on
ice, centrifugations were conducted at 4°C, 20 min, at 24 400 × g, and reagents were
ice-cold. Cells were first lifted by scraping, washed twice in PBS, and resuspended in
1.8 mL PBS. Trichloroacetic acid (TCA) was immediately added to a final
concentration of 10% (v/v) to precipitate all cellular proteins, and samples were
incubated on ice for 20 min. Precipitated protein was collected by centrifugation, and
the supernatant discarded. Pellets were then washed in 10% (v/v) TCA in PBS,
centrifuged again, and washed in 5% (v/v) TCA in PBS, then centrifuged again. The
resulting protein pellet was then resuspended in denaturing buffer (6 M urea, 10 mM
EDTA, 0.5% (w/v) SDS, in 0.2 M Tris-HCl pH 8.5) containing 100 mM iodoacetamide
(IAM, added fresh) to block any free thiol groups and prevent their subsequent
82

Chapter 4

oxidation. Samples were then incubated on ice for 30 min. Extracts were then cleared by
centrifugation, and the protein-containing supernatant was collected. Total protein
concentration was determined by BCA assay and equal amounts of each sample were
separated by SDS-PAGE using Any kD™ Mini-PROTEAN® TGX Stain-Free Protein
Gels (Bio-Rad), both in the presence and absence of β-mercaptoethanol. Proteins were
then transferred onto PVDF membrane and analysed by immunoblotting using the
mouse monoclonal anti-Hsp27 antibody.
4.2.1.1 Altering intracellular levels of reduced and oxidised glutathione

Treatment of cells, including SH-SY5Y cells, with the advanced glycation end-product
(AGE)-BSA (produced by incubation with glucose) alters the intracellular redox state,
and results in an increased ratio of oxidised:reduced glutathione (GSH:GSSG) (DeutherConrad et al., 2001). To determine whether an increase in GSSG triggers an increase in
the relative proportion of dimeric Hsp27 in cells, SH-SY5Y cells were treated with
AGE-BSA prepared using the rapid method developed by Bhatwadekar and Ghole
(2005). Briefly, BSA (~ 750 µM) in 0.2 M sodium phosphate buffer with 0.5 M glucose,
pH 7.4, sterile filtered, was incubated in a 50°C water bath for four days. A non-glucose
BSA control was also prepared by the same method. AGE-BSA and the control were
then dialysed overnight in PBS to remove any unbound glucose. Samples were then
filter-sterilised and the protein concentration determined by Nanodrop (Manufacturer,
Waltham, USA). The production of AGE-BSA can be monitored by an increase in
fluorescence with ex/em at 370/440 nm (Wu et al., 1996). Samples were adjusted to
contain equal concentrations of protein, and fluorescence was read using a FluoStar
Optima Plate Reader (BMG Labtech, Ortenberg, Germany) to confirm production of
AGEs in the AGE-BSA sample. Aliquots were stored at -20˚C.
SH-SY5Y cells were seeded into T25 cell culture flasks. Once cells reached 80%
confluency, they were treated with 100 µM AGE-BSA, or the heat-treated BSA control
made up in fresh cell culture media, for 18 h. To confirm that treatment with AGE-BSA
increased the GSSG:GSH ratio, 108 cells were analysed using the GSH/GSSG Ratio
Detection Assay Kit (Fluorometric - Green) (ab138881; Abcam), as per the
manufacturer’s instructions. The “Cell (adherent or suspension) samples” protocol was
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used and PBS/0.5% NP-40 was used for cell lysis. The samples were deprotonated
using the alternative method as described in the manufacturer’s instructions.
Proteins were then extracted and analysed using the TCA/IAM precipitation and
immunoblotting methods as described above. The relative amount of dimer to monomer
was determined by densitometry using ImageJ (Schindelin et al., 2012). Experiments
were repeated three times, and data was analysed using a one-way ANOVA, followed
by a Tukey’s post-hoc test.
4.2.2

Expression, extraction and purification of α-syn

4.2.2.1 Extraction

Protein was expressed as described (2.2.3.3), using a pT7-7 plasmid (Addgene,
Cambridge, MA, USA) containing the α-syn gene kindly gifted by Dr. James Brown
(University of Cambridge, UK). Harvested cell pellets were resuspended in lysis buffer
(EDTA (10 mM) in Tris-HCl (100 mM) pH 8.0, supplemented with 1 × Roche complete
inhibitor cocktail) (20 mL per L of original expression culture). Cell were lysed by 3 x
freeze-thaw cycles, followed by sonication (5 cycles, 30% amplitude, 15 s on, 30 s off).
Lysates were then incubated in a 95°C water bath for 20 min to remove host proteins,
then centrifuged (22 000 × g, 4°C, 20 min). Nucleic acids were removed from the
supernatant by addition of streptomycin sulfate (15 mM), and incubation at 4°C for 20
min with stirring, then centrifugation (22 000 × g, 4°C, 20 min). The supernatant was
collected, and the streptomycin sulfate and centrifugation steps were repeated. Protein
was precipitated from the supernatant by addition of ammonium sulfate (3 M final
concentration) and incubation at 4°C for 30 min with stirring. Protein was collected by
centrifugation, then resuspended in a minimal volume of Tris-HCl (25 mM), pH 7.7.
The protein was then dialysed into anion exchange buffer for further purification.
4.2.2.2 Purification

Extracted α-syn was purified using a mono-Q anion exchange column (GE Healthcare),
eluted with a 0 – 1 M gradient of NaCl over 300 mL. Fractions containing α-syn
(determined by SDS-PAGE) were pooled, concentrated, and further purified by size
exclusion chromatography using a Superdex 75 10/300 GL column (GE Healthcare),
and eluted into 50 mM PB at 0.5 mL/min. Fractions were collected and analysed by
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SDS-PAGE, and those containing pure α-syn were concentrated to a maximum of 300
µM (to prevent aggregation), snap-frozen in liquid nitrogen, and stored at -80°C.
4.2.3

Fluorometric analyses

Fluorometry was performed using a Cary Eclipse fluorescence spectrophotometer
(Agilent Technologies, Santa Clara, CA, USA). All spectra were collected with
excitation and emission slit widths set to 5 nm, 600 nm/min scanning, and averaging of
three scans. Samples were prepared in a 100 µL Hellma® ultra Micro fluorescence
cuvette (Sigma-Aldrich), at 50 µM for both techniques.
4.2.3.1 Extrinsic bis-ANS binding

The

maximum

binding

of

4,4′-Dianilino-1,1′-binaphthyl-5,5′-disulfonic

acid

dipotassium salt (bis-ANS) to Hsp27 and the mutant isoforms was determined by the
sequential addition of aliquots (2.5 µL) of a stock of bis-ANS (750 µM) to protein
samples (100 µL at 50 µM in 50 mM PB). Following addition of each aliquot of bisANS, samples were mixed thoroughly and incubated at RT for three minutes to ensure
complete binding. When a maximum fluorescence emission at 500 nm was reached,
emission spectra (400 to 650 nm) were recorded.
4.2.3.2 Intrinsic tryptophan fluorescence

The intrinsic tryptophan fluorescence of each Hsp27 isoform (50 µM, in 50 mM PB)
was measured with excitation at 295 nm, and spectra collected from 300 to 400 nm.
4.2.4

Circular dichroism (CD) spectroscopy

Hsp27WT and each of the mutant isoforms were analysed by CD using a J-810
spectropolarimeter with an attached Peltier temperature-controlled water circulator
(Jasco, Tokyo, Japan). Far-UV spectra from 190 – 240 nm of proteins at approximately
10 µM, and near-UV spectra from 240 – 350 nm were collected of protein samples at
approximately 50 µM, both in 5 mM PB, with or without the addition of 2.5 mM DTT.
This DTT concentration was chosen so as to ensure that the high tension voltage,
(HT(V)), remained below 700 V. In the case that HT(V) was ≥700 V, these data were
excluded from further analyses of secondary structure. All spectra were the result of 16
accumulated scans. The resulting spectra were blank-corrected, then converted to mean
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residue ellipticity ([θ]MRW; degrees.cm2.dmol 1.residue-1) using:
[𝜃𝜃]𝑀𝑀𝑀𝑀𝑀𝑀 = 𝜃𝜃𝑜𝑜𝑜𝑜𝑜𝑜 ×

0.1 × (𝑀𝑀𝑀𝑀 ÷ (𝑟𝑟𝑟𝑟𝑟𝑟 − 1))
𝑙𝑙 × 𝐶𝐶

such that θobs is the measured ellipticity in mdeg, MW is the molecular weight of the
protein (predicted molecular weights from ProtParam (Gasteiger et al., 2005) were used
for each mutant isoform), res is the number of residues in the protein (e.g. 205 for
Hsp27), l is the pathlength of the cuvette in cm, and C is the concentration of the protein
in g/L.
To obtain the most accurate protein concentration, samples used to collect CD spectra
were subsequently analysed by BCA assay, and this value was used to calculate the
mean residue ellipticity. Far-UV CD spectra were then analysed using SELCON3 (SelfConstrained Method) and reference dataset 7 (Sreerama and Woody, 2000) with the
DICHROWEB Online Circular Dichroism Analysis Suite (Lobley et al., 2002,
Whitmore and Wallace, 2004, Whitmore and Wallace, 2008).
4.2.5

Dynamic light scattering (DLS)

DLS was used to investigate the oligomeric size of Hsp27WT and the disease-associated
mutants. Samples of each isoform (50 µM) were prepared in 50 mM PB, containing 100
mM NaCl (pH 7.0), with or without the addition of 20 mM DTT in 96-well microtiter
plates at a total volume of 60 µL. DLS measurements were obtained using a Malvern
Zetasizer Auto Plate Sampler system (Malvern Panalytical, Worcestershire, UK). Plates
were held at 4°C, and measurements for each sample were taken at 37°C after a 30 s
equilibration. Accumulation times were determined automatically, and the intensity
curves across the hydrodynamic diameter range were used as an estimation of size
shifts. The thermal stability of each isoform was also measured using the inbuilt
temperature melt function with size measurements taken in 2°C increments from 25 to
90°C.
4.2.6

GSH:GSSG-induced disruption of the Hsp27 disulfide bond in recombinant
proteins

To determine the relative strength of the disulfide bond in each of the disease-related
mutant isoforms (compared to Hsp27WT), purified recombinant proteins (30 µM final
concentration; pre-equilibrated at 37°C for 1 h) were incubated with various molar
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ratios of reduced and oxidised L-glutathione (GSH:GSSG). GSH content was between 0
and 12% (corresponding to a molar ratio of 0:1 – 0.3:1 GSH:GSSG) with a constant
total (reduced equivalent) glutathione concentration of 12 mM. After incubation (2.5 h,
37°C) samples were prepared in non-reducing SDS-PAGE sample loading buffer, and
analysed by SDS-PAGE and band densitometry. The relative abundance of Hsp27
monomer as a proportion of the amount of Hsp27 (i.e. monomer and dimer) was
determined, and results were fit to a Boltzmann-Sigmoidal curve.
4.2.7

Aggregation assays to determine the relative chaperone ability of diseasecausing mutant isoforms of Hsp27

Aggregation assays were carried out as described in section 2.2.4. Specific details of the
assays presented in this chapter are outlined below.
4.2.7.1 Heat-induced amorphous aggregation assays
4.2.7.1.1

Creatine Phosphokinase (CPK)

The aggregation of CPK (50 µM) was performed in PBS, pH 7.4 at 42°C. Hsp27WT or
the mutant isoforms were added at molar ratios from 0.5:1 to 8:1 (CPK:Hsp27X), and
recombinant SOD1 was used as a negative control. Aggregation was monitored for 4 h.
4.2.7.1.2

Rhodanese

The amorphous aggregation of rhodanese (20 µM) was performed in PBS, pH 7.4, at
42°C. Hsp27WT or the mutant isoforms were added at molar ratios of 2:1 and 4:1
(rhodanese:Hsp27X) and recombinant SOD1 was used as a negative control.
Aggregation was monitored for 2 h.
4.2.7.2 Fibrillar aggregation assays
4.2.7.2.1

α-Syn

The aggregation of α-syn can be modified to essentially eliminate the aggregation lagphase (approximately 15 h) by addition of pre-formed α-syn seeds (Buell et al., 2014,
Cox et al., 2018). Small α-syn seeds were prepared by the stirred incubation of
recombinant monomeric α-syn (between 100 and 300 µM, in 50 mM PB), at 45°C for

24 h, before sonication (30% power, 3 × 10 s cycles). This incubation and sonication
was repeated, prior to snap-freezing aliquots in liquid nitrogen, and storage at -80°C.
The seeded fibrillar aggregation of α-syn was analysed using 50 µM monomeric α-syn,
87

Chapter 4

and 5 µM α-syn seed (monomeric equivalent) in 50 mM PB, pH 7.4, in the presence or
absence of 20 mM DTT. Hsp27WT, mutant isoforms, or CPK (as a negative control)
were added at molar ratios between 0.5:1 and 1:1 (monomeric α-syn:Hsp27X). All
reagents were pre-equilibrated to 37°C for 1 h before addition of α-syn seeds. Fibril
formation was monitored as the change in ThT (20 μM) fluorescence measured using
excitation at 440 nm and emission at 490 nm, read every 350 sec for 24 h.

4.3 Results
4.3.1

Hsp27 forms disulfide-bonded dimers in cells

To determine whether Hsp27 forms disulfide-bonded dimers in cells under
physiological conditions, protein was extracted from SH-SY5Y, HeLa and fibroblast
cells (each chosen for their high expression of endogenous Hsp27) using a method that
incorporated rapid TCA precipitation of cellular proteins followed by treatment with
IAM in order to retain disulfide bonds and free thiols in their original state upon
extraction. These cellular extracts were then analysed by SDS-PAGE under reducing
and non-reducing conditions, and the resultant gels were then immunoblotted for Hsp27
(Figure 4.1). Each sample showed a strong band at approximately 25 kDa,
corresponding to the monomeric size of Hsp27. However, under non-reducing
conditions, a band at approximately 50 kDa was also evident in each sample,
corresponding to the disulfide-bonded dimeric form of Hsp27 (Figure 4.1) and
demonstrating that Hsp27 does form disulfide-bonded dimers in cells.
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Figure 4.1: Hsp27 forms intracellular disulfide bonds. Protein from samples of SH-SY5Y, HeLa
and human skin fibroblast cells was extracted using the TCA/IAM method (Section 4.2.1), such that
existing disulfide bonds were retained, and free thiol groups were blocked to inhibit the formation of new
disulfide bonds. Extracts were then divided in half and prepared in SDS-PAGE loading buffer either
without (-) or with (+) the addition of β-mercaptoethanol, and analysed by SDS-PAGE and IB for Hsp27.
The positions of molecular weight markers (kDa) are indicated to the left.
4.3.1.1 Altering the intracellular redox state of SH-SY5Y cells affects the redox state of
endogenous Hsp27

It has been suggested that Hsp27 acts to mitigate the damage caused by oxidative stress
in cells (Huot et al., 1991, Huot et al., 1996, Mehlen et al., 1996, Rogalla et al., 1999).
Hence, SH-SY5Y cells were treated with AGE-BSA to alter the intracellular redox
state. SH-SY5Y cells were chosen as they are a neuron-like established cell line, and for
their high expression of endogenous Hsp27. As expected, treatment resulted in a
significant increase (t(4) = 3.795, p = 0.0192) in the amount of oxidised glutathione as a
percentage of total glutathione (Figure 4.2A). The percentage of GSSG appeared to
reach a maximum of approximately 26% of total glutathione in AGE-treated cells and
this was independent of the proportion of GSSG in the untreated cells within the same
experimental replicate (Figure 4.2A). Analysis of Hsp27 in these cells by
immunoblotting indicated that both monomers (at approximately 25 kDa) and dimers (at
approximately 50 kDa) were present. Bands in the AGE-BSA-treated samples appeared
diffuse due to treatment with AGEs (Figure 4.2B). The dimer band was more intense in
samples from cells treated with AGE-BSA (Figure 4.2B). Analysis of these blots by
densitometry revealed a trend towards an increase in the proportion of dimeric Hsp27 in
samples treated with AGE-BSA compared to untreated cells, although this increase was
not statistically significant (t(4) = 1.882, p = 0.1330) (Figure 4.2C).
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Figure 4.2: AGE-BSA increases the intracellular GSSG:GSH ratio and the proportion of
disulfide-bonded Hsp27 in SH-SY5Y cells. Cells were treated (AGE) or not (U) for 16 h with 100
µM AGE-BSA. A: The intracellular amount of GSSG was determined as a percentage of total glutathione
using the GSH/GSSG Ratio Detection Assay Kit from a fraction of each sample. B: The TCA/IAM
extraction method (Section 4.2.1) was then used to extract intracellular protein. The extracts were
separated by non-reducing SDS-PAGE, and Hsp27 was detected by IB. A representative blot is shown,
and the positions of molecular weight (kDa) markers are indicated to the left. C: Densitometry was
performed on resulting blots, and the amount of protein in the dimer band was determined as a percentage
of total Hsp27 (dimer + monomer bands). Each graph shows the mean and standard deviation of three
independent experiments, with individual data points indicated. Squares, circles and triangles each
represent data points from the same experimental replicate.

4.3.2

Disease-causing mutations in Hsp27 alter the strength of the disulfide bond

Given that Hsp27 forms a disulfide-bonded dimer in cells, that this can be altered by
changing the ratio of GSH:GSSG, and that various disease-causing mutations in Hsp27
are located in the vicinity of C137, experiments were performed to establish the relative
strength of the disulfide bond in each of the Hsp27 isoforms (Figure 4.3). Non-reducing
SDS-PAGE analysis of Hsp27WT incubated with varying molar ratios of GSH:GSSG
produced bands at approximately 50 kDa and approximately 25 kDa, corresponding to
dimers and monomers of Hsp27, respectively (Figure 4.3A). As the ratio of GSH:GSSG
was increased (i.e. the solution was made more reducing), the density of the dimer band
decreased, while the monomer band increased in density, indicating reduction of the
disulfide-bond (Figure 4.3A). Similar results were obtained for each of the diseasecausing mutant isoforms (SDS-PAGE gels shown in Appendix I). As expected, SDSPAGE analysis of a C137S isoform of Hsp27 incubated under the same conditions
resulted in only bands corresponding to the monomer (Figure 4.3B). There were distinct
differences in the amount of amount of GSH required for dissociation of the dimer
between the Hsp27 isoforms (Figure 4.3C, D, E). Interestingly, Hsp27G84R comprised
less dimeric protein at the lowest (i.e. least reducing) GSH:GSSG ratio (Figure 4.3C),
while Hsp27T151I had a profile almost identical to Hsp27WT (Figure 4.3D). The amount
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of GSH required to reach 50% monomer was similar for Hsp27WT, Hsp27P39L,
Hsp27G84R and Hsp27T151I (Figure 4.3E), but significantly lower for Hsp27R127W,
Hsp27S135F, Hsp27R136W and Hsp27R140G. The mutations in these latter isoforms are close
to the disulfide bond-forming C137 residue, suggesting that the strength of the disulfide
bond is weakened by these changes to the amino acid sequence.

Figure 4.3: Disease-causing mutations in Hsp27 alter the strength of the disulfide-bond
across the dimer interface. Samples of purified Hsp27WT and the mutant isoforms were incubated for
1 h at 37°C in varying ratios of GSH and GSSG, such that the total glutathione (GSH molar equivalent)
concentration remained the same (12 mM). A and B: Non-reducing SDS-PAGE of Hsp27WT and the nondisulfide-forming Hsp27C137S (respectively), after incubation with glutathione. The percent GSH of each
sample is indicated above the lanes and the positions of molecular weight markers are shown to the left of
the gels. C and D: Band densitometry of the resulting gels was used to determine the relative abundance
), Hsp27P39L (
), Hsp27G84R ( ),
of monomeric and dimeric Hsp27WT ( ), Hsp27C137S (
), Hsp27R136W ( ), Hsp27R140G ( ) or Hsp27T151I ( ) in each
Hsp27R127W ( ), Hsp27S135F (
sample, and the percentage of monomer was calculated for each molar ratio of GSH:GSSG. Results were
fitted with a Boltzmann sigmoidal curve. Note that for ease of comparison, the Hsp27WT and Hsp27C137S
samples are included in both graphs. E: The mid-point between the top and bottom values of the
Boltzmann sigmoidal curve was calculated and used to interpolate the corresponding GSH concentration
at half-maximum for each isoform (colours as per C and D). A and B are representative of two
independent experiments, and C shows the mean ±SEM of n = 2. Statistical significance as determined by
a one-way ANOVA and Dunnett’s post-test is shown; ** indicates P < 0.01, * indicates P < 0.05.

The relative particle size of Hsp27WT and the disease-causing mutant isoforms under
non-reducing and reducing was analysed by DLS (Figure 4.4A). The size at maximum
intensity for each sample and the range of particle sizes was determined by an area
under curve analysis, and the results are summarised in Table 4.1. Under non-reducing
conditions, the maximum intensity of Hsp27WT corresponded to particles with a
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hydrodynamic radius of 8.5 nm, and this was not affected by the presence of DTT,
although the particle size distribution was decreased with DTT (Figure 4.4A). Each of
the disease-causing mutant isoforms displayed an increase in particle size compared to
Hsp27WT both in the absence and presence of DTT (Figure 4.4A, Table 4.1). Hsp27S135F
and Hsp27R140G each had a substantially increased particle size at maximum intensity
(each 12.9 nm), as well as a wider range of sizes compared to Hsp27WT. With the
exceptions of Hsp27T151I and Hsp27G84R, the addition of DTT decreased the overall size
range, and in some cases reduced the size at maximum light scatter (Figure 4.4A, Table
4.1). It should be noted that subunit exchange within the samples likely mask the
detection of the smallest particle sizes representative of small oligomers and dimers
(Lorber et al. 2012).
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Figure 4.4: Mutations affect the size and thermostability of Hsp27 oligomers. A: The
), Hsp27G84R ( ), Hsp27R127W (
),
hydrodynamic diameter (d.nm) of Hsp27WT ( ), Hsp27P39L (
S135F
R136W
R140G
(
), Hsp27
(
), Hsp27
(
) and Hsp27T151I (
) was determined by DLS
Hsp27
using 50 µM of each sample in 50 mM PB, equilibrated at 37°C, in the absence (solid lines) or presence
(dotted lines) of 20 mM DTT. The intensity of peaks was normalised to the peak maximum for each
sample. B – D: Thermal denaturation of these samples was also measured both in the absence (solid lines)
and presence (dotted lines) of 20 mM DTT; note that Hsp27WT is shown on each plot for ease of
comparison, and colours correspond to those in A. DLS was used to determine the change in average
particle size (Z-average) over a temperature range from 25° to 90°C, increasing at 2°C every three min.

The thermostability of the Hsp27 isoforms between 25°C and 90°C was also examined
using the thermal melt function of the DLS system. All of the Hsp27 isoforms were
thermostable up to 60°C with no increase in Z-average size up to this temperature
(Figure 4.4B-D). Under non-reducing conditions, Hsp27WT, Hsp27S135F and Hsp27R140G
appeared to be relatively stable up to the highest temperature recorded, whereas
Hsp27G84R, Hsp27P39L, Hsp27R127W, and especially Hsp27S135Fand Hsp27T151I showed an
increase in particle size at < 85°C (Figure 4.4B-D; melting temperatures summarised in
Table 4.1). Whilst the addition of DTT decreased the melting temperature of Hsp27T151I,
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it did not affect the melting temperatures of Hsp27WT, Hsp27P39L, or Hsp27G84R.
Conversely, the presence of the reducing agent increased the melting temperatures of all
the other Hsp27 isoforms.
Table 4.1: Mutations and redox state affect the oligomeric size and thermostability of
Hsp27.The size of Hsp27WT and the disease-causing mutant isoforms was determined by DLS. Samples
(50 µM) in 50 mM PB, equilibrated at 37°C, both in the absence and presence of 20 mM DTT were
prepared. The average size and size range was determined by analysis of the area under the curve.
Thermostability is represented by the melting point for each isoform, which was calculated as the
temperature at which the hydrodynamic size of the particles were double that at 25°C.
Melting
point
Size at maximum
intensity (nm)
Size range (nm)
(°C)
8.5
5.4 - 20.5
69
-DTT
Hsp27WT
8.5
5.9 - 13.5
69
+DTT
9.8
6.8
16.2
69
-DTT
Hsp27P39L
9.8
6.4 - 15.5
71
+DTT
10.7
7.4
17.0
69
-DTT
Hsp27G84R
10.7
7.1 - 17.8
69
+DTT
11.8
8.1 - 18.7
77
-DTT
R127W
Hsp27
11.8
8.1 - 19.5
83
+DTT
12.9
7.1 - 28.3
75
-DTT
S135F
Hsp27
11.8
7.1 - 25.8
79
+DTT
10.2
7.4
16.2
73
-DTT
Hsp27R136W
10.2
7.1 - 15.5
81
+DTT
14.1
9.3
24.6
79
-DTT
Hsp27R140G
12.9
8.5 - 24.6
85
+DTT
8.9
5.9 - 14.1
65
-DTT
T151I
Hsp27
8.9
5.9 - 14.8
63
+DTT

4.3.2.1 Fluorometric and CD spectrophotometric analyses

The secondary structural content of a protein can be estimated using far-UV (~190 –
240 nm) CD spectroscopy, in which signal is detected from peptide bonds when they
are located in a well-ordered, folded environment, giving rise to distinct signals from αhelices and β-sheets (Johnson Jr, 1998, Greenfield, 2006). As such, a signal of zero
indicates a lack of ordered structure. The α-helical content of a protein can be estimated
by a positive band (or maxima) at 190 nm, and negative bands (minima) at 208 and 222
nm. Signal obtained at 190 nm for each of the Hsp27 isoforms was weak, as indicated
by a high HT(V), and so these data cannot be used reliably for estimation of protein
structure (Figure 4.5A, B). In the absence of DTT, Hsp27R140G had the most intense
minima at both 208 nm and 222 nm, indicating that it has an increased α-helical content
compared to Hsp27WT and the other mutant isoforms (Figure 4.5A). This was consistent
with the Dichroweb deconvolution of the data, which indicated 18.4% α-helical content
for Hsp27R140G, compared to less than 1% for Hsp27WT and Hsp27T151I, approximately
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4.8% for Hsp27P39L, and 8 – 9% for each of the other isoforms (Figure 4.5A, inset). The
presence of β-sheet structure is indicated by a positive signal between 195 and 200 nm,
and negative signal at 218 nm. In the absence of DTT, each of the isoforms displayed a
negative band between 210 nm and 220 nm, although to varying degrees, and the signal
was difficult to distinguish from that arising from the presence of α-helices (Figure
4.5A). Hsp27G84R had the most distinct minima at 218 nm, indicating an increase in βsheet content, which was reflected by a 40% β-sheet composition after deconvolution.
Interestingly, all of the mutant isoforms appear to have an increased proportion of βsheet compared to Hsp27WT, with the exception of Hsp27T151I and Hsp27R140G (Figure
4.5A).
The addition of DTT altered the secondary structure of the Hsp27 mutants (Figure
4.5B). The proportion of α-helix was increased in Hsp27P39L, Hsp27G84R, Hsp27S135F,
Hsp27R136W, and especially Hsp27R140G, whilst a distinct decrease in helical content in
Hsp27R127W and Hsp27T151I was observed (Figure 4.5B). In the presence of DTT the
proportion of β-sheet structure was increased in Hsp27WT and Hsp27R127W, relatively
unchanged in Hsp27P39L, and decreased in the remainder of the Hsp27 isoforms (Figure
4.5B).

Figure 4.5: Far-UV CD indicates that disease-causing mutations affect the secondary
structure of Hsp27, and that mutations in the vicinity of C137S make the protein more
susceptible to structural alteration by reduction. The secondary structures of Hsp27WT ( ),
), Hsp27G84R ( ), Hsp27R127W ( ), Hsp27S135F ( ), Hsp27R136W ( ), Hsp27R140G (
Hsp27P39L (
) (10 µM in 5 µM PB, pH 7.0) were examined using far-UV CD, in the absence
) and Hsp27T151I (
(A) or presence (B) of 2.5 mM DTT. Dotted lines indicate spectra for which the HT(V) crossed the limit
of 700 V. Inset in each graph is the proportion of α-helices ( ), β-sheets ( ), turns ( ), and disordered
( ) structure as determined by deconvolution of the spectra using the SELCON3 program on the
Dichroweb server.
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The tertiary folding state of a protein can be analysed using near-UV CD (~240 – 350
nm), in which signal arises from aromatic residues and/or disulfide-bonds at distinct
wavelengths, and are sensitive to the local environment surrounding the amino acid
(Tetin et al., 2003, Li et al., 2011). In the case of near-UV CD, a stronger signal
indicates a more folded protein, while a signal closer to zero indicates a loss of tertiary
structure. Hsp27WT contains 18 aromatic residues which may contribute to the near-UV
signal, consisting of 12 clustered in the N-terminal region (F8, 19, 29, and 33, Y23, 54,
and 73, and W16, 22, 42, 45, 51), five in the αCD (F104 and 138, Y133 and 142, and
W95), and one in the C-terminal region (F185). It is notable that Y133, Y142, and F138
are also clustered around the disulfide bond-forming C137. Interestingly, the near-UV
CD spectra of Hsp27WT suggests that it is in a more folded state than all of the diseasecausing mutant isoforms, both in the absence and presence of DTT (Figure 4.6A,B),
indicated by a more positive signal at 260 nm and 280 nm. Hsp27WT and Hsp27T151I
both had a small peak at approximately 280 nm, which may be attributed to the two
tyrosine residues of the αCD being in a more folded environment. Due to the location of
the majority of the aromatic residues of Hsp27 in the unstructured N- and C- terminal
regions, and the dynamic nature of the protein, signal in the near-UV region is difficult
to interpret in terms of the aromatic residues. It is possible, however, to detect the
reduction of the disulfide bond i.e. in the presence of DTT there was a loss of overall
near-UV CD signal for all Hsp27 isoforms compared to that observed in the absence of
DTT (Figure 4.6A,B), and signal between 300 nm and 310 nm (corresponding to
disulfide bonds, without the interference of aromatic residues) was distinctly altered
(Figure 4.6B).
The intensity of tryptophan fluorescence is sensitive to its environment, such that
exposure to solvent (or a more polar environment) results in a decrease in intensity,
compared to tryptophan that is more buried (or in a more hydrophobic environment). As
such, the tryptophan fluorescence of Hsp27WT and the disease-causing mutant isoforms
was measured (Figure 4.6C). It is of note that of the six tryptophan residues in Hsp27WT,
five are in the N-terminal region, and one is located at the start of the αCD. Hsp27WT,
Hsp27S135F, and Hsp27T151I had a maximum tryptophan fluorescence at 343.6 nm, 343.1
nm, and 342 nm, respectively, indicating that the tryptophan residues in these isoforms
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are relatively protected from the solvent (Figure 4.6C). Interestingly, each of the other
Hsp27 isoforms had much lower tryptophan fluorescence, indicating more solvent
exposure of these residues (Figure 4.6C). The presence of DTT resulted in a distinct
decrease in maximum fluorescence for all of the Hsp27 isoforms, with Hsp27WT,
Hsp27G84R, Hsp27S135F, Hsp27R140G, and Hsp27T151I showing the largest decrease (Figure
4.6C). For each of the isoforms, with the exception of Hsp27WT and Hsp27S135F, this
decrease in fluorescence was accompanied by a red-shift in the wavelength (i.e. shift to
longer wavelengths) at maximum fluorescence, further indicating an increase in polarity
in the environment surrounding the tryptophan residues in the presence of DTT (Figure
4.6C). Both Hsp27R127W and Hsp27R136W showed very similar tryptophan fluorescence
spectra to one another, although fluorescence was not increased in comparison to
Hsp27WT despite the introduction of an additional tryptophan residue. This is
particularly interesting as both of these mutations are located in the αCD of Hsp27,
indicating that these regions are solvent exposed in isoforms of Hsp27 containing these
mutations. These results indicate that the P39L, G84R, R127W, R136W, R140G and
T151I mutations all increase the solvent exposure of the N-terminally located
tryptophan residues.
The increase in fluorescence intensity of bis-ANS upon binding to clustered
hydrophobic regions was used as an indicator of exposed hydrophobicity in Hsp27WT
and the disease-causing mutant isoforms. Under non-reducing conditions, the
fluorescence maxima of Hsp27P39L, Hsp27S135F, and Hsp27R136W were all greater than
that of Hsp27WT (indicating an increase in exposed hydrophobicity), while Hsp27R140G,
Hsp27R127W, and especially Hsp27T151I were lower (Figure 4.6D). Hsp27G84R had an
almost identical bis-ANS fluorescence spectrum to Hsp27WT (Figure 4.6D). The
inclusion of DTT did not affect the fluorescence maximum of Hsp27WT, but increased
that of Hsp27R127W (such that it was almost identical to Hsp27WT), indicative of a slight
increase in exposed hydrophobicity in the presence of DTT for this mutant isoform
(Figure 4.6D). The fluorescence spectra of Hsp27S135F was unchanged in the presence of
DTT, and was reduced for all other mutants, indicating a decrease in exposed
hydrophobicity (Figure 4.6D).
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Figure 4.6: Analysis of the folding state of Hsp27WT and the disease-associated mutants by
near-UV CD, extrinsic bis-ANS fluorescence and intrinsic tryptophan fluorescence.
Biophysical analyses were used to compare the folding states of Hsp27WT (
) with Hsp27P39L (
),
G84R
R127W
S135F
R136W
R140G
( ), Hsp27
( ), Hsp27
(
), Hsp27
( ), Hsp27
( ) and Hsp27T151I
Hsp27
(
). A and B: Near-UV spectra of the Hsp27 isoforms (50 µM in 5 mM PB, pH 7.0) were collected in
the absence (A) or presence (B) of 2.5 mM DTT. The approximate wavelengths at which phenylalanine
(solid black line), tyrosine (long-dashed line), tryptophan (short-dashed line) and disulfide bonds (grey
line) influence CD signal are indicated at the top of each plot. Data are the result of the accumulation of
16 scans. C: Intrinsic tryptophan fluorescence was measured for each of the Hsp27 isoforms (50 µM in
50 mM PB, pH 7.4) in the absence (solid lines) or presence (dashed lines) of 20 mM DTT. Curves
represent the average of three scans. The maximum emission of each curve is indicated by a circle. Note
that Hsp27WT is shown in each graph for ease of comparison. D: Extrinsic bis-ANS binding fluorescence
was measured for each of the Hsp27 isoforms (45.5 µM in 50 mM PB, pH 7.4) with 68 µM bis-ANS
which corresponded with the maximum fluorescence signal, in the absence (solid lines) or presence
(dashed lines) of 20 mM DTT. The peak fluorescence of each sample is indicated by a circle. Curves
represent the average of three scans. Note that Hsp27WT is shown in each graph for ease of comparison.
Each plot (A - D) is representative of two independent experiments.
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4.3.3

Disease-causing mutations in Hsp27 affect its chaperone activity against
various aggregation-prone client proteins

The chaperone activity of the Hsp27 isoforms to inhibit protein aggregation under
reducing and non-reducing conditions was assessed using widely employed models of
protein aggregation: the heat-induced amorphous aggregation of CPK (Wyatt et al.,
2014), and rhodanese (Song and Wang, 1995, Mymrikov et al., 2016), and the fibrillar
aggregation of α-syn (Rekas et al., 2004, Alderson et al., 2019b, Cox et al., 2018).
The seeded aggregation of α-syn was monitored by an increase in ThT fluorescence
over time, indicative of the formation of fibrillar aggregates (Figure 4.7A). In the
presence of DTT, there was an increase in ThT fluorescence associated with the
aggregation of α-syn, although the maximum fluorescence level observed was lower
than that observed in the absence of DTT (Figure 4.7B). In both cases, α-syn
aggregation was inhibited by the addition of Hsp27WT at a 1:40 molar ratio (Hsp27:αsyn). The addition of CPK, a non-chaperone control, at the same molar ratio, did not
significantly affect the aggregation of α-syn in the absence of DTT (Figure 4.7A)
although it did slightly decrease aggregation of α-syn under reducing conditions (Figure
4.7B). As expected, in the absence of α-syn, incubation of Hsp27WT (Figure 4.7A, B) or
the disease-associated mutant isoforms (data not shown) did not result in any increase in
ThT fluorescence either in the presence or absence of DTT. The addition of Hsp27WT
and each of the disease-related mutant isoforms at a 1:20 molar ratio resulted in the
complete inhibition of α-syn aggregation in the absence of DTT (Figure 4.7C), while in
the presence of 20 mM DTT, all but Hsp27R140G completely inhibited α-syn aggregation
(Figure 4.7D). Interestingly, decreasing the molar ratio to 1:40 resulted in a large
increase in the variation between biological replicates of the same samples (SEM), both
in the presence and absence of DTT, however, this variation was smaller at the 1:100
ratio (Figure 4.7C, D). Only the R140G isoform displayed a concentration dependence
in terms of inhibition of α-syn aggregation in the presence of DTT (i.e. aggregation
inhibition decreased at a molar ratio of 1:100 (Figure 4.7D)), although the high efficacy
of the other isoforms at the concentrations used may have masked this effect of
concentration.
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Figure 4.7: Hsp27WT and disease-causing mutant isoforms inhibit the fibrillar aggregation
of α-syn under reducing and non-reducing conditions.Recombinant monomeric α-syn (50 µM)

was incubated at 37°C with α-syn seeds (5 µM; monomeric equivalent) in 50 mM PB, pH 7.4 in the
absence or presence of Hsp27 mutant isoforms or the non-chaperone control protein, CPK, either without
(A, C), or with (B, D) the addition of 20 mM DTT. Formation of fibrillar aggregates was monitored by
the change in ThT fluorescence over time at 490 nm. A: A representative trace of the aggregation of α-syn
) or CPK ( ) at a 1:40 molar ratio of Hsp27/CPK:αin the absence (
) or presence of Hsp27WT (
) is also shown. B: A
syn monomer. The negative control of Hsp27WT in the absence of α-syn (
representative trace of the aggregation of α-syn under reducing conditions (with 20 mM DTT) in the
) at a 1:40 molar ratio of Hsp27/CPK:α-syn
absence (
) or presence of Hsp27WT ( ) or CPK (
) is also shown. The overall
monomer. The negative control of Hsp27WT in the absence of α-syn (
change in aggregation (∆Agg) between α-syn alone and α-syn in the presence of Hsp27WT ( ), Hsp27P39L
( ), Hsp27G84R ( ), Hsp27R127W ( ), Hsp27S135F ( ), Hsp27R136W ( ), Hsp27R140G ( ) or Hsp27T151I ( )
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at molar ratios between 1:20 and 1:100 (Hsp27:α-syn) are shown in C in the absence of DTT, and D in
the presence of 20 mM DTT. The red line represents the mean ± SEM (shaded) whereby complete
inhibition of α-syn aggregation occurs as determined by ∆Aggα-syn (equal to 0) - ∆Fα-syn. Traces in panels
A and B show a representative replicate; shaded regions represent the range of duplicates. Histograms in
panels C and D show the means ± SEM of two to four independent replicates with individual data points
represented by grey circles. A one-way ANOVA showed no statistical differences between samples (p >
0.05).

Incubation of CPK at 42°C resulted in an increase in light scatter, indicative of the
formation of amorphous aggregates, both in the absence and presence of 20 mM DTT,
although the increase was less marked in the presence of DTT (Figure 4.8). This
increase in light scatter was unchanged by the addition of the non-chaperone control
protein, SOD1, under non-reducing conditions but was enhanced by its addition under
reducing conditions potentially due to the presence of an intramolecular disulfide bond
in SOD1 that, when reduced, destabilises the protein (Furukawa et al., 2004)(Figure
4.8A, B). As expected, incubation of Hsp27WT or the disease-associated mutant
isoforms in the absence of CPK did not result in any increase in light scatter. Under
both reducing and non-reducing conditions, when CPK was incubated in the presence of
Hsp27WT the light scatter increased compared to when CPK was incubated alone.
The change in light scatter for CPK alone under non-reducing conditions had a lag
phase of 0.18 ± 0.05 h. The lag phase of CPK aggregation was increased in the presence
of DTT (Figure 4.8A) to 0.34 ± 0.11 h. In the absence of DTT and at a molar ratio of
1:2 or 1:1 (Hsp27:CPK) the lag phase was increased by the addition of Hsp27WT by 0.20
± 0.06 h and 0.22 ± 0.08 h, respectively. Interestingly, Hsp27R140G significantly
increased the lag phase from that of CPK alone by 0.61 ± 0.13 h in the absence of DTT
compared to Hsp27WT at the 1:1 (Hsp27:CPK) molar ratio (P ≤ 0.01; Figure 4.8C),
while in the presence of DTT, Hsp27R127W significantly increased the lag phase by 1.64
± 0.20 h compared to Hsp27WT at a 1:2 molar ratio (Hsp27:CPK; P ≤ 0.05; Figure
4.8D). When used at a lower concentration (50 µM, corresponding to a 1:2 Hsp27:CPK
molar ratio) the Hsp27 isoforms had very little effect on the lag phase of CPK
aggregation, suggesting that the chaperone activity of Hsp27 against the onset of the
aggregation of CPK is not concentration dependent (Figure 4.8C, D).
The overall aggregation of CPK in the absence of DTT was increased in the presence of
Hsp27WT, Hsp27P39L, Hsp27R136W, and Hsp27T151I, unchanged in the presence of
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Hsp27R140G, and inhibited by the presence of Hsp27G84R, Hsp27R127W and Hsp27S135F at
both molar ratios tested (Figure 4.8E). Of these, the change in aggregation of CPK was
significantly reduced in the presence of Hsp27G84R (P ≤ 0.001), Hsp27R127W (P ≤ 0.001),
Hsp27S135F (P ≤ 0.001), Hsp27R136W (P ≤ 0.05) and Hsp27R140G (P ≤ 0.001) compared to
Hsp27WT (Figure 4.8E). The aggregation of CPK in the presence of DTT was also
increased in the presence of Hsp27WT, Hsp27R136W, and Hsp27T151I, and inhibited by the
presence of Hsp27P39L, Hsp27G84R, Hsp27R127W, Hsp27S135F and Hsp27R140G at 1:0.5
(Hsp27:CPK; Figure 4.8F). Of these, the change in aggregation of CPK was
significantly reduced in the presence of Hsp27P39L (P ≤ 0.01), Hsp27G84R (P ≤ 0.001),
and Hsp27S135F (P ≤ 0.01) compared to Hsp27WT (Figure 4.8F). At a 1:1 molar ratio
(Hsp27:CPK), the change in aggregation of CPK was significantly reduced in the
presence of all isoforms (P < 0.01 - < 0.001) with the exception of Hsp27T151I. In the
presence of DTT, each of the Hsp27 isoforms displayed a slight decrease in chaperone
activity (i.e. increase in ∆Agg of CPK) at a 1:1 molar ratio as compared to that seen at a
1:2 molar ratio, suggesting some influence of concentration on the anti-aggregation
activity of reduced Hsp27 against the formation of amorphous CPK aggregation (Figure
4.8F).
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Figure 4.8: Disease-related mutations alter the chaperone activity of Hsp27 against the
aggregation of CPK. CPK (100 µM) was incubated at 42°C in PBS, pH 7.4 in the absence or presence
of Hsp27 isoforms or the non-chaperone control protein SOD1, either without (A, C, E), or with (B, D, F)
the addition of 20 mM DTT. Formation of amorphous aggregates was monitored by the change in light
scatter over time at 340 nm. A: Representative trace of the aggregation of CPK in the absence (
) or
) or SOD1 (
) at a 1:2 or 1:1 molar ratio of Hsp27/SOD1:CPK, respectively.
presence of Hsp27WT (
) is also shown. B: Representative trace of the
The negative control, Hsp27WT in the absence of CPK (
aggregation of CPK under reducing conditions (with 20 mM DTT) in the absence (
) or presence of
) or SOD1 ( ) at a 1:2 or 1:1 molar ratio of Hsp27/SOD1:CPK, respectively. The
Hsp27WT (
) is also shown. The overall change in the length of
negative control Hsp27WT in the absence of CPK (
the lag phase (∆Lag; C, D) or aggregation (∆Agg; E, F) between CPK alone and CPK in the presence of
Hsp27WT ( ), Hsp27P39L ( ), Hsp27G84R ( ), Hsp27R127W ( ), Hsp27S135F ( ), Hsp27R136W ( ),
Hsp27R140G ( ) or Hsp27T151I ( ) at molar ratios between 1:0.5 and 1:2 (Hsp27:CPK) are shown in the
absence of DTT (C, E), and presence of 20 mM DTT (D, F). The red line represents the mean±SEM
(shaded) whereby complete inhibition of CPK aggregation occurs as determined by ∆AggCPK (equal to 0)
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- ∆FCPK. Traces in panels A and B show a representative replicate; error bars are ± SEM of duplicates.
Histograms in panels C - F show the means ± SEM of five independent replicates (each represented by a
grey circle). Statistical significance determined by a one-way ANOVA followed by a Tukey’s post hoc
test is indicated such that * denotes p < 0.05, ** denotes p < 0.01, and *** denotes p < 0.0001.

Incubation of rhodanese at 42°C resulted in an increase in light scatter, indicative of
amorphous protein aggregation, and this effect was decreased in the presence of 20 mM
DTT (Figure 4.9A,B). The increase in light scatter observed for rhodanese aggregation
was unchanged by the addition of the non-chaperone control protein, SOD1, under nonreducing conditions, but was slightly decreased in the presence of SOD1 and DTT
(Figure 4.9A,B). Addition of Hsp27WT at a 1:4 molar ratio (Hsp27:rhodanese) resulted
in an approximately 50% decrease in overall light scatter under non-reducing
conditions, and almost complete inhibition in the presence of DTT (Figure 4.9A,B). As
expected, incubation of Hsp27WT in the absence of rhodanese did not result in any
increase in light scatter (Figure 4.9A,B). The same was observed for the incubation of
each of the other Hsp27 mutant isoforms in the absence of rhodanese (data not shown).
Curve fitting of the data obtained for the change in light scatter for rhodanese alone in
the absence of DTT revealed a lag-phase of 15.84 ± 0.78 min (Figure 4.9C). In the
absence of DTT, the addition of Hsp27WT or Hsp27P39L at a molar ratio of 1:2 or 1:4
(Hsp27:rhodanese) did not affect the lag phase of rhodanese aggregation (Figure 4.9C);
however, at a molar ratio of 1:2 (Hsp27:rhodanese) the lag phase was increased
compared to rhodanese alone by the addition of Hsp27R127W (12.47 ± 11.64 min),
Hsp27S135F (21.80 ± 13.11 min), Hsp27R136W (17.47 ± 9.89 min), and Hsp27R140G (8.59
± 2.09 min) (Figure 4.9C). The addition of Hsp27G84R or Hsp27T151I at a 1:2 molar ratio
resulted in a highly variable lag phase such that ∆Lag was between -16.72 min to >200
min (i.e. the end of a lag phase was not detected before the end of the assay) (Figure
4.9C).
At a 1:4 molar ratio (Hsp27:rhodanese) addition of Hsp27S135F and Hsp27R140G
increased the lag-phase compared to rhodanese alone by 15.13 ± 4.68 min and 6.90 ±
0.94 min, respectively, while addition of the other Hsp27 mutant isoforms did not
significantly change the lag phase (Figure 4.9C). Inclusion of DTT resulted in an overall
increase in ∆Lag with the addition of all of the Hsp27 isoforms at the 1:2 and 1:4
(Hsp27:rhodanese) molar ratios tested (Figure 4.9D). In the presence of DTT, at a molar
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ratio of 1:2 or 1:4 (respectively), the lag phase was increased by the addition of
Hsp27R127W (19.34 ± 16.7 min and 39.08 ± 6.44 min, respectively) and Hsp27R140G
(14.75 ± 3.92 and 24.25 ± 4.59 min, respectively) (Figure 4.9D). Addition of each of the
other Hsp27 isoforms, at either molar ratio, resulted in highly variable lag phases, such
that the end of the lag phase was not detected (i.e. > 200 min) due to complete inhibition
of aggregation (Figure 4.9D). As the lag phase in the presence of these Hsp27 isoforms
was so variable, no statistically significant differences between Hsp27WT or any of these
disease-causing isoforms was evident.
At a 1:2 molar ratio (Hsp27:rhodanese), the aggregation of rhodanese in the absence of
DTT was decreased in the presence of Hsp27WT, Hsp27P39L, Hsp27G84R, and Hsp27T151I,
unchanged in the presence of Hsp27R127W, and increased in the presence of Hsp27S135F,
Hsp27R136W and Hsp27R140G (Figure 4.9E). However, due to the high variability between
independent replicates in this assay, the change in aggregation of rhodanese in the
presence of these Hsp27 isoforms was only significantly reduced by Hsp27R140G in
comparison to Hsp27WT (P ≤ 0.05). Interestingly, the inhibition of rhodanese
aggregation was greater for all of the Hsp27 isoforms at the 1:4 molar ratio in
comparison to 1:2 (Hsp27:rhodanese), i.e. when less Hsp27 was present in solution
(Figure 4.9E).
In the presence of 20 mM DTT, each of the Hsp27 isoforms inhibited the aggregation of
rhodanese at both a 1:2 and 1:4 molar ratio, with the exception of Hsp27R1340G, which
increased aggregation at a 1:4 molar ratio (Figure 4.9F). Again, due to the high
variability between independent replicates in this assay, there was no statistically
significant differences between the Hsp27 isoforms in inhibiting rhodanese aggregation
under non-reducing conditions. In contrast to assays conducted in the absence of DTT,
the chaperone ability of all of the Hsp27 isoforms was slightly diminished at the 1:4
molar ratio, compared to the 1:2 molar ratio (Figure 4.9E, F).
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Figure 4.9: Reduction and disease-causing mutations in Hsp27 affect its chaperone activity
against the heat-induced aggregation of rhodanese. Rhodanese (20 µM) was incubated at 42°C in
PBS, pH 7.4 in the absence or presence of Hsp27 isoforms or the non-chaperone control SOD1, either
without (A, C, E), or with (B, D, F) the addition of 20 mM DTT. Formation of amorphous aggregates was
monitored by the change in light scatter over time at 340 nm. A: A representative trace of the aggregation
) at a 1:2 or 1:4 molar ratio
of rhodanese in the absence (
) or presence of Hsp27WT ( ) or SOD1 (
of Hsp27/SOD1:rhodanese, respectively. The negative control of Hsp27WT in the absence of rhodanese (
) is also shown. B: A representative trace of the aggregation of α-syn under reducing conditions (with
) or SOD1 ( ) at a 1:2 or 1:4 molar
20 mM DTT) in the absence (
) or presence of Hsp27WT (
ratio of Hsp27/SOD1:rhodanese, respectively. The negative control of Hsp27WT in the absence of
rhodanese (
) is also shown. The overall change in the length of the lag phase (∆Lag; C, D) or
aggregation (∆agg; E, F) between CPK alone and CPK in the presence of Hsp27WT ( ), Hsp27P39L ( ),
Hsp27G84R ( ), Hsp27R127W ( ), Hsp27S135F ( ), Hsp27R136W ( ), Hsp27R140G ( ) or Hsp27T151I ( ) at
molar ratios of 1:2 and 1:4 (Hsp27:rhodanese) are shown in the absence of DTT (C, E), and in the
presence of 20 mM DTT (D, F). The red line represents the mean±SEM (shaded) whereby complete
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inhibition of rhodanese aggregation occurs as determined by ∆aggrhodanese (equal to 0) - ∆Absrhodanese.
Traces in panels A and B show a representative replicate; error bars are ± SEM of duplicates. Histograms
in panels C - F show the means ± SEM of five independent replicates (each represented by a grey circle).
Statistical significance determined by a one-way ANOVA followed by a Tukey’s post-hoc test is
indicated such that * denotes p < 0.05

4.4 Discussion
The dynamic nature of the structure and oligomerisation of sHsps is critical to their
interactions with themselves, other sHsps, and client proteins. Each structural region of
Hsp27 appears to play a specific role in these interactions, as indicated by the results of
this work and previous studies. Some of these roles have already been elucidated (e.g.
the WDPF domain in the N-terminal region (Lelj-Garolla and Mauk, 2005, Lelj-Garolla
and Mauk, 2012), and the IXI motif in the C-terminal extension (Laganowsky et al.,
2010, Hilton et al., 2013)); however, many remain to be established. Hsp27 is unique
among the human sHsps in that it contains a single cysteine residue in the αCD that is
capable of forming a disulfide bond at the dimer interface, stabilising the dimeric form.
The overall aims of this chapter were to determine the relevance of the Hsp27 disulfide
bond in a cellular context, to determine the effects of disease-causing mutations on the
relative strength of this bond, and to systematically examine the effects of diseaseassociated mutations in Hsp27 on its structure, oligomerisation and chaperone activity,
particularly in the context of the redox state of the protein.
To determine the relevance of the disulfide bond formed by C137 at the dimer interface
in recombinant Hsp27 purified from bacteria, Hsp27 was extracted from three different
mammalian cell types (SH-SY5Y, HeLa, and skin fibroblasts), such that the redox state
of thiol groups inside the cells was maintained. In all three cell types, endogenous
Hsp27 was present both in a non-disulfide bonded and disulfide bonded state (Figure
4.1), suggesting that Hsp27 can act as a redox-sensor within the cell by responding to
changes in the oxidative state so as to mitigate damage caused by oxidation (Arrigo,
2001, Rajagopal et al., 2015, Alderson et al., 2019b). To further explore this, the
intracellular GSSG:GSH ratio was increased in SH-SY5Y cells (i.e. a more oxidising
environment) by treating the cells with AGE-BSA as previously described (DeutherConrad et al., 2001). Under these conditions there was an increase in the proportion of
disulfide bonded dimeric Hsp27 detected in these cells, although this difference did not
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reach statistical significance. Under normal conditions, the cytosol is a reducing
environment (Hwang et al., 1992, Muller, 1996), with a concentration of glutathione in
the range of 0.5 to 10 mM in a cell (Kosower and Kosower, 1978); however, the
concentration and redox-state of glutathione can differ substantially in different cellular
compartments (Kosower and Kosower, 1978, Hwang et al., 1992, Merad-Boudia et al.,
1998, Schafer and Buettner, 2001). In the cytosol, the GSSG:GSH ratio is such that the
environment is highly reducing, at approximately 1:30 to 1:100 (Hwang et al., 1992,
Schafer and Buettner, 2001, Tu and Weissman, 2004). As such, conditions in the
cytosol do not typically favour disulfide bond formation. However, an early response to
oxidative stress is the formation of disulfide bonds, either between two cysteinecontaining proteins or between cysteine-containing proteins and other molecules, such
as GSH (Schafer and Buettner, 2001). This indicates that sulfhydryl-containing proteins
(such as Hsp27) can act as antioxidants (Schafer and Buettner, 2001). In fact, the
activity of a cysteine-containing bacterial chaperone, Hsp33, appears to be regulated by
its redox-status, such that oxidising conditions lead to the formation of disulfide bonds
and activates its chaperone function (Jakob et al., 1999, Graf et al., 2004, Hoffmann et
al., 2004, Segal and Shapira, 2015). Interestingly, C137 of Hsp27 aligns with C139 of
the E. coli Hsp33 and the surrounding amino acids are well conserved (alignment shown
in Appendix II). These data suggest that Hsp27 may act in a similar fashion to Hsp33 in
response to oxidative stress.
Schafer and Buettner (2001) discuss in detail the various types of thiol modifications
that occur in the cell in response to changes in redox status, one of which is the
formation of mixed disulfides such that:
①

in which

①PSH

and

𝑃𝑃𝑃𝑃𝑃𝑃 +

②PS-SG

②

𝑃𝑃𝑃𝑃 ̵𝑆𝑆𝑆𝑆 →

①

𝑃𝑃𝑃𝑃 ̵𝑆𝑆𝑃𝑃② + 𝐺𝐺𝐺𝐺𝐺𝐺

represent a free sulfhydryl-containing protein, and a

glutathione disulfide-bound second sulfhydryl-containing protein, respectively (reaction
mechanism modified from Schafer and Buettner (2001)). Through this mechanism,
Hsp27 may act as either ①PSH and/or ②PS-SG. In the case that Hsp27 was in the form

of ①PSH, ②PS-SG would represent another protein bound to glutathione in response to
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oxidative stress; Hsp27 would therefore replace GSH and remain bound to

②PS-SG

(forming ①PS-SP②) until such time as the redox environment became more favourable.

In the case that Hsp27 was in the form of
sulfhydryl-containing protein (i.e.

①PSH)

②PS-SG,

its interaction with another free

would similarly be one that protects other

proteins from oxidative damage. Finally, if both ①PSH and ②PS-SG represent forms of

Hsp27, this would act to maintain glutathione in a reduced state, such that GSH is free

to interact with other cellular components prone to damage from oxidative stress. In all
three cases, the end result is that proteins prone to oxidation are protected by the redoxsensitivity of Hsp27 as a result of C137, and glutathione is maintained in a reduced
state.
Considering that the formation of disulfide bonded dimers of Hsp27 is relevant to its
chaperone function (Eaton et al., 2002, Chalova et al., 2014a), the effects of diseasecausing mutations on the strength of the disulfide bond was examined. Mutations in the
vicinity of C137 and the dimer interface (i.e. Hsp27R127W, Hsp27S135F, Hsp27R136W and
Hsp27R140G) are more susceptible to reduction compared to Hsp27WT. This correlates
with the findings of Almeida-Souza et al. (2010) who found that the disease-related
mutant isoforms Hsp27R127W and Hsp27S135F result in increased monomerisation of the
protein, accompanied by increased chaperone activity compared to Hsp27WT. This
suggests that mutations in the αCD of Hsp27 disrupt the formation of disulfide-bonded
dimers, which may in turn, affect its chaperone activity.
The overall stability of the Hsp27 isoforms and the impact of the redox-status of the
protein was assessed by determining their melting temperature via dynamic light
scattering. The melting temperatures of Hsp27P39L and Hsp27G84R were the most similar
to Hsp27WT, indicating that these mutations in the N-terminal region of the protein do
not impact the thermostability of the protein. In contrast, as the melting temperatures of
Hsp27R127W, Hsp27R136W, and Hsp27R140G were all increased compared to Hsp27WT, this
suggests that replacement of positively charged arginine residues in the αCD with either
a hydrophobic (tryptophan) or non-charged (glycine) residue increases the
thermostability of Hsp27. This may be related to increased hydrophobic interactions
along the dimer interface of the protein, which, in the wild type protein, is partially
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stabilised by the formation of a salt bridge between R140 of one Hsp27 monomer and
D129 of the other (Alderson et al., 2019b).
Preservation of the positive charge at R116 of αA-crystallin (equivalent to R140G in
Hsp27), is necessary for normal αA-crystallin structure and function (Bera and
Abraham, 2002, Bera et al., 2002), and mutation of R116 in αA-crystallin causes
congenital cataract (Shroff et al., 2000). An R120G mutation in αB-crystallin (also
equivalent to R140 of Hsp27) is associated with desmin-related myopathy (Vicart et al.,
1998). This mutation in αB-crystallin supresses chaperone activity against the
aggregation of α-lac, alcohol dehydrogenase, and insulin, and is associated with altered
secondary structure, increased oligomer size and reduced stability compared to Hsp27WT
(Bova et al., 1999, Treweek et al., 2005). Taken together, these results highlight that
mutations at the R140 site in Hsp27 (or equivalent site in other sHsps) have a significant
effect on the structure and function of the protein. Indeed, in this work Hsp27R140G was
found to have a disulfide bond more susceptible to reduction, a larger oligomeric
distribution, higher increased thermostability, an increase in α-helical content, and
highly variable chaperone activity.
The impact of disease-related mutations on the oligomeric size distribution of Hsp27
was assessed by DLS under non-reducing and reducing conditions. The size distribution
of oligomers was increased for every mutant isoform compared to Hsp27WT, with the
exception of Hsp27T151I and Hsp27P39L. Interestingly, the distribution of Hsp27WT was
affected most by addition of DTT, with a distinct decrease in size-range. There was little
correlation, however, between oligomeric distribution and chaperone activity against the
aggregation of target proteins, either under reducing or non-reducing conditions. Indeed
Hsp27R140G and Hsp27S135F each display a similar size distribution, but do not confer the
same anti-aggregation properties as one another against the various model proteins
tested.
In contrast to the findings of Rajagopal et al. (2015), who observed an increase in bisANS fluorescence in oxidised Hsp27 compared to reduced Hsp27, the results of this
work revealed that fluorescence intensity of bis-ANS binding to Hsp27WT was relatively
unaffected by the presence of DTT. Nonetheless, each of the disease-causing mutant
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isoforms displayed an increase in bis-ANS binding under non-reducing conditions
compared to reducing conditions, indicating that more regions of hydrophobicity are
exposed in these mutants under oxidative conditions. It has been proposed that an
increase in exposed hydrophobicity correlates with increased chaperone function in the
sHsps (Peschek et al., 2009, Peschek et al., 2013); however, this is likely to be highly
dependent on the client protein and experimental conditions used to assess chaperone
function (see discussion below). Interestingly, all the disease-causing mutant isoforms
of Hsp27 also exhibited increased β-sheet content compared to Hsp27WT under nonreducing conditions. Together, these results suggest that mutations in Hsp27 may cause
disease through a toxic gain-of-function mechanism related to an increase in exposed
hydrophobicity under non-reducing conditions. This is in agreement with the work of
Almeida-Souza et al. (2010) who first suggested a gain-of-function disease mechanism
for the Hsp27R127W, Hsp27S135F, Hsp27R136W, and Hsp27T151I mutations based on
increased monomerisation in mutant isoforms, accompanied by increased chaperone
activity in the refolding of luciferase in SH-SY5Y cells, and increased binding to client
proteins. Interestingly, the strength of the disulfide bond was found to be weakest in
Hsp27S135F, and this mutant also had the largest size and range of oligomers, most
exposed hydrophobicity and it was more effective at preventing the aggregation of αsyn, CPK and rhodanese than Hsp27WT.
The oligomeric state of Hsp27 is highly dynamic, and is thought to regulate its
interactions with other proteins. Oligomer formation is facilitated by dimer formation,
mainly mediated by interactions of the αCD and disulfide bonding (Baranova et al.,
2011, Jovcevski et al., 2015), and the assembly of dimers into larger oligomers, which
involves interactions of the N-terminal unstructured region, and the IXI motif in the Cterminal region (Hilton et al., 2013, Alderson et al., 2019). Oligomer dissociation is
driven by phosphorylation and dilution of the protein, which drive the equilibrium
toward dimeric species (Hayes et al., 2009, Jovcevski et al., 2015). The influence of the
oligomeric state of Hsp27 on its chaperone function remains equivocal; many have
concluded that phosphorylation increases chaperone activity (e.g. Shashidharamurthy et
al. (2005), Jovcevski et al. (2015)), others have reported no difference (e.g. Knauf et al.,
(1994)), whilst yet others have reported that phosphorylation decreases chaperone
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activity (e.g. Rogalla et al., (1999)). The chaperone activity of the Hsp27 isoforms
against the aggregation of α-syn was highly variable at the 1:40 ratio (corresponding to
1.25 µM Hsp27), and less variable at both higher (2.5 µM) and lower (0.5 µM )
concentrations (especially in the absence of DTT). This may be an effect of variable
oligomeric size resulting from dissociation at this intermediate concentration – indeed
the distribution of oligomeric sizes increases with decreasing concentrations to as low as
2.9 µM (Jovcevski et al. 2015), however the concentration at which Hsp27 fully
dissociates into smaller species is unknown. Overall, the population of smaller
oligomers is relatively high at the concentrations used in this assay and would be
consistent with higher chaperone activity resulting from small oligomers.
Interestingly, the ability of all of the Hsp27 isoforms to inhibit rhodanese aggregation
was more variable at higher concentrations of the chaperone, and in the absence of DTT
(i.e. the conditions under which the oligomeric distribution of Hsp27 would mostly
favour larger oligomers, but smaller oligomers would also be present). Chaperone
activity increased and became less variable when the Hsp27s were used at a lower
concentration in the absence of DTT, or upon the addition of DTT. This suggests that
smaller sized oligomers may be more effective at inhibiting the heat-induced amorphous
aggregation of rhodanese. This is consistent with the findings of Alderson et al.
(2019b), who reported that reduction of Hsp27 increases the proportion of monomers,
and increases its chaperone activity against the aggregation of CS. Moreover, a purely
monomeric Hsp27 mutant (Hsp27H124K/C137S) was more potent in preventing the
aggregation of lactalbumin than dimeric (but not disulfide-bonded) Hsp27C137S
(Alderson et al., 2019b). These data support a model in which decreased oligomer size
increases the capacity of Hsp27 to inhibit the aggregation of certain target proteins.
It should be noted, however, that the chaperone activity of each of the Hsp27 isoforms
was highly variable between biological replicates of in vitro aggregation assays, and
that no single isoform showed consistently higher or lower chaperone activity across the
different client proteins utilised in comparison to Hsp27WT (e.g. Hsp27R136W was
significantly more effective in preventing the aggregation of CPK than Hsp27WT, but
less effective in preventing the aggregation of rhodanese). This variability made it
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impossible to draw clear conclusions on the effect of disease-causing mutations on the
chaperone function of Hsp27. Indeed, many published aggregation assay results either
do not report the number of independent replicates used (e.g (Shendelman et al., 2004))
or report only one replicate (e.g. (Jakob et al., 1993, Lindner et al., 2000, Kim et al.,
2004), which leaves the potential effects of variability on the conclusions drawn
somewhat ambiguous.
A drawback to using aggregation assays specifically to assess the effects of redox state
on chaperone activity is that aggregation dynamics are usually altered by changing
redox conditions, as is shown by the decreased overall aggregation of α-syn, CPK and
rhodanese under reducing conditions, compared to non-reducing conditions. Similarly,
sourcing suitable non-chaperone control proteins for aggregation assays can prove
challenging, given that many display different characteristics under different redox
conditions. For example, the increase in aggregation of CPK with SOD1 (as the control)
under reducing conditions, and the slight decrease in α-syn aggregation under reducing
conditions in the presence of CPK (as the control). Nevertheless, while these proteins
may not be the ideal controls, the differences are not to a degree comparable to those
seen in presence of the Hsp27 isoforms, so it can still be concluded that any reduction in
aggregation was due to the chaperone activity of Hsp27. While aggregation assays
provide a useful tool as an indicator of chaperone activity against an isolated model
aggregation protein (which is often unlikely to be a natural interactor of Hsp27), they do
not take into account the stoichiometry of protein aggregation dynamics, the range and
abundance of potential interactors in a physiological setting, and the influence of the
cellular environment in which these proteins reside. Furthermore, as Hsp27 has various
functions outside of its chaperone activity, aggregation assays provide limited
information on the mechanisms by which mutations may cause disease. As such, better
methods for exploring the influence of mutations on the function of Hsp27 in are
required, since these will provide valuable insights into understanding the basis of CMT
and dHMN progression.
Four observations provide evidence that the disease-related mutations in Hsp27 lead to
partial unfolding of the protein; (i) the observed decrease in tryptophan fluorescence
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(i.e. higher solvent exposure) for all mutants (except Hsp27S135F), (ii) the decrease in
tryptophan fluorescence of all samples upon reduction, (iii) the decreased exposed
hydrophobicity of all of the mutant isoforms, and (iv) the decrease in β-sheet content
upon reduction. The observed unfolding of Hsp27 upon mutation correlates with
previous work using NMR that reported that monomerisation of Hsp27 results in partial
unfolding of the protein due to the dimer interface becoming more dynamic (Alderson
et al., 2019b). Given that most of the residues in the region of the dimer interface are
charged or polar, mutations in this region may alter the electrostatic state, and lead to
variations in (partial loss of) secondary structure, resulting in changes to the oligomeric
state of Hsp27 and its interactions with other proteins. Based on the results presented in
this chapter, this effect may be especially enhanced under reducing conditions. Further
analysis of the dynamics of oligomer formation in disease-causing Hsp27 mutants
would lead to a better understanding of these mechanisms.
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5 The effect of Hsp27 on neurite outgrowth, axonal
transport of mitochondria, and mitochondrial morphology
5.1
5.1.1

Introduction
Neuronal differentiation, axon survival, and interactions with the
cytoskeleton

The neuronal cytoskeleton is an elaborate system made up of three main structures:
microtubules, actin filaments, and intermediate filaments (including neurofilaments
which are exclusively expressed in neurons). The cytoskeleton in motor neurons is
particularly important in maintaining the structure and proper function of long axonal
projections. A variety of other proteins are involved in modulating cytoskeleton
dynamics, and many more utilise the structural network of the cytoskeleton to modulate
processes that include cell growth, differentiation, transport and anchoring of organelles
and other cellular cargo (including axonal transport), cell-cell interactions and
signalling. Of the approximately 80 different genes in which mutations cause CMT
and/dHMN, many are involved in cell growth and differentiation, including gene
expression and specific neuronal differentiation (Baxter et al., 2001) and cytoskeleton
formation and maintenance (De Jonghe et al., 2001, Brownlees et al., 2002, Fabrizi et
al., 2006, Abe et al., 2009, Almeida-Souza et al., 2011).
Various roles of Hsp27 in modulating cytoskeleton dynamics have been identified,
including interactions with microtubules, actin filaments and neurofilaments. Hsp27
localises with tubulin and microtubules in HeLa (Hino et al., 2000) and CHO (Hargis et
al., 2004) cells and is suggested to play a role in stabilisation of microtubules (Casado et
al., 2007). This interaction may be via direct interaction of Hsp27 with tubulin, or
through chaperoning of other microtubule-associated proteins. For example, Hdac6 is
responsible for the deacetylation of tubulin (Hubbert et al., 2002). Acetylated α-tubulin
is a stabiliser of microtubules, and in HeLa cells in which Hsp27 has been knocked
down, Hdac6 is depleted, and tubulin is hyperacetylated, leading to potential overstabilising of the dynamic microtubule network (Gibert et al., 2012).
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Hsp27 influences the polymerisation of actin (Lavoie et al., 1993, Lavoie et al., 1995,
Huot et al., 1996, Guay et al., 1997) by acting as an actin-capping protein promoting
both filament branching (Pichon et al., 2004) and disassembly (Miron et al., 1988,
Miron et al., 1991), stabilisation of the existing actin filament network (Pichon et al.,
2004), and/or inhibition of actin depolymerisation under cytotoxic stress (Lavoie et al.,
1993). The expression levels of Hsp27 during development appear to be tightly related
to actin content and molecular organisation (Aquino et al., 1996), suggesting that these
roles in actin filament formation are linked to cell growth and differentiation.
The interactions of Hsp27 with neurofilaments are less studied, but disruptions to the
neurofilament network are associated with CMT and dHMN-causing mutations in
Hsp27 (Ackerley et al., 2006, Holmgren et al., 2013), while mutations in neurofilament
genes also cause CMT (Mersiyanova et al., 2000, De Jonghe et al., 2001, Jordanova et
al., 2003, Abe et al., 2009) and are linked to defects in neurofilament assembly and
axonal transport (Brownlees et al., 2002).
Correct cytoskeleton assembly and dynamics are essential for cell growth and
differentiation, and the effects of Hsp27 modulation of the cytoskeleton are linked to
these processes. Hsp27 has been implicated in differentiation (Mehlen et al., 1999),
neurite development (Williams et al., 2005, Williams et al., 2006, Shi et al., 2008,
Williams and Mearow, 2011), neuronal survival (Mehlen et al., 1999), and axonal repair
after injury (Lewis et al., 1999, Benn et al., 2002, Kalmár et al., 2002). Moreover, it is
possible that Hsp27 plays a role in axon formation, or the regeneration of axons in
motor and/or sensory neurons of the peripheral nervous system (which can be
regenerated after damage, unlike those of the central nervous system). It is unknown,
however, whether these functions are a result of the anti-apoptotic, anti-oxidative-stress,
protein quality control, cytoskeleton stabilisation, or some other activity of Hsp27 (or a
combination of these).
Axonal maintenance and function rely on a constant supply of energy via mitochondrial
transport. Proteins synthesised in the cell body (such as neurofilaments, actin and
tubulin) (Hoffman and Lasek, 1975, Lasek and Hoffman, 1976, Hoffman and Lasek,
1980), organelles, and protein synthesis machinery, all undergo anterograde transport
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from the cell body. In addition, the turnover and retrograde transport of signalling
molecules, organelles and proteins are essential to axonal integrity and patency
(reviewed in Grafstein and Forman (1980)). Actin, as well as providing structural
support for the cell, is also important in the transport of cellular cargo (Hasaka et al.,
2004). This suggests that cytoskeleton stabilisation by Hsp27 may influence cellular
transport, and that mutations may lead to destabilisation of actin microfilaments and
other cytoskeletal elements. In turn, this would have a negative effect on cell and axon
structure, as well as on the transport of cellular cargo.
5.1.2

Mitochondrial dynamics

Mitochondria are responsible for signalling in cell-death pathways (reviewed in Elmore
(2007)), production of ROS and maintaining redox homeostasis (reviewed in Willems et
al. (2015)), production of neurotransmitters (Sandoval, 1980), steroids (Rossier, 2006)
and heme compounds (Barros et al., 2002), maintaining intracellular calcium levels and
signalling (Nicholls and Åkerman, 1982, Kirichok et al., 2004), and providing energy in
the form of ATP, via electron transport. In neurons, the production of ATP and
maintenance of calcium homeostasis is essential in neuronal excitability and survival
(Ichas et al., 1997, Kann and Kovács, 2007). The mitochondria are highly dynamic
organelles, and processes of transport, fusion, fission and mitophagy control their
morphology. Mitochondrial morphology itself is tightly linked to the function of these
organelles and facilitates quality control and the exchange of mitochondrial DNA,
lipids, and proteins (Bereiter-Hahn, 1990, Nunnari et al., 1997).
In neurons, mitochondria are produced in the cell body, and undergo both anterograde
and retrograde axonal transport, which involves transport along microtubules and actin
filaments, and interactions with kinesins, dynein, myosin V and various other proteins,
some of which are yet to be identified (reviewed in Hollenbeck (2005), Hollenbeck and
Saxton (2005) and Saxton and Hollenbeck (2012)). A fraction of mitochondria also
remain static in the synapses of axons, and are involved in energy supply, neuronal
firing, and signalling (Chang et al., 2006, Sheng and Cai, 2012), before being
transported back to the cell body, fused with “new” mitochondria that have arrived via
anterograde transport, or degraded via mitophagy (Hollenbeck, 2005, Ashrafi et al.,
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2014). Alterations to both mitochondrial transport and function have been implicated in
various neurodegenerative disorders including Alzheimer’s, Parkinson’s, Huntington’s
and Wilson’s diseases, Amyotrophic Lateral Sclerosis, Friedrich’s ataxia, multiple
sclerosis, and mitochondrial encephalomyopathies (reviewed in Sas et al. (2007) and
Mattson et al. (2008)). Furthermore, mitochondrial dysfunction and disruption of
mitochondrial transport are associated with the pathology of various forms of CMT and
dHMN (Züchner et al., 2004, Kijima et al., 2005, Niemann et al., 2005, Pedrola et al.,
2005, Engelfried et al., 2006, Baloh et al., 2007, Cassereau et al., 2009, Pitceathly et al.,
2012, Kalmar et al., 2017), including those resulting from mutations in Hsp27 (Kalmar
et al., 2017). Despite this, the specific mechanisms by which Hsp27 impacts
mitochondrial function are, as yet, not understood, but may result from direct
interactions with mitochondrial proteins, or with proteins involved in axonal transport
or cytoskeletal organisation.
5.1.3

Aims

The aims of the work presented in this chapter were to:
1. Establish a system for the use of shRNA to knockdown Hsp27 in human neuronlike SH-SY5Y cells.
2. Use Hsp27-knockdown to assess the role of Hsp27 on neurite outgrowth during
neuronal differentiation, and
3. Use Hsp27-knockdown to establish the potential role of Hsp27 in axonal
transport of mitochondria, and in mitochondrial morphology in human neuronlike cells.

5.2 Materials and methods
5.2.1

Plasmid constructs

A plasmid for the expression of C-terminally Myc-tagged Hsp27WT (Hsp27WT-c-Myc) was
cloned by Ms. Le May Thai (School of Biological Sciences, University of Wollongong,
Australia). Plasmids for the mammalian co-expression of GFP and four unique antiHsp27 29mer shRNA sequences (TG320383; pGFP-V-RS-G1378749, G1378750,
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G1378751, & G1378752; henceforth referred to as pGFP-V-RS-1, -2, -3, and -4,
respectively)

and

a

negative

control

scrambled

RNA

sequence

(5'

GCACTACCAGAGCTAACTCAGATAGTACT 3') were purchased from OriGene
Technologies (Rockville, MD, USA).
5.2.2

Immunoprecipitation of Hsp27WT-c-Myc

To determine whether Hsp27 interacts with components of the cytoskeleton, NSC-34
cells at ~80% confluency in a T25 flask were transfected with the plasmid encoding
Hsp27WT-c-Myc, and incubated for 48 h (with media changed at 16 h) to allow protein
expression. Cells were then lifted by scraping, washed twice with ice-cold PBS, then
resuspended in 700 µL ice-cold lysis buffer (5 mM EDTA, 0.5% Triton X-100 in PBS,
pH 7.4, supplemented with 1 × Halt™ Protease and Phosphatase Inhibitor Cocktail).
Cells were incubated on ice for 30 min, with brief vortexing every 5 min. Lysates were
cleared by centrifugation (20 000 × g, 10 min, 4°C), and the supernatant was retained.
Total protein concentration was determined by BCA assay (Section 2.2.3). Meanwhile,
50 µL of anti-c-Myc Affinity Gel (A7470; Sigma-Aldrich) beads were washed five
times in PBS, before addition of lysate at a 1:0.5 ratio (µL bead:µg total protein)
following optimisation of maximal protein-bead binding. The total volume was adjusted
to 300 µL using lysis buffer, and samples were incubated overnight at 4°C on an orbital
shaker. Beads and bound proteins were then separated from the unbound supernatant by
centrifugation at 20 000 × g, 30 s. Beads were then washed four times with 1 mL of icecold PBS, leaving behind approximately 10 µL of PBS with the beads after the final
wash. Samples were then prepared for SDS-PAGE separation by addition of nonreducing SDS-PAGE loading buffer directly to the bead sample or unbound sample, and
incubation at 95°C for 5 min. Samples were then separated by SDS-PAGE, transferred
to PVDF membrane, and probed for the presence of Hsp27 and β-actin.
5.2.3

shRNA knockdown of endogenous Hsp27 in SH-SY5Y cells

SH-SY5Y cells, a neuron-like cell line was chosen for its high expression levels of
endogenous Hsp27. To determine which of the shRNA sequences resulted in the most
efficient knockdown of Hsp27, cells were transfected with each of the four pGFP-VRS-shRNA plasmids, as well as the shRNA scrambled control. After 72 h, cells were
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lifted with trypsin, washed twice with PBS, and resuspended in sterilised fluorescenceactivated cell sorting (FACS) buffer (25mM HEPES, 1 mM EDTA, 0.5% (w/v) BSA
(added fresh) in PBS, pH 7.0). Cells were strained through an EASYstrainer 40 micron
nylon mesh (Greiner Bio One) to remove clumps before analysis. Cells were then sorted
using an S3e Cell Sorter, with excitation by a 488 nm laser, and a 502 – 550 nm
emission filter (Bio-Rad) to purify transfected (GFP-positive) cells. Gating was set such
that cell debris was eliminated (based on forward- and side-scatter), and GFP-positive
and GFP-negative cells were separated (based on green fluorescence) and both were
collected, with cell counts recorded. Fifty thousand cells from each sample were then
washed twice with PBS, collected by centrifugation (1 000 × g, 10 min), and lysates
were prepared and analysed by SDS-PAGE (using stain-free gels) and immunoblotting
for Hsp27. The intensity of bands on the membrane was normalised using the
densitometry of the corresponding lane of the stain-free membrane taken prior to
blocking.
5.2.3.1 Differentiation of SH-SY5Y-Hsp27-knockdown cells

To determine the effect of knocking down Hsp27 on neurite development of SH-SY5Y
cells, cells were seeded into 96-well microplates at a density of 20 000 cells/mL, precoated with MaxGel ECM substrate (Section 2.2.5.2), transfected with the pGFP-V-RS1 (anti-Hsp27 shRNA) or the scrambled control construct, and incubated for 72 h. Cells
were then differentiated in 1% (v/v) FBS DMEM-F12 with 10 µM retinoic acid (RA;
refreshed every 48 h with half-media changes). Neurite outgrowth was monitored using
the IncuCyte Zoom, with images taken every 3 h and analysed using the IncuCyte
NeuroTrack software module (Essen Bioscience). As readings were highly variable
between consecutive time points (likely a result of disturbances when the machine was
opened), the end point was taken as the average of readings of neurite lengths or branch
point counts between 60 h and 72 h (which represented the “plateau” phase of neurite
extension).
5.2.3.2 Tracking the axonal transport of mitochondria in SH-SY5Y-Hsp27-knockdown
cells

Cells seeded into 8-well µ-slides were differentiated as previously described (Section
2.2.5.2). Cells were then transfected with pGFP-V-RS-G1378749, incubated for 72 h,
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and stained with 150 nM MitoTracker Red CMXRos for 30 min at 37°C. Culture media
was changed to remove any free dye, then live cells were imaged using a HCX PL APO
CS 100.0×/1.40 oil objective on a Leica SP5 confocal microscope, in 5% atmospheric
CO2, with incubation at 37°C. Images were taken every min, for 15 to 20 min from both
GFP-positive (Hsp27-knockdown cells) and GFP-negative (untransfected) cells. As
laser-exposure induced neurite-retraction the image format was reduced to 512 × 512
pixels, and the 488 laser power was lowered to 1% intensity after the initial scan,
thereby allowing identification of transfected cells for analysis while minimising cell
damage. Images were analysed for mitochondrial transport with CellProfiler (Carpenter
et al., 2006, Kamentsky et al., 2011) using the TrackObjects module with the pipeline
modified to suit mitochondrial movement, and restricted to the neurites of either
untransfected cells, or cells transfected with anti-Hsp27 shRNA or the shRNA
scrambled control. The CellProfiler TrackObjects outputs used in analysing
mitochondrial transport and/or morphology are shown in (Table 5.1). These data were
then deconvolved to yield “per mitochondria” results using R 3.5.0 (R Development
Core Team, 2018), and all distance data was converted to µm/min based on individual
image magnification. The X and Y trajectories, and the position of the cell body in each
image were used to manually determine the direction of transport (i.e. anterograde or
retrograde). The mitochondrial network formations were analysed using the
Mitochondrial Network Analysis (MiNA) plugin for ImageJ (Valente et al., 2017).
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Table 5.1: The CellProfiler/TrackObjects and MiNA measurement outputs used in
assessing mitochondrial transport and morphology.
CellProfiler per-object outputs
Output name

Description

TrajectoryX/TrajectoryY

The direction of motion (in x- and y-coordinates) of the object from the previous
frame to the current frame.

Distance travelled

The distance travelled by the object from the previous frame to the current
frame (calculated as the magnitude of the trajectory vectors).

Integrated distance

The total distance traveled by the object during the lifetime of the object.

Linearity

A measure of how linear the object trajectory is during the object lifetime.
Calculated as (displacement from initial to final location)/(integrated object
distance). Value is in range of [0,1].

Eccentricity

The eccentricity of the ellipse that has the same second-moments as the region.
The eccentricity is the ratio of the distance between the foci of the ellipse and its
major axis length. The value is between 0 and 1 (0 and 1 are degenerate cases;
an ellipse whose eccentricity is 0 is actually a circle, while an ellipse whose
eccentricity is 1 is a line segment).
CellProfiler per-image outputs

Split object count

The number of objects in the current frame that resulted from a split from a
parent object in the previous frame.

Merged object count

The number of objects in the current frame that resulted from the merging of
child objects in the previous frame.
MiNA outputs

Branch length mean

The mean length of all the lines used to represent the mitochondrial structures.

Network branches mean The mean number of attached lines used to represent each structure.

5.3 Results
5.3.1

Hsp27WT binds to β-actin in NSC-34 cells

To assess whether an interaction between Hsp27WT and the cytoskeletal component βactin occurs in motor-neuron-like NSC-34 cells, a co-IP using Myc-tagged Hsp27 and
anti-Myc-conjugated agarose beads was performed. Immunoblotting of the resulting
fractions showed that the lysate from the untransfected control sample did not contain
any Hsp27 (or Hsp25, which was also detectable with the anti-Hsp27 antibody used),
while lysate from cells transfected with the plasmid encoding Hsp27WT-c-Myc showed a
dense band at approximately 25 kDa, indicating the presence of Hsp27 in the lysate
(Figure 5.1). As expected, the negative control containing the anti-Myc conjugated
beads in the presence of untransfected cell lysate did not contain any Hsp27. From the
sample in which anti-Myc-conjugated beads were incubated with lysate from
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transfected cells, the unbound (UB; supernatant) fraction contained an extremely faint
band corresponding to Hsp27. In contrast, the sample eluted from the beads showed a
strong band at approximately 25 kDa, and a fainter band at approximately 50 kDa,
indicative of monomeric and dimeric Hsp27, respectively. Incubation of the same bound
protein blot with an antibody against β-actin revealed two additional bands; one at
approximately 42 kDa corresponding to β-actin, and another at approximately 250 kDa.
The latter band corresponds to the non-reduced anti-Myc antibody, which is bound by
the anti-rabbit secondary antibody used to probe for β-actin. Probing of the
untransfected bound sample for β-actin showed the band corresponding to the anti-Myc
antibody, but no band corresponding to β-actin, indicating that the interaction is specific
to Hsp27-transfected samples (Figure 5.1).

Figure 5.1: Hsp27 interacts with β-actin in NSC-34 cells. NSC-34 cells (either untransfected, or
transfected with Hsp27WT-c-Myc) were lysed, and incubated with anti-Myc antibody-conjugated agarose
beads, at a ratio of 1:0.5 (µL bead:µg total protein), to precipitate Hsp27 and any interacting proteins.
Samples of purified recombinant Hsp27WT (Rec), untransfected NSC-34 lysate (UT Lys), lysate from
transfected NSC-34 cells (WT Lys), bound protein resulting from the incubation of anti-Myc-conjugated
beads with untransfected (UT Bound) or transfected (WT Bound) NSC-34 lysates, and unbound protein
resulting from the incubation of anti-Myc-conjugated beads with untransfected (UT Unbound) or
transfected (WT Unbound) NSC-34 lysates were analysed by SDS-PAGE and immunoblotting for Hsp27.
The blot containing bound proteins was then re-probed for the presence of β-actin in the untransfected
(UT β-A) and transfected (WT β-A) samples. The positions of molecular weight markers are indicated to
the left, and the identity of each band is indicated to the right.

5.3.2

Hsp27WT localises throughout the cytoplasm of SH-SY5Y cells, and in
neurite outgrowths

To determine whether Hsp27 localises to neurite outgrowths, and/or colocalises with βtubulin, differentiating SH-SY5Y cells were immunolabelled for endogenous Hsp27
and β-tubulin. Hsp27 was expressed in a diffuse pattern throughout the cytoplasm and
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in the neurites, and was absent from the nucleus (Figure 5.2A). Of note is the presence
of Hsp27 in the branch points and growth cones of neurites (Figure 5.2A). β-Tubulin
showed low level expression in the cytoplasm, and instead localised mainly to neurite
projections (Figure 5.2A). Isotype controls for the anti-Hsp27 and anti-tubulin controls
showed no signal from the respective secondary antibodies, indicating that the signal
recorded for each protein was specific (Figure 5.2B).

Figure 5.2: Hsp27 localisation in differentiating SH-SY5Y cells. SH-SY5Y cells were seeded
into MaxGel-coated Ibidi chamber slides, and treated with RA for 72 h. A: Endogenous Hsp27 (magenta)
was labelled with anti-Hsp27 primary and DyLight 650-conjugated secondary antibodies, and β-tubulin
(green) was labelled with an anti-β-tubulin and DyLight 488-conjugated secondary antibodies. A merged
image of both proteins showing colocalisation is shown to the right. Arrow heads indicate growth cones.
B: Mouse IgG1 and Rabbit IgG isotype controls, and appropriate DyLight-conjugated secondary
antibodies were used to ensure that labelling of Hsp27 and β-tubulin (respectively) was specific. Images
of fluorescence signals and fluorescence merged with the corresponding bright field images are shown for
each. Cells were imaged using a Leica Confocal SP5 system and a 63x oil immersion objective. Scale
bars represent 50 µm.
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5.3.3

shRNA knockdown substantially reduces expression of Hsp27 in
transfected SH-SY5Y cells

In order to determine whether Hsp27 plays a role in the differentiation of neuronal cells,
and the transport of mitochondria in these cells, a method of knocking down the
expression of endogenous Hsp27 in SH-SY5Y cells using shRNA-encoding plasmids
was developed. SH-SY5Y cells transfected with plasmids encoding shRNA sequences
against Hsp27 (pGFP-V-RS-1, -2, -3, and -4) or the scrambled control, were sorted to
purify transfected cells using the co-expressed GFP encoded in the plasmids (Figure
5.3A, B). Forward and side-scatter indicated that ~90% of cells were viable in the
scrambled control sample (Figure 5.3A), and similar results were obtained for each of
the shRNA plasmid-transfected cells (data not shown). Of this viable population, ~30%
of cells were GFP-positive in the scrambled control (Figure 5.3B), with the samples
transfected to express the other four shRNA ranging from 20 – 35% GFP-positive cells.
Fifty thousand cells from each GFP-positive population were lysed and analysed by
immunoblotting (Figure 5.3C (top panel)). A stain-free image of the membrane prior to
blocking was used to ensure approximately equal loading of protein between samples
(Figure 5.3C (bottom panel)). An intense band at ~25 kDa was present in the scrambled
control sample but was less intense in each of the shRNA-transfected cell samples.
When quantified by densitometry (normalised to the total lane densitometry of the stainfree image), the expression levels of Hsp27 were decreased by 96, 60, 66, and 16% in
cells transfected with pGFP-V-RS-1, -2, -3, and -4 (respectively), compared to cells
transfected with the plasmid encoding the scrambled control (Figure 5.3D). The pGFPV-RS-1 construct and the scrambled control were therefore used in subsequent
experiments.
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Figure 5.3: Hsp27 knockdown in SH-SY5Y cells using shRNA-expressing plasmids. A: SHSY5Y cells were gated based on forward and side-scatter to isolate viable cells. The untransfected
negative control is shown, and similar results were obtained for cells transfected with each of the four
shRNA-encoding plasmids, and the scrambled control. B: Viable cells as determined by forward and
side-scatter were then gated based on GFP-fluorescence (indicating transfection). The untransfected
sample ( ) used to determine the GFP-negative population, and cells transfected with the scrambled
control ( ) are shown. C: The GFP-positive cells were sorted and collected, and 50 000 cells from the
scrambled control (S), and each of the four shRNA-encoding plasmids (1 – 4) were lysed and analysed by
(top panel): immunoblotting against Hsp27, with (bottom panel): equal loading indicated by stain-free
imaging of the blot before blocking. The positions of molecular weight standards are indicated to the left.
D: Densitometry of the bands shown in C was used to analyse the relative amount of Hsp27 present in
each sample, normalised to total protein (the total densitometry of the stain-free lanes). These results were
then used to assess the reduction in Hsp27 expression in cells transfected with each of the four shRNAencoding plasmids (1 – 4), compared to cells transfected with the scrambled control.

5.3.4

Knockdown of Hsp27 expression slows the rate of neurite outgrowth and
increases neurite branching in SH-SY5Y cells

In order to assess whether Hsp27 plays a role in neurite outgrowth during neuronal
differentiation, neurite outgrowth in SH-SY5Y cells was assessed using the IncuCyte,
and the IncuCyte-Zoom NeuroTracker analysis platform. After 72 h, cells treated with
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RA-alone showed an increased neurite length of approximately 200 mm/mm2 of cell
body area, and an increase in branch points of approximately 20 per mm2 of cell body
area, compared to untreated cells (Figure 5.4A – C). Cells transfected with pGFP-V-RS1 (and then incubated for 72 h before treatment to allow expression of shRNA and
knockdown of Hsp27) showed a significantly decreased neurite length after 72 h
compared to cells transfected with the scrambled control construct (55.3 ± 3.0 mm/mm2
compared to 145 ± 22.1 mm/mm2, respectively, (unpaired t(30) = 2.714, p = 0.019))
(Figure 5.4D – F). While the total length of neurites was smaller, these short neurites
showed significantly higher numbers of branch points in cells in which Hsp27 was
knocked down, compared to the scrambled control (161.5 ± 34.5 per mm2 compared to
45.9 ± 14.2 per mm2, respectively, (unpaired t(30) = 3.099, p = 0.0042)) (Figure 5.4D –
G).
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Figure 5.4: Knockdown of Hsp27 decreases neurite length and promotes the formation of
short, branched neurites in differentiating SH-SY5Y cells. A: SH-SY5Y cells were plated at
low density in 96-well plates coated with MaxGel ECM substrate, then treated 16 h later with 10 µM RA
in DMEM-F12 cell media, supplemented with 1% (v/v) FBS to promote exit of the cell cycle, and neurite
outgrowth. Cells were imaged using the IncuCyte and analysed starting at time 0 (top panel) to 72 h
(lower panel) using the IncuCyte Zoom NeuroTrack analysis software. The mask overlay shows the
detected cell-bodies in yellow, and the neurites in magenta. The right-hand panel shows a zoomed phasecontrast image of the area indicated by the solid or dotted rectangles in the mask overlay. B: Tracking of
the neurite length measured as a function of cell body area over the 72 h period for cells either treated
with RA (
), or untreated (
). C: Tracking of the neurite branch points measured as a function of cell
body area over the 72 h period for cells either treated with RA (
), or untreated (
). D and E: SHSY5Y cells plated as in A, were transfected with the plasmids encoding the shRNA scrambled control (D)
or anti-Hsp27 shRNA (E), incubated for 72 h to allow expression and knockdown, before treatment with
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10 µM RA. The images shown are at the 72 h time point. The left panels show GFP fluorescence, and the
middle panels show the analysis mask-overlay, indicating GFP-positive cell bodies in yellow, and
neurites in magenta. The right-hand panels show the zoomed-in area indicated by dotted rectangles in the
GFP and mask images. F: Neurite length after 72 h for cells treated with RA and transfected with either
the shRNA scrambled control (Ctrl) or the anti-Hsp27 shRNA (knockdown, KD) encoding plasmids. G:
Neurite branch points per cell body area after 72 h for cells treated with RA and transfected with either
the shRNA scrambled control (Ctrl) or the anti-Hsp27 shRNA (knockdown, KD) encoding plasmids.
Traces shown in B and C are representative of 3 independent replicates; and error bars indicate the mean
± SEM of duplicate wells from one experiment, with four images taken per well. Data in F and G indicate
the mean ±SEM of four independent replicates (each with four data points), and individual data points are
shown in grey.

5.3.5

Knockdown of Hsp27 increases the speed of axonal mitochondrial transport

As a result of previous studies indicating that Hsp27 mutations alter the axonal transport
of mitochondria (Kalmar et al., 2017), and the effect of Hsp27 knockdown on neurite
development observed here (Figure 5.4), the effects of Hsp27 knockdown on the
movement of mitochondria in the axonal projections of SH-SY5Y cells was examined
(Figure 5.5). Imaging of cells stained with MitoTracker each minute over a 15 min time
period produced images in which mitochondrial movement could be tracked visually
(Figure 5.5A). These images were analysed using the Track Objects pipeline in
CellProfiler to identify mitochondria and track their movement. This data was then
resolved to the single mitochondrion level using R software. The overall velocity of
mitochondrial movement was significantly higher (F(2,1637) = 48.83, p < 0.0001) in
SH-SY5Y cells transfected with the anti-Hsp27-encoding pGFP-V-RS-1 (0.520 ± 0.015
µm/min) than either untransfected cells (0.336 ± 0.010 µm/min), or those transfected
with the shRNA scrambled control (0.382 ± 0.009 µm/min) (Figure 5.5B). Interestingly,
both anterograde and retrograde transport were significantly faster (F(2,1472) = 22.59, p
< 0.0001, and F(2,1452) = 27.04, p < 0.0001, respectively) in cells transfected with
pGFP-V-RS-1 (anterograde: 0.509 ± 0.018 µm/min, retrograde: 0.503 ± 0.021 µm/min)
than both the untransfected cells (anterograde: 0.353 ± 0.015 µm/min, retrograde: 0.334
± 0.013 µm/min) and those expressing the scrambled shRNA control (anterograde:0.376
± 0.015 µm/min, retrograde: 0.355 ± 0.012 µm/min) (Figure 5.5C, D)).
The linearity of mitochondrial movement pathways was also analysed in CellProfiler,
giving a score between zero (completely non-linear movement) and one (a straight line).
The pathways of mitochondrial movement were significantly more linear (F(2,1481) =
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3.655, p = 0.0261) in cells transfected with pGFP-V-RS-1 (0.590 ± 0.012) than in the
shRNA scrambled (0.551 ± 0.012) control, but not in the untransfected control (0.590 ±
0.012) (Figure 5.5E).

Figure 5.5: Knockdown of Hsp27 increases the speed of axonal mitochondrial transport in
SH-SY5Y cells. SH-S75Y cells were plated at low density in 8-well Ibidi µ-plates coated with MaxGel
ECM substrate, then incubated overnight before transfection with the plasmids encoding the anti-Hsp27
shRNA or shRNA scrambled control. Cells were then incubated for 72 h to allow expression and
knockdown, before treatment with 10 µM RA in DMEM-F12 cell media, supplemented with 1% (v/v)
FBS to promote exit of the cell cycle, and neurite outgrowth. After 72 h, cells were stained with 150 nM
MitoTracker Red-CMXRos before imaging every min for 15 min using the Confocal SP5 equipped with
488 and 594 nm lasers to detect GFP (indicating transfected cells) and MitoTracker, respectively. Images
were then analysed using the Track Objects module for CellProfiler. Data for individual mitochondria
were then extracted using R software. A: The mitochondria contained in the neurite of an SH-SY5Y cell
transfected with the shRNA scrambled control at 0, 7 and 15 min showing the movement of individual
mitochondria. B: The average speed of all axonal mitochondria in untransfected cells (UT), and cells
transfected with the shRNA scrambled control (SC), or the anti-Hsp27 shRNA (knockdown, KD)
plasmids. The direction of movement (anterograde or retrograde) was determined at each time interval for
each mitochondrion based on its XY coordinates in relation to the cell body. The speed of movement in
each direction was then determined, and the average velocity of C: anterograde, and D: retrograde
transport are given. E: The average linearity score of each mitochondrial trajectory. Error bars represent
the SEM of individual mitochondria data points from all cells across two independent experiments, and
individual points are shown in grey, * represents a p-value of < 0.05, *** represents a p-value of < 0.0001
as determined by a one-way ANOVA followed by a Tukey’s multiple comparison test.

5.3.6

Hsp27 knockdown alters the morphology of mitochondria in SH-SY5Y cells

As mitochondrial function is closely linked to the dynamic fusion, fission and network
formation of these organelles, the effect of Hsp27 knockdown on mitochondrial
morphology was examined. Untransfected SH-SY5Y cells featured elongated, tubular
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mitochondrial networks with long branched filamentous structures (Figure 5.6A, B).
Cells transfected with the shRNA scrambled control showed similar mitochondrial
structures, with the addition of some punctate, fragmented mitochondria (Figure 5.6A,
B). In contrast, SH-SY5Y cells transfected with the anti-Hsp27-encoding pGFP-V-RS-1
plasmid showed a reduction in tubular mitochondrial networks, and featured more
punctate, fragmented mitochondria (Figure 5.6A, B). The average number of network
branches was not reduced by Hsp27-knockdown (1.669 ± 0.079/mitochondrial
structure) compared to the untransfected (1.532 ± 0.046/mitochondrial structure) or
scrambled (1.680 ± 0.139/mitochondrial structure) controls (Figure 5.6C). Interestingly,
the average length of mitochondrial branches was reduced in Hsp27-knockdown cells
(1.348 ± 0.166 µm) compared to the untransfected (1.658 ± 0.458 µm) or scrambled
(1.688 ± 0.090 µm) controls, although not to statistical significance (Figure 5.6D). The
reduction in mitochondrial branch length was reflected by a statistically significant
increase (F(2,5438) = 15.80, p < 0.0001) in the average eccentricity (or roundness) of
mitochondria in Hsp27-knockdown cells (0.763 ± 0.004) compared to the untransfected
(0.786 ± 0.004) or scrambled shRNA (0.790 ± 0.004) control cells (Figure 5.6E).
Fusion and fission heavily influence the morphology of mitochondria, so the rate of
each was also measured (Figure 5.7). The number of merged mitochondria per min was
significantly increased (F(2,531) = 121.1, p < 0.0001) in Hsp27-knockdown cells (11.14
± 1.01) compared to either the untransfected (0.77 ± 0.13) or scrambled controls (3.13 ±
0.29) (Figure 5.7E). The number of split mitochondria per min was also significantly
increased (F(2,531) = 70.61, p < 0.0001) in Hsp27-knockdown cells (5.52 ± 0.64)
compared to either the untransfected (0.40 ± 0.08) or scrambled controls (1.80 ± 0.20)
(Figure 5.7F).
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Figure 5.6: Knockdown of Hsp27 alters mitochondrial morphology in SH-SY5Y cells. SHS75Y cells were plated at low density in 8-well Ibidi µ-plates coated with MaxGel ECM substrate, then
incubated overnight, before transfection with the plasmids encoding the shRNA scrambled control or
anti-Hsp27 shRNA. Cells were then incubated for 72 h to allow expression and knockdown, then treated
with 10 µM RA in DMEM-F12 cell media, supplemented with 1% (v/v) FBS to promote exit of the cell
cycle, and neurite outgrowth. After 72 h, cells were stained with 150 nM MitoTracker Red-CMXRos
before imaging using a Confocal SP5 equipped with 488 and 594 nm lasers to detect GFP (indicating
transfected cells) and MitoTracker, respectively. Images were then analysed using CellProfiler
(eccentricity) and the MiNa plugin for ImageJ (branch measurements). A: Confocal images of SH-SY5Y
cells transfected with the shRNA scrambled control plasmid, or the anti-Hsp27 shRNA-encoding pGFPV-RS-1 (GFP fluorescence; green) and stained with MitoTracker (magenta). Boxes indicate the areas
shown in B. B: Zoomed images of areas indicated in A, showing mitochondrial morphology typical of
cells containing the shRNA scrambled control, untransfected cells, and cells expressing the anti-Hsp27
shRNA. White arrows indicate example branch points. For untransfected cells (UT) and cells transfected
with the shRNA scrambled control (SC) or the anti-Hsp27 shRNA (knockdown, KD) shown are; C: the
mean number of branches, D: the mean branch length of MitoTracker-stained objects, and E: the average
eccentricity score of each mitochondrion, Error bars in C and D represent the SEM mitochondrial
formations in each cell from two independent experiments with ≥ 3 cells each, and error bars in E
represent the SEM of individual mitochondria data points from all cells across two independent
experiments. Individual points are shown in grey. *** represents a p-value of < 0.0001 as determined by a
one-way ANOVA followed by a Tukey’s multiple comparison test, and all scale bars indicate 10 µm.
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Figure 5.7: Knockdown of Hsp27 alters mitochondrial fusion and fission in SH-SY5Y cells.
SH-S75Y cells were plated at low density in 8-well Ibidi µ-plates coated with MaxGel ECM substrate,
then incubated overnight, before transfection with the plasmids encoding the shRNA scrambled control or
anti-Hsp27 shRNA. Cells were then incubated for 72 h to allow expression and knockdown, then treated
with 10 µM RA in DMEM-F12 cell media, supplemented with 1% (v/v) FBS to promote exit of the cell
cycle, and neurite outgrowth. After 72 h, cells were stained with 150 nM MitoTracker Red-CMXRos
before imaging using a Confocal SP5 equipped with 488 and 594 nm lasers to detect GFP (indicating
transfected cells) and MitoTracker, respectively. Images were then analysed using CellProfiler. A and B:
Confocal images of the neurites of SH-SY5Y cells (brightfield, grey) transfected with the shRNA
scrambled control plasmid, (GFP fluorescence; green) and stained with MitoTracker (magenta). Boxes
indicate the areas shown in C and D. C: Zoomed images of areas indicated in A, at 0 – 3 min (indicated to
the left) showing the fusion (merge) of three mitochondria. White arrows indicate individual
mitochondria as analysed by CellProfiler. D: Zoomed images of areas indicated in B, at 0 – 3 min
(indicated to the left) showing the fission (split) of one mitochondrion into three. White arrows indicate
individual mitochondria as analysed by CellProfiler. E: the mean number of merged mitochondria per
min, and F: the mean number of split mitochondria per min. Error bars in E and F represent the SEM of
individual mitochondria data points from all cells across two independent experiments. Individual points
are shown in grey. *** represents a p-value of < 0.0001 as determined by a one-way ANOVA followed
by a Tukey’s multiple comparison test, and all scale bars indicate 5 µm.

5.4 Discussion
5.4.1

Knockdown of Hsp27 affects the differentiation of SH-SY5Y cells

The data presented in this chapter aimed to establish whether Hsp27 plays a role in
cytoskeletal dynamics during neuronal differentiation, axonal transport of mitochondria
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and/or mitochondrial morphology in neuronal cells. Co-IP of Hsp27 and β-actin from
motor neuron-like NSC-34 cells (Figure 5.1), and the presence of Hsp27 in neurite
outgrowths of differentiating SH-SY5Y cells (Figure 5.2), provide strong evidence for a
role of Hsp27 in these cellular processes. Of particular interest is the localisation of
Hsp27 in the neurite outgrowths and growth cones in differentiating neuronal cells.
Williams et al., (2005) and (2006) observed similar localisation of Hsp27 in the
lamellipodia, filopodia, focal contacts, and growth cones of differentiating and mature
dorsal root ganglion sensory neurons. Growth cones facilitate axon guidance in
differentiating cells, or cells repairing from axonal injury. They are dynamic actin-based
structures, which also contain microtubules, organelles and vesicles that provide energy
and protein synthesis machinery to the growing axon. The localisation of Hsp27 to these
structures may be related to its interactions with actin and/or tubulin, chaperoning of
newly synthesised proteins, or interactions with other, as yet unknown, proteins.
The successful knockdown of Hsp27 in SH-SY5Y cells (Figure 5.3) enabled the
investigation of the role of Hsp27 in neurite outgrowth in differentiating SH-SY5Y
cells. Hsp27 knockdown reduced the overall length of neurite outgrowths, and increased
the number of neurite branch points in these cells compared to cells transfected with the
shRNA scrambled control (Figure 5.4). Overall, knockdown of Hsp27 resulted in fewer
cells undergoing differentiation, and those that did undergo differentiation had an
increased number of short, disordered neurite extensions. This demonstrates that Hsp27
plays an important role in the extension of neurites, as well as in directing their pattern
of growth. This role is likely linked to interactions between Hsp27 and cytoskeletal
elements such as actin, and may also involve the chaperone activity of Hsp27 in the
synthesis of new proteins in growing neurites. In the study by Williams et al. (2005),
inhibition of MAPKAP kinase 2 (the kinase primarily responsible for the
phosphorylation of Hsp27) resulted in shorter neurite extensions, and a flattening of
neurites and growth cones, suggesting that non-phosphorylated Hsp27 is responsible for
its positive influence on neurite development. These adverse effects on neurite
outgrowth were suggested to be the result of perturbations to actin and microtubule
bundling necessary for normal neurite development. Interestingly, a similar trend was
observed here in differentiating SH-SY5Y cells in which Hsp27 was knocked-down
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compared to those expressing the scrambled control, suggesting that alterations to
oligomerisation and subunit exchange resulting from mutations in Hsp27 may alter its
interactions with cytoskeletal elements and affect neurite outgrowth and axon
development.
A disease mechanism for CMT and dHMN involving interruptions to cytoskeletal
dynamics has been suggested in relation to various CMT-causing mutations in genes
that include Inf2 (Boyer et al., 2011, Korobova et al., 2013), Nf-L (Fabrizi et al., 2006),
Pmp22 (Sahenk et al., 1999), Gjb1 (Hahn et al., 2001) and Fgd4 (Delague et al., 2007),
and Hsp27 (Almeida-Souza et al., 2011, d'Ydewalle et al., 2011, Kalmar et al., 2017).
Using immunoprecipitation from HEK293 cells overexpressing Hsp27 isoforms,
Almeida-Souza et al., (2011) found an increased interaction between tubulin and
Hsp27R127W, Hsp27S135F, and Hsp27R136W (but not Hsp27T151I or Hsp27P39L) compared to
Hsp27WT. These same Hsp27 mutations were also found to lead to an over-stabilisation
of microtubules in cells cultured in vitro (Almeida-Souza et al., 2011). Taken together,
these results indicate that Hsp27 mutations that interfere with client protein binding may
act to over-stabilise the microtubule network (i.e. such that it is less dynamic), and may
contribute to disease via a toxic gain-of-function mechanism. Considering that
microtubule dynamics are essential to the maintenance of the cytoskeleton, axoskeleton,
the transport of cellular cargo, and in neurotransmitter signalling (Gardiner et al., 2011),
a decrease in microtubule dynamics as a result of mutations in Hsp27 may underlie
disease progression.
Disruptions to proteostasis and protein translation are also implicated in CMT, with
mutations in the P0 glycoprotein causing its accumulation in the endoplasmic reticulum,
resulting in activation of the unfolded protein response, and a decrease in translation
(D’Antonio et al., 2013). CMT can also be caused by mutations in many protein folding
or degradation-related proteins (Table 1.1). Mutations in tyrosyl-tRNA synthestase
(Yars) cause CMT (Jordanova et al., 2006). In differentiating neurons, Yars localises to
axonal termini and is thought to be involved in protein synthesis as part of the
generation of axonal projections. This axonal localisation is lost when disease-causing
mutant isoforms of Yars are expressed in differentiating primary neurons and
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neuroblastoma cells in culture (Jordanova et al., 2006). Mutations in various other
protein-synthesis related proteins can also cause CMT or dHMN suggesting that
disturbances in protein synthesis in axons affects axon survival and their capacity to
regenerate in response to stress or injury. Since Hsp27 stabilises unfolded or
intermediately-folded states of proteins, it may also protect newly synthesised peptides.
Thus, the observed localisation of Hsp27 in growth cones and branch points of neurites
indicate a potential role for Hsp27 in the folding of newly synthesised axonal proteins.
Taken together, these findings suggest that the molecular mechanism(s) underpinning
the onset and progression of CMT and dHMN may involve alterations to the transport
and/or synthesis of proteins involved in normal axonal function, including those
synthesised in the cell body and/or those involved in protein synthesis within the axon
itself.
In addition to various mutations that directly affect the structure of the cytoskeleton,
mutations in proteins involved in intracellular transport also cause CMT and/or dHMN.
Interestingly, Amyotrophic Lateral Sclerosis-causing SOD1 mutations are associated
with disorganisation of neurofilaments and a reduction in the velocity of slow-axonal
transport of cargo, such as tubulin, early in disease (Williamson and Cleveland, 1999).
Motor proteins are implicated in various cellular functions, including cell division and
axonal transport. For example the kinesin family (Kif) of motor proteins are involved in
intracellular transport towards the plus end of microtubules (which in axonal transport
facilitates anterograde axonal transport). Dyneins, on the other hand, are the motor
proteins responsible for microtubule transport towards the minus end (or retrograde
transport). CMT and/or dHMN-causing mutations have been identified in members of
both of these motor protein families (Zhao et al., 2001, Weedon et al., 2011, Crimella et
al., 2012). A dynamitin-overexpression mouse-model (which leads to disruption of the
dynein-dynactin complex) showed inhibition of retrograde axonal transport, and
development of a motor neuropathy phenotype (LaMonte et al., 2002), suggesting that
disruptions to axonal transport are involved in the pathogenesis of motor neuropathies.
It is unknown, however, whether disease progression is related to disrupted transport in
general, or to the loss of supply of a specific molecule or organelle. It also remains to be
established how Hsp27 impacts this form of cellular transport.
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5.4.2

Knockdown of Hsp27 in SH-SY5Y cells dysregulates mitochondrial
trafficking and morphology

Mitochondrial dysfunction and disruption of mitochondrial transport are associated with
the pathology of various forms of CMT and dHMN (Züchner et al., 2004, Kijima et al.,
2005, Niemann et al., 2005, Pedrola et al., 2005, Engelfried et al., 2006, Baloh et al.,
2007, Cassereau et al., 2009, Pitceathly et al., 2012, Kalmar et al., 2017), and a link
between mitochondrial dynamics and disease progression caused by Hsp27 mutations
has been suggested (Kalmar et al., 2017). Hence, knockdown of Hsp27 in SH-SY5Y
cells was utilised to examine the effects on the axonal transport of mitochondria and on
mitochondrial morphology. The overall velocity of mitochondrial transport in SHSY5Y cells was increased by the knockdown of Hsp27, as was the velocity of both
anterograde and retrograde transport of the organelles (Figure 5.5). This increase in
velocity was paired with a more linear pattern of movement of mitochondria when
levels of Hsp27 were reduced, reflected in a decrease in shifts between anterograde and
retrograde transport over the course of observation. This suggests a regulatory function
of Hsp27 in axonal mitochondrial transport. Primary motor neurons expressing the
P39L, S135F, or R140G mutant isoforms of Hsp27 have been shown to exhibit slower
retrograde transport of mitochondria, while anterograde mitochondrial transport, or
axonal transport of other molecules was not affected (Kalmar et al., 2017). Moreover,
expression of Hsp27S135F in murine sensory neurons results in altered mitochondrial
movements (d'Ydewalle et al., 2011). Interestingly, the loss of mitochondrial transport
control in the absence of Hsp27 is consistent with a toxic gain-of-function disease
mechanism for Hsp27 mutations given that mutation seems to enhance this “slowing”
effect.
While the processes of mitochondrial transport are constant and dynamic, a proportion
of mitochondria in neurons remains stationary at any given time. It is currently
unknown whether these stationary mitochondria are simply uncoupled from motor
proteins, or whether there are anchoring mechanisms at play. Growing evidence
suggests that actin, neurofilaments, Ifn2 (Korobova et al., 2013, Korobova et al., 2014),
and Spire1C (Manor et al., 2015) are all important in the tethering of mitochondria in
axons, and disruptions to these proteins results in an increase in the velocity and number
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of moving mitochondria (Chada and Hollenbeck, 2004). Decreases in the levels of
Hsp27 may result in destabilisation of the cytoskeleton, or affect proteins involved in
the tethering and morphological maintenance of mitochondria, although as yet these
potential interactions have not been identified.
Mitochondrial morphology is integral to the function of these organelles, and is
controlled by dynamic processes of fusion, fission, mitophagy and transport.
Dysregulation of the transport of mitochondria in cells lacking Hsp27 may be linked to
the overall decrease in branch length, loss of tubular mitochondrial structures, and
increase in punctate and rounded mitochondria observed in these cells (Figure 5.6).
These changes were accompanied by an increase in both merging and splitting events in
cells lacking Hsp27 compared to the controls over the 15 minute period of imaging. The
splitting of mitochondria in the Hsp27-knockdown cells increased the number of small,
rounded mitochondria over time, and the subsequent merging resulted in large
disordered clumps. Control cells appeared to undergo a more controlled pattern of
mitochondrial fusion and fission, resulting in discreet, branched, tubular formations.
This indicates that the regulation of mitochondrial fusion and fission was disrupted by
removal of Hsp27.
A similar role for Hsp27 in the regulation of mitochondrial morphology has been
suggested previously by Kang et al. (2011), in which knockdown of Hsp27 in mouse
embryonic fibroblasts and cancer cells resulted in mitochondrial fragmentation, a
decrease in mitophagy, a decrease in oxidative phosphorylation, glycolysis and
production of ATP and aerobic respiration. This role was linked to HMGB1-dependent
control of Hsp27 expression as HMGB1 knock out inhibited Hsp27 expression (but not
that of other Hsps) (Kang et al., 2011, Tang et al., 2011). This role in the control of
mitophagy was suggested to be related to the function of Hsp27 in regulating
cytoskeleton dynamics, and could potentially underlie the effects observed here on
knockdown of Hsp27 in SH-SY5Y cells. This further suggests that altered
mitochondrial morphology and transport may be involved in the pathophysiology of
CMT and dHMN resulting from Hsp27 mutations. Indeed, mitofusin 2 (Mfn2) is
involved in mitochondrial fusion, trafficking, turnover, and interactions with other
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organelles. Mutations in this protein are the most common cause of CMT2 (Strickland
et al., 2014), and expression of disease-causing mutants of Mfn2 in dorsal root ganglion
neurons results in impaired mitochondrial transport and clustering of small, fragmented
mitochondria (Baloh et al., 2007).
A CMT and dHMN disease mechanism involving dysregulation of mitochondrial
morphology, transport and/or function is also consistent with the loss of mitochondrial
morphology observed in patients with mutations in ganglioside-induced differentiationassociated protein 1 (Gdap1) (Niemann et al., 2005, Huber et al., 2013, Niemann et al.,
2014), Hsp27 (d'Ydewalle et al., 2011, Kalmar et al., 2017), or Mfn2 (Baloh et al.,
2007, Misko et al., 2012). Expression of disease-causing Hsp27 mutant isoforms that
result in altered mitochondrial transport (d'Ydewalle et al., 2011, Kalmar et al., 2017) is
also associated with mitochondrial dysfunction, dysregulation of mitochondrial GSH
levels, and an increase in oxidised proteins in affected neurons (Kalmar et al., 2017).
Gdap1 is a mitochondrial membrane protein (Pedrola et al., 2005) that promotes
mitochondrial fission in response to changes in mitochondrial membrane potential,
independently of apoptosis (Niemann et al., 2005). Fission and fusion are essential to
the maintenance of mitochondrial morphology and function (reviewed in Chen and
Chan (2005) and Pernas and Scorrano (2016)); and various mutations have been found
in Gdap1 that cause CMT (Baxter et al., 2001, Cuesta et al., 2002, Senderek et al.,
2003). Niemann et al. (2005) found that CMT-causing mutations in Gdap1 result in
increased mitochondrial fragmentation, coinciding with a loss of tubular mitochondrial
architecture. Gdap1 knock out mice display an increase in mitochondrial size, alongside
impaired mitochondrial transport, and oxidative stress in peripheral neurons, while
Gdap1L1 (a Gdap1 paralogue mainly expressed in the CNS) compensates for Gdap1
deficiency in the CNS (Niemann et al., 2014). This implicates improper mitochondrial
morphology in the disease pathogenesis of CMT, although the precise mechanism is
unknown. However, various other mutations that cause CMT and/or dHMN have been
linked to alterations in mitochondrial functions, which suggests that energy supply
and/or recycling of mitochondria back to the cell body may be affected in the long
axonal projections of motor neurons.
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Taken together, the results presented in this chapter support a role for Hsp27 in
cytoskeleton dynamics, regulation of neuronal differentiation, and the transport and
morphological maintenance of mitochondria in neurons. As yet, the precise mechanisms
by which Hsp27 influences these processes is unknown, but are likely the result of
transient, chaperone-like interactions with various proteins, or more specific interactions
with cytoskeletal, transport and mitochondrial proteins. In any case, altered function of
Hsp27 in these processes is likely a factor underlying the development of CMT and
dHMN caused by Hsp27 mutations. Motor neurons are particularly susceptible to
altered cytoskeleton dynamics given their reliance on actin filaments, neurofilaments
and microtubules in order to maintain axon structure, transmit signals, translocate
organelles, maintain membranes, and carry cellular cargo along lengths of up to one
metre.
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6 The interactome of Hsp27 in motor neuron-like cells and
the effect of disease-causing mutations
6.1

Introduction

6.1.1

Interactions of Hsp27 disease-associated mutations in the cell

Hsp27 disease-associated mutations have been found to alter the behaviour of Hsp27 in
the cell. For example, it has been reported that some mutant isoforms of Hsp27 form
cytoplasmic aggregates when expressed in various cell types, such as Hsp27G84R,
Hsp27S135F, and Hsp27P182L in HeLa cells (James et al., 2008), and Hsp27S187L in SHSY5Y cells (Echaniz‐Laguna et al., 2017). Similarly, dHMN-associated mutations in
Hsp22 are associated with increased formation of intracellular aggregates (Fontaine et
al., 2006). However, other disease-associated Hsp27 mutations have been found not to
influence intracellular aggregate formation, e.g. Hsp27P7S, Hsp27G53D, and Hsp27Q128R
when expressed in SH-SY5Y cells (Echaniz‐Laguna et al., 2017). Furthermore,
phosphorylation of Hsp27 has been shown to promote the formation of puncta of Hsp27
in the dendrites of rat hippocampal neurons (Schmidt et al., 2012), suggesting that the
focal association of Hsp27 in the cytoplasm may be the result of its activation (by
phosphorylation), which possibly leads to a change in the client proteins with which it
interacts. It remains to be established whether this propensity to form intracellular
aggregates influences the progression of CMT or dHMN resulting from mutations in
Hsp27.
Aside from the formation of intracellular aggregates, disease-associated mutations in
Hsp27 have been proposed to interfere with its roles in cytoskeletal dynamics,
intracellular transport, redox homeostasis and mitochondrial function (Kalmar et al.,
2017). To verify that Hsp27 plays a role in these processes, the results presented in
Chapter 5 confirmed the interaction of Hsp27 with tubulin in NSC34 cells (by co-IP)
and showed that knockdown of Hsp27 affects neurite development, and mitochondrial
transport and morphology in SH-SY5Y cells. Disturbances in any of these processes
143

Chapter 6

may be involved in the progression of disease. However, our knowledge of how
mutations in Hsp27 lead to disease is limited by our lack of understanding of the actual
proteins with which Hsp27 interacts. While progress has been made in exploring the
involvement of Hsp27 in discrete cellular processes (such as protein homeostasis,
cytoskeleton regulation, apoptosis, and redox homeostasis), the protein interactome of
Hsp27 remains unknown, and thus our ability to identify the potential effects mutations
have on its cellular function are limited.
The BioGRID database for protein interactions identifies 452 interactors of Hsp27, 160
of which were identified via affinity-capture based techniques. The remaining suggested
interactors are inferred by biochemical activity, colocalisation, two-hybrid systems, cofractionation or complexes reconstituted in vitro using experimental techniques.
Overall, the BioGRID database indicates that Hsp27 interacts with a wide array of
proteins involved in protein folding (e.g. Hsp70 (Ehrnsperger et al., 1997)), protein
degradation (e.g. ubiquitin (Parcellier et al., 2003)) and protein aggregation (e.g. α-syn
(Cox et al., 2018)), modulation of transcription (e.g. signal transducer and activator of
transcription 3 (Rocchi et al., 2005) and translation (e.g. eukaryotic translation initiation
factor 4 gamma (Cuesta et al., 2000), modulation of intra- and extracellular signalling
pathways (e.g. estrogen receptor β (Al-Madhoun et al., 2007)), cytoskeleton dynamics
(e.g. F-actin (Clarke and Mearow, 2013)), cell adhesion (e.g. β-Catenin (Fanelli et al.,
2008)) and epithelial-mesenchymal transition (e.g. Snail1 (Wettstein et al., 2013)),
redox modulation (e.g. glucose 6-phosphate dehydrogenase (Préville et al., 1999)),
inhibition of apoptosis (e.g. caspase-3 (Pandey et al., 2000)), inhibition of cellular
senescence (e.g. HDM2 (O'Callaghan-Sunol et al., 2007)), and cell survival (e.g.
eukaryotic translation initiation factor 4E (Andrieu et al., 2010)). Our current
understanding of the Hsp27 interactome has been thoroughly reviewed in the context of
the effect of phosphorylation on Hsp27 interactions, and the roles of Hsp27 in cancer
(Arrigo, 2013, Arrigo, 2012, Arrigo, 2013). To date, no study has experimentally
determined the interactome of Hsp27 in the cell, nor identified the specific interactions
of Hsp27 with other proteins in the context of motor neurons.
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An understanding of the proteins with which Hsp27 interacts would also provide
insights into the mechanisms underlying these interactions. Thus far, it is suggested that
Hsp27 interacts with proteins via hydrophobic interactions (Cox et al., 2018), redoxrelated interactions mediated by the dimer-stabilising cysteine residue in the αCD
(Bruey et al., 2000), and/or interactions of IXI motifs in other proteins with the IXI
binding pocket located in the Hsp27 αCD (Alderson et al., 2019a). Many of these
interactions are also thought to be influenced by the phosphorylation/oligomeric state of
Hsp27.
6.1.2

Aims

Given that the interactome of Hsp27 has not yet been determined, and that we do not
fully understand the molecular mechanisms underlying the interactions between Hsp27
and its binding partners, nor how these interactions may be affected by mutations, the
aims of the experimental work described in this chapter were to:
1. Clone a set of Myc-tagged Hsp27 constructs for the mammalian expression of
Hsp27WT, Hsp27P39L, Hsp27R136W, Hsp27R140G, and Hsp27T151I,
2. Utilise these Myc-tagged Hsp27 constructs to analyse the intracellular
localisation of Hsp27WT, Hsp27P39L, Hsp27R136W, Hsp27R140G, and Hsp27T151I
when expressed in SH-SY5Y and NSC-34 cells,
3. Determine the level of colocalisation of Hsp27WT, Hsp27P39L, Hsp27R136W,
Hsp27R140G, and Hsp27T151I with tubulin (representing the cytoskeleton) and
mitochondria when expressed in SH-SY5Y and NSC-34 cells,
4. Determine the protein interactome of Hsp27WT, Hsp27R136W, and Hsp27T151I
when

expressed

in

motor

neuron-like

NSC-34

cells

using

co-

immunoprecipitation and proteomic identification, and to
5. Analyse the properties of proteins identified to interact with these Hsp27
isoforms, particularly as they relate to CMT and dHMN pathogenesis.
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6.2 Materials and methods
6.2.1

Plasmid constructs

Plasmids for the mammalian expression of Myc-tagged Hsp27P39L, Hsp27R140G, and
Hsp27T151I were cloned by PCR amplification of the coding sequence from the
corresponding pET3a(+)-Hsp27X constructs using PrimeSTAR HS DNA Polymerase
(Takara Bio Inc., Kyoto, Japan) and Hsp27 gene-specific primers that incorporated
suitable

cloning

restriction

ATGAATTCATGACCGAGCGCCGC

sites
and

(5'Hsp27-EcoRI;
3'Hsp27-SalI;

TTAGTCGACGGAGCCTTACTTGGC). The PCR product was isolated by agarose gel
electrophoresis and purified using the Isolate II PCR and Gel Kit (as per the
manufacturer’s instructions; Bioline) to prevent carryover of the original plasmid. The
PCR products and the pCMV-c-Myc vector were then digested with EcoRI and SalI,
(Thermo-Fisher Scientific) and ligated overnight at 16°C with T4 DNA ligase (Bioline)
to produce pCMV-Hsp27X-c-Myc. Ligations were then transformed into E. coli DH5α,
and resulting colonies were PCR-screened (using CMV-forward and M13-reverse
primers: CGCAAATGGGCGGTAGGCGTG, and GGAAACAGCTATGACCATG,
respectively). Clones resulting in the desired PCR product size (as determined by
agarose gel electrophoresis) were then sequenced using the BigDye Terminator Cycle
Sequencing Kit V3.1 (Applied Biosystems, Foster City, CA, USA). Sequencing was
performed by Ms. M. Phillips (School of Biological Sciences, University of
Wollongong) using a 3130xL Genetic Analyzer, (Applied Biosystems). Sequencing data
was then analysed using Sequencher® DNA Sequence Analysis Software (Gene Codes
Corporation, Ann Arbour, MI, USA). Plasmids for the expression of Myc-tagged
Hsp27WT and Hsp27R136W were cloned using the same methods, by Ms. Le May Thai
(School of Biological Sciences, University of Wollongong). The plasmid for the
bacterial expression of Hsp25 (pET3a(+)-Hsp25) was cloned by GenScript.
6.2.2

Immunohistochemistry

Cells were seeded into 8-well µ-slides at 5 000 cells/well, and differentiated as per
section 2.2.5.2, then transfected with Hsp27-c-Myc constructs, and incubated for 48 h.
Mitochondria were then stained by addition of Mitotracker Red CMX-Ros (300 nM)
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(Thermo-Fisher), and cells were incubated for 30 min at 37°C. Cells were then washed
twice with PBS, then fixed by incubation with paraformaldehyde (4% (w/v) in PBS) at
RT, with gentle rocking for 20 min. Cells were then washed twice in PBS and
permeabilised using 0.5% (v/v) Triton X-100 in PBS for 20 min at RT. Cells were again
washed twice in PBS and blocking was performed by incubating at 37°C for 30 min in
5% (w/v) BSA in PBS. After washing twice with PBS-T (PBS with 0.05% Tween 20),
primary antibody (either rabbit anti-Myc, mouse anti-α tubulin, or anti-mouse or rabbit
IgG isotype controls), diluted in PBS-T, was added and the cells incubated for 1 h at
37°C in a humidity-controlled incubator. Cells were then washed three times with PBST and incubated in the presence of the appropriate Dylight-conjugated secondary
antibody diluted in PBS-T, at 37°C for 30 min in a humidity-controlled incubator.
Finally, cells were washed three times with PBS-T, and Duolink® In Situ Mounting
Medium with DAPI (Sigma-Aldrich) was added. Cells were then imaged using a Leica
TCS SP8 Advanced System confocal microscope (Leica Microsystems, Wetzlar,
Germany). Images were analysed for colocalisation and formation of intracellular
Hsp27 aggregates using CellProfiler Cell Image Analysis Software (Carpenter et al.,
2006, Lamprecht et al., 2007, Kamentsky et al., 2011) using a custom-made processing
pipeline based on the ‘Example Colocalisation’ pipeline

(available from

https://cellprofiler.org/examples). The Manders colocalisation coefficient (Manders et
al., 1993) using Costes automatic background thresholding (Costes et al., 2004) was
used to identify the fraction of fluorescently labelled β-tubulin that colocalised with
fluorescently labelled Hsp27. Hsp27 aggregates were identified based on fluorescence
intensity and size.
6.2.3

Identification of the intracellular binding partners of Hsp27WT and Hsp27
disease-causing mutants

6.2.3.1 FRET-determination of subunit exchange between human Hsp27 and mouse
Hsp25

NSC-34 cells are a mouse cell line that express very little endogenous Hsp25 (the
murine ortholog of human Hsp27) such that it is not detectable in whole-cell NSC-34
lysates by standard western blotting using the anti-Hsp27 antibody (which reacts with
Hsp25 via immunoblotting of purified recombinant Hsp25, data not shown).
Nonetheless, to ensure that co-IP of human Hsp27 expressed in NSC-34 cells could also
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pull-down any Hsp25 expressed in these cells, the ability of Hsp27 and Hsp25 to form
hetero-oligomers was first established. Thus, recombinant Hsp25 was expressed and
purified (2.2.3.3, and 3.2.2), and labelled as per the Hsp27 isoforms (Section 2.2.1.3.3).
Subunit exchange between Hsp27/Hsp27, Hsp25/Hsp25, and Hsp27/Hsp25 was
monitored by FRET as described in section 3.2.5.
6.2.3.2 Co-IP of Hsp27WT and disease-causing mutants from NSC-34 cells

To determine the intracellular binding partners of Hsp27 and whether disease-causing
mutations in Hsp27 alter these interactions, co-IPs of Myc-tagged Hsp27 isoforms
expressed in NSC-34 cells were performed. First, a method of estimating the amount of
Hsp27 expressed in transfected cells was developed by transfecting separate T25 flasks
of NSC-34 cells at approximately 80% confluency with either Hsp27WT-c-Myc, or a 1:4
ratio of pCMV-GFP to Hsp27WT-c-Myc (so that GFP expression could be used to
determine transfection efficiency). An untransfected control was also prepared.
Following incubation for 48 h, the flask containing cells transfected to express GFP and
Hsp27WT-c-Myc was imaged using the IncuCyte, and the total number of GFP-positive
cells calculated. Cells were then lifted by scraping and lysed as previously described (
Section 2.2.1.1.1). Total protein concentration was determined by BCA assay (2.2.1.2),
then equal amounts of total protein from each sample were separated by SDS-PAGE,
alongside purified, recombinant Hsp27WT (2.34 ng – 75 ng, used as standards) and
analysed by semi-quantitative immunoblotting using the anti-Hsp27 antibody. Based on
this experiment it was determined that the transfected cells contained approximately
0.16 µg of Hsp27 per 1 µg total protein (approximately 5.17 × 10-4 ng Hsp27 per
transfected cell). These values were used to estimate the total amount of Hsp27 in each
sample, and therefore the amount of antibody used for co-IP to ensure complete pulldown of all the Hsp27 expressed in these cells.
NSC-34 cells at 80% confluency in T25 cell culture flasks were transfected with the
Hsp27WT, Hsp27R136W, or Hsp27T151I-c-Myc constructs, or left untransfected as a control.
In addition, one flask of cells was co-transfected with pCMV-GFP and Hsp27WT-c-Myc
plasmids (at a ratio of 1:4 ratio) in order to monitor the transfection efficiency. After 48
h, cells transfected to express just the Hsp27X-c-Myc constructs and the untransfected
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control were lifted by scraping, washed twice with ice-cold PBS, then resuspended in
700 µL ice cold lysis buffer (5 mM EDTA, 0.5% Triton X-100 in PBS, pH 7.4,
supplemented with 1 × Halt™ Protease and Phosphatase Inhibitor Cocktail). Cells were
incubated on ice for 30 min, with brief vortexing every 5 min. Lysates were cleared by
centrifugation (20 000 × g, 10 min, 4°C), and the supernatant was retained. Total
protein concentration was determined by BCA assay and the amount of Hsp27
approximated based on the calculations described above. Mouse anti-Myc antibody was
then added to samples at a ratio of 2.5 µg antibody per 1 µg Hsp27 and the samples
incubated for 2 h at RT on a rotary tube mixer at low speed. Antigen/antibody samples
were then added to 0.2 mg (resulting in an antibody:bead ratio of ~ 2 µg:1 mg) of Pierce
Protein A/G Magnetic beads (washed twice with wash buffer; TBS containing 0.05%
Tween-20) and incubated for 1 h at RT with gentle agitation on a rotary tube mixer.
Beads were then collected using a magnetic stand, the supernatant (unbound sample)
was removed and retained for immunoblot analysis. Beads and bound proteins were
then washed three times with wash buffer, and once with Milli-Q water. Finally, all
liquid was carefully aspirated, and samples were stored at -80°C prior to proteomic
analysis. At least three biological replicates of each sample were prepared. iTRAQ mass
spectrometry proteomic analysis was performed by Dr. Matt Dun, Mr. David SkerrettByrne, and Dr. Muhammad Fairuz Jamaluddin of the University of Newcastle,
Australia.
6.2.3.2.1

Filtering of co-IP proteomic data

To select valid interacting partners of each Hsp27 isoform, the proteomic abundance
data obtained for each mutant isoform (three biological repeats per isoform), and the
untransfected control (six replicates consisting of two technical replicates of the three
biological replicates) were averaged. Replicates in which a protein was not detected
were included as zero-values in averages (and the large majority were found in the
untransfected samples). Only proteins identified in the Hsp27WT, Hsp27R136W, or
Hsp27T151I samples with an abundance ≥ 1.5-fold higher than in the untransfected
control, and which appeared in at least two replicates of each sample were considered
for further analyses.
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6.2.3.2.2

Analysis of functional pathway enrichment of identified binding partners

Venn diagrams of protein interactors were produced using the Ven de Peer lab’s
Bioinformatics

and

Evolutionary

Genomics

online

tool

(available

from

http://bioinformatics.psb.ugent.be/webtools/Venn/). FASTA amino acid sequences for
each

interactor

were

downloaded

from

Batch

Entrez

(available

from

https://www.ncbi.nlm.nih.gov/sites/batchentrez, provided by the National Centre for
Biotechnology Information). Sequence similarity between mouse and human gene
orthologs were accessed via Ensembl Genes (release 97; (Cunningham et al., 2018)).
The functional enrichment of pathways represented by each set of interactors identified
for Hsp27WT and the mutant isoforms was analysed using g:Profiler (Raudvere et al.,
2019) with optional selections as follows: ordered query (with binding partners
imported in descending order of abundance), statistical domain scope: only annotated
genes, multiple testing significance threshold: g:Profiler tailor made g:SCS, user
threshold: p ≤ 0.05, and data sources: Gene Ontology biological process (GO BP), no
electronic GO annotations. The resulting output was then simplified using REVIGO
(Supek et al., 2011) and manual filtering to combine redundant GO terms.
6.2.3.2.3

Analysis of biophysical features of identified binding partners

The Sequence Manipulation Suite (Stothard, 2000) was used to batch-generate the grand
average hydropathy (GRAVY) score (Kyte and Doolittle, 1982), the amino acid
properties (i.e. the protein stats tool), the molecular weights, and the isoelectric point
(pI) values for each binding partner of each Hsp27 isoform based on the amino acid
FASTA sequence. Three-state secondary structure predictions (proportions of α-helix,
β-sheet, and coil) were made using the RaptorX-Property server (Peng and Xu, 2011,
Wang et al., 2016). IUPred2A (Mészáros et al., 2018) was used to identify intrinsically
disordered regions in each of the binding partners, as well as the regions predicted to
have redox-dependent disorder. The multi FASTA file input was used to generate batch
results for each set of interactors, and IUPred2 long disorder, and redox state
(experimental) context-dependent predictions were used. As a control comparison for
all structure and protein property related analyses, a random selection of 100 mouse
proteins (Appendix IV) was also analysed. The FASTA amino acid sequences of these
randomly selected proteins were downloaded from the NCBI Taxonomy Protein
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Database (Federhen, 2012). Excreted or extracellular proteins were excluded from the
selection, but controls were not limited to a specific intracellular compartment, as the
binding partners identified in co-IP samples represented proteins from various cellular
compartments.

6.3 Results
6.3.1

Disease-causing mutations have minimal effect on the intracellular
localisation of Hsp27

To determine whether mutations in Hsp27 affect its cellular localisation and interaction
with tubulin or mitochondria, both NSC-34 and SH-SY5Y cells expressing Myc-tagged
Hsp27 were analysed by IHC. First, the propensity of each Hsp27 isoform to form
intracellular aggregates was analysed (Figure 6.1). Expression of each of the Hsp27
isoforms in either SH-SY5Y or NSC-34 cells resulted in a proportion of cells that
contained punctate Myc-tagged Hsp27 fluorescence at the edges of cells (potentially
corresponding to focal adhesions), indicative of Hsp27 aggregate formation (Figure
6.1A-D). These cells tended to be those with a higher level of Hsp27 expression, as
indicated by the higher fluorescence intensity of Hsp27-labelling throughout the cell.
Overall, there was a trend towards the fraction of Hsp27-positive cells that contained
fluorescent puncta being higher in NSC-34 cells compared to SH-SY5Y cells for each
of the mutant isoforms examined (Figure 6.1C-D); however, there was no statistically
significant difference between the two cell types, as determined by a two-way ANOVA
(F(1,10) = 2.325, p = 0.1273). The number of Hsp27 aggregates per aggregatecontaining cell was also determined and found to be from 5 - 10 aggregates per cell,
with again no significant differences between isoforms (NSC-34: F(4,5) = 0.1483, p
=0.9559, SH-SY5Y: F(4,5) = 1.405, p = 0.3533 or cell type (F(1,10) = 1.006, p 0.4487;
Figure 6.1E-F). There was a trend towards Hsp27R136W forming more aggregates in
aggregate-positive SH-SY5Y cells than each of the other isoforms (Figure 6.1E). There
was little variation in the number of aggregates formed by each Hsp27 isoform in NSC34 cells (Figure 6.1F).
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Figure 6.1: Hsp27 mutation does not affect its propensity to form intracellular aggregates
in SH-SY5Y or NSC-34 cells. SH-SY5Y and NSC-34 cells were transfected with Myc-tagged
Hsp27WT ( ), the Myc-tagged disease mutants Hsp27P39L ( ), Hsp27R136W ( ), Hsp27R140G ( ), or
Hsp27T151I ( ). These cells were then immunolabelled using an anti-Myc antibody to reveal the
intracellular localisation of Myc-tagged Hsp27. A and B: Representative images of Hsp27 aggregatecontaining SH-SY5Y (left panels) and NSC-34 cells (right panels) transfected with either Myc-tagged
Hsp27WT or Myc-tagged Hsp27R136W as indicated (magenta), with nuclei stained with DAPI (blue). Scale
bars represent 20 µm. C and D: The mean percentage of Hsp27-positive SH-SY5Y and NSC-34 cells
(respectively) that contained Hsp27 aggregates E and F: The average number of aggregates per Hsp27
aggregate-positive SH-SY5Y and NSC-34 cell (respectively). Data in C – F represents the mean ± SEM
(with individual data points overlayed) of two independent biological replicates, each containing ≥ 10
Hsp27-positive cells per Hsp27 isoform.

Analysis of the colocalisation of β-tubulin with Hsp27 revealed that all the mutations
tested significantly increased the fraction of β-tubulin that colocalised with Hsp27
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compared to Hsp27WT in SH-SY5Y cells (F(4,5) = 7.103, p = 0.0271; Figure 6.2, Figure
6.3). However, no significant difference in the association of the Hsp27 isoforms with
β-tubulin was found in NSC-34 cells (F(4,5) = 0.5455, p = 0.7155; Figure 6.3). βTubulin and Hsp27P39L were significantly less colocalised in NSC-34 cells compared to
SH-SY5Y (two-way ANOVA; F(1,10) = 22.68, p < 0.0001; followed by a Bonferroni
post-hoc test (p < 0.05)), although no significant difference for any other Hsp27 isoform
was observed (Figure 6.3). In contrast, the colocalisation of Hsp27 with mitochondria
was not affected by mutation (Figure 6.2), and neither Hsp27WT nor Hsp27T151I
colocalised with mitochondria to any significant extent (Figure 6.2). Similar results
were observed for Hsp27P39L, Hsp27R136W, Hsp27R140G, and Hsp27T151I in both SHSY5Y and NSC-34 cells (data not shown).
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Figure 6.2: Disease-associated mutations affect the colocalisation of Hsp27 with β-tubulin
but not mitochondria in SH-SY5Y cells. SH-SY5Y cells were seeded into MaxGel-coated Ibidi
chamber slides, and treated with RA for 72 h. Cells were then transfected with the plasmids for the
expression of Myc-tagged Hsp27WT, the disease-associated Hsp27P39L, Hsp27R136W, Hsp27R140G, or
Hsp27T151I and incubated for 48 h to allow expression. A, C: Myc-tagged Hsp27WT (A) or Hsp27T151I (C)
(magenta) were labelled with anti-Myc primary and DyLight 650-conjugated secondary antibodies, β-
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tubulin (green) was labelled with an anti-β-tubulin and DyLight 488-conjugated secondary antibodies,
and mitochondria were stained with MitoTracker. A merged image of Hsp27, tubulin, mitochondria, and
DAPI-labelled nucleus is shown to the right. B, D: Zoomed-in merged images showing the localisation of
Hsp27WT (B), and Hsp27T151I (D) in relation to β-tubulin (left) and mitochondria (right). Arrow heads in D
indicate a region of high colocalisation between Hsp27T151I and β-tubulin (filled arrow) and for
comparison, a representative area in which neither protein was detected (unfilled arrow). Images were
acquired using a Leica SP8 confocal imaging system fitted with a 100 x oil immersion objective, and are
representative of two independent biological replicates, each containing ≥10 Hsp27-positive cells per
Hsp27 isoform. All scale bars represent 20 µm.

Figure 6.3: Colocalisation of β-tubulin with Hsp27 is affected by mutation. SH-SY5Y ( )
and NSC-34 ( ) cells were seeded into MaxGel-coated Ibidi chamber slides, and treated with RA for 72
h. Cells were then transfected with the plasmids for the expression of Myc-tagged Hsp27WT, the diseaseassociated Hsp27P39L, Hsp27R136W, Hsp27R140G, or Hsp27T151I and incubated for 48 h to allow expression.
Cells were then imaged using a Leica SP8 confocal microscope fitted with a 100 x oil immersion
objective. Images were then analysed using CellProfiler, and a customised pipeline to determine the
Manders’ colocalisation coefficient using Costes method of threshold adjustment for the colocalisation of
β-tubulin and each of the Hsp27 isoforms. Data shown is the mean ± SEM of two independent biological
replicates, each of which represents data from ≥ 10 Hsp27-positive cells for each Hsp27 isoform. Results
of a one-way ANOVA followed by a Dunnett’s multiple comparisons post-hoc test between Hsp27WT and
each mutant isoform are shown for SH-SY-5Y cells (no significant difference was found between
isoforms in NSC-34 cells); * indicates a p < 0.05, ** indicates p < 0.01. Significant differences between
SH-SY5Y and NSC-34 cells determined by a two-way ANOVA followed by a Bonferroni post-hoc test
for each isoform are shown; * indicates p < 0.05.

6.3.2

The interactome of Hsp27 in motor neuron-like NSC-34 cells

Prior to performing immunoaffinity experiments in cells in order to identify binding
partners of Hsp27 in motor neurons, it was first necessary to assess whether Hsp27 was
capable of forming hetero-oligomers with Hsp25. This is because it was important to
also demonstrate pull-down of any endogenous Hsp25 (and its binding partners) in
complex with Hsp27 in these experiments. To assess whether Hsp27 and Hsp25 are
capable of forming hetero-oligomers, subunit exchange from homo-oligomers was
analysed by bulk-FRET in vitro (Figure 6.4). The negative control (Hsp27/SOD1) did
not undergo subunit exchange, indicated by a lack of increase in F(t)/F(0) over time;
155

Chapter 6

(Figure 6.4A). In contrast, there was an increase in the F(t)/F(0) ratio over time for each
sHsp combination tested (i.e. Hsp27/Hsp27, Hsp25/Hsp25, and Hsp27/Hsp25),
indicative of subunit exchange, and this reached a plateau after ~15 min (Figure 6.4A).
Interestingly, the rate of subunit exchange was fastest for Hsp27 with itself (k = 0.0487
± 0.0012 min-1; F(3,4) = 477.2, p < 0.0001). The rate of subunit exchange was
comparable between Hsp27 and Hsp25 (k = 0.0487 ± 0.0012 min-1) and Hsp25 with
itself (k = 0.0099 ± 0.0009 min-1) (Figure 6.4B). Thus, it was concluded that
immunoprecipitation of Hsp27 from cell lysates was highly likely to also pull down any
endogenous Hsp25 (and its binding partners) present in these cells.

Figure 6.4: FRET analysis of Hsp27 and Hsp25 subunit exchange. Bulk FRET was used to
), Hsp25
analyse subunit exchange between Hsp27WT (488-labelled) and Hsp27WT (647-labelled;
(488-labelled) and Hsp25 (647-labelled;
), and Hsp27WT (488-labelled) and Hsp25 (647-labelled;
), at equimolar ratios (30 µM total concentration) in PBS. SOD1 (647-labelled) with Hsp27WT (488labelled) was included as a negative control (
). A: F(t)/F(0) values obtained over a 30 min period for
each FRET-pair; smooth lines indicate a one-phase association (exponential) curve fit to the data. B: The
subunit exchange rate constant (k) values obtained from each curve. Data in A represent the mean of
duplicate samples in one representative biological replicate ±SEM, data in B represents the average of
two independent biological replicates ± SEM, analysis by one-way ANOVA followed by a Tukey’s
multiple comparisons post-hoc test, *** denotes statistical significance p<0.001.

In order to identify the binding partners of Hsp27 in NSC-34 cells, co-IP of Myc-tagged
Hsp27 with anti-Myc antibody and magnetic protein A/G beads was utilised. To
confirm that all of the Hsp27 was pulled down from cells expressing Myc-tagged
Hsp27, samples were analysed by immunoblotting (Figure 6.5). As expected, the lysate
of control untransfected cells did not contain any Hsp27 (or endogenous Hsp25), while
lysate from cells transfected with the plasmid encoding Hsp27WT-c-Myc showed a
prominent band at approximately 25 kDa, indicating the presence of Hsp27 (Figure 6.5).
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A sample of unbound protein (supernatant from samples after incubation of lysate,
antibody and protein A/G beads) did not contain any Hsp27, however bands at
approximately 25 and 50 kDa in the bound sample indicated the presence of Hsp27
monomer and disulfide-bonded dimer, respectively (Figure 6.5). Thus, these data show
that this co-IP procedure resulted in all of the Hsp27 being pulled down from the lysate
such that none remained in the unbound fraction.

Figure 6.5: Myc-tagged Hsp27 can be immunoprecipitated from NSC-34 cells. To confirm
pull-down of Myc-tagged Hsp27 using the anti-Myc antibody and magnetic protein A/G beads, NSC-34
cells transfected with Myc-tagged Hsp27WT were lysed and incubated with a 1:2.5 (w/w) ratio of
Hsp27:antibody. These samples were then incubated with magnetic protein A/G beads at a ratio of 2 µg:
1 mg (antibody:bead) in order to precipitate all of the Hsp27 and its interacting proteins. Samples of
purified recombinant Hsp27WT (Rec), untransfected NSC-34 lysate (UT), lysate from transfected NSC-34
cells (Lys), and unbound (UB) and bound (B) proteins resulting from incubation of anti-Myc conjugated
beads with transfected NSC-34 lysate were analysed by SDS-PAGE and immunoblotting for Hsp27. The
positions of molecular weight markers are indicated to the left, and the identity of each band is indicated
to the right.

Myc-tagged Hsp27WT, Hsp27R136W, and Hsp27T151I were used in co-IP experiments to
determine the interactome of Hsp27 in a motor neuron-like cell, and assess the influence
of disease-related mutations on the interactions of the protein. Hsp27R136W and
Hsp27T151I were chosen for these experiments as they are two isoforms that show
interesting variability in the analysis of their in vitro structure and function (results
presented in Chapters 3 and 4). Furthermore, R136 is directly adjacent to the disulfide
bond-forming C137, and T151 is located at the αCD/C-terminal domain border. To
identify the interactome of Hsp27

WT

, Hsp27R136W, and Hsp27T151I in NSC-34 cells

samples from the co-IP were sent for quantitative proteomic analysis by iTRAQ mass
spectrometry to Dr Matt Dun (University of Newcastle) as described in Nixon et al.
(2019). A principle component analysis performed by Dr. Matt Dunn showed tight
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clustering of biological replicates indicating high quantitative reproducibility, and
clustering of the two disease-causing isoforms, Hsp27R136W and Hsp27T151I, separated
from Hsp27WT (Appendix II).
Filtration of identified proteins based on the untransfected control (such that only
proteins with an abundance score at least 1.5 times that of the untransfected were
counted), resulted in a list of 56 proteins that interact with Hsp27WT, and 38 each with
Hsp27R136W and Hsp27T151I (Figure 6.6, Appendix III). The majority of the proteins
identified have high sequence similarities between the mouse and human orthologs
indicating that general pathway analysis is robust based on the mouse proteins identified
as interacting with human Hsp27 (Figure 6.6).

158

Chapter 6

159

Chapter 6

Figure 6.6: Binding partners of Hsp27WT, R136W, and T151I in NSC34 cells. Positive interactions of
each Hsp27 isoform were identified by filtering abundance results according to the untransfected control.
The binding interaction of a protein was deemed positive if its abundance was > 1.5 times that of the
untransfected control and it was identified in 2 of the 3 biological repeats. Orthologous human proteins
were identified, and the percent similarity of the mouse to human (M > H) sequences and the human to
mouse (H > M) sequences were accessed via Ensembl Genes. Genes marked in red represent binding
partners in which mutations have been found to cause CMT and/or dHMN.

Orthogonal validation of the filtering parameters used to identify positive interactions
within the proteomic data was conducted using immunoblot analysis. Two proteins were
used for this purpose: Ste20-like serine/threonine protein kinase (Slk; a protein involved
in mitochondrial fission and apoptosis mediation) and clip-associating protein 2
(Clasp2; involved in microtubule plus-end tracking and stabilisation) (Figure 6.7).
According to the proteomic quantification of these proteins in the co-IP samples, the
abundance of both of these proteins was ≥ 1.5 times higher in both the Hsp27R136W and
Hsp27T151I samples compared to the untransfected sample, and they were not identified
in the Hsp27WT samples. The results from the immunoblot analysis of the co-IP samples
was consistent with these results; prominent bands corresponding to Slk and Clasp2
were found in Hsp27R136W and Hsp27T151I co-IP samples compared to Hsp27WT and the
untransfected controls, and these results were consistent with the proteomic data when
accounting for the band density corresponding to total protein density (Figure 6.7). It
should be noted that the loading of protein samples in these blots was calculated based
on the concentration of total protein in lysates prior to co-IP, and as such, the final
protein amount varies depending on the total amount of protein bound in each sample.
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Figure 6.7: Orthogonal validation of the filtering parameters used to identify Hsp27
binding partners. A: SDS-PAGE and immunoblot analysis of co-IP antibody/bead-bound samples of
untransfected NSC-34 cells (UT), and cells transfected with Hsp27WT, R136W and T151I for Slk. B: SDS-PAGE
and immunoblot analysis of co-IP antibody/bead-bound samples of untransfected NSC-34 cells (UT), and
cells transfected with Hsp27WT, Hsp27R136W and Hsp27T151I for Clasp2. The upper panels in A and B show
chemiluminescent immunoblot band density, and the lower panel shows the total protein present on the
stain-free image of the blot before blocking (used to normalise for protein loading). The locations of
molecular weight markers are indicated to the left, and band identities are indicated to the right. The black
bar in B indicates an omitted lane. C and D: Band density of Slk and Clasp2 (respectively) identified for
the IP samples from untransfected cells ( ), and cells expressing Hsp27WT ( ), Hsp27R136W ( ), and
Hsp27T151I ( ), normalised to the total band density of the corresponding stain-free blot.

Hsp27WT shared surprisingly few binding partners with Hsp27R136W (Irak4, Pdcd6ip),
Hsp27T151I (Psmd13, Gna13, Rtraf, Wars) or both (Eif3e, Arfgap3 Ptrh2; Figure 6.8,
Figure 6.6). There was substantial overlap between the interactomes of the two disease
mutant isoforms. Interestingly, of the 80 genes identified to carry mutations that cause
CMT and/or dHMN (Chapter 1, Table 1.3), Wars was identified as a binding partner of
both Hsp27WT and Hsp27T151I, Ptrh2 was identified as a binding partner of Hsp27R136W
and Hsp27T151I, and Dnmt1, Aifm1 and Hint1 were identified as interactors with
Hsp27WT (Figure 6.8).
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Figure 6.8: Disease-associated mutations in Hsp27 affect the protein interactome in NSC34 cells. Proteins identified as positive interactors with Hsp27WT, Hsp27R136W, and Hsp27T151I and the
list of 80 proteins which carry CMT and/or dHMN-associated mutations were used to generate a Venn
diagram (using the Van de Peer lab’s Bioinformatics and Evolutionary Genomics online tool) to show the
overlap between each group.

The functional enrichment of cellular processes represented by the binding partners of
the Hsp27 isoforms was analysed (Figure 6.9). Of note, binding partners of the two
disease-associated mutants, Hsp27R136W and Hsp27T151I, represent a higher number of
functional processes than Hsp27WT. The Hsp27WT interactome is involved in various
cellular metabolic and biosynthetic pathways, and is particularly enriched for proteins
involved in oxidation-reduction processes (Figure 6.9). For each of the diseaseassociated mutants, and in particular Hsp27T151I, there is an increased number of
proteins involved in gene expression (Figure 6.9). Proteins that have roles in
mitochondrial function, protein transport, and cell death pathways are also represented
in the interactomes of each Hsp27 isoform.
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amide biosynthetic process
anterograde axonal protein transport
ATP biosynthetic process
blood vessel endothelial cell migration
carboxylic acid metabolic process
cell junction assembly
cell-cell recognition
cellular amide metabolic process
cellular aromatic compound metabolic process
cellular response to vascular endothelial growth factor stimulus
chaperone-mediated protein folding
cofactor metabolic process
cytokine metabolic process
D-ribose metabolic process
drug metabolic process
fatty acid derivative catabolic process
fertilisation
focal adhesion assembly
glycerol biosynthetic process
hepatocyte differentiation
heterocycle metabolic process
mitochondrial alanyl-tRNA aminoacylation
mitochondrial respiratory chain complex assembly
multi-organism process
NADH oxidation
ncRNA metabolic process
negative regulation of necrotic cell death
negative regulation of oxidative stress-induced cell death
negative regulation of protein modification process
negative regulation of protein ubiquitination
negative regulation of Rho guanyl-nucleotide exchange factor activity
negative regulation of transferase activity
nuclear-transcribed mRNA catabolic process, nonsense-mediated decay
nucleobase-containing compound catabolic process
organic cyclic compound metabolic process
organic substance metabolic process
organonitrogen compound biosynthetic process
organophosphate metabolic process
oxaloacetate metabolic process
oxidation-reduction process
positive regulation of angiogenesis
positive regulation of anoikis
positive regulation of ATP biosynthetic process
positive regulation of calcium-mediated signalling
positive regulation of chromosome organisation
positive regulation of endothelial cell chemotaxis
positive regulation of mitochondrial membrane potential
positive regulation of telomere maintenance via telomerase
positive regulation of vascular endothelial cell proliferation
propionate metabolic process
protein deneddylation
protein folding
protein lipidation involved in autophagosome assembly
protein lipoylation
protein stabilisation
purine-containing compound metabolic process
regulation of aminoacyl-tRNA ligase activity
regulation of cellular response to oxidative stress

WT

R136W

T151I
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regulation of establishment of protein localisation to chromosome
regulation of intrinsic apoptotic signalling pathway
regulation of protein localisation
regulation of response to external stimulus
regulation of RNA binding
regulation of tumour necrosis factor biosynthetic process
response to external stimulus
response to insulin
response to osmotic stress
response to peptide
response to starvation
response to unfolded protein
ribose phosphate metabolic process
RNA splicing
RNA-dependent DNA biosynthetic process
sulfur compound metabolic process
thioester metabolic process
translation
transmembrane receptor protein tyrosine kinase signalling pathway
tRNA metabolic process
type B pancreatic cell development

Figure 6.9. Heat map of GO biological process enrichment analysis of the binding partners
of Hsp27WT, Hsp27R136W, and Hsp27T151I. g:Profiler (Raudvere et al., 2019) was used to determine
the functional enrichment of GO biological processes represented by the list of binding partners identified
for each Hsp27 isoform. The resulting output was simplified using REVIGO (Supek et al., 2011) to filter
redundant GO terms. Other redundant terms such as “biosynthetic process” vs. “cellular biosynthetic
process” were filtered manually. Colours represent p-values, such that the lowest values (highest
enrichment) are in red, and the highest values (lowest enrichment) are in yellow, and dark grey boxes
represent a pathway that was not enriched in that sample.

The lists of positive interacting proteins for each Hsp27 isoform were analysed for
various biochemical properties to identify possible modes of interaction between Hsp27
and its binding partners (Figure 6.10). Interestingly, the interacting partners of Hsp27WT
showed a statistically significant (F(3, 228) = 4.601, p = 0.0038) increase in the
proportion of aliphatic amino acids compared to a random selection of mouse proteins
used as a control, but there were no significant differences between any of the other
groups (p > 0.05; Figure 6.10A). There were no significant differences in the proportion
of aromatic (F(3, 228) = 0.037, p = 0.9906), positive (F(3, 228) = 1.882, p = 0.1334), or
negative (F(3, 228) = 0.2382, p = 0.8697; Figure 6.10A) residues between the binding
partners of each of the Hsp27 isoforms or the random control. It has been suggested that
Hsp27 acts as a redox sensor in the cell via interactions of the single cysteine residue
(Arrigo, 2005, Arrigo, 2001, Alderson et al 2019b). Interestingly, neither the interacting
partners of Hsp27WT, nor the disease-causing mutants Hsp27R136W or Hsp27T151I showed
any significant difference in the proportion of sulfur-containing residues compared to
each other or the random protein control (F(3, 228) = 0.2382, p = 0.8697; Figure
6.10A).
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The molecular weights of each interacting partner were also predicted based on the
amino acid sequence to assess whether Hsp27 preferentially interacts with larger or
smaller proteins, and whether mutation influences this propensity (Figure 6.10B). None
of the Hsp27 mutant isoforms showed any difference compared to Hsp27WT or the
control (F(3, 228) = 0.4062, p = 0.7487), with each set of interacting proteins having an
average molecular weight of approximately 55 kDa, and the control set approximately
62 kDa (Figure 6.10B).
The pI of each interacting partner was predicted, and the average pI of the binding
partners of each Hsp27 isoform tended towards being slightly higher than that of the
control set, and that of each of the mutant isoforms was slightly higher than Hsp27WT
(7.2932, 7.41304, 7.56553, and 7.82474 (control, Hsp27WT, Hsp27R136W and Hsp27T151I,
respectively; Figure 6.10C). However, no significant difference in the pI value of the
interacting proteins was observed between any of the samples (F(3, 228) = 0.7981, p =
0.4961; Figure 6.10C).
The GRAVY, a measure of overall hydrophobicity, was calculated for each of the
binding partners identified for the Hsp27 isoforms and the control selection (Figure
6.10D). Almost all proteins scored below zero, indicating that the binding partners of
Hsp27 are globular, hydrophilic proteins. The average GRAVY score of the binding
partners of Hsp27WT was slightly higher than each of the other sample sets; however,
again there was no significant difference between any of the samples (F(3, 228) = 1.299,
p = 0.2756).
Analysis of the predicted secondary structures of the binding partners of the Hsp27
isoforms indicated that the average proportion of α-helix is increased in Hsp27R136W
(37.6%) and Hsp27T151I (38.6%) compared to the control (30.2%) or Hsp27WT (31.6%;
Figure 6.10E). However, this difference was only significant between Hsp27T151I and
the control (F(3, 228) = 3.412, p = 0.0183). The inverse pattern was observed for the
proportion of coiled-coil, with a statistically significant (F(3, 228) = 5.095, p = 0.002)
decrease in the average predicted proportion of coiled-coil structure for the binding
partners of Hsp27T151I (47.9%) compared to the control (56.6%), Hsp27WT (51.9%), or
Hsp27R136W (50.2%). The average proportion of β-sheet in the interacting proteins is
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increased in Hsp27WT (16.5%) compared to the control (13.1%), Hsp27R136W (12.2%),
or Hsp27T151I (12.8%); however, this difference was not significant (F(3, 228) = 1.593, p
= 0.1918; Figure 6.10E).
The proportion of disordered and redox-sensitive disordered regions in each binding
partner set were also analysed (Figure 6.10F, G). Under each set of parameters, the
binding partners of Hsp27WT were proportionally less disordered than the diseasemutant isoforms or the control proteins. The decrease in the proportion of redoxsensitive disorder was statistically significant between Hsp27WT and the control proteins
(F(3, 228) = 5.526, p = 0.0011; Figure 6.10G), but no significant difference in general
disorder was found between any of the protein sets (F(3, 228) = 1.136, p = 0.3354;
Figure 6.10F).
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Figure 6.10: Biochemical properties of Hsp27WT, R136W, T151I and C137S binding partners in
NSC34 cells. Biochemical property analysis of identified interactors of Hsp27WT ( ), Hsp27R136W ( ),
and Hsp27T151I ( ) were analysed, and a random selection of 100 known mouse proteins are included as a
control ( ). For each set of proteins the protein statistics (proportion of amino acids that fall into the
aliphatic (A, G, I, L, V), aromatic (F, W, Y), positively charged (H, K, R), negatively charged (D, E), and
sulfur-containing categories (M, S)) (A), the molecular weight (B), the pI (C), the GRAVY score (D), the
predicted proportion of α-helix, β-sheet, and coiled-coil secondary structure (E), and the predicted
proportion of disordered regions (F), and redox-sensitive disordered regions (G) are shown. Columns
represent the mean ± SEM of all identified interacting partners within a sample, and individual data points
are overlayed. Statistical significance determined by one-way ANOVA (B, C, D, F, G) or two-way
ANOVA (A, E) followed by either a Dunnett’s or Bonferroni post-hoc test (respectively) to determine
differences between each isoform and the control, or between each mutant and Hsp27WT. * denotes a pvalue < 0.05, ** denotes p < 0.01, and *** denotes p < 0.001.

Hsp27 oligomer formation is partially mediated by the interaction of the IPV motif in
the C-terminal region with a binding pocket in the αCD, and it has been suggested that
proteins containing an [I/V]X[I/V] motif may also interact with this binding pocket. As
such, the amino acid sequences of each binding partner were searched for this motif.
The majority of binding partners of each isoform contained at least one copy of the
[I/V]X[I/V] motif (Hsp27WT: 51 of 56, Hsp27R136W: 34 of 38, Hsp27T151I: 33 of 38);
however, it is likely that only those accessible in disordered regions of the protein (like
the C-terminal region of Hsp27) would be available to interact with the binding pocket
in Hsp27. Hence, the locations of the identified motifs were cross-referenced with the
locations of IUPred2a-predicted disordered regions in each protein sequence, and a list
of proteins that contain an [I/V]X[I/V] motif in a disordered region was generated
(Table 6.1). Overall, 32%, 50%, and 42% of the total interactors of Hsp27WT,
Hsp27R136W and Hsp27T151I, respectively contained the motif in a disordered region.
Among the proteins identified were Dnajb1 and Hspa14, an Hsp40 and Hsp70,
respectively, as well as two other proteins involved in protein folding: Cct4 and Fkbp8.
Table 6.1: Hsp27-interacting proteins that contain [I/V]X[I/V] motif(s) in disordered
regions. The locations of I/VXI/V motifs were identified in the sequences of each protein found to
interact with Hsp27WT, Hsp27R136W, or Hsp27T151I, and cross referenced with predicted regions of
disorder. Only those that are located within a predicted disordered region are reported here. The Hsp27
isoform(s) with which each protein interacts is indicated.
Motif
count

Binding partner of:
WT

R136W

T151I
T151I

Binding partner of:

Motif
count

WT

Mpo

2

WT

Mrpl2

1

WT
WT

R136W

Acot7

4

R136W

Actc1

1

R136W

Aifm1

2

Nmral1

1

Cct4

3

R136W

T151I

Nudt5

5

R136W

Cip2a

1

R136W

T151I

Pck2

3

R136W

WT

T151I

T151I
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Clasp2

4

R136W

T151I

Pdpk1

1

Cops3

1

R136W

T151I

Phf21B

6

Dnajb1

1

R136W

T151I

Polr2k

1

Dnmt1

4

Farsb

2

Fkbp8

1

Gm27029

1

Gzmc

2

Hnrnph3

1

Hnrnpul2

T151I
R136W

T151I

Rab11a

2

Rbm8a

1

R136W

Ripor1

3

R136W

Rpl26

3

WT

WT

Sec16a

9

WT

WT

Slk

4

1

WT

Snrpd3

1

WT

Hspa14

2

WT

Sod1

3

WT

Irak4

2

WT

Suclg1

1

Irf2bpl

3

WT

Tmpo

1

WT

Lias

1

Tsc22d4

3

WT

Mcm3

2

WT
R136W
WT
R136W

T151I

R136W
R136W

T151I

T151I

WT
T151I

R136W

T151I

R136W

T151I

T151I

6.4 Discussion
Hsp27 is thought to play a role in many different cellular processes including
cytoskeletal dynamics, intracellular transport, mitochondrial maintenance, redox
homeostasis, regulation of apoptosis, and proteostasis via its chaperone activity. Due to
the promiscuity of this sHsp, the molecular mechanisms underlying disease causation
associated with Hsp27 mutations is unclear. Identification of the disease mechanism is
further complicated by a lack of understanding of the precise interactions that determine
the role(s) of Hsp27 in the cell under normal conditions. Given that mutations in the
αCD of Hsp27 destabilise the basic dimeric subunit of Hsp27 and increase the
proportion of monomeric protein, this may affect the interaction of mutant isoforms
with other proteins, and may underlie disease causation. Therefore, the work presented
in this chapter investigated the intracellular behaviour of Hsp27WT, and four diseaseassociated isoforms (Hsp27P39L, Hsp27R136W, Hsp27R140G, and Hsp27T151I).
Previous studies have indicated that some disease mutations in Hsp27 (Hsp27G84R,
Hsp27S135F, and Hsp27P182L) cause the protein to form punctate intracellular aggregates
when analysed by immunohistochemistry (James et al., 2008, Echaniz‐Laguna et al.,
2017), while others (Hsp27P7S, Hsp27G53D, and Hsp27Q128R) do not share this feature
(Echaniz‐Laguna et al., 2017). Having successfully cloned mammalian expression
constructs for Hsp27WT, the disease-causing mutants Hsp27P39L, Hsp27R136W,
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Hsp27R140G, and Hsp27T151, the propensity of these isoforms to form aggregates when
expressed in human neuroblastoma SH-SY5Y cells and mouse motor neuron-like NSC34 cells was assessed by immunohistochemistry. Expression of all the Hsp27 isoforms,
regardless of mutation, resulted in a similar proportion of cells with aggregates, and a
similar number of aggregates per cell within this population. This suggests that the
pathogenicity of these mutations is not the result of inappropriate self-association into
aggregates. Interestingly, the formation of puncta in the cell by Hsp27 is also associated
with phosphorylation of the protein, and it has been suggested that the process is
associated with neuroprotective activity of Hsp27 in the dendrites and synapses of
neuronal cells (Schmidt et al., 2012). The increase in the number of aggregates in NSC34 cells compared to SH-SY5Y cells observed in this work suggests that this motor
neuron-like cell type is either less able to mitigate protein aggregation, or that the
puncta formed by Hsp27 is indeed related to its neuroprotective activity.
Hsp27 has been shown to colocalise with both actin and tubulin in the lamellipodia,
filopodia, focal contacts, and growth cones of differentiating dorsal root ganglion
sensory neurons (Williams et al., 2006), as well as in mature neurites (Williams et al.,
2005), suggesting a role for Hsp27 in the development of new neurites, and the
subsequent growth and patterning of maturing neurites and axons. Indeed, similar
results were observed in the work presented in Chapter 5 in differentiating SH-SY5Y
cells. However, it should be noted that the Hsp27 was not always colocalised with actin
and tubulin. Rather, Hsp27 also showed diffuse localisation throughout the cytoplasm,
and some punctate staining in areas in which actin and tubulin were present at high
abundance.
Another postulated role for Hsp27 is the modulation of cytoskeletal dynamics (Gusev et
al., 2002, Mounier and Arrigo, 2002, Hargis et al., 2004), and it is possible that the
disease-causing mechanism(s) underlying Hsp27 mutations may be related to this
property. As such, the colocalisation of each Myc-tagged Hsp27 isoform with β-tubulin
was assessed by immunohistochemistry in SH-SY5Y and NSC-34 cells. An increase in
the colocalisation between β-tubulin and each of the disease-associated mutant proteins,
compared to Hsp27WT, was observed in SH-SY5Y cells, but not in NSC-34 cells.
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Interestingly, the degree of colocalisation between Hsp27 and β-tubulin was lower in
NSC-34 cells than in SH-SY5Y cells, suggesting a possible difference in the role of
endogenous Hsp27/Hsp25 between these two cell lines. However, it should be noted
that the colocalisation of Hsp27 with β-tubulin was by no means exclusive – i.e. not all
the Hsp27 was colocalised with β-tubulin, but most β-tubulin was colocalised with
Hsp27 in both cell types. This suggests that while an interaction with cytoskeletal
elements is likely, Hsp27 is also involved with other cellular processes.
As the interactome of Hsp27 had not yet been experimentally established, a method
using anti-Myc antibody and magnetic protein A/G beads to co-IP Myc-tagged Hsp27
expressed in CMT/dHMN-relevant motor neuron-like NSC-34 cells was developed. As
NSC-34 cells are a mouse cell type (currently a human motor neuron-like cell line has
not been developed), the compatibility of the intrinsic hetero-oligomer-forming
propensity of human Hsp27 with mouse Hsp25 (the murine ortholog) was first
examined via FRET since this would enable subunit exchange between the two isoforms
to be investigated. The high similarity between the subunit exchange rates of Hsp25
with Hsp27 compared to between the sHsp homo-oligomers demonstrated that the
human and mouse isoforms are capable of interacting when co-expressed in cells. Thus,
if any endogenous Hsp25 were to be expressed in NSC-34 cells, it was highly likely that
it (and its binding partners) would also be pulled down during the co-IP of Hsp27. The
co-IP resulted in the complete pull-down of Hsp27 from the cell lysate as demonstrated
via immunoblotting. This procedure was then utilised to identify the interactome of
Hsp27WT, and the disease-associated mutants Hsp27R136W and Hsp27T151I in motorneuron-like cells. The abundance data was filtered based on the untransfected control to
eliminate proteins identified as a result of non-specific interactions with the antibody
and/or beads. Analysis of co-IP samples via immunoblotting for Slk and Clasp2
indicated that these two proteins were most abundant in the Hsp27R136W and Hsp27T151I
samples, and present at a level at least 1.5-fold higher in these samples than in the
untransfected sample. This orthogonal approach validated the proteomic data and the
filtering applied to identify interactors for Hsp27WT, Hsp27R136W, and Hsp27T151I.
The chaperone activity of Hsp27 is suggested to arise from its interaction with proteins
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in their non-native folding state. To date, various mechanisms of interaction between
Hsp27 and its client proteins have been suggested, including hydrophobic interactions
arising from the β-sheet rich αCD (Cox et al., 2018), redox-related interactions
mediated by the dimer-stabilising cysteine residue in the αCD (Bruey et al., 2000),
interactions of [I/V]X[I/V] motifs (Alderson et al., 2019a), or as a result of the
intrinsically disordered N- and C-terminal regions of the sHsp (V Sudnitsyna et al.,
2012) that favour interactions with other intrinsically disordered proteins (Carver et al.,
2017). Various biochemical properties of the interacting partners of each Hsp27 isoform
were analysed (based on primary structure).
The binding partners of Hsp27WT contain (on average) a higher portion of aliphatic
residues than a randomly selected set of cellular proteins, or the two disease-causing
Hsp27 isoforms. Recent studies have highlighted the importance of aliphatic residues in
amyloid formation (which is related to various neurodegenerative diseases such as
Alzheimer’s) (Chauhan et al., 2000, Lakshmanan et al., 2013, Ninković et al., 2017). As
Hsp27 is involved in the prevention of amyloid formation, these results suggest that
interaction with aliphatic residues may be involved in this function, and that these
interactions are altered by the R136W and T151I mutations. In addition, both diseasecausing mutant isoforms of Hsp27 showed a trend towards binding to proteins with
increased α-helical and decreased coil content, indicating that these mutations may alter
the affinity of Hsp27 for certain types of protein-protein interactions.
Hsp27WT bound to proteins with a trend towards decreased average proportion of
disordered and redox-sensitive disordered regions compared to the two mutants, and the
randomly selected control proteins. It also interacted with slightly fewer sulfurcontaining proteins than the mutants. This is interesting as Hsp27 is suggested to act as
a redox-sensor in the cell and to protect other proteins from oxidative damage
(Alderson, 2019b, Arrigo, 2001), so these results indicate that mutations may increase
the interaction of Hsp27 with disordered and redox-sensitive proteins. It would be
interesting in future to further explore the interactions of Hsp27 and the disease-mutants
in the context of oxidative stress, potentially by combining redox cell-stress experiments
with the co-IP of binding partners.
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The IPV (IXI/V) motif in Hsp27 is known to mediate oligomer formation by interacting
with the β4/8 groove in the αCD. Recent work has shown that [I/V]X[I/V] motifs in
disordered regions of other proteins, such as Bag3 (Alderson et al., 2019a) and poly Cbinding protein 1 (Pcbp1) (Geuens et al., 2017), may also interact in a similar fashion.
A substantial proportion of each isoform’s interactome contained the [I/V]X[I/V] motif
in a disordered region. The [I/V]X[I/V] motif is present in a large proportion of proteins
(about 91% of all mouse proteins), however its presence in disordered regions
represents only about 8% of these occurrences in the human proteome (Alderson et al.
2019a), indicating that the Hsp27 isoforms bind a high proportion of proteins that
contain this motif in an unstructured region. This may be of particular importance with
regard to mutations that affect the IPV motif, or the β4/8 groove. Indeed the interaction
of Hsp27 with Pcbp1 is increased in the Hsp27P182L variant, and this interaction is
postulated to occur via the IPV motif of Hsp27 (Geuens et al., 2017).
The interactome of Hsp27WT was found to be enriched for proteins involved in
oxidation-reduction processes, including the redox sensor protein NmrA-like family
domain-containing protein 1 (Nmral1), and apoptosis inducing factor 1 (Aifm1).
Mutations in the latter are associated with a rare form of CMT, CMTX4. Interestingly,
an interaction between Hsp27WT with dihydrolipoamide S-acetyltransferase (Dlat) was
identified. It has been previously suggested that Hsp27 interacts with G6PD in the
pentose phosphate pathway and glutathione ascorbate pathways (Préville et al., 1999,
Cosentino et al., 2011) to maintain NADPH and reduced glutathione levels in the cell.
While G6PD was not identified as an interactor, Dlat is an upstream regulator of the
pathway. Furthermore, the Hsp27WT interactors were enriched for proteins involved in
sulfur compound metabolic processes, which encompasses sulfur-containing amino
acids, and glutathione. Intriguingly, the interactome of Hsp27 was enriched for proteins
involved in various redox-related pathways, including NADH oxidation (R136W and
T151I), negative regulation of oxidative stress-induced cell death (R136W), oxidationreduction processes (WT), and regulation of cellular response to oxidative stress
(R136W and T151I). Taken together, these findings support a model in which Hsp27
acts as a redox sensor in the cell and, under oxidative conditions, is involved in the
mitigation of oxidative damage. It would be interesting to explore this further using
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experiments that examine the interactomes of Hsp27 under oxidative stress.
The interacting partners of Hsp27R136W and Hsp27T151I, but not Hsp27WT, were all
enriched for proteins that are involved in intrinsic apoptosis signalling, and oxidative
stress-induced apoptosis. Representative proteins of these pathways that interacted with
the disease mutants are T-complex protein 1 theta (Cct8), 3-phosphoinositide-dependent
protein kinase 1 (Pdpk1), 60S ribosomal protein L5 (Rpl5), Slk, Dnajb1, NADH
dehydrogenase [ubiquinone] 1 subunit C2 (Ndufc2), actin, alpha cardiac muscle 1
(Actc1), and phenylalanine-tRNA ligase β (Farsb). While the large number of proteins
in the Hsp27WT interactome reduced the significance of many potential enrichments,
various apoptosis-related proteins were nonetheless identified to interact with Hsp27WT.
These included the CMT-related Aifm1, the redox sensor Nmral1, programmed cell
death 6-interacting protein (Pdcd6ip), and Bcl2-modulating peptidyl-prolyl cis-trans
isomerase (Fkbp8). These findings provide further evidence that Hsp27 is involved in
the regulation of apoptosis. Interestingly, mutations in Aifm1 are known to cause CMT
(Hangen et al., 2015), and in the current study Aifm1 was found to interact with
Hsp27WT, but not with either of the Hsp27 mutants. Moreover, the set of apoptosisrelated proteins that interacted with Hsp27WT did not overlap with those that interacted
with the mutants. This suggests that mutation may interfere with the role of Hsp27 in
inhibiting apoptosis and may contribute to disease progression.
The trademark role of Hsp27 is in proteostasis and, specifically, in the prevention of
protein aggregation, protein folding, and protein degradation. In accordance with these
roles, proteins involved in each process were identified as binding partners of Hsp27.
Heat shock 70 kDa protein 14 (Hspa14) bound to Hsp27WT, while the Hsp70 interactor
DnaJ homolog subfamily B member 1 (Dnajb1) interacts with Hsp27R136W and
Hsp27T151I. Three molecular chaperone T-complex protein 1 subunits delta, eta, and
theta (Cct4, Cct7, and Cct8, respectively) were all found to interact with the two
disease-mutants Hsp27R136W and Hsp27T151I, but not Hsp27WT. In contrast, various
proteins were also identified that interacted with the ubiquitin-proteasome system of
protein degradation. These included the Hsp27WT interactor 26S proteasome nonATPase regulatory subunit 13 (Psmd13; a component of the 26S proteasome), as well as
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interleukin-1 receptor-associated kinase 4 (Irak4; phosphorylates E3 ubiquitin ligases),
which was found to interact with Hsp27WT and Hsp27R136W, and COP9 signalosome
complex subunit 3 (Cops3; regulates the ubiquitin conjugation pathway by mediating
deneddylation (removal of the ubiquitin-like protein Nedd8)), which was found to
interact with the two disease-related isoforms. These interactions suggest that the
disease mechanism of Hsp27 mutation may be related to aberrant interactions with other
proteostasis-related proteins.
There is growing evidence that Hsp27 plays a role in the modulation and stabilisation of
cytoskeletal proteins including actin, tubulin, and neurofilaments. In support of this, the
Hsp27 interactome includes proteins that are involved in cytoskeletal dynamics. Emerin
(Emd) and myosin regulatory light chain 12B (Myl12b) are involved in actin
polymerisation. Tubulin β-2a (Tubb2a; the major component of microtubules) interacts
with Hsp27WT, as was tubulin tyrosine ligase-like family member 12 (Ttll12), which is
thought to play a role similar to tubulin tyrosine ligase in the addition of tyrosine to
tubulin. Furthermore, Slk, an interactor of Hsp27R136W and Hsp27T151I, is involved in the
dissolution of actin stress fibres. Hsp27R136W was found to interact with actin (Actc1),
but this interaction was not found for Hsp27WT. Furthermore, Clasp2, a microtubule
plus-end tracking protein which promotes the stabilisation of microtubules, was found
to interact with both disease-associated mutants Hsp27R136W and Hsp27T151I. Cct4, Cct7,
and Cct8 are components of the chaperonin-containing T molecular chaperone complex,
which is involved in the folding of both actin and tubulin, and were identified as
interactors of both Hsp27R136W and Hsp27T151I. Finally, tryptophan tRNA ligase (Wars),
mutations in which cause dHMN type I, was identified to interact with Hsp27WT and
Hsp27T151I. Taken together, these findings suggest the inappropriate or enhanced
interaction of mutant Hsp27 with actin and tubulin, and proteins involved in modulating
these cytoskeletal elements. The enhanced interaction resulting from these diseasecausing mutations is in accordance with a toxic gain-of-function mechanism underlying
disease.
In addition to proteins related to cytoskeleton dynamics, various proteins involved in
intracellular transport were identified as Hsp27 binding partners. Cct4, Cct7 and Cct8
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(interactors of Hsp27R136W and Hsp27T151I) are thought to play a role in vesicle transport
along microtubules. Ras-related protein (Rab11a; a small GTPase which regulates
intracellular membrane trafficking), protein transport protein sec16 (Sec16a; involved in
trafficking of secretory cargo), and RNA transcription, translation and transport factor
protein (Rtraf; involved in RNA transport) were all found to interact with Hsp27WT.
Moreover, the interactomes of Hsp27R136W and Hsp27T151I were enriched for proteins
involved in localisation of proteins to the presynapse and anterograde protein transport,
which suggests that the sHsp may play a role in signal transduction, and that disease
mutations that result in increased monomerisation of the protein may affect this role.
Another emerging role of Hsp27 is in mitochondrial transport and maintenance.
Evidence suggests that Hsp27 can be translocated into the mitochondria (Shepherd et
al., 2013). Accordingly, various binding proteins were identified in this work that are
involved in mitochondrial functions, such as mitochondrial gene expression, electron
transport, and redox processes. Interestingly, the interacting partners of both diseaserelated mutants Hsp27R136W and Hsp27T151I were enriched for three mitochondrial
pathways: mitochondrial alanyl-tRNA aminoacylation, mitochondrial respiratory chain
complex assembly and positive regulation of mitochondrial membrane potential.
Moreover, the S135F disease-mutation in Hsp27 has been shown to decrease
mitochondrial membrane potential when expressed in primary motor neurons (Kalmar
et al., 2017). Taken together, this strongly suggests that disease-causing mutations in
Hsp27 may have an inhibitory effect on the pathways that increase mitochondrial
membrane potential, and this may be involved in the progression of CMT and dHMN.
The work presented in this chapter provides the first broad affinity-capture of the
interactome of Hsp27 and, importantly, in the context of a motor neuron-like cell type
relevant to the study of CMT and dHMN. It provides strong evidence that Hsp27 is
involved in redox homeostasis, regulation of apoptosis, protein homeostasis, and
modulation of the cytoskeleton in these cells. Differences between Hsp27WT and two
disease-associated mutant isoforms Hsp27R136W and Hsp27T151I are highlighted by the
drastic changes in their interactomes. Significantly, the two distinct disease-associated
mutations studied here have a similar effect on the interactome of the protein,
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suggesting that there may be some commonality in the mechanism(s) by which
mutations in Hsp27 lead to CMT and dHMN.
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7 Discussion and future directions
7.1

Overview

Mutations in the small heat shock protein Hsp27 are associated with CMT and/or
dHMN, but the mechanism(s) underlying disease pathogenesis are unknown. It is likely
that mutations alter the structure, chaperone activity, and/or interactions of Hsp27 with
cellular partners. As such, in this work a set of disease-associated recombinant isoforms
of Hsp27 were generated and their structure and chaperone function were analysed
(relative to Hsp27WT) using various in vitro techniques. Hsp27 is known to be involved
in the development of neurites and axons (Williams et al., 2005, Williams et al., 2006),
and mutations in Hsp27 are suggested to alter the integrity of cytoskeletal elements
(Ackerley et al., 2006), and the axonal transport of mitochondria (Kalmar et al., 2017).
Hence, the role of Hsp27 in these processes was also investigated in this work using an
Hsp27 knockdown model in SH-SY5Y cells. While Hsp27 is known to be involved in
many cellular processes, including proteostasis (Treweek et al., 2015), redox
homeostasis (Arrigo, 2001, Arrigo et al., 2005), inhibition of apoptosis (Havasi et al.,
2008, Matsumoto, 2015), and cytoskeleton dynamics (Gusev et al., 2002, Hargis et al.,
2004, Clarke and Mearow, 2013), the interactions and mechanisms underlying these
activities are unknown. To better understand the cytoprotective roles of Hsp27, the
interactome of Hsp27 and how it is affected by mutations was investigated. Overall, the
results presented in this thesis highlight the dynamic nature of the structure and function
of Hsp27 and provide insights into the effects disease-associated mutations have on the
protein.

7.2 Disease-associated mutations alter the structure of Hsp27 and
chaperone activity of Hsp27
An overall trend that appeared in the structural analyses of Hsp27 (Chapters 3 and 4)
was that disease-associated mutations lead to partial unfolding or loss of structure. This
is based on findings that show decreased intrinsic tryptophan fluorescence (higher
solvent exposure) and changes in exposed hydrophobicity in the disease-associated
mutant isoforms compared to Hsp27WT. This affect may be related to weakening of the
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disulfide bond in the central core domain, which may explain the decrease in the
proportion of β-sheet and decrease in tryptophan fluorescence upon reduction of the
mutant isoforms compared to Hsp27WT. This loss of structure likely affects the
interactions of Hsp27 with itself and other proteins in the cell, potentially via altered
electrostatic interactions. Indeed, Fossa and Chichero (2015) examined the electrostatic
interactions between residues in mutant and wild type Hsp27. Hsp27WT contains a polar
region in which D107, S135, R136, T139, and R140 reside, and R136 forms an H-bond
with D107 (Fossa and Cichero, 2015). R136W and R136L mutations disrupt this
organisation and these isoforms lack the H-bond with D107. Similarly, P150, T151,
Q152, S187, T180, P182, R188, Q190, D200 and K205 were found to all be involved in
hydrophilic interactions, and are in proximity to the αCD (Fossa and Cichero, 2015).
Mutation of T151 was found to interrupt electrostatic interactions between T151 and
Q152, resulting in an hydrophobic contact between T151 and V148 (Fossa and Cichero,
2015).
Size exclusion chromatography and DLS revealed that mutations in Hsp27 increase the
size of the large oligomers (with the exception of Hsp27T151I) and decrease the size of
the small oligomer population. Like Hsp27WT, the oligomeric size of each of the disease
mutant isoforms, especially Hsp27R140G and Hsp27T151I, was found to be concentrationdependent, with at least partial dissociation with decreased concentration. FRET
analysis of subunit exchange showed that all the disease-associated mutant isoforms
underwent subunit exchange with Hsp27WT, but the exchange rate was slower than that
of Hsp27WT homo-oligomers. This reduced rate of subunit exchange was reflected in
reduced chaperone activity in preventing the aggregation of the model client proteins αlac, CS and rhodanese for the two disease-associated mutants with the lowest exchangerate (Hsp27P39L and Hsp27G84R). It has been theorised that decreased oligomer size may
lead to higher chaperone activity (Shashidharamurthy et al., 2005, Hayes et al., 2009,
Jovcevski et al., 2015); however, in this work it was found that most of the mutant
isoforms have a population of smaller oligomers, but do not consistently display higher
chaperone activity. Thus, these data indicate that decreased oligomer size does not
always lead to increased chaperone activity at least when this is assessed by in vitro
aggregation assays.
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Based on the work presented in Chapters 3 and 4 of this thesis, it is clear that different
mutations induce various changes to the secondary, tertiary and quaternary structure of
Hsp27. However, the Hsp27 mutant isoforms showed unpredictable and highly variable
efficacy in preventing the aggregation of different model client proteins; the same
isoform was found to perform better than Hsp27WT against one target, and worse against
another. This phenomenon has been reported in previous studies on sHsp chaperone
action, including Hsp27 (summarised in Treweek et al. (2015)). Thus, it is concluded
that in vitro aggregation assays using non-physiologically relevant proteins have limited
scope in evaluating the relative activity of Hsp27 disease mutants.

7.3 The interactome of Hsp27, and the influence of disease-causing
mutations
Hsp27 is thought to modulate a number of cellular processes, however, until the work
presented in this thesis (Chapter 6), the cellular interactome of Hsp27 had not been
determined outside of the context of cancer. As such, co-IP of Hsp27WT in motor
neuron-like NSC-34 cells was used to establish the interacting partners of this sHsp. The
identified interactors of Hsp27 are in accord with previous evidence that Hsp27 is
involved in pathways that control apoptosis, redox modulation, cytoskeleton dynamics,
protein folding, protein degradation and regulation of mitochondria. Given that the
changes to structure and chaperone function imparted by disease-associated mutations
(see Section 7.2, Chapters 3 and 4) are likely to alter the interactions of Hsp27 with
other proteins, the interactors of the disease-mutant isoforms Hsp27R136W and Hsp27T151I
were also analysed by co-IP from NSC-34 cells (Chapter 6).
7.3.1

Hsp27 and proteostasis-related interactions

While it is widely accepted that Hsp27 possesses chaperone activity with regards to
maintaining proteins in a foldable state and preventing aggregation, the interactions of
this sHsp with other proteostasis mechanisms are less well understood. Hsp27 is known
to influence protein (re)folding by the Hsp70s, ubiquitinated proteasomal protein
degradation, and autophagic removal of proteins. The co-IP of Hsp27 from NSC-34
cells identified a number of proteostasis-related interactors of Hsp27WT (Figure 7.1) and
the disease-related mutant isoforms Hsp27R136W and Hsp27T151I.
180

Chapter 7

Figure 7.1. Summary of proteostasis-related interactions of Hsp27.Hsp27 is involved in
maintaining proteostasis. The results of this thesis define previously unknown interactions between Hsp27
and proteins involved in protein synthesis, folding, and degradation which are represented in the diagram.
Red arrows and bars represent previously defined promotion or inhibition (respectively) of a pathway by
Hsp27. These interactions provide insight into the molecular mechanisms underlying the activity of
Hsp27. These interactions, and the altered interactome caused by Hsp27 disease-related mutations are
discussed in detail in the following sections.
7.3.1.1 Protein synthesis

Hsp27WT was found to interact with eukaryotic translation initiation factor 3E (Eif3e),
part of the Eif-3 complex which is involved in various steps of protein synthesis
initiation. Specifically, the Eif-3 complex initiates the translation of proteins involved in
cell cycling, differentiation and apoptosis (Lee et al., 2015, Lee et al., 2016).
Furthermore, it has previously been shown that an interaction between Hsp27 and Eif4g
during heat shock inhibits protein translation which, during a period of cell stress, could
result in a build-up of misfolding-prone protein intermediates (Cuesta et al., 2000).
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Hsp27R136W and Hsp27T151I were also found to interact with Eif3e, and the two mutants
also interact with Eif3a. This increased interaction with Eif proteins may have a
negative effect on protein synthesis under non-cell stress conditions, thereby causing
under-expression of other cellular proteins. Further to its role in translation initiation,
Eif3a is known to interact with microtubules through interactions with CLIP proteins
(Hašek et al., 2000, Mills et al., 2012), and to possess an actin binding domain (Scholler
and Kanner, 1997). Thus, these proteins provide a link between protein translation and
the cytoskeleton.
Each Hsp27 isoform also interacts with a number of DNA and RNA-processing
proteins, as well as ribosome-related proteins. The subset of these interactors was
different for each isoform, with more overlap between Hsp27R136W and Hsp27T151I than
either with Hsp27WT. These interactions include proteins involved in both mitochondrial
and cellular gene expression. These included interactions with aminoacyl-tRNA
synthetase (Ars) proteins; Aars2 and Mars were found to interact with both of the
disease-mutant isoforms of Hsp27, while Wars interacts with Hsp27WT and Hsp27T151I.
Mutations in both Mars and Wars, as well as the cytoplasmic version of Aars2 (Aars)
and other Ars proteins are causative of CMT and/or dHMN (McLaughlin et al., 2010,
McLaughlin et al., 2012, Gonzalez et al., 2013, Tsai et al., 2017). Together, these
indicate a potential novel function of Hsp27 in the regulation of protein synthesis, and
that alterations to this activity may underly disease phenotypes associated with Hsp27
mutations. It would be interesting to further explore this possibility, potentially utilising
Hsp27 knockdown and analysis of resulting protein expression, as well analysing the
effect of Hsp27 disease-causing mutations on this activity.
7.3.1.2 Protein folding

Hsp27WT interacts with Hspa14 (a member of the Hsp70 family), which is part of the
ribosome-associated complex, a stress-inducible chaperone complex involved in the
folding of nascent polypeptides. Previous studies have shown an involvement of Hsp27
with Hsp70, suggesting that misfolded proteins held in complex by Hsp27 are then
folded by Hsp70 (Ehrnsperger et al., 1997), or an interaction of Hsp27 and Hsp70 via
the co-chaperone Bag3, wherein Hsp27 delivers proteins for degradation by autophagy
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(Seidel et al., 2012). Until now, a direct interaction of Hsp27 with an Hsp70 in cells had
not been confirmed.
The two disease mutants did not co-IP with Hspa14, but did interact with Cct4 and
Cct8, and Hsp27T151I also interacts with Cct7. The Cct proteins (Cct1 – 8) are the
building block subunits of the chaperonin tailless complex polypeptide 1 ring complex
(TRiC). TRiC is involved in several proteostasis-related processes, including the folding
of up to 15% of cellular proteins (Thulasiraman et al., 1999, Reviewed by Grantham,
2020). This means that the interactions between Hsp27 and TRiC proteins are either
exclusive to the mutant isoforms or that, under normal conditions, Hsp27 and TRiC
interact transiently such that these interactions are therefore not detected in the co-IP of
Hsp27WT. The TRiC proteins are thought to interact with other proteins by either
specific binding interactions, hydrophobic interactions (Joachimiak et al., 2014) and/or
electrostatic interactions (Gestaut et al., 2019). As the disease-mutant isoforms each
showed a partial loss of structure (with increased exposure of the N-terminal tryptophan
residues and increased exposure of hydrophobic regions; Chapter 4), this may lead to an
increase in electrostatic or hydrophobic interactions with other proteins including the
Ccts. Interestingly, the TRiC complex is required for the production of both actin and
tubulin, interacting with these proteins in a sequence-specific electrostatic manner
(Brackley and Grantham, 2009). This provides an important link between the
interactions of Hsp27 with the Cct proteins and its activity in modulating the
cytoskeleton network.
Similarly, the two disease mutant isoforms, but not Hsp27WT, were precipitated with
Dnajb1 (Hsp40B1), which may also represent a novel interaction restricted to some
mutated Hsp27 isoforms, or an existing interaction strengthened by the structural
alterations introduced by mutations. While Hsp27 is known to interact with various
other chaperone proteins, and the Hsp40s interact with Hsp70 (Greene et al., 1998,
Faust et al., 2020) and Hsp90 (Hernández et al., 2002), up until this work there has been
little evidence for a direct interaction between Hsp27 and the Hsp40s in cells. The
interactions between disease mutants of Hsp27 and TRiC or Hsp40 may disrupt the
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normal interactions of these folding chaperones with other proteins, and thereby alter
their protein folding abilities.
While it has long been established that Hsp27 plays a role in maintaining a properly
folded proteome, the binding interaction between this sHsp and folding chaperones has
not previously been reported, nor has the interaction of disease-causing mutant isoforms
of Hsp27 with protein refolding mechanisms. This could be further explored utilising
intracellular protein folding assays such as those developed by San Gil et al. (2017)
using the expression of fluorescently tagged, aggregation prone proteins in cells,
alongside the overexpression of Hsps.
7.3.1.3 Protein degradation

Both Hsp27WT and Hsp27T151I were found to interact with Psmd13, which is a subunit of
the 26S proteasome. The 26S proteasome, responsible for degradation of
polyubiquitinated proteins (Voges et al., 1999), is made up of at least 32 subunits,
arranged into two main complexes. Psmd13 is part of the regulatory complex, which
recognises ubiquitinated proteins, removes the ubiquitin tag and unfolds the protein,
then shuttles it into the proteolytic core particle (Glickman et al., 1999, Lander et al.,
2012). While previous studies have linked Hsp27 expression to the removal of
ubiquitinated proteins (Parcellier et al., 2003), this co-IP of Hsp27 and Psmd13 provides
the first evidence of a direct interaction between Hsp27 and the ubiquitin proteasome
system. Hsp27R136W was not found to interact with Psmd13, indicating that a disrupted
protein degradation system may contribute to disease pathogenesis caused by this
mutation. Further exploration of the specific proteins that may be degraded via this
Hsp27/Psmd13 complex would indicate potential systems that are interrupted by
disease-causing mutations in Hsp27.
7.3.2

Hsp27 and the cytoskeleton

Previous work has indicated a role for Hsp27 in cytoskeleton dynamics, neuronal
differentiation, and intracellular transport via modulation of microtubule and actin
dynamics. The co-IP of Hsp27 from NSC-34 cells support these findings and indicate
that diverse interactions underlie the cytoskeleton-modulation activity of this sHsp
(Figure 7.2), many of which are affected by disease-associated mutations.
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Figure 7.2 Summary of cytoskeleton-related interactions of Hsp27.Hsp27 is involved in
modulating cytoskeleton dynamics. The results of this work provide evidence that Hsp27 is involved in
modulation of the cytoskeleton and intracellular transport. These interactions provide insight into the
molecular mechanisms underlying the activity of Hsp27. These interactions, and the altered interactome
caused by Hsp27 disease-related mutations are discussed in detail in the following sections.
7.3.2.1 Maintenance of the cytoskeletal network

Hsp27WT immunoprecipitated from NSC-34 cells bound to actin (Chapter 5), tubulin,
and various proteins involved in regulating the cytoskeleton (Chapter 6). Moreover,
Emd and Myl12b were identified as interacting partners of Hsp27WT. Emd and Myl12b,
together with lamin A/C, are involved in the polarisation of actin to facilitate the
movement of nuclei (Lee et al., 2007, Chang et al., 2013), regulate gene expression, and
modulate nuclear and cytoskeletal actin polymerisation (Lattanzi et al., 2003, Holaska et
al., 2004, Ho et al., 2013). Interestingly, mutations in Emd cause Emery Dreifuss
disease (a muscular dystrophy) (Haraguchi et al., 2004, Muntoni et al., 2006), while
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mutations in lamin A/C cause CMT (De Sandre‐Giovannoli et al., 2002). Emd stabilises
the minus end of actin filaments, increasing their polymerisation rate (Haraguchi et al.,
2004). Conversely, Hsp27 has previously been identified as a negative regulator of actin
polymerisation by capping the plus end of an actin filament (Miron et al., 1988, Miron
et al., 1991), and this activity is attributed to monomeric Hsp27 (Benndorf et al., 1994).
The interaction of Hsp27 with Myl12b and Emd may positively regulate the minus end
actin polymerising activity of Emd, which may contribute to the dysregulation of
neurite outgrowth on knockdown of Hsp27 as observed in Chapter 5. Altered Emd
function may contribute to disease progression resulting from mutations in Hsp27 since
neither Hsp27R136W nor Hsp27T151I interacted with Emd, and Hsp27R136W showed
increased binding to actin, likely enhancing its inhibition of actin polymerisation. This
enhanced interaction between Hsp27R136W and actin may be attributed to the partial loss
of structure and decreased size of small oligomers of this mutant isoform observed in
Chapters 3 and 4.
Wars is implicated in CMT/dHMN (Tsai et al., 2017), and was identified as an
interactor with Hsp27WT and the T151I mutant isoform. Wars is also involved in
modulating cytoskeleton organisation via actin polymerisation (Tzima et al., 2003).
Both disease-causing Hsp27 mutants also interacted with Slk, which binds to alphatubulin, localises to vinculin-containing adhesion complexes with unpolymerised
tubulin in presence of microtubule disrupting agents, and induces the disassembly of
actin stress fibres (Wagner et al., 2002). These activities are linked to caspase 3
cleavage and induction of apoptosis (Sabourin et al., 2000). Together, these results
suggest that Hsp27 is involved in modulation of the actin and tubulin networks, and that
alteration of these interactions may underlie the disease mechanisms caused by Hsp27
mutation.
Hsp27WT binds to tubulin beta 2a (Tubb2a), one of the major tubulin isotypes that forms
microtubules, but this interaction was not detected for Hsp27T151I or Hsp27R136W. Hsp27
has previously been shown to have a stabilising interaction with microtubule seeds and
newly formed microtubules in HeLa and CHO cells (Almeida-Souza et al., 2013). The
R136W isoform of Hsp27 has previously been shown to increase binding to α-tubulin
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and this led to over-stabilised microtubules in HEK293 cells (Almeida-Souza et al.,
2011). However, in the present work, the interaction between β-tubulin and Hsp27 was
lost in the R136W and T151I mutant isoforms, and α-tubulin was not identified as an
interacting partner of any of the Hsp27 isoforms co-precipitated from NSC-34 cells.
Fragile histidine triad protein (Fhit) was fount to interact with Hsp27WT, but

not

Hsp27R136W or Hsp27T151I. Fhit shows specific, strong binding to tubulin and, in
conjunction with other microtubule associated proteins, promotes the assembly of
microtubules (Chaudhuri et al., 1999, Wali, 2010). The loss of interaction between the
disease-causing mutant isoforms and tubulin and Fhit may lead to loss of microtubule
organisation, and thereby contribute to disease progression.
Hsp27WT was found to interact with Ttll12, a protein involved in tubulin
polyglutamylation, the expression of which affects detyrosination rates of the α-tubulin
C-terminus

by

an

unknown

mechanism

(Brants

et

al.,

2012).

The

tyrosination/detyrosination of tubulin acts as a switch between recruitment of the Kif1
motor proteins (mutations of which also cause CMT (Zhao et al., 2001)) to
detyrosinated tubulin (Liao and Gundersen, 1998, reviewed in Moutin et al., 2021), and
microtubule plus-end tracking proteins to tyrosinated tubulin (Peris et al., 2006). Clasp2
is one such plus-end tracking protein (Akhmanova et al., 2001, Efimov et al., 2007,
Engel et al., 2014), also involved in microtubule anchoring and stabilisation (Efimov et
al., 2007, Maki et al., 2015). Clasp2 was identified as an interactor of both Hsp27R136W
and Hsp27T151I. The interplay between tubulin tyrosination and detyrosination have
important implications in the growth, survival and differentiation of cells. A lack of
tubulin tyrosination provides a cell survival advantage in tumorigenesis (Mialhe et al.,
2001), but during development leads to a loss of neuronal organisation (Erck et al.,
2005). The amounts of tyrosinated/detyrosinated tubulin have been shown to influence
neurite extension and axon specification, potentially via altering interactions of plus-end
tracking proteins (Erck et al., 2005) such as CLIP proteins or Clasp2. The slowed rate of
neurite outgrowth, and increased neurite disorganisation in differentiating SH-SY5Y
cells caused by knockdown of Hsp27 (Chapter 5), the potentially stabilising interaction
between Hsp27WT and Tubb2a (Chapter 6; Almeida-Souza et al. (2011)), the loss of
interaction between Ttll12 or β-tubulin 2a and Hsp27R136W and Hsp27T151I, and the
187

Chapter 7

increased interaction of Clasp2 with the two disease-causing mutants together provide
compelling evidence for an important role of Hsp27 in microtubule organisation.
Furthermore, these results indicate that mutations in Hsp27 may pathologically alter
these interactions.
Application of previously developed in vitro methods of quantifying tubulin (Mirigian
et al., 2013) or actin (Doolittle et al., 2013) dynamics in the presence of Hsp27 isoforms
as well as cytoskeleton-related interactors identified in this work would provide a means
by which to test how these interactions influence cytoskeleton formation and the impact
of disease-causing mutations. Furthermore, utilising the methods presented in Chapter 5
to track neurite outgrowth in differentiating cells expressing mutant isoforms of Hsp27
may provide insight into whether this process is involved in the disease phenotypes
caused by Hsp27 mutations.
7.3.2.2 Regulation of transport and localisation

Interactions between Hsp27 and cytoskeletal dynamics likely influence trafficking of
cellular cargo. Additionally, each isoform of Hsp27 was found to interact with a subset
of proteins specifically involved in intracellular trafficking. Hsp27WT was found to
interact with Rab-11A, a microtubule binding protein that regulates dynein-dependent
endosome localisation (Hehnly and Doxsey, 2014). The Rab small GTPases are
important regulators of membrane trafficking involved in the formation of transport
vesicles (Kessler et al., 2012) through to their fusion with membranes (Lindsay et al.,
2013). Hsp27WT also interacts with Sec16a, which is essential for trafficking of
vesicular cargo between the endoplasmic reticulum and the Golgi apparatus (Budnik et
al., 2011), as well as conserved oligomeric Golgi complex subunit 1 (Cog1), which
regulates retrograde vesicle transport within the Golgi (Miller and Ungar, 2012). These
interactions are lost for Hsp27R136W and Hsp27T151I; however, their interactions with the
Cct proteins implicate a potential role in vesicular transport via formation of the
BBsome (Wingfield et al., 2018, Akella et al., 2020), a complex of seven Bardet-Biedl
syndrome proteins (BBS1, 2, 4, 5, 7, 8 and 9). The Cct/TRiC proteins interact with
BBS6, 10 and 12, and then form the BBS-chaperonin complex via interactions with
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BBS7 (Seo et al., 2010). Overall, these interactions suggest Hsp27 plays a role in
vesicular trafficking and that mutation of Hsp27 alters its trafficking functions.
Vesicular membrane trafficking is integral to the formation and maintenance of various
cellular compartments. Neurons are particularly sensitive to defects in membrane
trafficking, which can affect the growth, maintenance and repair of axons (Bloom and
Morgan, 2011). Indeed, a number of neurodegenerative diseases are linked to defective
membrane trafficking (Schreij et al., 2016, Kiral et al., 2018). Utilising knockdown of
Hsp27 and the tracking of vesicle transport in cells would confirm the potential activity
of Hsp27 in this process. To further explore the potential effects of Hsp27 mutation,
future study may involve tracking of vesicular transport in cells expressing diseasecausing mutant isoforms of Hsp27.
7.3.3

Hsp27 and mitochondria

Hsp27 has previously been implicated in mitochondrial functions including having antiapoptotic activity (Mehlen et al., 1997, Charette et al., 2000, Arrigo, 2007, Havasi et al.,
2008). Many genetic mutations that cause CMT and dHMN are associated with altered
mitochondrial function, transport and morphology (Kijima et al., 2005, Baloh et al.,
2007, Cassereau et al., 2009, Irobi et al., 2012, Huber et al., 2013, Lacerda et al., 2014,
López Del Amo et al., 2014, Gregianin et al., 2016, Kim et al., 2016, Nafisinia et al.,
2017, Schwartz et al., 2018), including mutations in Hsp27 which have been reported to
alter mitochondrial transport and membrane potential (Kalmar et al., 2017). In the co-IP
of Hsp27 from NSC-34 cells, a subset of mitochondrial proteins were identified as
interactors of Hsp27WT, Hsp27R136W and Hsp27T151I, although there was little crossover
between the proteins that interacted with the wild type and mutant isoforms. These
protein interactors included those from the mitochondrial outer and inner membranes,
the intermembrane space and the mitochondrial matrix (Figure 7.3). There has been
little study thus far of the activity of Hsp27 with regards to mitochondria, but there is
evidence of mitochondrial localisation of sHsps in maize and Drosophila (Downs et al.,
1999, Hamilton and Heckathorn, 2001, Morrow and Tanguay, 2015).
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Figure 7.3. Summary of mitochondria-related interactions of Hsp27.An emerging area of
research is the involvement of Hsp27 in modulating mitochondrial functions, including morphology,
apoptosis, and modulating intracellular redox status. The results of the work presented in this thesis
provide evidence of the interactions that may underlie these activities (and are indicted by the interactions
of Hsp27 in this figure). These interactions, and the altered interactome caused by Hsp27 disease-related
mutations are discussed in detail in the following sections.

7.3.3.1 Mitochondrial morphology

The dynamic and constantly changing morphology of mitochondria is integral to their
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function, and is controlled by fusion and fission of the organelles. Misato homolog 1
(Msto1) is a mitochondrial outer membrane protein required for fusion of mitochondria
and formation of the filamentous mitochondrial network (Kimura and Okano, 2007),
and was identified in this work as an interacting partner of Hsp27WT. Knockdown of
Msto1 leads to fragmentation of the mitochondrial network and apoptosis (Gal et al.,
2017). The loss of filamentous mitochondria observed as a result of Hsp27 knockdown
in SH-SY5Y cells (Chapter 5), and the lack of interaction between the disease mutant
isoforms of Hsp27 and Msto1 in NSC-34 cells suggest that Hsp27 may act as a positive
regulator of Msto1. Interestingly, Msto1 contains homologous regions with tubulin GTP
binding motifs, which could provide a common interacting sequence for Hsp27.
7.3.3.2 Glycolysis, lipid metabolism, the tricarboxylic acid (TCA) cycle, the respiratory
chain, and ATP synthesis

Perhaps the most well-known function of mitochondrial proteins is the generation of
ATP, which combines a multitude of proteins involved in pyruvate/acetyl CoA
integration, the TCA, electron transport, and ATP synthesis. Hsp27WT was found to
interact with proteins from each of these processes, including Dlat, a component of the
pyruvate dehydrogenase complex, which links glycolysis to the TCA cycle by
conversion of pyruvate to acetyl-CoA. Acyl-CoA dehydrogenase very long chain
(Acadvl), another interactor of Hsp27, is involved in the β-oxidation of fatty acids
(Aoyama et al., 1995, Shin et al., 2014), which also produces acetyl-CoA that feeds into
the TCA cycle. Hsp27 also binds malate dehydrogenase (Mdh2) and succinate CoA
ligase ADP-forming subunit beta (Sucla2), components of the TCA cycle which uses
acetyl-CoA to generate NADH, FADH2 and GTP which feed into the respiratory chain.
Interestingly, Hsp27R136W and Hsp27T151I were found not to interact with Sucla2;
however, both mutants precipitated Suclg1, the α-subunit of succinate-CoA ligase.
The respiratory chain is made up of four complexes. Hsp27WT interacts with
mitochondrial amidoxime reducing component 2 (Marc2) and cytochrome b-c1
complex subunit 2 (Uqcrc2) while the two mutant isoforms interact with Ndufc2.
Ndufc2 is an accessory protein required for the assembly and function of complex I
(Stroud et al., 2016) which converts NADH to NAD+, and Marc2 reduces N-oxygenated
molecules coordinated with electron transfer from NADH to Uqcrc2 (Kotthaus et al.,
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2011). Uqcrc2 is part of complex III, responsible for electron transfer from ubiquinol to
Cyt-c (Yu et al., 1977). Acadvl is also involved in maintenance respiratory chain
function (Seminotti et al., 2019), and was found to be an interactor of Hsp27WT.
Hamilton and Heckathorn (2001) found that complex I of the maize respiratory chain
was protected from oxidative stress by sHsps, although little is known of the roles of
Hsp27 or other mammalian sHsps in the respiratory chain.
The final step of ATP production is carried out by the ATP synthase complex, which
uses the membrane proton gradient created by the respiratory chain to convert ADP to
ATP (Aggeler et al., 2002). Hsp27WT binds to ATP synthase subunit beta (Atp5b), and
Hsp27R136W interacts with ATP synthase protein 8 of this complex. Overall, this
implicates Hsp27 in multiple steps of the mitochondrial production of ATP. In this
work, neither Hsp27R136W nor Hsp27T151I were found to interact with the same subset of
respiratory chain proteins as Hsp27WT, and CMT and dHMN mutations in both Hsp27
and Hsp22 have been shown previously to reduce mitochondrial membrane potential
(Irobi et al., 2012, Kalmar et al., 2017). Membrane potential in the mitochondria of
motor neuron cells expressing the disease-associated Hsp27S135F has been shown to be
reduced compared to cells expressing Hsp27WT, and this decrease is accompanied by
sensitivity of the cells to oxidative stress, and a decrease in mitochondrial glutathione
(Kalmar et al., 2017), suggesting that Hsp27 positively interacts with the respiratory
chain. Taken together, these data imply that disease-associated mutations interrupt
interactions of Hsp27 with respiratory chain proteins, leading to malfunction of electron
transport, and loss of mitochondrial membrane potential.
7.3.3.3 Redox and apoptosis

Mitochondrial function is tightly linked to the cellular redox state and apoptosis, and
Hsp27 is thought to regulate both processes in order to maintain cell viability. The co-IP
of Hsp27WT from NSC-34 cells identified multiple binding partners that may be
involved in these activities of Hsp27. Among these was the pro-apoptotic protein
Aifm1, which is released from the intermembrane space of mitochondria in response to
apoptotic stimuli. It localises to the nucleus, and positively regulates the caspaseindependent apoptosis pathways via fragmentation of DNA, and inhibition of the Eif3192
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mediated protein synthesis (Galluzzi et al., 2008). Given that Hsp27 acts in an antiapoptotic manner, its interaction with Aifm1 may block its induction of apoptosis.
Conversely, Hsp27R136W interacts with Fhit, a tumour suppressor which plays a role in
the activation of the intrinsic (through loss of mitochondrial membrane potential) and
extrinsic (with the activation of caspase-8, caspase-3, and Parp) pathways of apoptosis
(Askari and Vo‐Dinh, 2004). Moreover, both Hsp27 disease mutants interact with Slk,
which, upon cleavage by caspase 3, has pro-apoptotic functions via cytoskeletal
rearrangement, the disassembly of actin stress fibres and focal adhesions (Sabourin et
al., 2000). Hsp27 was also found to interact with various other anti-apoptotic proteins,
including Fkbp8, Cyb5r3, and myeloperoxidase (Mpo). Fkbp8 acts as a chaperone for
Bcl2 (Kang et al., 2005), targets it to the mitochondria and modulates its
phosphorylation state, likely interfering with the interactions of Bcl2 with its targets and
thereby inhibiting the pro-apoptotic activity of Bcl2. In its reduced form Cyb5r3
(involved in the reduction of Cyt-c (Rogers and Strittmatter, 1975)) is unable to induce
the formation of the apoptosome, an activity carried out by oxidised Cyt-c in response
to ROS (Rogers and Strittmatter, 1975). Mpo is also involved in the negative regulation
of oxidation-induced apoptosis (Wagner et al., 2000), possibly via ROS scavenger
activity (Podrez et al., 2000).
The interacting partners of Hsp27WT are enriched for proteins involved in oxidationreduction processes, supporting the suggestion that Hsp27 may act as a cellular redox
sensor. via the maintenance of reduced Cyt-c by Cyb5r3, Cyt-c protects neuronal cells
against H2O2-induced oxidative stress by maintaining the redox state and bioenergetics,
as well as the NAD+/NADH ratio (Hyun and Lee, 2015). Another redox-related protein
that was identified to interact with Hsp27WT was SOD1, which is involved in the
elimination of ROS (Lin et al., 2013). Interestingly, SOD1 deficiency also causes
mitochondrial damage (Aquilano et al., 2006). Besides its maintenance of respiratory
chain function, Acadvl is also involved in reducing the generation of ROS (Seminotti et
al., 2019). Hsp27WT interacts with NmrA-like family domain-containing protein 1
(Nmral1), a redox sensor protein which normally exists as a dimer, but in response to
lowered NADPH concentrations dissociates into monomers. The monomeric form binds
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argininosuccinate synthase and impairs its nitric oxide synthesis activity (Seminotti et
al., 2019).
The pathways that influence cellular redox homeostasis, and apoptosis are diverse and
interconnected. Future work may involve exploration of the specific interactions
identified between Hsp27 and mitochondrial proteins, and how these fit into the larger
context of cell survival. This would provide an understanding of the mechanisms
underlying the cytoprotective function of Hsp27, and a basis on which to explore the
effects of Hsp27 mutations.

7.4 Conclusions and future directions
Overall, the results of this thesis bring to light some of the potential mechanisms that
contribute to development of CMT and dHMN as a result of Hsp27 mutations, both in
the context of structural changes, and the functional interactions of Hsp27 with other
proteins. While some structural similarities were found between mutant isoforms of
Hsp27 (e.g. increased solvent exposure, altered oligomerisation, and weakening of the
disulfide bond), there is pronounced variability in chaperone activity as assessed by in
vitro protein aggregation assays. Moreover, while there is substantial commonality in
the identified interactomes of Hsp27R136W and Hsp27T151I in motor neuron-like cells,
there is also a subset of interactions not shared between the mutant isoforms. This
highlights the importance of structure on the function of Hsp27 and indicates that
various mechanisms likely underlie disease caused by Hsp27 mutation. This work has
provided a first look at the neuronal interactome of Hsp27 and the results not only
highlight the complexity of its interactions with proteins and cellular pathways, but also
confirm previous findings that implicate Hsp27 in proteostasis, modulation of the
cytoskeleton and intracellular transport, inhibition of apoptosis, and protection against
oxidative stress. Future work following from this initial investigation of the Hsp27
interactome would be to validate these specific interactions in primary neurons and/or
neuronal induced pluripotent stem cells. Their biological function and disease relevance
can then be explored in both in vitro and animal-based models. These insights into the
molecular interactions of Hsp27 in cells provide a basis from which to explore the
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mechanisms underlying disease-causing mutations in Hsp27, a necessary first step
towards the development of therapeutic treatments for CMT and dHMN.
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Marusich, M. F. (2002). A functionally active human F1F0 ATPase can be
purified by immunocapture from heart tissue and fibroblast cell lines. Journal of
Biological Chemistry 277(37): 33906-33912.
Ahner, A., Gong, X., Schmidt, B. Z., Peters, K. W., Rabeh, W. M., Thibodeau, P. H.,
Lukacs, G. L. and Frizzell, R. A. (2013). Small heat shock proteins target mutant
cystic fibrosis transmembrane conductance regulator for degradation via a small
ubiquitin-like modifier–dependent pathway. Molecular Biology of the Cell
24(2): 74-84.
Akella, J. S., Carter, S. P., Nguyen, K., Tsiropoulou, S., Moran, A. L., Silva, M., Rizvi,
F., Kennedy, B. N., Hall, D. H. and Barr, M. M. (2020). Ciliary Rab28 and the
BBSome negatively regulate extracellular vesicle shedding. eLife 9: e50580.
Akhmanova, A., Hoogenraad, C. C., Drabek, K., Stepanova, T., Dortland, B., Verkerk,
T., Vermeulen, W., Burgering, B. M., De Zeeuw, C. I. and Grosveld, F. (2001).
Clasps are CLIP-115 and-170 associating proteins involved in the regional
regulation of microtubule dynamics in motile fibroblasts. Cell 104(6): 923-935.
Akkaya, Ç., Yavuzer, S. S., Yavuzer, H., Erkol, G., Bozluolcay, M. and Dinçer, Y.
(2017). DNA damage, DNA susceptibility to oxidation and glutathione redox
status in patients with Alzheimer's disease treated with and without memantine.
Journal of the Neurological Sciences 378: 158-162.
Al-Madhoun, A. S., Chen, Y.-X., Haidari, L., Rayner, K., Gerthoffer, W., McBride, H.
and O’Brien, E. R. (2007). The interaction and cellular localization of HSP27
and ERβ are modulated by 17β-estradiol and HSP27 phosphorylation. Molecular
and Cellular Endocrinology 270(1-2): 33-42.
Al-Tahan, S., Weiss, L., Yu, H., Tang, S., Saporta, M., Vihola, A., Mozaffar, T., Udd,
B. and Kimonis, V. (2019). New family with HSPB8-associated autosomal
dominant rimmed vacuolar myopathy. Neurology Genetics 5(4).
Alazami, A. M., Patel, N., Shamseldin, H. E., Anazi, S., Al-Dosari, M. S., Alzahrani, F.,
Hijazi, H., Alshammari, M., Aldahmesh, M. A. and Salih, M. A. (2015).
Accelerating novel candidate gene discovery in neurogenetic disorders via
whole-exome sequencing of prescreened multiplex consanguineous families.
Cell Reports 10(2): 148-161.
196

References

Alderson, T. R., Adriaenssens, E., Asselbergh, B., Pritisanac, I., Gastall, H. Y., Walti,
M. A., Louis, J. M., Timmerman, V., Baldwin, A. and Benesch, J. L. (2019a).
Dysregulated interactions triggered by a neuropathy-causing mutation in the IPV
motif of HSP27. BioRxiv: 708180.
Alderson, T. R., Benesch, J. L. and Baldwin, A. J. (2017). Proline isomerization in the
C-terminal region of HSP27. Cell Stress and Chaperones 22(4): 639-651.
Alderson, T. R., Roche, J., Gastall, H. Y., Dias, D. M., Pritišanac, I., Ying, J., Bax, A.,
Benesch, J. L. and Baldwin, A. J. (2019b). Local unfolding of the HSP27
monomer regulates chaperone activity. Nature Communications 10(1): 1-16.
Almeida-Souza, L., Asselbergh, B., d'Ydewalle, C., Moonens, K., Goethals, S., de
Winter, V., Azmi, A., Irobi, J., Timmermans, J.-P. and Gevaert, K. (2011).
Small heat-shock protein HspB1 mutants stabilize microtubules in CharcotMarie-Tooth neuropathy. The Journal of Neuroscience 31(43): 15320-15328.
Almeida-Souza, L., Asselbergh, B., De Winter, V., Goethals, S., Timmerman, V. and
Janssens, S. (2013). HSPB1 facilitates the formation of non-centrosomal
microtubules. Public Library of Science One 8(6): e66541.
Almeida-Souza, L., Goethals, S., de Winter, V., Dierick, I., Gallardo, R., Van Durme,
J., Irobi, J., Gettemans, J., Rousseau, F. and Schymkowitz, J. (2010). Increased
monomerization of mutant HspB1 leads to protein hyperactivity in CharcotMarie-Tooth neuropathy. Journal of Biological Chemistry 285(17): 1277812786.
Amornvit, J., Yalvac, M. E., Chen, L. and Sahenk, Z. (2017). A novel p. T139M
mutation in HSPB1 highlighting the phenotypic spectrum in a family. Brain and
Behavior 7: e00774.
Andley, U. P., Patel, H. C. and Xi, J.-H. (2002). The R116C mutation in αA-crystallin
diminishes its protective ability against stress-induced lens epithelial cell
apoptosis. Journal of Biological Chemistry 277(12): 10178-10186.
Andrieu, C., Taieb, D., Baylot, V., Ettinger, S., Soubeyran, P., De-Thonel, A., Nelson,
C., Garrido, C., So, A. and Fazli, L. (2010). Heat shock protein 27 confers
resistance to androgen ablation and chemotherapy in prostate cancer cells
through eIF4E. Oncogene 29(13): 1883.
Antonellis, A., Ellsworth, R. E., Sambuughin, N., Puls, I., Abel, A., Lee-Lin, S.-Q.,
Jordanova, A., Kremensky, I., Christodoulou, K. and Middleton, L. T. (2003).
Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and
distal spinal muscular atrophy type V. The American Journal of Human
Genetics 72(5): 1293-1299.
Antoniadi, T., Buxton, C., Dennis, G., Forrester, N., Smith, D., Lunt, P. and BurtonJones, S. (2015). Application of targeted multi-gene panel testing for the
diagnosis of inherited peripheral neuropathy provides a high diagnostic yield
with unexpected phenotype-genotype variability. BioMed Central Medical
Genetics 16(1): 84.
Aoyama, T., Souri, M., Ueno, I., Kamijo, T., Yamaguchi, S., Rhead, W. J., Tanaka, K.
and Hashimoto, T. (1995). Cloning of human very-long-chain acyl-coenzyme A
dehydrogenase and molecular characterization of its deficiency in two patients.
American Journal of Human Genetics 57(2): 273.
Aquilano, K., Vigilanza, P., Rotilio, G., Ciriolo, M. R., Aquilano, K., Vigilanza, P.,
Rotilio, G. and Ciriolo, M. R. (2006). Mitochondrial damage due to SOD1
197

References

deficiency in SH‐SY5Y neuroblastoma cells: a rationale for the redundancy of
SOD1. The Federation of American Societies for Experimental Biology Journal
20(10): 1683-1685.
Aquilina, J. A., Benesch, J. L., Bateman, O. A., Slingsby, C. and Robinson, C. V.
(2003). Polydispersity of a mammalian chaperone: mass spectrometry reveals
the population of oligomers in alphaB-crystallin. Proceedings of the National
Academy of Science 100(19): 10611-10616.
Aquilina, J. A., Shrestha, S., Morris, A. M. and Ecroyd, H. (2013). Structural and
functional aspects of hetero-oligomers formed by the small heat shock proteins
αB-crystallin and Hsp27. Journal of Biological Chemistry 288(19): 1360213609.
Arhar, T., Shkedi, A., Nadel, C.M. and Gestwicki, J.E., 2021. The interactions of
molecular chaperones with client proteins: why are they so weak?. Journal of
Biological Chemistry, 297(5).
Arrigo, A. P. (2007). The cellular “networking” of mammalian Hsp27 and its functions
in the control of protein folding, redox state and apoptosis. Molecular aspects of
the stress response: chaperones, membranes and networks. Csermely, P. and
Vígh, L. New York, Springer-Verlag: 14-26.
Arrigo, A. P. (2013). Human small heat shock proteins: Protein interactomes of homo‐
and hetero‐oligomeric complexes: An update. Federation of European
Biochemical Societies Letters 587(13): 1959-1969.
Arrigo, A. P., Virot, S., Chaufour, S., Firdaus, W., Kretz-Remy, C. and Diaz-Latoud, C.
(2005). Hsp27 consolidates intracellular redox homeostasis by upholding
glutathione in its reduced form and by decreasing iron intracellular levels.
Antioxidants and Redox Signaling 7(3-4): 414-422.
Arrigo, A. P. (2001). Hsp27: novel regulator of intracellular redox state. International
Union of Biochemistry and Molecular Biology - Life 52(6): 303-307.
Arrigo, A. P. (2005). In search of the molecular mechanism by which small stress
proteins counteract apoptosis during cellular differentiation. Journal of Cellular
Biochemistry 94(2): 241-246.
Ashrafi, G., Schlehe, J. S., LaVoie, M. J. and Schwarz, T. L. (2014). Mitophagy of
damaged mitochondria occurs locally in distal neuronal axons and requires
PINK1 and Parkin. The Journal of Cell Biology 206(5): 655-670.
Askari, M. D. and Vo‐Dinh, T. (2004). Implication of mitochondrial involvement in
apoptotic activity of fragile histidine triad gene: application of synchronous
luminescence spectroscopy. Biopolymers: Original Research on Biomolecules
73(4): 510-523.
Atkinson, D., Glumac, J. N., Asselbergh, B., Ermanoska, B., Blocquel, D., Steiner, R.,
Estrada-Cuzcano, A., Peeters, K., Ooms, T. and De Vriendt, E. (2017).
Sphingosine 1-phosphate lyase deficiency causes Charcot-Marie-Tooth
neuropathy. Neurology 88(6): 533-542.
Azevedo, H., Costa, H., Davidovich, E., Pupe, C. and Nascimento, O. J. M. (2021).
Prevalence and characterization of pain in patients with Charcot-Marie-Tooth
disease type 1A. Arquivos de Neuro-Psiquiatria 79: 415-419.
Baek, S. H., Min, J. N., Park, E. M., Han, M. Y., Lee, Y. S., Lee, Y. J. and Park, Y. M.
(2000). Role of small heat shock protein HSP25 in radioresistance and
glutathione‐redox cycle. Journal of Cellular Physiology 183(1): 100-107.
198

References

Balch, W. E., Morimoto, R. I., Dillin, A. and Kelly, J. W. (2008). Adapting proteostasis
for disease intervention. Science 319(5865): 916-919.
Baloh, R. H., Schmidt, R. E., Pestronk, A. and Milbrandt, J. (2007). Altered axonal
mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease
from mitofusin 2 mutations. Journal of Neuroscience 27(2): 422-430.
Baranova, E., Weeks, S., Beelen, S., Bukach, O., Gusev, N. and Strelkov, S. (2011).
Three-dimensional structure of α-crystallin domain dimers of human small heat
shock proteins HspB1 and HspB6. Journal of Molecular Biology 411(1): 110122.
Barros, M. H., Nobrega, F. G. and Tzagoloff, A. (2002). Mitochondrial ferredoxin
isrequired for heme acsynthesis in Saccharomyces cerevisiae. Journal of
Biological Chemistry 277(12): 9997-10002.
Baumann, M., Schreiber, H., Schlotter‐Weigel, B., Löscher, W. N., Stucka, R., Karall,
D., Strom, T. M., Bauer, P., Krabichler, B. and Fauth, C. (2019). MPV17
mutations in juvenile‐and adult‐onset axonal sensorimotor polyneuropathy.
Clinical Genetics 95(1): 182-186.
Baxter, R. V., Othmane, K. B., Rochelle, J. M., Stajich, J. E., Hulette, C., Dew-Knight,
S., Hentati, F., Hamida, M. B., Bel, S. and Stenger, J. E. (2001). Gangliosideinduced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth
disease type 4A/8q21. Nature Genetics 30(1): 21.
Ben-Zvi, A., Miller, E. A. and Morimoto, R. I. (2009). Collapse of proteostasis
represents an early molecular event in Caenorhabditis elegans aging.
Proceedings of the National Academy of Sciences 106(35): 14914-14919.
Benedetti, S., Previtali, S. C., Coviello, S., Scarlato, M., Cerri, F., Di Pierri, E.,
Piantoni, L., Spiga, I., Fazio, R. and Riva, N. (2010). Analyzing
histopathological features of rare Charcot-Marie-Tooth neuropathies to unravel
their pathogenesis. Archives of Neurology 67(12): 1498-1505.
Benesch, J. L., Ayoub, M., Robinson, C. V. and Aquilina, J. A. (2008). Small heat
shock protein activity is regulated by variable oligomeric substructure. Journal
of Biological Chemistry 283(42): 28513-28517.
Benn, S. C., Perrelet, D., Kato, A. C., Scholz, J., Decosterd, I., Mannion, R. J.,
Bakowska, J. C. and Woolf, C. J. (2002). Hsp27 upregulation and
phosphorylation is required for injured sensory and motor neuron survival.
Neuron 36(1): 45-56.
Benndorf, R., Sun, X., Gilmont, R. R., Biederman, K. J., Molloy, M. P., Goodmurphy,
C. W., Cheng, H., Andrews, P. C. and Welsh, M. J. (2001). Hsp22, a new
member of the small heat shock protein superfamily, interacts with mimic of
phosphorylated Hsp27 (3DHsp27). Journal of Biological Chemistry 276(29):
26753-26761.
Benoy, V., Berghe, P. V., Jarpe, M., Van Damme, P., Robberecht, W. and Van Den
Bosch, L. (2017). Development of improved HDAC6 inhibitors as
pharmacological therapy for axonal Charcot–Marie–Tooth disease.
Neurotherapeutics 14(2): 417-428.
Bera, S. and Abraham, E. C. (2002). The αA-crystallin R116C mutant has a higher
affinity for forming heteroaggregates with αB-crystallin. Biochemistry 41(1):
297-305.
Bera, S., Thampi, P., Cho, W. J. and Abraham, E. C. (2002). A positive charge
199

References

preservation at position 116 of αA-crystallin is critical for its structural and
functional integrity. Biochemistry 41(41): 12421-12426.
Bereiter-Hahn, J. (1990). Behavior of mitochondria in the living cell. International
Review of Cytology. Jeon, K. W. and Friedlander, M., Elsevier. 122: 1-63.
Bergoffen, J., Scherer, S., Wang, S., Scott, M. O., Bone, L., Paul, D., Chen, K., Lensch,
M., Chance, P. and Fischbeck, K. (1993). Connexin mutations in X-linked
Charcot-Marie-Tooth disease. Science 262(5142): 2039-2042.
Berry, V., Francis, P., Reddy, M. A., Collyer, D., Vithana, E., MacKay, I., Dawson, G.,
Carey, A. H., Moore, A., Bhattacharya, S. S. and Quinlan, R. A. (2001). αBcrystallin gene (CRYAB) mutation causes dominant congenital posterior polar
cataract. American Journal of Human Genetics 69(5): 1141-1145.
Bertini, E., Gadisseux, J., Palmieri, G., Ricci, E., Capua, M. D., Ferriere, G. and Lyon,
G. (1989). Distal infantile spinal muscular atrophy associated with paralysis of
the diaphragm: a variant of infantile spinal muscular atrophy. American Journal
of Medical Genetics 33(3): 328-335.
Bhatwadekar, A. and Ghole, V. (2005). Rapid method for the preparation of an AGE‐
BSA standard calibrator using thermal glycation. Journal of Clinical Laboratory
Analysis 19(1): 11-15.
Bienfait, H. M., Verhamme, C., van Schaik, I. N., Koelman, J. H., de Visser, B. W. O.,
de Haan, R. J., Baas, F., van Engelen, B. G. and de Visser, M. (2006).
Comparison of CMT1A and CMT2: similarities and differences. Journal of
Neurology 253(12): 1572-1580.
Bjørklund, G., Peana, M., Maes, M., Dadar, M. and Severin, B. (2021). The glutathione
system in Parkinson’s disease and its progression. Neuroscience &
Biobehavioral Reviews 120: 470-478.
Bloom, O. E. and Morgan, J. R. (2011). Membrane trafficking events underlying axon
repair, growth, and regeneration. Molecular and Cellular Neuroscience 48(4):
339-348.
Bousset, L., Pieri, L., Ruiz-Arlandis, G., Gath, J., Jensen, P. H., Habenstein, B.,
Madiona, K., Olieric, V., Böckmann, A. and Meier, B. H. (2013). Structural and
functional characterization of two alpha-synuclein strains. Nature
Communications 4: 2575.
Bova, M. P., Yaron, O., Huang, Q. L., Ding, L., Haley, D. A., Stewart, P. L. and
Horwitz, J. (1999). Mutation R120G in αB-crystallin, which is linked to a
desmin-related myopathy, results in an irregular structure and defective
chaperone-like function. Proceedings of the National Academy of Sciences
96(11): 6137-6142.
Boyer, O., Nevo, F., Plaisier, E., Funalot, B., Gribouval, O., Benoit, G., Cong, E. H.,
Arrondel, C., Tête, M.-J. and Montjean, R. (2011). INF2 mutations in Charcot–
Marie–Tooth disease with glomerulopathy. New England Journal of Medicine
365(25): 2377-2388.
Braathen, G., Høyer, H., Busk, Ø., Tveten, K., Skjelbred, C. and Russell, M. (2016).
Variants in the genes DCTN 2, DNAH 10, LRIG 3, and MYO 1A are associated
with intermediate Charcot–Marie–Tooth disease in a Norwegian family. Acta
Neurologica Scandinavica 134(1): 67-75.
Braathen, G., Sand, J., Lobato, A., Høyer, H. and Russell, M. (2011). Genetic
epidemiology of Charcot–Marie–Tooth in the general population. European
200

References

Journal of Neurology 18(1): 39-48.
Brackley, K. I. and Grantham, J. (2009). Activities of the chaperonin containing TCP-1
(CCT): implications for cell cycle progression and cytoskeletal organisation.
Cell Stress and Chaperones 14(1): 23-31.
Brants, J., Semenchenko, K., Wasylyk, C., Robert, A., Carles, A., Zambrano, A.,
Pradeau-Aubreton, K., Birck, C., Schalken, J. A. and Poch, O. (2012). Tubulin
tyrosine ligase like 12, a TTLL family member with SET-and TTL-like domains
and roles in histone and tubulin modifications and mitosis. Public Library of
Science One 7(12): e51258.
Brennan, K. M., Bai, Y., Pisciotta, C., Wang, S., Feely, S. M., Hoegger, M., Gutmann,
L., Moore, S. A., Gonzalez, M. and Sherman, D. L. (2015). Absence of
Dystrophin Related Protein-2 disrupts Cajal bands in a patient with Charcot–
Marie–Tooth disease. Neuromuscular Disorders 25(10): 786-793.
Brodehl, A., Gaertner‐Rommel, A., Klauke, B., Grewe, S. A., Schirmer, I.,
Peterschröder, A., Faber, L., Vorgerd, M., Gummert, J. and Anselmetti, D.
(2017). The novel αB‐crystallin (CRYAB) mutation p. D109G causes restrictive
cardiomyopathy. Human Mutation 38(8): 947-952.
Brownlees, J., Ackerley, S., Grierson, A. J., Jacobsen, N. J., Shea, K., Anderton, B. H.,
Leigh, P. N., Shaw, C. E. and Miller, C. C. (2002). Charcot–Marie–Tooth
disease neurofilament mutations disrupt neurofilament assembly and axonal
transport. Human Molecular Genetics 11(23): 2837-2844.
Bruey, J.-M., Ducasse, C., Bonniaud, P., Ravagnan, L., Susin, S. A., Diaz-Latoud, C.,
Gurbuxani, S., Arrigo, A.-P., Kroemer, G. and Solary, E. (2000). Hsp27
negatively regulates cell death by interacting with cytochrome c. Nature Cell
Biology 2(9): 645-652.
Bryantsev, A. L., Kurchashova, S. Y., Golyshev, S. A., Polyakov, V. Y., Wunderink, H.
F., Kanon, B., Budagova, K. R., Kabakov, A. E. and Kampinga, H. H. (2007).
Regulation of stress-induced intracellular sorting and chaperone function of
Hsp27 (HspB1) in mammalian cells. Biochemical Journal 407(3): 407-417.
Budnik, A., Heesom, K. J. and Stephens, D. J. (2011). Characterization of human
Sec16B: indications of specialized, non-redundant functions. Scientific Reports
1: 77.
Buell, A. K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles, T. P.,
Linse, S. and Dobson, C. M. (2014). Solution conditions determine the relative
importance of nucleation and growth processes in α-synuclein aggregation.
Proceedings of the National Academy of Sciences 111(21): 7671-7676.
Bukach, O. V., Glukhova, A. E., Seit-Nebi, A. S. and Gusev, N. B. (2009).
Heterooligomeric complexes formed by human small heat shock proteins HspB1
(Hsp27) and HspB6 (Hsp20). Biochimica et Biophysica Acta - Proteins and
Proteomics 1794(3): 486-495.
Bulteau, A., Planamente, S., Jornea, L., Dur, A., Lesuisse, E., Camadro, J. and Auchère,
F. (2012). Changes in mitochondrial glutathione levels and protein thiol
oxidation in∆ yfh1 yeast cells and the lymphoblasts of patients with Friedreich's
ataxia. Biochimica et Biophysica Acta: Molecular Basis of Disease 1822(2):
212-225.
Bustin, M. (1999). Regulation of DNA-dependent activities by the functional motifs of
the high-mobility-group chromosomal proteins. Molecular and Cellular Biology
201

References

19(8): 5237-5246.
Capponi, S., Geroldi, A., Fossa, P., Grandis, M., Ciotti, P., Gulli, R., Schenone, A.,
Mandich, P. and Bellone, E. (2011). HSPB1 and HSPB8 in inherited
neuropathies: study of an Italian cohort of dHMN and CMT2 patients. Journal
of the Peripheral Nervous System 16(4): 287-294.
Carelli, V., Ross-Cisneros, F. N. and Sadun, A. A. (2002). Optic nerve degeneration and
mitochondrial dysfunction: genetic and acquired optic neuropathies.
Neurochemistry International 40(6): 573-584.
Carelli, V., Ross-Cisneros, F. N. and Sadun, A. A. (2004). Mitochondrial dysfunction as
a cause of optic neuropathies. Progress in Retinal and Eye Research 23(1): 5389.
Carija, A., Navarro, S., de Groot, N. S. and Ventura, S. (2017). Protein aggregation into
insoluble deposits protects from oxidative stress. Redox Biology 12: 699-711.
Carpenter, A. E., Jones, T. R., Lamprecht, M. R., Clarke, C., Kang, I. H., Friman, O.,
Guertin, D. A., Chang, J. H., Lindquist, R. A. and Moffat, J. (2006).
CellProfiler: image analysis software for identifying and quantifying cell
phenotypes. Genome Biology 7(10): R100.
Carra, S., Rusmini, P., Crippa, V., Giorgetti, E., Boncoraglio, A., Cristofani, R.,
Naujock, M., Meister, M., Minoia, M., Kampinga, H. H. and Poletti, A. (2013).
Different anti-aggregation and pro-degradative functions of the members of the
mammalian sHSP family in neurological disorders. Philosophical Transactions
of the Royal Society of London. Series B, Biological Sciences 368: 20110409.
Cartoni, R. and Martinou, J.-C. (2009). Role of mitofusin 2 mutations in the
physiopathology of Charcot–Marie–Tooth disease type 2A. Experimental
Neurology 218(2): 268-273.
Carver, J. A., Grosas, A. B., Ecroyd, H. and Quinlan, R. A. (2017). The functional roles
of the unstructured N-and C-terminal regions in αB-crystallin and other
mammalian small heat-shock proteins. Cell Stress and Chaperones 22(4): 627638.
Carver, J. A., Nicholls, K. A., Aquilina, J. A. and Truscott, R. J. (1996). Age-related
changes in bovine alpha-crystallin and high-molecular-weight protein.
Experimental Eye Research 63(6): 639-647.
Casado, P., Zuazua-Villar, P., Prado, M. A., del Valle, E., Iglesias, J. M., MartínezCampa, C., Lazo, P. S. and Ramos, S. (2007). Characterization of HSP27
phosphorylation induced by microtubule interfering agents: implication of p38
signalling pathway. Archives of Biochemistry and Biophysics 461(1): 123-129.
Cassereau, J., Chevrollier, A., Gueguen, N., Malinge, M.-C., Letournel, F., Nicolas, G.,
Richard, L., Ferre, M., Verny, C. and Dubas, F. (2009). Mitochondrial complex I
deficiency in GDAP1-related autosomal dominant Charcot-Marie-Tooth disease
(CMT2K). Neurogenetics 10(2): 145.
Chada, S. R. and Hollenbeck, P. J. (2004). Nerve growth factor signaling regulates
motility and docking of axonal mitochondria. Current Biology 14(14): 12721276.
Chalova, A. S., Sudnitsyna, M. V., Semenyuk, P. I., Orlov, V. N. and Gusev, N. B.
(2014a). Effect of disulfide crosslinking on thermal transitions and chaperonelike activity of human small heat shock protein HspB1. Cell Stress and
Chaperones 19(6): 963-972.
202

References

Chalova, A. S., Sudnitsyna, M. V., Strelkov, S. V. and Gusev, N. B. (2014b).
Characterization of human small heat shock protein HspB1 that carries Cterminal domain mutations associated with hereditary motor neuron diseases.
Biochimica et Biophysica Acta - Proteins and Proteomics 1844(12): 2116-2126.
Chang, D. T., Honick, A. S. and Reynolds, I. J. (2006). Mitochondrial trafficking to
synapses in cultured primary cortical neurons. Journal of Neuroscience 26(26):
7035-7045.
Chang, W., Folker, E. S., Worman, H. J. and Gundersen, G. G. (2013). Emerin
organizes actin flow for nuclear movement and centrosome orientation in
migrating fibroblasts. Molecular Biology of the Cell 24(24): 3869-3880.
Charette, S. J. and Landry, J. (2000). The interaction of HSP27 with Daxx identifies a
potential regulatory role of HSP27 in fas‐induced apoptosis. Annals of the New
York Academy of Sciences 926(1): 126-131.
Charette, S. J., Lavoie, J. N., Lambert, H. and Landry, J. (2000). Inhibition of Daxxmediated apoptosis by heat shock protein 27. Molecular and Cellular Biology
20(20): 7602-7612.
Chaudhuri, A. R., Khan, I. A., Prasad, V., Robinson, A. K., Ludueña, R. F. and Barnes,
L. D. (1999). The tumor suppressor protein Fhit a novel interaction with tubulin.
Journal of Biological Chemistry 274(34): 24378-24382.
Chauhan, A., Ray, I. and Chauhan, V. P. S. (2000). Interaction of amyloid beta-protein
with anionic phospholipids: possible involvement of Lys28 and C-terminus
aliphatic amino acids. Neurochemical Research 25(3): 423-429.
Chen, H. and Chan, D. C. (2005). Emerging functions of mammalian mitochondrial
fusion and fission. Human Molecular Genetics 14(suppl_2): R283-R289.
Chen, S. and Brown, I. R. (2007). Neuronal expression of constitutive heat shock
proteins: implications for neurodegenerative diseases. Cell Stress and
Chaperones 12(1): 51-58.
Chi, E. Y., Krishnan, S., Randolph, T. W. and Carpenter, J. F. (2003). Physical stability
of proteins in aqueous solution: mechanism and driving forces in nonnative
protein aggregation. Pharmaceutical Research 20(9): 1325-1336.
Choi, B.-O., Park, M.-H., Chung, K., Woo, H.-M., Koo, H., Chung, H.-K., Choi, K.-G.,
Park, K., Lee, H. and Hyun, Y. (2013). Clinical and histopathological study of
Charcot-Marie-Tooth neuropathy with a novel S90W mutation in BSCL2.
Neurogenetics 14(1): 35-42.
Ciechanover, A. (1998). The ubiquitin–proteasome pathway: on protein death and cell
life. The European Molecular Biology Organization Journal 17(24): 7151-7160.
Clarke, J. P. and Mearow, K. M. (2013). Cell stress promotes the association of
phosphorylated HspB1 with F-actin. Public Library of Science One 8(7):
e68978.
Clouser, A. F. and Klevit, R. E. (2017). pH-dependent structural modulation is
conserved in the human small heat shock protein HSBP1. Cell Stress and
Chaperones 22(4): 569-575.
Cobb, B. A. and Petrash, J. M. (2000). Structural and functional changes in the αAcrystallin R116C mutant in hereditary cataracts. Biochemistry 39(51): 1579115798.
Colomer, J., Gooding, R., Angelicheva, D., King, R. H., Guillén-Navarro, E., Parman,
Y., Nascimento, A., Conill, J. and Kalaydjieva, L. (2006). Clinical spectrum of
203

References

CMT4C disease in patients homozygous for the p. Arg1109X mutation in
SH3TC2. Neuromuscular Disorders 16(7): 449-453.
Combarros, O., Calleja, J., Polo, J. and Berciano, J. (1987). Prevalence of hereditary
motor and sensory neuropathy in Cantabria. Acta Neurologica Scandinavica
75(1): 9-12.
Concannon, C., Gorman, A. and Samali, A. (2003). On the role of Hsp27 in regulating
apoptosis. Apoptosis 8(1): 61-70.
Contaxis, C., Bigelow, C. and Zarkadas, C. (1977). The thermal denaturation of bovine
cardiac G-actin. Canadian Journal of Biochemistry 55(4): 325-331.
Cosentino, C., Grieco, D. and Costanzo, V. (2011). ATM activates the pentose
phosphate pathway promoting anti‐oxidant defence and DNA repair. The
European Molecular Biology Organization Journal 30(3): 546-555.
Costes, S. V., Daelemans, D., Cho, E. H., Dobbin, Z., Pavlakis, G. and Lockett, S.
(2004). Automatic and quantitative measurement of protein-protein
colocalization in live cells. Biophysical Journal 86(6): 3993-4003.
Cottenie, E., Kochanski, A., Jordanova, A., Bansagi, B., Zimon, M., Horga, A.,
Jaunmuktane, Z., Saveri, P., Rasic, V. M. and Baets, J. (2014). Truncating and
missense mutations in IGHMBP2 cause Charcot-Marie Tooth disease type 2.
The American Journal of Human Genetics 95(5): 590-601.
Cox, D., Selig, E., Griffin, M. D., Carver, J. A. and Ecroyd, H. (2016). Small heat-shock
proteins prevent α-synuclein aggregation via transient interactions and their
efficacy is affected by the rate of aggregation. Journal of Biological Chemistry
291(43): 22618-22629.
Cox, D., Whiten, D. R., Brown, J., Horrocks, M. H., San Gil, R., Dobson, C. M.,
Klenerman, D., van Oijen, A. M. and Ecroyd, H. (2018). The small heat shock
protein Hsp27 binds α-synuclein fibrils, preventing elongation and cytotoxicity.
Journal of Biological Chemistry 293(12): 4486 - 4497.
Cozzolino, M. and Carrì, M. T. (2012). Mitochondrial dysfunction in ALS. Progress in
Neurobiology 97(2): 54-66.
Crimella, C., Baschirotto, C., Arnoldi, A., Tonelli, A., Tenderini, E., Airoldi, G.,
Martinuzzi, A., Trabacca, A., Losito, L. and Scarlato, M. (2012). Mutations in
the motor and stalk domains of KIF5A in spastic paraplegia type 10 and in
axonal Charcot–Marie–Tooth type 2. Clinical Genetics 82(2): 157-164.
Crippa, V., Carra, S., Rusmini, P., Sau, D., Bolzoni, E., Bendotti, C., De Biasi, S. and
Poletti, A. (2010a). A role of small heat shock protein B8 (HspB8) in the
autophagic removal of misfolded proteins responsible for neurodegenerative
diseases. Autophagy 6(7): 958-960.
Crippa, V., D’Agostino, V. G., Cristofani, R., Rusmini, P., Cicardi, M. E., Messi, E.,
Loffredo, R., Pancher, M., Piccolella, M., Galbiati, M., Meroni, M., Cereda, C.,
Carra, S., Provenzani, A. and Poletti, A. (2016). Transcriptional induction of the
heat shock protein B8 mediates the clearance of misfolded proteins responsible
for motor neuron diseases. Scientific Reports 6: 22827.
Crippa, V., Sau, D., Rusmini, P., Boncoraglio, A., Onesto, E., Bolzoni, E., Galbiati, M.,
Fontana, E., Marino, M., Carra, S., Bendotti, C., De Biasi, S. and Poletti, A.
(2010b). The small heat shock protein B8 (HspB8) promotes autophagic
removal of misfolded proteins involved in amyotrophic lateral sclerosis (ALS).
Human Molecular Genetics 19(17): 3440-3456.
204

References

Cuesta, R., Laroia, G. and Schneider, R. J. (2000). Chaperone hsp27 inhibits translation
during heat shock by binding eIF4G and facilitating dissociation of capinitiation complexes. Genes and Development 14(12): 1460-1470.
Cumming, R. C., Andon, N. L., Haynes, P. A., Park, M., Fischer, W. H. and Schubert,
D. (2004). Protein disulfide bond formation in the cytoplasm during oxidative
stress. Journal of Biological Chemistry 279(21): 21749-21758.
Cunningham, F., Achuthan, P., Akanni, W., Allen, J., Amode, M. R., Armean, I. M.,
Bennett, R., Bhai, J., Billis, K. and Boddu, S. (2018). Ensembl 2019. Nucleic
Acids Research 47(D1): D745-D751.
d'Ydewalle, C., Krishnan, J., Chiheb, D. M., Van Damme, P., Irobi, J., Kozikowski, A.
P., Berghe, P. V., Timmerman, V., Robberecht, W. and Van Den Bosch, L.
(2011). HDAC6 inhibitors reverse axonal loss in a mouse model of mutant
HspB1-induced Charcot-Marie-Tooth disease. Nature Medicine 17(8): 968-974.
Das, K. P. and Surewicz, W. K. (1995). Temperature‐induced exposure of hydrophobic
surfaces and its effect on the chaperone activity of α‐crystallin. Federation of
European Biochemical Societies Letters 369(2-3): 321-325.
de Jong, W. W., Caspers, G.-J. and Leunissen, J. A. (1998). Genealogy of the αcrystallin-small heat-shock protein superfamily. International Journal of
Biological Macromolecules 22(3): 151-162.
De Jonghe, P., Auer‐Grumbach, M., Irobi, J., Wagner, K., Plecko, B., Kennerson, M.,
Zhu, D., De Vriendt, E., Van Gerwen, V. and Nicholson, G. (2002). Autosomal
dominant juvenile amyotrophic lateral sclerosis and distal hereditary motor
neuronopathy with pyramidal tract signs: synonyms for the same disorder?
Brain 125(6): 1320-1325.
De Jonghe, P., Mersivanova, I., Nelis, E., Del Favero, J., Martin, J. J., Van
Broeckhoven, C., Evgrafov, O. and Timmerman, V. (2001). Further evidence
that neurofilament light chain gene mutations can cause Charcot‐Marie‐Tooth
disease type 2E. Annals of Neurology 49(2): 245-249.
De Jonghe, P., Timmerman, V., Ceuterick, C., Nelis, E., De Vriendt, E., Löfgren, A.,
Vercruyssen, A., Verellen, C., Van Maldergem, L. and Martin, J.-J. (1999). The
Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is
associated with a clinically distinct Charcot–Marie–Tooth phenotype. Brain
122(2): 281-290.
De Sandre‐Giovannoli, A., Chaouch, M., Kozlov, S., Vallat, J.-M., Tazir, M., Kassouri,
N., Szepetowski, P., Hammadouche, T., Vandenberghe, A. and Stewart, C. L.
(2002). Homozygous defects in LMNA, encoding lamin A/C nuclear‐envelope
proteins, cause autosomal recessive axonal neuropathy in human (Charcot‐
Marie‐Tooth disorder type 2) and mouse. Journal of the Peripheral Nervous
System 7(3): 205-205.
Delague, V., Jacquier, A., Hamadouche, T., Poitelon, Y., Baudot, C., Boccaccio, I.,
Chouery, E., Chaouch, M., Kassouri, N. and Jabbour, R. (2007). Mutations in
FGD4 encoding the Rho GDP/GTP exchange factor FRABIN cause autosomal
recessive Charcot-Marie-Tooth type 4H. The American Journal of Human
Genetics 81(1): 1-16.
Der Perng, M., Wen, S. F., van den IJssel, P., Prescott, A. R. and Quinlan, R. A. (2004).
Desmin aggregate formation by R120G αB-crystallin is caused by altered
filament interactions and is dependent upon network status in cells. Molecular
205

References

Biology of the Cell 15(5): 2335-2346.
Deuther-Conrad, W., Loske, C., Schinzel, R., Dringen, R., Riederer, P. and Münch, G.
(2001). Advanced glycation endproducts change glutathione redox status in SHSY5Y human neuroblastoma cells by a hydrogen peroxide dependent
mechanism. Neuroscience Letters 312(1): 29-32.
Dierick, I., Baets, J., Irobi, J., Jacobs, A., De Vriendt, E., Deconinck, T., Merlini, L.,
Van den Bergh, P., Rasic, V. M. and Robberecht, W. (2008). Relative
contribution of mutations in genes for autosomal dominant distal hereditary
motor neuropathies: a genotype–phenotype correlation study. Brain 131(5):
1217-1227.
Dill, K. A. (1990). Dominant forces in protein folding. Biochemistry 29(31): 7133-7155.
DiVincenzo, C., Elzinga, C. D., Medeiros, A. C., Karbassi, I., Jones, J. R., Evans, M.
C., Braastad, C. D., Bishop, C. M., Jaremko, M. and Wang, Z. (2014). The
allelic spectrum of Charcot–Marie–Tooth disease in over 17,000 individuals
with neuropathy. Molecular Genetics and Genomic Medicine 2(6): 522-529.
Doolittle, L. K., Rosen, M. K. and Padrick, S. B. (2013). Measurement and analysis of
in vitro actin polymerization. Adhesion Protein Protocols. A., C. Totowa, NJ,
Humana Press. 1046: 273-293.
Downs, C. A., Jones, L. R. and Heckathorn, S. A. (1999). Evidence for a novel set of
small heat-shock proteins that associates with the mitochondria of murine PC12
cells and protects NADH: ubiquinone oxidoreductase from heat and oxidative
stress. Archives of Biochemistry and Biophysics 365(2): 344-350.
Dyck, P. J. and Lambert, E. H. (1968). Lower motor and primary sensory neuron
diseases with peroneal muscular atrophy: II. Neurologic, genetic, and
electrophysiologic findings in various neuronal degenerations. Archives of
Neurology 18(6): 619-625.
Eaton, P., Fuller, W. and Shattock, M. J. (2002). S-thiolation of HSP27 regulates its
multimeric aggregate size independently of phosphorylation. Journal of
Biological Chemistry 277(24): 21189-21196.
Echaniz-Laguna, A., Ghezzi, D., Chassagne, M., Mayençon, M., Padet, S., Melchionda,
L., Rouvet, I., Lannes, B., Bozon, D. and Latour, P. (2013). SURF1 deficiency
causes demyelinating Charcot-Marie-Tooth disease. Neurology 81(17): 15231530.
Echaniz‐Laguna, A., Geuens, T., Petiot, P., Péréon, Y., Adriaenssens, E., Haidar, M.,
Capponi, S., Maisonobe, T., Fournier, E. and Dubourg, O. (2017). Axonal
neuropathies due to mutations in small heat shock proteins: clinical, genetic, and
functional insights into novel mutations. Human Mutation 38(5): 556-568.
Ecroyd, H. and Carver, J. A. (2008). The effect of small molecules in modulating the
chaperone activity of alphaB-crystallin against ordered and disordered protein
aggregation. Federation of European Biochemical Societies Journal 275(5):
935-947.
Edwards, H. V., Scott, J. D. and Baillie, G. S. (2012). PKA phosphorylation of the small
heat-shock protein Hsp20 enhances its cardioprotective effects. Biochemical
Society Transactions 40(1): 210-214.
Efimov, A., Kharitonov, A., Efimova, N., Loncarek, J., Miller, P. M., Andreyeva, N.,
Gleeson, P., Galjart, N., Maia, A. R. and McLeod, I. X. (2007). Asymmetric
CLASP-dependent nucleation of noncentrosomal microtubules at the trans-Golgi
206

References

network. Developmental Cell 12(6): 917-930.
Ehrnsperger, M., Gräber, S., Gaestel, M. and Buchner, J. (1997). Binding of non‐native
protein to Hsp25 during heat shock creates a reservoir of folding intermediates
for reactivation. The European Molecular Biology Organization Journal 16(2):
221-229.
Ehrnsperger, M., Lilie, H., Gaestel, M. and Buchner, J. (1999). The dynamics of Hsp25
quaternary structure structure and function of different oligomeric Species.
Journal of Biological Chemistry 274(21): 14867-14874.
Ellis, R. J. (1994). Roles of molecular chaperones in protein folding. Current Opinion in
Structural Biology 4(1): 117-122.
Ellis, R. J. and Van der Vies, S. M. (1991). Molecular chaperones. Annual Review of
Biochemistry 60(1): 321-347.
Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicologic
Pathology 35(4): 495-516.
Engel, U., Zhan, Y., Long, J. B., Boyle, S. N., Ballif, B. A., Dorey, K., Gygi, S. P.,
Koleske, A. J. and VanVactor, D. (2014). Abelson phosphorylation of CLASP2
modulates its association with microtubules and actin. Cytoskeleton 71(3): 195209.
Engelfried, K., Vorgerd, M., Hagedorn, M., Haas, G., Gilles, J., Epplen, J. T. and
Meins, M. (2006). Charcot-Marie-Tooth neuropathy type 2A: novel mutations in
the mitofusin 2 gene (MFN2). BioMed Central Medical Genetics 7(1): 53.
Erck, C., Peris, L., Andrieux, A., Meissirel, C., Gruber, A. D., Vernet, M., Schweitzer,
A., Saoudi, Y., Pointu, H. and Bosc, C. (2005). A vital role of tubulin-tyrosineligase for neuronal organization. Proceedings of the National Academy of
Sciences 102(22): 7853-7858.
Evgrafov, O. V., Mersiyanova, I., Irobi, J., Van Den Bosch, L., Dierick, I., Leung, C. L.,
Schagina, O., Verpoorten, N., Van Impe, K., Fedotov, V., Dadali, E., AuerGrumbach, M., Windpassinger, C., Wagner, K., Mitrovic, Z., Hilton-Jones, D.,
Talbot, K., Martin, J. J., Vasserman, N., Tverskaya, S., Polyakov, A., Liem, R.
K., Gettemans, J., Robberecht, W., De Jonghe, P. and Timmerman, V. (2004).
Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease
and distal hereditary motor neuropathy. Nature Genetics 36(6): 602-606.
Fabrizi, G., Ferrarini, M., Cavallaro, T., Cabrini, I., Cerini, R., Bertolasi, L. and
Rizzuto, N. (2007). Two novel mutations in dynamin-2 cause axonal Charcot–
Marie–Tooth disease. Neurology 69(3): 291-295.
Fabrizi, G. M., Cavallaro, T., Angiari, C., Cabrini, I., Taioli, F., Malerba, G., Bertolasi,
L. and Rizzuto, N. (2006). Charcot–Marie–Tooth disease type 2E, a disorder of
the cytoskeleton. Brain 130(2): 394-403.
Fan, G. C., Chu, G. X., Mitton, B., Song, Q. J., Yuan, Q. Y. and Kranias, E. G. (2004).
Small heat-shock protein Hsp20 phosphorylation inhibits β-agonist-induced
cardiac apoptosis. Circulation Research 94: 1474-1482.
Fanelli, M. A., Montt-Guevara, M., Diblasi, A. M., Gago, F. E., Tello, O., CuelloCarrión, F. D., Callegari, E., Bausero, M. A. and Ciocca, D. R. (2008). Pcadherin and β-catenin are useful prognostic markers in breast cancer patients;
β-catenin interacts with heat shock protein Hsp27. Cell Stress and Chaperones
13(2): 207-220.
Faust, O., Abayev-Avraham, M., Wentink, A.S., Maurer, M., Nillegoda, N.B., London,
207

References

N., Bukau, B. and Rosenzweig, R., 2020. HSP40 proteins use class-specific
regulation to drive HSP70 functional diversity. Nature, 587(7834), pp.489-494.
Federhen, S. (2012). The NCBI taxonomy database. Nucleic Acids Research 40(D1):
D136-D143.
Fichna, J. P., Potulska-Chromik, A., Miszta, P., Redowicz, M. J., Kaminska, A. M.,
Zekanowski, C. and Filipek, S. (2017). A novel dominant D109A CRYAB
mutation in a family with myofibrillar myopathy affects αB-crystallin structure.
Biochimica et Biophysica Acta - Clinical 7: 1-7.
Fischer, C., Trajanoski, S., Papić, L., Windpassinger, C., Bernert, G., Freilinger, M.,
Schabhüttl, M., Arslan-Kirchner, M., Javaher-Haghighi, P. and Plecko, B.
(2012). SNP array-based whole genome homozygosity mapping as the first step
to a molecular diagnosis in patients with Charcot-Marie-Tooth disease. Journal
of Neurology 259(3): 515-523.
Flatters, S. J. and Bennett, G. J. (2006). Studies of peripheral sensory nerves in
paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial
dysfunction. Pain 122(3): 245-257.
Foley, C., Schofield, I., Eglon, G., Bailey, G., Chinnery, P. F. and Horvath, R. (2012).
Charcot–Marie–Tooth disease in Northern England. Journal of Neurology
Neurosurgury and Psychiatry 83(5): 572-573.
Fontaine, J.-M., Sun, X., Hoppe, A. D., Simon, S., Vicart, P., Welsh, M. J. and
Benndorf, R. (2006). Abnormal small heat shock protein interactions involving
neuropathy-associated Hsp22 (HspB8) mutants. The Federation of American
Societies for Experimental Biology Journal 20(12): 2168-2170.
Fortun, J., Dunn, W. A., Joy, S., Li, J. and Notterpek, L. (2003). Emerging role for
autophagy in the removal of aggresomes in Schwann cells. Journal of
Neuroscience 23(33): 10672-10680.
Fortunato, F., Neri, M., Geroldi, A., Bellone, E., De Grandis, D., Ferlini, A. and
Gualandi, F. (2017). A CMT2 family carrying the P7R mutation in the Nterminal region of the HSPB1 gene. Clinical neurology and neurosurgery 163:
15.
Fossa, P. and Cichero, E. (2015). In silico evaluation of human small heat shock protein
HSP27: homology modeling, mutation analyses and docking studies. Bioorganic
and Medicinal Chemistry 23(13): 3215-3220.
Fragoso, G., Robertson, J., Athlan, E., Tam, E., Almazan, G. and Mushynski, W. E.
(2003). Inhibition of p38 mitogen-activated protein kinase interferes with cell
shape changes and gene expression associated with Schwann cell myelination.
Experimental Neurology 183(1): 34-46.
Freed, A. S., Weiss, M. D., Malouf, E. A. and Hisama, F. M. (2019). CNTNAP1
mutations in an adult with Charcot Marie Tooth Disease. Muscle and Nerve.
Friedrich, K. L., Giese, K. C., Buan, N. R. and Vierling, E. (2004). Interactions between
small heat shock protein subunits and substrate in small heat shock proteinsubstrate complexes. Journal of Biological Chemistry 279(2): 1080-1089.
Fu, L. and Liang, J. J. N. (2003). Alteration of protein–protein interactions of congenital
cataract crystallin mutants. Investigative Ophthalmology and Visual Science
44(3): 1155-1159.
Furukawa, Y., Torres, A. S. and O'Halloran, T. V. (2004). Oxygen‐induced maturation
of SOD1: a key role for disulfide formation by the copper chaperone CCS. The
208

References

European Molecular Biology Organization Journal 23(14): 2872-2881.
Gabrikova, D., Mistrik, M., Bernasovska, J., Bozikova, A., Behulova, R., Tothova, I.
and Macekova, S. (2013). Founder mutations in NDRG1 and HK1 genes are
common causes of inherited neuropathies among Roma/Gypsies in Slovakia.
Journal of Applied Genetics 54(4): 455-460.
Gaeta, M., Mileto, A., Mazzeo, A., Minutoli, F., Di Leo, R., Settineri, N., Donato, R.,
Ascenti, G. and Blandino, A. (2012). MRI findings, patterns of disease
distribution, and muscle fat fraction calculation in five patients with CharcotMarie-Tooth type 2 F disease. Skeletal Radiology 41(5): 515-524.
Gal, A., Balicza, P., Weaver, D., Naghdi, S., Joseph, S. K., Várnai, P., Gyuris, T.,
Horváth, A., Nagy, L. and Seifert, E. L. (2017). MSTO 1 is a cytoplasmic pro‐
mitochondrial fusion protein, whose mutation induces myopathy and ataxia in
humans. European Molecular Biology Organization Molecular Medicine 9(7):
967-984.
Galluzzi, L., Joza, N., Tasdemir, E., Maiuri, M., Hengartner, M., Abrams, J.,
Tavernarakis, N., Penninger, J., Madeo, F. and Kroemer, G. (2008). No death
without life: vital functions of apoptotic effectors. Cell Death and
Differentiation 15(7): 1113-1123.
Gamerdinger, M., Kaya, A. M., Wolfrum, U., Clement, A. M. and Behl, C. (2011).
BAG3 mediates chaperone‐based aggresome‐targeting and selective autophagy
of misfolded proteins. European Molecular Biology Organization Reports 12(2):
149-156.
Gasteiger, E., Hoogland, C., Gattiker, A., Wilkins, M. R., Appel, R. D. and Bairoch, A.
(2005). Protein identification and analysis tools on the ExPASy server. The
Proteomics Protocols Handbook. Walker, J. M., Humana Press: 571-607.
Gemignani, F., Marbini, A., Di Giovanni, G., Salih, S. and Terzano, M. (1999).
Charcot-Marie-Tooth disease type 2 with restless legs syndrome. Neurology
52(5): 1064-1064.
Gestaut, D., Roh, S. H., Ma, B., Pintilie, G., Joachimiak, L. A., Leitner, A., Walzthoeni,
T., Aebersold, R., Chiu, W. and Frydman, J. (2019). The chaperonin TRiC/CCT
associates with prefoldin through a conserved electrostatic interface essential for
cellular proteostasis. Cell 177(3): 751-765.
Gething, M.-J. and Sambrook, J. (1992). Protein folding in the cell. Nature 355(6355):
33.
Geuens, T., De Winter, V., Rajan, N., Achsel, T., Mateiu, L., Almeida-Souza, L.,
Asselbergh, B., Bouhy, D., Auer-Grumbach, M. and Bagni, C. (2017). Mutant
HSPB1 causes loss of translational repression by binding to PCBP1, an RNA
binding protein with a possible role in neurodegenerative disease. Acta
Neuropathologica Communications 5(1): 1-15.
Ghodasara, M. K., Sankhla, C. S., Lovhale, N. S. and Borse, S. T. (2018). Charcot
Marie Tooth disease 2F and a novel mutation from India. Neurology India 66(2):
528.
Gibert, B., Eckel, B., Fasquelle, L., Moulin, M., Bouhallier, F., Gonin, V., Mellier, G.,
Simon, S., Kretz-Remy, C. and Arrigo, A.-P. (2012). Knock down of heat shock
protein 27 (HspB1) induces degradation of several putative client proteins.
Public Library of Science One 7(1): e29719.
Gilbert, H. F. (1990). Molecular and cellular aspects of thiol–disulfide exchange.
209

References

Advances in Enzymology and Related Areas of Molecular Biology 63: 69-172.
Gill, S. C. and Von Hippel, P. H. (1989). Calculation of protein extinction coefficients
from amino acid sequence data. Analytical Biochemistry 182(2): 319-326.
Giordano, C., Montopoli, M., Perli, E., Orlandi, M., Fantin, M., Ross-Cisneros, F. N.,
Caparrotta, L., Martinuzzi, A., Ragazzi, E. and Ghelli, A. (2010). Oestrogens
ameliorate mitochondrial dysfunction in Leber’s hereditary optic neuropathy.
Brain 134(1): 220-234.
Glickman, M. H. and Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic
pathway: destruction for the sake of construction. Physiological Reviews 82(2):
373-428.
Glickman, M. H., Rubin, D. M., Fu, H., Larsen, C. N., Coux, O., Wefes, I., Pfeifer, G.,
Cjeka, Z., Vierstra, R. and Baumeister, W. (1999). Functional analysis of the
proteasome regulatory particle. Molecular Biology Reports 26(1-2): 21-28.
Gonzalez, M., McLaughlin, H., Houlden, H., Guo, M., Yo-Tsen, L., Hadjivassilious,
M., Speziani, F., Yang, X.-L., Antonellis, A. and Reilly, M. M. (2013). Exome
sequencing identifies a significant variant in methionyl-tRNA synthetase
(MARS) in a family with late-onset CMT2. Journal of Neurology Neurosurgery
and Psychiatry 84(11): 1247-1249.
Gonzalez, M. A., Feely, S. M., Speziani, F., Strickland, A. V., Danzi, M., Bacon, C.,
Lee, Y., Chou, T.-F., Blanton, S. H. and Weihl, C. C. (2014). A novel mutation
in VCP causes Charcot–Marie–Tooth Type 2 disease. Brain 137(11): 28972902.
Graceffa, P. (2011). Hsp27-actin interaction. Biochemistry Research International 2011.
Graf, P. C., Martinez-Yamout, M., VanHaerents, S., Lilie, H., Dyson, H. J. and Jakob,
U. (2004). Activation of the redox-regulated chaperone Hsp33 by domain
unfolding. Journal of Biological Chemistry 279(19): 20529-20538.
Grafstein, B. and Forman, D. S. (1980). Intracellular transport in neurons. Physiological
Reviews 60(4): 1167-1283.
Grantham, J., 2020. The molecular chaperone CCT/TRiC: An essential component of
proteostasis and a potential modulator of protein aggregation. Frontiers in
Genetics, 11, p.172.
Graw, J., Klopp, N., Illig, T., Preising, M. N. and Lorenz, B. (2006). Congenital cataract
and macular hypoplasia in humans associated with a de novo mutation in
CRYAA and compound heterozygous mutations in P. Graefe's Archive for
Clinical and Experimental Ophthalmology 244(8): 912-919.
Graziano, G., Catanzano, F., Riccio, A. and Barone, G. (1997). A reassessment of the
molecular origin of cold denaturation. The Journal of Biochemistry 122(2): 395401.
Greene, M. K., Maskos, K. and Landry, S. J. (1998). Role of the J-domain in the
cooperation of Hsp40 with Hsp70. Proceedings of the National Academy of
Sciences 95(11): 6108-6113.
Greenfield, N. J. (2006). Using circular dichroism spectra to estimate protein secondary
structure. Nature protocols 1(6): 2876.
Gregianin, E., Pallafacchina, G., Zanin, S., Crippa, V., Rusmini, P., Poletti, A., Fang,
M., Li, Z., Diano, L. and Petrucci, A. (2016). Loss-of-function mutations in the
SIGMAR1 gene cause distal hereditary motor neuropathy by impairing ERmitochondria tethering and Ca2+ signalling. Human Molecular Genetics 25(17):
210

References

3741-3753.
Gross, D., Rajput, A. and Yeung, M. (1998). Distal hereditary upper limb muscular
atrophy. Journal of Neurology, Neurosurgery and Psychiatry 64(2): 217-220.
Gu, F., Luo, W., Li, X., Wang, Z., Lu, S., Zhang, M., Zhao, B., Zhu, S., Feng, S., Yan,
Y., Huang, S. and Ma, X. (2008). A novel mutation in αA-crystallin (CRYAA)
caused autosomal dominant congenital cataract in a large Chinese family.
Human Mutation 29(5): 769-769.
Guay, J., Lambert, H., Gingras-Breton, G., Lavoie, J. N., Huot, J. and Landry, J. (1997).
Regulation of actin filament dynamics by p38 map kinase-mediated
phosphorylation of heat shock protein 27. Journal of Cell Science 110(3): 357368.
Guðmundsson, B., Olafsson, E., Jakobsson, F. and Lúðvígsson, P. (2010). Prevalence of
symptomatic Charcot-Marie-Tooth disease in Iceland: a study of a well-defined
population. Neuroepidemiology 34(1): 13.
Guernsey, D. L., Jiang, H., Bedard, K., Evans, S. C., Ferguson, M., Matsuoka, M.,
Macgillivray, C., Nightingale, M., Perry, S. and Rideout, A. L. (2010). Mutation
in the gene encoding ubiquitin ligase LRSAM1 in patients with Charcot-MarieTooth disease. Public Library of Science One Genetics 6(8): e1001081.
Gusev, N. B., Bogatcheva, N. V. and Marston, S. B. (2002). Structure and properties of
small heat shock proteins (sHsp) and their interaction with cytoskeleton proteins.
Biochemistry 67(5): 511-519.
Hagberg, B. and Westerberg, B. (1983). Hereditary motor and sensory neuropathies in
Swedish children: prevalence and distribution by disability groups. Acta
Pædiatrica 72(3): 379-383.
Hahn, A. F., Ainsworth, P. J., Bolton, C. F., Bilbao, J. M. and Vallat, J.-M. (2001).
Pathological findings in the x-linked form of Charcot-Marie-Tooth disease: a
morphometric and ultrastructural analysis. Acta Neuropathologica 101(2): 129139.
Haidar, M., Asselbergh, B., Adriaenssens, E., De Winter, V., Timmermans, J.-P., AuerGrumbach, M., Juneja, M. and Timmerman, V. (2019). Neuropathy-causing
mutations in HSPB1 impair autophagy by disturbing the formation of
SQSTM1/p62 bodies. Autophagy 15(6): 1051-1068.
Hamilton, E. W. and Heckathorn, S. A. (2001). Mitochondrial adaptations to NaCl.
Complex I is protected by anti-oxidants and small heat shock proteins, whereas
complex II is protected by proline and betaine. Plant Physiology 126(3): 12661274.
Hangen, E., Féraud, O., Lachkar, S., Mou, H., Doti, N., Fimia, G. M., Lam, N.-v., Zhu,
C., Godin, I. and Muller, K. (2015). Interaction between AIF and CHCHD4
regulates respiratory chain biogenesis. Molecular Cell 58(6): 1001-1014.
Haraguchi, T., Holaska, J. M., Yamane, M., Koujin, T., Hashiguchi, N., Mori, C.,
Wilson, K. L. and Hiraoka, Y. (2004). Emerin binding to Btf, a death‐promoting
transcriptional repressor, is disrupted by a missense mutation that causes
Emery–Dreifuss muscular dystrophy. European Journal of Biochemistry 271(5):
1035-1045.
Hargis, M. T., Storck, C., Wickstrom, E., Yakubov, L. A., Leeper, D. B. and Coss, R.
A. (2004). Hsp27 anti-sense oligonucleotides sensitize the microtubular
cytoskeleton of Chinese hamster ovary cells grown at low pH to 42° C-induced
211

References

reorganization. International Journal of Hyperthermia 20(5): 491-502.
Hartl, F.-U., Martin, J. and Neupert, W. (1992). Protein folding in the cell: the role of
molecular chaperones Hsp70 and Hsp60. Annual Review of Biophysics and
Biomolecular Structure 21(1): 293-322.
Hartl, F. U., Bracher, A. and Hayer-Hartl, M. (2011). Molecular chaperones in protein
folding and proteostasis. Nature 475(7356): 324.
Hasaka, T. P., Myers, K. A. and Baas, P. W. (2004). Role of actin filaments in the
axonal transport of microtubules. Journal of Neuroscience 24(50): 11291-11301.
Hašek, J., Kovarik, P., Valášek, L., Malinska, K., Schneider, J., Kohlwein, S. and Ruis,
H. (2000). Rpg1p, the subunit of the Saccharomyces cerevisiae eIF3 core
complex, is a microtubule‐interacting protein. Cell Motility and the Cytoskeleton
45(3): 235-246.
Havasi, A., Li, Z., Wang, Z., Martin, J. L., Botla, V., Ruchalski, K., Schwartz, J. H. and
Borkan, S. C. (2008). Hsp27 inhibits Bax activation and apoptosis via a
phosphatidylinositol 3-kinase-dependent mechanism. Journal of Biological
Chemistry 283(18): 12305-12313.
Hayes, D., Napoli, V., Mazurkie, A., Stafford, W. F. and Graceffa, P. (2009).
Phosphorylation dependence of Hsp27 multimeric size and molecular chaperone
function. Journal of Biological Chemistry 284(28): 18801-18807.
Hehnly, H. and Doxsey, S. (2014). Rab11 endosomes contribute to mitotic spindle
organization and orientation. Developmental Cell 28(5): 497-507.
Heim, R. and Tsien, R. Y. (1996). Engineering green fluorescent protein for improved
brightness, longer wavelengths and fluorescence resonance energy transfer.
Current Biology 6(2): 178-182.
Heirbaut, M., Lermyte, F., Martin, E. M., Beelen, S., Verschueren, T., Sobott, F.,
Strelkov, S. V. and Weeks, S. D. (2016). The preferential heterodimerization of
human small heat shock proteins HSPB1 and HSPB6 is dictated by the Nterminal domain. Archives of Biochemistry and Biophysics 610: 41-50.
Hernandez, A. V. S., Deeks, L. S. and Shield, A. J. (2020). Understanding medication
safety and Charcot-Marie-Tooth disease: a patient perspective. International
Journal of Clinical Pharmacy 42(6): 1507-1514.
Hernández, M. P., Chadli, A. and Toft, D. O. (2002). HSP40 binding is the first step in
the HSP90 chaperoning pathway for the progesterone receptor. Journal of
Biological Chemistry 277(14): 11873-11881.
Higuchi, Y., Hashiguchi, A., Yuan, J., Yoshimura, A., Mitsui, J., Ishiura, H., Tanaka,
M., Ishihara, S., Tanabe, H. and Nozuma, S. (2016). Mutations in MME cause
an autosomal‐recessive Charcot–Marie–Tooth disease type 2. Annals of
Neurology 79(4): 659-672.
Hilton, G. R., Hochberg, G. K. A., Laganowsky, A., McGinningle, S. I., Baldwin, A. J.
and Benesch, J. L. P. (2013). C-terminal interactions mediate the quaternary
dynamics of αB-crystallin. Philosophical Transactions of the Royal Society B:
Biological Sciences 368(20110405): 1-13.
Hino, M., Kurogi, K., Okubo, M.-A., Murata-Hori, M. and Hosoya, H. (2000). Small
heat shock protein 27 (HSP27) associates with tubulin/microtubules in HeLa
cells. Biochemical and Biophysical Research Communications 271(1): 164-169.
Hipp, M. S., Kasturi, P. and Hartl, F. U. (2019). The proteostasis network and its
decline in ageing. Nature Reviews Molecular Cell Biology 20(7): 421-435.
212

References

Hirata, K., He, J., Hirakawa, Y., Liu, W., Wang, S. and Kawabuchi, M. (2003). Hsp27
is markedly induced in Schwann cell columns and associated regenerating
axons. Glia 42(1): 1-11.
Ho, C. Y., Jaalouk, D. E., Vartiainen, M. K. and Lammerding, J. (2013). Lamin A/C
and emerin regulate MKL1–SRF activity by modulating actin dynamics. Nature
497(7450): 507-511.
Hochberg, G. K. and Benesch, J. L. (2014). Dynamical structure of αB-crystallin.
Progress in Biophysics and Molecular Biology S0079-6107(14): 00013-00013.
Hochberg, G. K., Ecroyd, H., Liu, C., Cox, D., Cascio, D., Sawaya, M. R., Collier, M.
P., Stroud, J., Carver, J. A., Baldwin, A. J., Robinson, C. V., Eisenberg, D. S.,
Benesch, J. L. and Laganowsky, A. (2014). The structured core domain of
alphaB-crystallin can prevent amyloid fibrillation and associated toxicity.
Proceedings of the National Academy of Science 111(16): E1562-1570.
Hoffman, P. N. and Lasek, R. J. (1975). The slow component of axonal transport.
Identification of major structural polypeptides of the axon and their generality
among mammalian neurons. The Journal of Cell Biology 66(2): 351-366.
Hoffman, P. N. and Lasek, R. J. (1980). Axonal transport of the cytoskeleton in
regenerating motor neurons: constancy and change. Brain Research 202(2): 317333.
Hoffmann, J. H., Linke, K., Graf, P. C., Lilie, H. and Jakob, U. (2004). Identification of
a redox‐regulated chaperone network. The European Molecular Biology
Organization Journal 23(1): 160-168.
Holaska, J. M., Kowalski, A. K. and Wilson, K. L. (2004). Emerin caps the pointed end
of actin filaments: evidence for an actin cortical network at the nuclear inner
membrane. Public Library of Science One 2(9): e231.
Hollenbeck, P. J. (2005). Mitochondria and neurotransmission: evacuating the synapse.
Neuron 47(3): 331-333.
Hollenbeck, P. J. and Saxton, W. M. (2005). The axonal transport of mitochondria.
Journal of Cell Science 118(23): 5411-5419.
Holmberg, B. (1993). Charcot‐Marie‐Tooth disease in northern Sweden: an
epidemilogical and clinical study. Acta Neurologica Scandinavica 87(5): 416422.
Holmgren, A., Bouhy, D., De Winter, V., Asselbergh, B., Timmermans, J.-P., Irobi, J.
and Timmerman, V. (2013). Charcot–Marie–Tooth causing HSPB1 mutations
increase
Cdk5-mediated
phosphorylation
of
neurofilaments.
Acta
Neuropathologica 126(1): 93-108.
Horwitz, J., Huang, Q.-L., Ding, L. and Bova, M. P. (1998). Lens α-crystallin:
Chaperone-like properties. Methods in Enzymology. Lorimer, G. H. and
Baldwin, T. O., Elsevier. 290: 365-383.
Houlden, H., Laura, M., Wavrant–De Vrièze, F., Blake, J., Wood, N. and Reilly, M.
(2008). Mutations in the Hsp27 (HspB1) gene cause dominant, recessive, and
sporadic distal HMN/CMT type 2. Neurology 71(21): 1660-1668.
Høyer, H., Braathen, G. J., Busk, Ø. L., Holla, Ø. L., Svendsen, M., Hilmarsen, H. T.,
Strand, L., Skjelbred, C. F. and Russell, M. B. (2014). Genetic diagnosis of
Charcot-Marie-Tooth disease in a population by next-generation sequencing.
BioMed Research International 2014: 210401.
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M.,
213

References

Wang, X.-F. and Yao, T.-P. (2002). HDAC6 is a microtubule-associated
deacetylase. Nature 417(6887): 455-458.
Huber, N., Guimaraes, S., Schrader, M., Suter, U. and Niemann, A. (2013). Charcot‐
Marie‐Tooth disease‐associated mutants of GDAP1 dissociate its roles in
peroxisomal and mitochondrial fission. European Molecular Biology
Organization Reports 14(6): 545-552.
Huot, J., Houle, F., Spitz, D. R. and Landry, J. (1996). HSP27 phosphorylationmediated resistance against actin fragmentation and cell death induced by
oxidative stress. Cancer Research 56(2): 273-279.
Huot, J., Roy, G., Lambert, H., Chrétien, P. and Landry, J. (1991). Increased survival
after treatments with anticancer agents of Chinese hamster cells expressing the
human Mr 27,000 heat shock protein. Cancer Research 51(19): 5245-5252.
Hwang, C., Sinskey, A. J. and Lodish, H. F. (1992). Oxidized redox state of glutathione
in the endoplasmic reticulum. Science 257(5076): 1496-1502.
Hyun, D.-H. and Lee, G.-H. (2015). Cytochrome b5 reductase, a plasma membrane
redox enzyme, protects neuronal cells against metabolic and oxidative stress
through maintaining redox state and bioenergetics. Age 37(6): 122.
Hyun, Y., Park, H., Heo, S. H., Yoon, B., Nam, S., Kim, S. B., Park, C., Choi, B. O. and
Chung, K. (2014). Rare variants in methionyl‐and tyrosyl‐tRNA synthetase
genes in late‐onset autosomal dominant Charcot–Marie–Tooth neuropathy.
Clinical Genetics 86(6): 592-594.
Ichas, F., Jouaville, L. S. and Mazat, J.-P. (1997). Mitochondria are excitable organelles
capable of generating and conveying electrical and calcium signals. Cell 89(7):
1145-1153.
Ikeda, Y., Abe, A., Ishida, C., Takahashi, K., Hayasaka, K. and Yamada, M. (2009). A
clinical phenotype of distal hereditary motor neuronopathy type II with a novel
HspB1 mutation. Journal of the Neurological Sciences 277(1): 9-12.
Ingolia, T. D. and Craig, E. A. (1982). Four small Drosophila heat shock proteins are
related to each other and to mammalian alpha-crystallin. Proceedings of the
National Academy of Sciences 79(7): 2360-2364.
Irobi, J., De Jonghe, P. and Timmerman, V. (2004a). Molecular genetics of distal
hereditary motor neuropathies. Human Molecular Genetics 13(suppl_2): R195R202.
Irobi, J., Dierick, I., Jordanova, A., Clayes, K. G., De Jonghe, P. and Timmerman, V.
(2006). Unraveling the genetics of distal hereditary motor neuronopathies.
Neuromolecular Medicine 8(1-2): 131-146.
Irobi, J., Holmgren, A., De Winter, V., Asselbergh, B., Gettemans, J., Adriaensen, D.,
Ceuterick-de Groote, C., Van Coster, R., De Jonghe, P. and Timmerman, V.
(2012). Mutant HSPB8 causes protein aggregates and a reduced mitochondrial
membrane potential in dermal fibroblasts from distal hereditary motor
neuropathy patients. Neuromuscular Disorders 22(8): 699-711.
Irobi, J., Van Impe, K., Seeman, P., Jordanova, A., Dierick, I., Verpoorten, N.,
Michalik, A., De Vriendt, E., Jacobs, A. and Van Gerwen, V. (2004b). Hot-spot
residue in small heat-shock protein 22 causes distal motor neuropathy. Nature
Genetics 36(6): 597-601.
Ito, H., Okamoto, K., Nakayama, H., Isobe, T. and Kato, K. (1997). Phosphorylation of
αB-crystallin in response to various types of stress. Journal of Biological
214

References

Chemistry 272(47): 29934-29941.
Jakob, U., Gaestel, M., Engel, K. and Buchner, J. (1993). Small heat shock proteins are
molecular chaperones. Journal of Biological Chemistry 268(3): 1517-1520.
Jakob, U., Muse, W., Eser, M. and Bardwell, J. C. (1999). Chaperone activity with a
redox switch. Cell 96(3): 341-352.
James, P., Rankin, J. and Talbot, K. (2008). Asymmetrical late onset motor neuropathy
associated with a novel mutation in the small heat shock protein HspB1 (Hsp27).
Journal of Neurology, Neurosurgery and Psychiatry 79(4): 461-463.
Jeong, N. Y., Shin, Y. H. and Jung, J. (2013). Neuropathic pain in hereditary peripheral
neuropathy. Journal of Exercise Rehabilitation 9(4): 397.
Joachimiak, L. A., Walzthoeni, T., Liu, C. W., Aebersold, R. and Frydman, J. (2014).
The structural basis of substrate recognition by the eukaryotic chaperonin
TRiC/CCT. Cell 159(5): 1042-1055.
Johnson Jr, W. C. (1988). Secondary structure of proteins through circular dichroism
spectroscopy. Annual Review of Biophysics and Biophysical Chemistry 17(1):
145-166.
Johnson, N. E., Heatwole, C. R., Dilek, N., Sowden, J., Kirk, C. A., Shereff, D., Shy, M.
E., Herrmann, D. N. and Consortium, I. N. (2014). Quality-of-life in Charcot–
Marie–Tooth disease: The patient’s perspective. Neuromuscular Disorders
24(11): 1018-1023.
Jordanova, A., De Jonghe, P., Boerkoel, C., Takashima, H., De Vriendt, E., Ceuterick,
C., Martin, J. J., Butler, I., Mancias, P. and Papasozomenos, S. C. (2003).
Mutations in the neurofilament light chain gene (NEFL) cause early onset severe
Charcot–Marie–Tooth disease. Brain 126(3): 590-597.
Jovcevski, B., Kelly, M. A., Rote, A. P., Berg, T., Gastall, H. Y., Benesch, J. L.,
Aquilina, J. A. and Ecroyd, H. (2015). Phosphomimics destabilize Hsp27
oligomeric assemblies and enhance chaperone activity. Chemistry and Biology
22(2): 186-195.
Kaarniranta, K., Salminen, A., Eskelinen, E.-L. and Kopitz, J. (2009). Heat shock
proteins as gatekeepers of proteolytic pathways—implications for age-related
macular degeneration (AMD). Ageing Research Reviews 8(2): 128-139.
Kabzińska, D., Drac, H., Sherman, D., Kostera-Pruszczyk, A., Brophy, P., Kochański,
A. and Hausmanowa-Petrusewicz, I. (2006). Charcot–Marie–Tooth type 4F
disease caused by S399fsx410 mutation in the PRX gene. Neurology 66(5): 745747.
Kalmár, B., Burnstock, G., Vrbová, G. and Greensmith, L. (2002). The effect of
neonatal nerve injury on the expression of heat shock proteins in developing rat
motoneurones. Journal of Neurotrauma 19(5): 667-679.
Kalmar, B., Innes, A., Wanisch, K., Koyen Kolaszynska, A., Pandraud, A., Kelly, G.,
Abramov, A. Y., Reilly, M. M., Schiavo, G. and Greensmith, L. (2017).
Mitochondrial deficits and abnormal mitochondrial retrograde axonal transport
play a role in the pathogenesis of mutant Hsp27 induced Charcot Marie Tooth
Disease. Human Molecular Genetics.
Kamentsky, L., Jones, T. R., Fraser, A., Bray, M.-A., Logan, D. J., Madden, K. L.,
Ljosa, V., Rueden, C., Eliceiri, K. W. and Carpenter, A. E. (2011). Improved
structure, function and compatibility for CellProfiler: modular high-throughput
image analysis software. Bioinformatics 27(8): 1179-1180.
215

References

Kandil, M. R., Darwish, E. S., Khedr, E. M., Sabry, M. M. and Abdulah, M. A. (2012).
A community-based epidemiological study of peripheral neuropathies in Assiut,
Egypt. Neurological Research 34(10): 960-966.
Kang, C. B., Tai, J., Chia, J. and Yoon, H. S. (2005). The flexible loop of Bcl-2 is
required for molecular interaction with immunosuppressant FK-506 binding
protein 38 (FKBP38). Federation of European Biochemical Societies Letters
579(6): 1469-1476.
Kang, K.-h., Han, J. E., Hong, Y. B., Nam, S. H., Choi, B.-O. and Koh, H. (2020).
Human HSPB1 mutation recapitulates features of distal hereditary motor
neuropathy (dHMN) in Drosophila. Biochemical and Biophysical Research
Communications 521(1): 220-226.
Kang, R., Livesey, K. M., Zeh, I., Herbert J, Lotze, M. T. and Tang, D. (2011a).
HMGB1 as an autophagy sensor in oxidative stress. Autophagy 7(8): 904-906.
Kang, R., Livesey, K. M., Zeh, I., Herbert J, Loze, M. T. and Tang, D. (2011b).
Metabolic regulation by HMGB1-mediated autophagy and mitophagy.
Autophagy 7(10): 1256-1258.
Kann, O. and Kovács, R. (2007). Mitochondria and neuronal activity. American Journal
of Physiology - Cell Physiology 292(2): C641-C657.
Kanwal, S. and Perveen, S. (2019). Association of SNP in JPH1 gene with severity of
disease in Charcot Marie Tooth 2K patients. Journal Of Pakistan Medical
Association 69(2): 241 - 243.
Katz, M., Davis, M., Garton, F. C., Henderson, R., Bharti, V., Wray, N. and McCombe,
P. (2020). Mutations in heat shock protein beta-1 (HSPB1) are associated with a
range of clinical phenotypes related to different patterns of motor neuron
dysfunction: A case series. Journal of the Neurological Sciences 413: 116809.
Kelley, P. M. and Schlesinger, M. J. (1978). The effect of amino acid analogues and
heat shock on gene expression in chicken embryo fibroblasts. Cell 15(4): 12771286.
Kennerson, M. L., Nicholson, G. A., Kaler, S. G., Kowalski, B., Mercer, J. F., Tang, J.,
Llanos, R. M., Chu, S., Takata, R. I. and Speck-Martins, C. E. (2010). Missense
mutations in the copper transporter gene ATP7A cause X-linked distal
hereditary motor neuropathy. The American Journal of Human Genetics 86(3):
343-352.
Kennerson, M. L., Yiu, E. M., Chuang, D. T., Kidambi, A., Tso, S.-C., Ly, C.,
Chaudhry, R., Drew, A. P., Rance, G. and Delatycki, M. B. (2013). A new locus
for X-linked dominant Charcot–Marie–Tooth disease (CMTX6) is caused by
mutations in the pyruvate dehydrogenase kinase isoenzyme 3 (PDK3) gene.
Human Molecular Genetics 22(7): 1404-1416.
Kessler, D., Gruen, G.-C., Heider, D., Morgner, J., Reis, H., Schmid, K. W. and
Jendrossek, V. (2012). The action of small GTPases Rab11 and Rab25 in vesicle
trafficking during cell migration. Cellular Physiology and Biochemistry 29(5-6):
647-656.
Kijima, K., Numakura, C., Goto, T., Takahashi, T., Otagiri, T., Umetsu, K. and
Hayasaka, K. (2005a). Small heat shock protein 27 mutation in a Japanese
patient with distal hereditary motor neuropathy. Journal of Human Genetics
50(9): 473-476.
Kijima, K., Numakura, C., Izumino, H., Umetsu, K., Nezu, A., Shiiki, T., Ogawa, M.,
216

References

Ishizaki, Y., Kitamura, T. and Shozawa, Y. (2005b). Mitochondrial GTPase
mitofusin 2 mutation in Charcot–Marie–Tooth neuropathy type 2A. Human
Genetics 116(1-2): 23-27.
Kim, H.-J., Sohn, K.-M., Shy, M. E., Krajewski, K. M., Hwang, M., Park, J.-H., Jang,
S.-Y., Won, H.-H., Choi, B.-O. and Hong, S. H. (2007). Mutations in PRPS1,
which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for
nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing
loss and optic neuropathy (cmtx5). The American Journal of Human Genetics
81(3): 552-558.
Kim, H. J., Hong, Y. B., Park, J.-M., Choi, Y.-R., Kim, Y. J., Yoon, B. R., Koo, H.,
Yoo, J. H., Kim, S. B. and Park, M. (2013). Mutations in the PLEKHG5 gene is
relevant with autosomal recessive intermediate Charcot-Marie-Tooth disease.
Orphanet Journal of Rare Diseases 8(1): 104.
Kim, H. J., Lee, J., Hong, Y. B., Kim, Y. J., Lee, J. H., Nam, S. H., Choi, B.-O. and
Chung, K. W. (2015). Ser135Phe mutation in HSPB1 (HSP27) from Charcot–
Marie–Tooth disease type 2F families. Genes and Genomics 37(3): 295-303.
Kim, J.-Y., Woo, S.-Y., Hong, Y. B., Choi, H., Kim, J., Choi, H., Mook-Jung, I., Ha,
N., Kyung, J. and Koo, S. K. (2016). HDAC6 inhibitors rescued the defective
axonal mitochondrial movement in motor neurons derived from the induced
pluripotent stem cells of peripheral neuropathy patients with HSPB1 mutation.
Stem Cells International 2016: 14.
Kim, K. (2021). Glutathione in the Nervous System as a Potential Therapeutic Target to
Control the Development and Progression of Amyotrophic Lateral Sclerosis.
Antioxidants 10(7): 1011.
Kim, M. V., Seit-Nebi, A. S., Marston, S. B. and Gusev, N. B. (2004). Some properties
of human small heat shock protein Hsp22 (H11 or HspB8). Biochemical and
Biophysical Research Communications 315(4): 796-801.
Kim, S.-A., Taylor, G. S., Torgersen, K. M. and Dixon, J. E. (2002). Myotubularin and
MTMR2, phosphatidylinositol 3-phosphatases mutated in myotubular myopathy
and type 4B Charcot-Marie-Tooth disease. Journal of Biological Chemistry
277(6): 4526-4531.
Kimura, M. and Okano, Y. (2007). Human Misato regulates mitochondrial distribution
and morphology. Experimental Cell Research 313(7): 1393-1404.
Kiral, F. R., Kohrs, F. E., Jin, E. J. and Hiesinger, P. R. (2018). Rab GTPases and
membrane trafficking in neurodegeneration. Current Biology 28(8): R471-R486.
Kirichok, Y., Krapivinsky, G. and Clapham, D. E. (2004). The mitochondrial calcium
uniporter is a highly selective ion channel. Nature 427(6972): 360.
Klein, C. J., Botuyan, M.-V., Wu, Y., Ward, C. J., Nicholson, G. A., Hammans, S.,
Hojo, K., Yamanishi, H., Karpf, A. R. and Wallace, D. C. (2011). Mutations in
DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss.
Nature Genetics 43(6): 595.
Knauf, U., Jakob, U., Engel, K., Buchner, J. and Gaestel, M. (1994). Stress‐and
mitogen‐induced phosphorylation of the small heat shock protein Hsp25 by
MAPKAP kinase 2 is not essential for chaperone properties and cellular
thermoresistance. The European Molecular Biology Organization Journal 13(1):
54-60.
Kolb, S., Snyder, P., Poi, E., Renard, E., Bartlett, A., Gu, S., Sutton, S., Arnold, W.,
217

References

Freimer, M. and Lawson, V. (2010). Mutant small heat shock protein B3 causes
motor neuropathy: utility of a candidate gene approach. Neurology 74(6): 502506.
Kopito, R. R. (2000). Aggresomes, inclusion bodies and protein aggregation. Trends in
Cell Biology 10(12): 524-530.
Korobova, F., Gauvin, T. J. and Higgs, H. N. (2014). A role for myosin II in
mammalian mitochondrial fission. Current Biology 24(4): 409-414.
Korobova, F., Ramabhadran, V. and Higgs, H. N. (2013). An actin-dependent step in
mitochondrial fission mediated by the ER-associated formin INF2. Science
339(6118): 464-467.
Kosower, N. S. and Kosower, E. M. (1978). The glutathione status of cells.
International Review of Cytology, Elsevier. 54: 109-160.
Kotthaus, J., Wahl, B., Havemeyer, A., Kotthaus, J., Schade, D., Garbe-Schönberg, D.,
Mendel, R., Bittner, F. and Clement, B. (2011). Reduction of Nω-hydroxy-Larginine by the mitochondrial amidoxime reducing component (mARC).
Biochemical Journal 433(2): 383-391.
Kourtis, N., Nikoletopoulou, V. and Tavernarakis, N. (2012). Small heat-shock proteins
protect from heat-stroke-associated neurodegeneration. Nature 490(7419): 213218.
Kriehuber, T., Rattei, T., Weinmaier, T., Bepperling, A., Haslbeck, M. and Buchner, J.
(2010). Independent evolution of the core domain and its flanking sequences in
small heat shock proteins. The Federation of American Societies for
Experimental Biology Journal 24(10): 3633-3642.
Kurihara, S., Adachi, Y., Wada, K., Awaki, E., Harada, H. and Nakashima, K. (2002).
An epidemiological genetic study of Charcot-Marie-Tooth disease in Western
Japan. Neuroepidemiology 21(5): 246-250.
Kyte, J. and Doolittle, R. F. (1982). A simple method for displaying the hydropathic
character of a protein. Journal of Molecular Biology 157(1): 105-132.
Lacerda, A. F., Hartjes, E. and Brunetti, C. R. (2014). LITAF mutations associated with
Charcot-Marie-Tooth disease 1C show mislocalization from the late
endosome/lysosome to the mitochondria. Public Library of Science One 9(7):
e103454.
Laganowsky, A., Benesch, J. L. P., Landau, M., Ding, L., Sawaya, M. R., Cascio, D.,
Huang, Q., Robinson, C. V., Horwitz, J. and Eisenberg, D. (2010). Crystal
structures of truncated alphaA and alphaB crystallins reveal structural
mechanisms of polydispersity important for eye lens function. Protein Science
19(5): 1031-1043.
Lakshmanan, A., Cheong, D. W., Accardo, A., Di Fabrizio, E., Riekel, C. and Hauser,
C. A. E. (2013). Aliphatic peptides show similar self-assembly to amyloid core
sequences, challenging the importance of aromatic interactions in amyloidosis.
Proceedings of the National Academy of Sciences 110(2): 519-524.
LaMonte, B. H., Wallace, K. E., Holloway, B. A., Shelly, S. S., Ascaño, J., Tokito, M.,
Van Winkle, T., Howland, D. S. and Holzbaur, E. L. (2002). Disruption of
dynein/dynactin inhibits axonal transport in motor neurons causing late-onset
progressive degeneration. Neuron 34(5): 715-727.
Lamprecht, M. R., Sabatini, D. M. and Carpenter, A. E. (2007). CellProfiler™: free,
versatile software for automated biological image analysis. Biotechniques 42(1):
218

References

71-75.
Lander, G. C., Estrin, E., Matyskiela, M. E., Bashore, C., Nogales, E. and Martin, A.
(2012). Complete subunit architecture of the proteasome regulatory particle.
Nature 482(7384): 186-191.
Landouré, G., Zdebik, A. A., Martinez, T. L., Burnett, B. G., Stanescu, H. C., Inada, H.,
Shi, Y., Taye, A. A., Kong, L. and Munns, C. H. (2010). Mutations in TRPV4
cause Charcot-Marie-Tooth disease type 2C. Nature Genetics 42(2): 170.
Lariviere, R. C. and Julien, J. P. (2004). Functions of intermediate filaments in neuronal
development and disease. Journal of Neurobiology 58(1): 131-148.
Larkin, M. A., Blackshields, G., Brown, N., Chenna, R., McGettigan, P. A.,
McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A. and Lopez, R. (2007).
Clustal W and Clustal X version 2.0. Bioinformatics 23(21): 2947-2948.
Lasek, R. J. and Hoffman, P. N. (1976). The neuronal cytoskeleton, axonal transport
and axonal growth. Cell Motility 3: 1021-1049.
Lassuthova, P., Rebelo, A. P., Ravenscroft, G., Lamont, P. J., Davis, M. R., Manganelli,
F., Feely, S. M., Bacon, C., Brožková, D. Š. and Haberlova, J. (2018). Mutations
in ATP1A1 cause dominant Charcot-Marie-Tooth type 2. The American Journal
of Human Genetics 102(3): 505-514.
Lattanzi, G., Cenni, V., Marmiroli, S., Capanni, C., Mattioli, E., Merlini, L., Squarzoni,
S. and Maraldi, N. M. (2003). Association of emerin with nuclear and
cytoplasmic actin is regulated in differentiating myoblasts. Biochemical and
Biophysical Research Communications 303(3): 764-770.
Laurà, M., Hutton, E. J., Blake, J., Lunn, M. P., Fox, Z., Pareyson, D., Solari, A.,
Radice, D., Koltzenburg, M. and Reilly, M. M. (2014). Pain and small fiber
function in Charcot–Marie–Tooth disease type 1A. Muscle and Nerve 50(3):
366-371.
Laurá, M., Pipis, M., Rossor, A. M. and Reilly, M. M. (2019). Charcot–Marie–Tooth
disease and related disorders: an evolving landscape. Current Opinion in
Neurology 32(5): 641-650.
Lavoie, J. N., Gingras-Breton, G., Tanguay, R. and Landry, J. (1993). Induction of
Chinese hamster HSP27 gene expression in mouse cells confers resistance to
heat shock. HSP27 stabilization of the microfilament organization. Journal of
Biological Chemistry 268(5): 3420-3429.
Lavoie, J. N., Lambert, H., Hickey, E., Weber, L. A. and Landry, J. (1995). Modulation
of cellular thermoresistance and actin filament stability accompanies
phosphorylation-induced changes in the oligomeric structure of heat shock
protein 27. Molecular and Cellular Biology 15(1): 505-516.
Leak, R. K. (2014). Heat shock proteins in neurodegenerative disorders and aging.
Journal of Cell Communication and Signaling 8(4): 293-310.
Leal, A., Huehne, K., Bauer, F., Sticht, H., Berger, P., Suter, U., Morera, B., Del Valle,
G., Lupski, J. R. and Ekici, A. (2009). Identification of the variant Ala335Val of
MED25 as responsible for CMT2B2: molecular data, functional studies of the
SH3 recognition motif and correlation between wild-type MED25 and PMP22
RNA levels in CMT1A animal models. Neurogenetics 10(4): 275-287.
Lee, A. S., Kranzusch, P. J. and Cate, J. H. (2015). eIF3 targets cell-proliferation
messenger RNAs for translational activation or repression. Nature 522(7554):
111-114.
219

References

Lee, A. S., Kranzusch, P. J., Doudna, J. A. and Cate, J. H. (2016). eIF3d is an mRNA
cap-binding protein that is required for specialized translation initiation. Nature
536(7614): 96-99.
Lee, G. J., Roseman, A. M., Saibil, H. R. and Vierling, E. (1997). A small heat shock
protein stably binds heat‐denatured model substrates and can maintain a
substrate in a folding‐competent state. The European Molecular Biology
Organization Journal 16(3): 659-671.
Lee, G. J. and Vierling, E. (2000). A small heat shock protein cooperates with heat
shock protein 70 systems to reactivate a heat-denatured protein. Plant
Physiology 122(1): 189-198.
Lee, J. H., Koh, H., Kim, M., Kim, Y., Lee, S. Y., Karess, R. E., Lee, S.-H., Shong, M.,
Kim, J.-M. and Kim, J. (2007). Energy-dependent regulation of cell structure by
AMP-activated protein kinase. Nature 447(7147): 1017-1020.
Lefter, S., Hardiman, O. and Ryan, A. M. (2017). A population-based epidemiologic
study of adult neuromuscular disease in the Republic of Ireland. Neurology
88(3): 304-313.
Lelj-Garolla, B. and Mauk, A. G. (2005). Self-association of a small heat shock protein.
Journal of Molecular Biology 345(3): 631-642.
Lelj-Garolla, B. and Mauk, A. G. (2012). Roles of the N- and C-terminal sequences in
Hsp27 self-association and chaperone activity. Protein Science 21(1): 122-133.
Lewis-Smith, D., Duff, J., Pyle, A., Griffin, H., Polvikoski, T., Birchall, D., Horvath, R.
and Chinnery, P. (2016). Novel HSPB1 mutation causes both motor
neuronopathy and distal myopathy. Neurology Genetics 2(6): e110.
Lewis, S. E., Mannion, R. J., White, F. A., Coggeshall, R. E., Beggs, S., Costigan, M.,
Martin, J. L., Dillmann, W. H. and Woolf, C. J. (1999). A role for HSP27 in
sensory neuron survival. Journal of Neuroscience 19(20): 8945-8953.
Li, C. H., Nguyen, X., Narhi, L., Chemmalil, L., Towers, E., Muzammil, S., Gabrielson,
J. and Jiang, Y. (2011). Applications of circular dichroism (CD) for structural
analysis of proteins: qualification of near‐and far‐UV CD for protein higher
order structural analysis. Journal of Pharmaceutical Sciences 100(11): 46424654.
Li, L. K. and Spector, A. (1974). Circular dichroism and optical rotatory dispersion of
the aggregates of purified polypeptides of alpha-crystallin. Experimental Eye
Research 19(1): 49-56.
Li, X., Hu, Z., Liu, L., Xie, Y., Zhan, Y., Zi, X., Wang, J., Wu, L., Xia, K. and Tang, B.
(2015). A SIGMAR1 splice-site mutation causes distal hereditary motor
neuropathy. Neurology 84(24): 2430-2437.
Li, Z., Slone, J., Wu, L. and Huang, T. (2018). Neurodegenerative diseases associated
with mutations in SLC25A46. Recent Advances in Neurodegeneration. Borreca,
A., IntechOpen.
Liao, G. and Gundersen, G. G. (1998). Kinesin is a candidate for cross-bridging
microtubules and intermediate filaments selective binding of Kinesin to
detyrosinated tubulin and vimentin. Journal of Biological Chemistry 273(16):
9797-9803.
Lin, M. T. and Beal, M. F. (2006). Mitochondrial dysfunction and oxidative stress in
neurodegenerative diseases. Nature 443(7113): 787.
Lin, K. P., Soong, B.-W., Yang, C.-C., Huang, L.-W., Chang, M.-H., Lee, I.-H.,
220

References

Antonellis, A. and Lee, Y.-C. (2011). The mutational spectrum in a cohort of
Charcot-Marie-Tooth disease type 2 among the Han Chinese in Taiwan. PLoS
One 6(12): e29393.
Lin, Z. F., Xu, H.-B., Wang, J.-Y., Lin, Q., Ruan, Z., Liu, F.-B., Jin, W., Huang, H.-H.
and Chen, X. (2013). SIRT5 desuccinylates and activates SOD1 to eliminate
ROS. Biochemical and Biophysical Research Communications 441(1): 191-195.
Lindeman, E., Spaans, F., Reulen, J., Leffers, P. and Drukker, J. (1999). Progressive
resistance training in neuromuscular patients. Effects on force and surface EMG.
Journal of Electromyography and Kinesiology 9(6): 379-384.
Lindner, R. A., Carver, J. A., Ehrnsperger, M., Buchner, J., Esposito, G., Behlke, J.,
Lutsch, G., Kotlyarov, A. and Gaestel, M. (2000). Mouse Hsp25, a small heat
shock protein: The role of its C‐terminal extension in oligomerization and
chaperone action. European Journal of Biochemistry 267(7): 1923-1932.
Lindsay, A. J., Jollivet, F., Horgan, C. P., Khan, A. R., Raposo, G., McCaffrey, M. W.
and Goud, B. (2013). Identification and characterization of multiple novel Rab–
myosin Va interactions. Molecular Biology of the Cell 24(21): 3420-3434.
Litt, M., Kramer, P., LaMorticella, D. M., Murphey, W., Lovrien, E. W. and Weleber,
R. G. (1998). Autosomal dominant congenital cataract associated with a
missense mutation in the human alpha crystallin gene CRYAA. Human
Molecular Genetics 7(3): 471-474.
Lobley, A., Whitmore, L. and Wallace, B. (2002). DICHROWEB: an interactive
website for the analysis of protein secondary structure from circular dichroism
spectra. Bioinformatics 18(1): 211-212.
López Del Amo, V., Seco-Cervera, M., García-Giménez, J. L., Whitworth, A. J.,
Pallardó, F. V. and Galindo, M. I. (2014). Mitochondrial defects and
neuromuscular degeneration caused by altered expression of Drosophila Gdap1:
implications for the Charcot–Marie–Tooth neuropathy. Human Molecular
Genetics 24(1): 21-36.
Lorber, B., Fischer, F., Bailly, M., Roy, H. and Kern, D. (2012). Protein analysis by
dynamic light scattering: Methods and techniques for students. Biochemistry and
Molecular Biology Education 40(6): 372-382.
Lousa, M., Vázquez‐Huarte‐Mendicoa, C., Gutiérrez, A. J., Saavedra, P., Navarro, B.
and Tugores, A. (2018). Genetic epidemiology, demographic, and clinical
characteristics of Charcot‐Marie‐tooth disease in the island of Gran Canaria
(Spain). Journal of the Peripheral Nervous System 24(1): 131-138.
Luigetti, M., Fabrizi, G., Madia, F., Ferrarini, M., Conte, A., Del Grande, A., Tasca, G.,
Tonali, P. A. and Sabatelli, M. (2010). A novel HspB1 mutation in an Italian
patient with CMT2/dHMN phenotype. Journal of the Neurological Sciences
298(1): 114-117.
Luigetti, M., Fabrizi, G. M., Bisogni, G., Romano, A., Taioli, F., Ferrarini, M.,
Bernardo, D., Rossini, P. M. and Sabatelli, M. (2016). Charcot-Marie-Tooth
type 2 and distal hereditary motor neuropathy: Clinical, neurophysiological and
genetic findings from a single-centre experience. Clinical Neurology and
Neurosurgery 144: 67-71.
Lupo, V., García-García, F., Sancho, P., Tello, C., García-Romero, M., Villarreal, L.,
Alberti, A., Sivera, R., Dopazo, J. and Pascual-Pascual, S. I. (2016). Assessment
of targeted next-generation sequencing as a tool for the diagnosis of Charcot221

References

Marie-Tooth disease and hereditary motor neuropathy. The Journal of
Molecular Diagnostics 18(2): 225-234.
Lupski, J. R., de Oca-Luna, R. M., Slaugenhaupt, S., Pentao, L., Guzzetta, V., Trask, B.
J., Saucedo-Cardenas, O., Barker, D. F., Killian, J. M. and Garcia, C. A. (1991).
DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell
66(2): 219-232.
Ma, A. S., Grigg, J. R., Ho, G., Prokudin, I., Farnsworth, E., Holman, K., Cheng, A.,
Billson, F. A., Martin, F. and Fraser, C. (2016). Sporadic and familial congenital
cataracts: mutational spectrum and new diagnoses using next‐generation
sequencing. Human Mutation 37(4): 371 - 384.
Mackay, D. S., Andley, U. P. and Sheils, A. (2003). Cell death triggered by a novel
mutation in the alphaA-crystallin gene underlies autosomal dominant cataract
linked to chromosome 21q. European Journal of Human Genetics 11(10): 784793.
MacMillan, J. C. and Harper, P. S. (1994). The Charcot‐Marie‐Tooth syndrome: clinical
aspects from a population study in South Wales, UK. Clinical Genetics 45(3):
128-134.
Maeda, K., Idehara, R., Hashiguchi, A. and Takashima, H. (2014). A family with distal
hereditary motor neuropathy and a K141Q mutation of small heat shock protein
HSPB1. Internal Medicine 53(15): 1655-1658.
Maki, T., Grimaldi, A. D., Fuchigami, S., Kaverina, I. and Hayashi, I. (2015). CLASP2
has two distinct TOG domains that contribute differently to microtubule
dynamics. Journal of Molecular Biology 427(14): 2379-2395.
Maloyan, A., Sanbe, A., Osinska, H., Westfall, M., Robinson, D., Imahashi, K.-i.,
Murphy, E. and Robbins, J. (2005). Mitochondrial dysfunction and apoptosis
underlie the pathogenic process in alpha-B-crystallin desmin related
cardiomyopathy. Circulation 112(22): 3451-3461.
Mandal, P. K., Shukla, D., Tripathi, M. and Ersland, L. (2019). Cognitive improvement
with glutathione supplement in Alzheimer’s disease: A way forward. Journal of
Alzheimer's Disease 68(2): 531-535.
Manders, E., Verbeek, F. and Aten, J. (1993). Measurement of co‐localization of objects
in dual‐colour confocal images. Journal of Microscopy 169(3): 375-382.
Mandich, P., Grandis, M., Varese, A., Geroldi, A., Acquaviva, M., Ciotti, P., Gulli, R.,
Doria-Lamba, L., Fabrizi, G. M. and Giribaldi, G. (2010). Severe neuropathy
after diphtheria-tetanus-pertussis vaccination in a child carrying a novel frameshift mutation in the small heat-shock protein 27 gene. Journal of Child
Neurology 25(1): 107-109.
Manfredi, G. and Xu, Z. (2005). Mitochondrial dysfunction and its role in motor neuron
degeneration in ALS. Mitochondrion 5(2): 77-87.
Manganelli, F., Tozza, S., Pisciotta, C., Bellone, E., Iodice, R., Nolano, M., Geroldi, A.,
Capponi, S., Mandich, P. and Santoro, L. (2014). Charcot‐Marie‐Tooth disease:
frequency of genetic subtypes in a Southern Italy population. Journal of the
Peripheral Nervous System 19(4): 292-298.
Manor, U., Bartholomew, S., Golani, G., Christenson, E., Kozlov, M., Higgs, H.,
Spudich, J. and Lippincott-Schwartz, J. (2015). A mitochondria-anchored
isoform of the actin-nucleating spire protein regulates mitochondrial division.
eLife 4: e08828.
222

References

Marie, P. and Charcot, J. (1886). Sur une forme particulière datrophie musculaire
progressive souvent familiale débutant par les pieds et les jambs et atteignant
plus tard les mains. Archives of Neurology 6: 511-512.
Martyn, C. and Hughes, R. (1997). Epidemiology of peripheral neuropathy. Journal of
Neurology, Neurosurgery, and Psychiatry 62(4): 310.
Matsumoto, T. (2015). Small heat shock protein beta-1 (HSPB1) is upregulated and
regulates autophagy and apoptosis of renal tubular cells in acute kidney injury.
Public Library of Science One 10(5): e0126229.
Mattson, M. P., Gleichmann, M. and Cheng, A. (2008). Mitochondria in neuroplasticity
and neurological disorders. Neuron 60(5): 748-766.
McLaughlin, H. M., Sakaguchi, R., Giblin, W., Center, N. I. S., Wilson, T. E.,
Biesecker, L., Lupski, J. R., Talbot, K., Vance, J. M. and Züchner, S. (2012). A
recurrent loss‐of‐function alanyl‐tRNA synthetase (AARS) mutation in patients
with Charcot‐Marie‐Tooth disease type 2N (CMT2N). Human Mutation 33(1):
244-253.
McLaughlin, H. M., Sakaguchi, R., Liu, C., Igarashi, T., Pehlivan, D., Chu, K., Iyer, R.,
Cruz, P., Cherukuri, P. F. and Hansen, N. F. (2010). Compound heterozygosity
for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral
neuropathy. The American Journal of Human Genetics 87(4): 560-566.
Medicherla, B. and Goldberg, A. L. (2008). Heat shock and oxygen radicals stimulate
ubiquitin-dependent degradation mainly of newly synthesized proteins. The
Journal of Cell Biology 182(4): 663-673.
Mehlen, P., Briolay, J., Smith, L., DIAZ‐LATOUD, C., Fabre, N., Pauli, D. and
ARRIGO, A. P. (1993). Analysis of the resistance to heat and hydrogen
peroxide stresses in COS cells transiently expressing wild type or deletion
mutants of the Drosophila 27‐kDa heat‐shock protein. European Journal of
Biochemistry 215(2): 277-284.
Mehlen, P., Coronas, V., Ljubic-Thibal, V., Ducasse, C., Granger, L., Jourdan, F. and
Arrigo, A.-P. (1999). Small stress protein Hsp27 accumulation during
dopamine-mediated differentiation of rat olfactory neurons counteracts
apoptosis. Cell Death and Differentiation 6(3): 227.
Mehlen, P., Hickey, E., Weber, L. A. and Arrigo, A. P. (1997a). Large
unphosphorylated aggregates as the active form of Hsp27 which controls
intracellular reactive oxygen species and glutathione levels and generates a
protection against TNFα in NIH-3T3-ras cells. Biochemical and Biophysical
Research Communications 241(1): 187-192.
Mehlen, P., Kretz-Remy, C., Briolay, J., Fostan, P., Mirault, M. E. and Arrigo, A. P.
(1995a). Intracellular reactive oxygen species as apparent modulators of heatshock protein 27 (Hsp27) structural organization and phosphorylation in basal
and tumour necrosis factor alpha-treated T47D human carcinoma cells.
Biochemical Journal 312(1): 367-375.
Mehlen, P., Kretz-Remy, C., Préville, X. and Arrigo, A. P. (1996). Human Hsp27,
Drosophila Hsp27 and human B-crystallin expression-mediated increase in
glutathione is essential for the protective activity of these proteins against TNFinduced cell death. European Molecular Biology Organization Journal 15(1):
2695-2706.
Mehlen, P., Mehlen, A., Godet, J. and Arrigo, A. P. (1997b). Hsp27 as a switch between
223

References

differentiation and apoptosis in murine embryonic stem cells. Journal of
Biological Chemistry 272(50): 31657-31665.
Mehlen, P., Preville, X., Chareyron, P., Briolay, J., Klemenz, R. and Arrigo, A.-P.
(1995b). Constitutive expression of human hsp27, Drosophila hsp27, or human
alpha B-crystallin confers resistance to TNF-and oxidative stress-induced
cytotoxicity in stably transfected murine L929 fibroblasts. The Journal of
Immunology 154(1): 363-374.
Menezes, M. P., Waddell, L., Lenk, G. M., Kaur, S., MacArthur, D. G., Meisler, M. H.
and Clarke, N. F. (2014). Whole exome sequencing identifies three recessive
FIG4 mutations in an apparently dominant pedigree with Charcot–Marie–Tooth
disease. Neuromuscular Disorders 24(8): 666-670.
Merad-Boudia, M., Nicole, A., Santiard-Baron, D., Saillé, C. and Ceballos-Picot, I.
(1998). Mitochondrial impairment as an early event in the process of apoptosis
induced by glutathione depletion in neuronal cells: relevance to Parkinson’s
disease. Biochemical Pharmacology 56(5): 645-655.
Merksamer, P. I., Trusina, A. and Papa, F. R. J. C. (2008). Real-time redox
measurements during endoplasmic reticulum stress reveal interlinked protein
folding functions. Cell 135(5): 933-947.
Mersiyanova, I. V., Perepelov, A. V., Polyakov, A. V., Sitnikov, V. F., Dadali, E. L.,
Oparin, R. B., Petrin, A. N. and Evgrafov, O. V. (2000). A new variant of
Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the
neurofilament-light gene. The American Journal of Human Genetics 67(1): 3746.
Mészáros, B., Erdős, G. and Dosztányi, Z. (2018). IUPred2A: context-dependent
prediction of protein disorder as a function of redox state and protein binding.
Nucleic Acids Research 46(W1): W329-W337.
Mialhe, A., Lafanechèere, L., Treilleux, I., Peloux, N., Dumontet, C., Brémond, A.,
Panh, M.-H., Payan, R., Wehland, J. and Margolis, R.-L. (2001). Tubulin
detyrosination is a frequent occurrence in breast cancers of poor prognosis.
Cancer Research 61(13): 5024-5027.
Miao, J., Ye, S., Lan, J., Ye, P., Wen, Q., Mei, L., Liu, X., Lin, J., Zhou, X., Du, S. and
Liu, X., 2020. Nuclear HMGB1 promotes the phagocytic ability of
macrophages. Experimental Cell Research, 393(1), p.112037.
Miller, V. J. and Ungar, D. (2012). Re‘COG’nition at the Golgi. Traffic 13(7): 891-897.
Mills, D. R., Rozich, R. A., Flanagan, D. L., Brilliant, K. E., Yang, D. and Hixson, D.
C. (2012). The cholangiocyte marker, BD. 1, forms a stable complex with
CLIP170 and shares an identity with eIF3a, a multifunctional subunit of the eIF3
initiation complex. Experimental and Molecular Pathology 93(2): 250-260.
Mirigian, M., Mukherjee, K., Bane, S. L. and Sackett, D. L. (2013). Measurement of in
vitro microtubule polymerization by turbidity and fluorescence. Methods in Cell
Biology. Correia, J. J. and Wilson, L., Elsevier. 115: 215-229.
Miron, T., Vancompernolle, K., Vandekerckhove, J., Wilchek, M. and Geiger, B.
(1991). A 25-kD inhibitor of actin polymerization is a low molecular mass heat
shock protein. The Journal of Cell Biology 114(2): 255-261.
Miron, T., Wilchek, M. and Geiger, B. (1988). Characterization of an inhibitor of actin
polymerization in vinculin‐rich fraction of turkey gizzard smooth muscle.
European Journal of Biochemistry 178(2): 543-553.
224

References

Misko, A. L., Sasaki, Y., Tuck, E., Milbrandt, J. and Baloh, R. H. (2012). Mitofusin2
mutations disrupt axonal mitochondrial positioning and promote axon
degeneration. Journal of Neuroscience 32(12): 4145-4155.
Mladenovic, J., Rasic, V. M., Markovic, M. K., Romac, S., Todorovic, S., Stojanovic,
V. R., Tepavcevic, D. K., Hofman, A. and Pekmezovic, T. (2011).
Epidemiology of Charcot-Marie-Tooth disease in the population of Belgrade,
Serbia. Neuroepidemiology 36(3): 177-182.
Moinuddin, M. (2021). Charcot-Marie-Tooth Disease: Genetic predisposition and effect
of resistance training, endurance training, physical activity and orthosis in
attenuating its severity. European Journal of Molecular and Clinical Medicine
7(10): 1333-1342.
Montecchiani, C., Pedace, L., Lo Giudice, T., Casella, A., Mearini, M., Gaudiello, F.,
Pedroso, J. L., Terracciano, C., Caltagirone, C. and Massa, R. (2015).
ALS5/SPG11/KIAA1840 mutations cause autosomal recessive axonal Charcot–
Marie–Tooth disease. Brain 139(1): 73-85.
Morelli, F. F., Mediani, L., Heldens, L., Bertacchini, J., Bigi, I., Carrà, A. D., Vinet, J.
and Carra, S. (2017). An interaction study in mammalian cells demonstrates
weak binding of HSPB2 to BAG3, which is regulated by HSPB3 and abrogated
by HSPB8. Cell Stress and Chaperones 22: 531 - 540.
Morimoto, R. I. (2008). Proteotoxic stress and inducible chaperone networks in
neurodegenerative disease and aging. Genes and Development 22(11): 14271438.
Morocutti, C., Colazza, G. B., Soldati, G., D’Alessio, C., Damiano, M., Casali, C. and
Pierelli, F. (2002). Charcot-Marie-Tooth disease in Molise, a central-southern
region of Italy: an epidemiological study. Neuroepidemiology 21(5): 241-245.
Morrow, G. and Tanguay, R. M. (2015). Drosophila melanogaster Hsp22: a
mitochondrial small heat shock protein influencing the aging process. Frontiers
in Genetics 6: 103.
Mostacciuolo, M., Micaglio, G., Fardin, P. and Danieli, G. (1991). Genetic
epidemiology of hereditary motor sensory neuropathies (type I). American
Journal of Medical Genetics 39(4): 479-481.
Mounier, N. and Arrigo, A.-P. (2002). Actin cytoskeleton and small heat shock
proteins: how do they interact? Cell Stress and Chaperones 7(2): 167.
Moutin, M.J., Bosc, C., Peris, L. and Andrieux, A., 2021. Tubulin post‐translational
modifications control neuronal development and functions. Developmental
neurobiology, 81(3), pp.253-272.
Muller, E. (1996). A glutathione reductase mutant of yeast accumulates high levels of
oxidized glutathione and requires thioredoxin for growth. Molecular Biology of
the Cell 7(11): 1805-1813.
Muntoni, F., Bonne, G., Goldfarb, L., Mercuri, E., Piercy, R., Burke, M., Yaou, R. B.,
Richard, P., Recan, D. and Shatunov, A. (2006). Disease severity in dominant
Emery Dreifuss is increased by mutations in both emerin and desmin proteins.
Brain 129(5): 1260-1268.
Muranova, L. K., Ryzhavskaya, A. S., Sudnitsyna, M. V., Shatov, V. M. and Gusev, N.
B. (2019). Small heat shock proteins and human neurodegenerative diseases.
Biochemistry (Moscow) 84(11): 1256-1267.
Muranova, L. K., Weeks, S. D., Strelkov, S. V. and Gusev, N. B. (2015).
225

References

Characterization of mutants of human small heat shock protein HspB1 carrying
replacements in the N-terminal domain and associated with hereditary motor
neuron diseases. Public Library of Science One 10(5): e0126248.
Mymrikov, E. V., Daake, M., Richter, B., Haslbeck, M. and Buchner, J. (2016). The
chaperone activity and substrate spectrum of human small heat shock proteins.
Journal of Biological Chemistry 292(2): 672 - 684.
Nafisinia, M., Riley, L. G., Gold, W. A., Bhattacharya, K., Broderick, C. R., Thorburn,
D. R., Simons, C. and Christodoulou, J. (2017). Compound heterozygous
mutations in glycyl-tRNA synthetase (GARS) cause mitochondrial respiratory
chain dysfunction. Public Library of Science One 12(6): e0178125.
Nakhro, K., Park, J.-M., Hong, Y. B., Park, J. H., Nam, S. H., Yoon, B. R., Yoo, J. H.,
Koo, H., Jung, S.-C. and Kim, H.-L. (2013a). SET binding factor 1 (SBF1)
mutation causes Charcot-Marie-Tooth disease type 4B3. Neurology 81(2): 165173.
Nakhro, K., Park, J.-M., Kim, Y. J., Yoon, B. R., Yoo, J. H., Koo, H., Choi, B.-O. and
Chung, K. W. (2013b). A novel Lys141Thr mutation in small heat shock protein
22 (HSPB8) gene in Charcot-Marie-Tooth disease type 2L. Neuromuscular
Disorders 23(8): 656-663.
Nam, D. E., Jung, S. C., Yoo, D. H., Choi, S. S., Seo, S. Y., Kim, G. H., Kim, S. J.,
Nam, S. H., Choi, B. O. and Chung, K. W. (2017). Axonal Charcot‐Marie‐Tooth
neuropathy concurrent with distal and proximal weakness by translational
elongation of the 3′ UTR in NEFH. Journal of the Peripheral Nervous System
22(3): 200-207.
Nam, D. E., Nam, S. H., Lee, A. J., Hong, Y. B., Choi, B. O. and Chung, K. W. (2018).
Small heat shock protein B3 (HSPB3) mutation in an axonal Charcot‐Marie‐
Tooth disease family. Journal of the Peripheral Nervous System 23(1): 60-66.
Nangaku, M., Sato-Yoshitake, R., Okada, Y., Noda, Y., Takemura, R., Yamazaki, H.
and Hirokawa, N. (1994). KIF1B, a novel microtubule plus end-directed
monomeric motor protein for transport of mitochondria. Cell 79(7): 1209-1220.
Nicholls, D. and Åkerman, K. (1982). Mitochondrial calcium transport. Biochimica et
Biophysica Acta -Reviews on Bioenergetics 683(1): 57-88.
Nicolau, S., Liewluck, T., Elliott, J. L., Engel, A. G. and Milone, M. (2020). A novel
heterozygous mutation in the C-terminal region of HSPB8 leads to limb-girdle
rimmed vacuolar myopathy. Neuromuscular Disorders 30(3): 236-240.
Nicolaou, P., Zamba-Papanicolaou, E., Koutsou, P., Kleopa, K. A., Georghiou, A.,
Hadjigeorgiou, G., Papadimitriou, A., Kyriakides, T. and Christodoulou, K.
(2010). Charcot-Marie-Tooth disease in Cyprus: epidemiological, clinical and
genetic characteristics. Neuroepidemiology 35(3): 171-177.
Niemann, A., Huber, N., Wagner, K. M., Somandin, C., Horn, M., Lebrun-Julien, F.,
Angst, B., Pereira, J. A., Halfter, H. and Welzl, H. (2014). The Gdap1 knockout
mouse mechanistically links redox control to Charcot–Marie–Tooth disease.
Brain 137(3): 668-682.
Niemann, A., Ruegg, M., La Padula, V., Schenone, A. and Suter, U. (2005).
Ganglioside-induced differentiation associated protein 1 is a regulator of the
mitochondrial network: new implications for Charcot-Marie-Tooth disease.
Journal of Cell Biology 170(7): 1067-1078.
Ninković, D. B., Malenov, D. P., Petrović, P. V., Brothers, E. N., Niu, S., Hall, M. B.,
226

References

Belić, M. R. and Zarić, S. D. (2017). Unexpected importance of aromatic–
aliphatic and aliphatic side chain–backbone interactions in the stability of
amyloids. Chemistry–A European Journal 23(46): 11046-11053.
Nixon, B., De Iuliis, G. N., Hart, H. M., Zhou, W., Mathe, A., Bernstein, I. R.,
Anderson, A. L., Stanger, S. J., Skerrett-Byrne, D. A. and Jamaluddin, M. F. B.
(2019). Proteomic profiling of mouse epididymosomes reveals their
contributions to post-testicular sperm maturation. Molecular and Cellular
Proteomics 18(Supplement 1): S91-S108.
Novy, R. and Morris, B. (2001). Use of glucose to control basal expression in the pET
system. Innovations 13: 13-15.
Nunnari, J., Marshall, W. F., Straight, A., Murray, A., Sedat, J. W. and Walter, P.
(1997). Mitochondrial transmission during mating in Saccharomyces cerevisiae
is determined by mitochondrial fusion and fission and the intramitochondrial
segregation of mitochondrial DNA. Molecular Biology of the Cell 8(7): 12331242.
O'Callaghan-Sunol, C., Gabai, V. L. and Sherman, M. Y. (2007). Hsp27 modulates p53
signaling and suppresses cellular senescence. Cancer Research 67(24): 1177911788.
Oberstadt, M., Mitter, D., Classen, J. and Baum, P. (2016). Late onset dHMN II caused
by c. 404C> G mutation in HSPB1 gene. Journal of the Peripheral Nervous
System 21(2): 111-113.
Ogata, K. and Volini, M. (1990). Mitochondrial rhodanese: membrane-bound and
complexed activity. Journal of Biological Chemistry 265(14): 8087-8093.
Østergaard, H., Tachibana, C. and Winther, J. R. (2004). Monitoring disulfide bond
formation in the eukaryotic cytosol. Journal of Cell Biology 166(3): 337-345.
Osuntokun, B., Adeuja, A., Schoenberg, B., Bademosi, O., Nottidge, V., Olumide, A.,
Lge, O., Yaria, F. and Bolis, C. (1987). Neurological disorders in Nigerian
Africans: a community‐based study. Acta Neurologica Scandinavica 75(1): 1321.
Outeiro, T. F., Klucken, J., Strathearn, K. E., Liu, F., Nguyen, P., Rochet, J.-C., Hyman,
B. T. and McLean, P. J. (2006). Small heat shock proteins protect against αsynuclein-induced toxicity and aggregation. Biochemical and Biophysical
Research Communications 351(3): 631-638.
P Drew, A., P Blair, I. and A Nicholson, G. (2011). Molecular genetics and mechanisms
of disease in distal hereditary motor neuropathies: insights directing future
genetic studies. Current Molecular Medicine 11(8): 650-665.
Pace, C. N., Shirley, B. A., McNutt, M. and Gajiwala, K. (1996). Forces contributing to
the conformational stability of proteins. The Federation of American Societies
for Experimental Biology Journal 10(1): 75-83.
Pace, C. N., Vajdos, F., Fee, L., Grimsley, G. and Gray, T. (1995). How to measure and
predict the molar absorption coefficient of a protein. Protein Science 4(11):
2411-2423.
Pan, L., Zhang, P., Hu, F., Yan, R., He, M., Li, W., Xu, J. and Xu, K., 2019. Hypotonic
stress induces fast, reversible degradation of the vimentin cytoskeleton via
intracellular calcium release. Advanced Science, 6(18), p.1900865.
Pandey, P., Farber, R., Nakazawa, A., Kumar, S., Bharti, A., Nalin, C., Weichselbaum,
R., Kufe, D. and Kharbanda, S. (2000). Hsp27 functions as a negative regulator
227

References

of cytochrome c-dependent activation of procaspase-3. Oncogene 19(16): 19751981.
Parcellier, A., Gurbuxani, S., Schmitt, E., Solary, E. and Garrido, C. (2003a). Heat
shock proteins, cellular chaperones that modulate mitochondrial cell death
pathways. Biochemical and Biophysical Research Communications 304(3): 505512.
Parcellier, A., Schmitt, E., Gurbuxani, S., Seigneurin-Berny, D., Pance, A., Chantôme,
A., Plenchette, S., Khochbin, S., Solary, E. and Garrido, C. (2003b). Hsp27 is a
ubiquitin-binding protein involved in I-κBα proteasomal degradation. Molecular
and Cellular Biology 23(16): 5790-5802.
Pareyson, D. and Marchesi, C. (2009). Diagnosis, natural history, and management of
Charcot–Marie–Tooth disease. The Lancet Neurology 8(7): 654-667.
Park, Y. M., Han, M. Y., Blackburn, R. V. and Lee, Y. J. (1998). Overexpression of
HSP25 reduces the level of TNFα‐induced oxidative DNA damage biomarker,
8‐hydroxy‐2′‐deoxyguanosine, in L929 cells. Journal of Cellular Physiology
174(1): 27-34.
Pasta, S. Y., Raman, B., Ramakrishna, T. and Rao, C. M. (2004). The IXI/V motif in the
C-terminal extension of alpha-crystallins: alternative interactions and oligomeric
assemblies. Molecular Vision 10: 655-662.
Pasupuleti, N., Gangadhariah, M., Padmanabha, S., Santhoshkumar, P. and Nagaraj, R.
H. (2010). The role of the cysteine residue in the chaperone and anti‐apoptotic
functions of human Hsp27. Journal of Cellular Biochemistry 110(2): 408-419.
Paul, C. and Arrigo, A.-P. (2000). Comparison of the protective activities generated by
two survival proteins: Bcl-2 and Hsp27 in L929 murine fibroblasts exposed to
menadione or staurosporine. Experimental Gerontology 35(6-7): 757-766.
Pedrola, L., Espert, A., Wu, X., Claramunt, R., Shy, M. E. and Palau, F. (2005).
GDAP1, the protein causing Charcot–Marie–Tooth disease type 4A, is
expressed in neurons and is associated with mitochondria. Human Molecular
Genetics 14(8): 1087-1094.
Peeters, K., Litvinenko, I., Asselbergh, B., Almeida-Souza, L., Chamova, T., Geuens,
T., Ydens, E., Zimoń, M., Irobi, J. and De Vriendt, E. (2013). Molecular defects
in the motor adaptor BICD2 cause proximal spinal muscular atrophy with
autosomal-dominant inheritance. The American Journal of Human Genetics
92(6): 955-964.
Peng, J. and Xu, J. (2011). RaptorX: exploiting structure information for protein
alignment by statistical inference. Proteins: Structure, Function, and
Bioinformatics 79(S10): 161-171.
Peris, L., Thery, M., Fauré, J., Saoudi, Y., Lafanechère, L., Chilton, J. K., GordonWeeks, P., Galjart, N., Bornens, M. and Wordeman, L. (2006). Tubulin
tyrosination is a major factor affecting the recruitment of CAP-Gly proteins at
microtubule plus ends. The Journal of Cell Biology 174(6): 839-849.
Perlson, E., Maday, S., Fu, M.-m., Moughamian, A. J. and Holzbaur, E. L. (2010).
Retrograde axonal transport: pathways to cell death? Trends in Neurosciences
33(7): 335-344.
Pernas, L. and Scorrano, L. (2016). Mito-morphosis: mitochondrial fusion, fission, and
cristae remodeling as key mediators of cellular function. Annual Review of
Physiology 78: 505-531.
228

References

Perng, M. D., Cairns, L., van den IJssel, P., Prescott, A., Hutcheson, A. M. and Quinlan,
R. A. (1999). Intermediate filament interactions can be altered by Hsp27 and
alphaB-crystallin. Journal of Cell Science 112(13): 2099-2112.
Peschek, J., Braun, N., Franzmann, T. M., Georgalis, Y., Haslbeck, M., Weinkauf, S.
and Buchner, J. (2009). The eye lens chaperone alpha-crystallin forms defined
globular assemblies. Proceedings of the National Academy of Sciences 106(32):
13272-13277.
Peschek, J., Braun, N., Rohrberg, J., Back, K. C., Kriehuber, T., Kastenmuller, A.,
Weinkauf, S. and Buchner, J. (2013). Regulated structural transitions unleash the
chaperone activity of alphaB-crystallin. Proceedings of the National Academy of
Sciences 110(40): E3780-3789.
Peters Jr, T. (1995). All about albumin: biochemistry, genetics, and medical
applications. Baltimore, Md., Academic Press.
Phadke, R., Rossor, A., Benoy, V., Kalmar, B., King, R., Greensmith, L., Bosch, L.,
Reilly, M. and Houlden, H. (2015). Neuropathological findings from a human
post mortem case of distal hereditary motor neuropathy (dHMN) due to p.
Ser135Phe HSPB1 mutation and transgenic mice with mutant or wild-type
HSP27 overexpression. Neuromuscular Disorders 25: S283.
Pichon, S., Bryckaert, M. and Berrou, E. (2004). Control of actin dynamics by p38
MAP kinase–Hsp27 distribution in the lamellipodium of smooth muscle cells.
Journal of Cell Science 117(12): 2569-2577.
Pitceathly, R. D., Murphy, S. M., Cottenie, E., Chalasani, A., Sweeney, M. G.,
Woodward, C., Mudanohwo, E. E., Hargreaves, I., Heales, S. and Land, J.
(2012). Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth
disease. Neurology 79(11): 1145-1154.
Pocernich, C. B. and Butterfield, D. A. (2012). Elevation of glutathione as a therapeutic
strategy in Alzheimer disease. Biochimica et Biophysica Acta: Molecular Basis
of Disease 1822(5): 625-630.
Podrez, E. A., Febbraio, M., Sheibani, N., Schmitt, D., Silverstein, R. L., Hajjar, D. P.,
Cohen, P. A., Frazier, W. A., Hoff, H. F. and Hazen, S. L. (2000). Macrophage
scavenger receptor CD36 is the major receptor for LDL modified by monocytegenerated reactive nitrogen species. The Journal of Clinical Investigation
105(8): 1095-1108.
Pohl, C. and Dikic, I. (2019). Cellular quality control by the ubiquitin-proteasome
system and autophagy. Science 366(6467): 818-822.
Porollo, A. and Meller, J. (2007). Versatile annotation and publication quality
visualization of protein complexes using POLYVIEW-3D. BioMed Central
Bioinformatics 8(1): 316.
Préville, X., Salvemini, F., Giraud, S., Chaufour, S., Paul, C., Stepien, G., Ursini, M. V.
and Arrigo, A. P. (1999). Mammalian small stress proteins protect against
oxidative stress through their ability to increase glucose-6-phosphate
dehydrogenase activity and by maintaining optimal cellular detoxifying
machinery. Experimental Cell Research 247(1): 61-78.
Privalov, P. L. (1990). Cold denaturation of protein. Critical Reviews in Biochemistry
and Molecular Biology 25(4): 281-306.
Puls, I., Jonnakuty, C., LaMonte, B. H., Holzbaur, E. L., Tokito, M., Mann, E., Floeter,
M. K., Bidus, K., Drayna, D. and Oh, S. J. (2003). Mutant dynactin in motor
229

References

neuron disease. Nature Genetics 33(4): 455-456.
Puls, I., Oh, S.J., Sumner, C.J., Wallace, K.E., Floeter, M.K., Mann, E.A., Kennedy,
W.R., Wendelschafer‐Crabb, G., Vortmeyer, A., Powers, R. and Finnegan, K.,
(2005). Distal spinal and bulbar muscular atrophy caused by dynactin mutation.
Annals of Neurology: Official Journal of the American Neurological
Association and the Child Neurology Society, 57(5), pp.687-694.
Radhakrishnan, K., El‐Mangoush, M. and Gerryo, S. (1987). Descriptive epidemiology
of selected neuromuscular disorders in Benghazi, Libya. Acta Neurologica
Scandinavica 75(2): 95-100.
Raeymaekers, P., Timmerman, V., Nelis, E., De Jonghe, P., Hoogenduk, J., Baas, F.,
Barker, D., Martin, J., De Visser, M. and Bolhuis, P. (1991). Duplication in
chromosome 17p11. 2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a).
Neuromuscular Disorders 1(2): 93-97.
Rajagopal, P., Liu, Y., Shi, L., Clouser, A. F. and Klevit, R. E. (2015). Structure of the
α-crystallin domain from the redox-sensitive chaperone, HSPB1. Journal of
Biomolecular NMR 63(2): 223-228.
Ramchandren, S. (2017). Charcot-Marie-Tooth disease and other genetic
polyneuropathies. Continuum: Lifelong Learning in Neurology 23(5): 13601377.
Ramdharry, G. M., Pollard, A. J., Grant, R., Dewar, E. L., Laurá, M., Moore, S. A.,
Hallsworth, K., Ploetz, T., Trenell, M. I. and Reilly, M. M. (2017). A study of
physical activity comparing people with Charcot-Marie-Tooth disease to normal
control subjects. Disability and Rehabilitation 39(17): 1753-1758.
Ramdharry, G., Singh, D., Gray, J., Kozyra, D., Skorupinska, M., Reilly, M. M. and
Laurá, M. (2021). A prospective study on surgical management of foot
deformities in Charcot Marie Tooth disease. Journal of the Peripheral Nervous
System.
Rauch, J. N., Tse, E., Freilich, R., Mok, S.-A., Makley, L. N., Southworth, D. R. and
Gestwicki, J. E. (2017). BAG3 Is a Modular, Scaffolding Protein that physically
Links Heat Shock Protein 70 (Hsp70) to the Small Heat Shock Proteins. Journal
of Molecular Biology 429(1): 128-141.
Raudvere, U., Kolberg, L., Kuzmin, I., Arak, T., Adler, P., Peterson, H. and Vilo, J.
(2019). g: Profiler: a web server for functional enrichment analysis and
conversions of gene lists (2019 update). Nucleic Acids Research 47(W1):
W191–W198.
Rebelo, A. P., Saade, D., Pereira, C. V., Farooq, A., Huff, T. C., Abreu, L., Moraes, C.
T., Mnatsakanova, D., Mathews, K. and Yang, H. (2018). SCO2 mutations cause
early-onset axonal Charcot-Marie-Tooth disease associated with cellular copper
deficiency. Brain 141(3): 662-672.
Reddy, G. B., Kumar, P. A. and Kumar, M. S. (2006). Chaperone‐like activity and
hydrophobicity of α‐crystallin. International Union of Biochemistry and
Molecular Biology Life 58(11): 632-641.
Reilly, M. M. and Shy, M. E. (2009). Diagnosis and new treatments in genetic
neuropathies. Journal of Neurology, Neurosurgery and Psychiatry 80(12): 13041314.
Reis, L. M., Tyler, R. C., Muheisen, S., Raggio, V., Salviati, L., Han, D. P., Costakos,
D., Yonath, H., Hall, S. and Power, P. (2013). Whole exome sequencing in
230

References

dominant cataract identifies a new causative factor, CRYBA2, and a variety of
novel alleles in known genes. Human Genetics 132(7): 761-770.
Rekas, A., Adda, C. G., Aquilina, J. A., Barnham, K. J., Sunde, M., Galatis, D.,
Williamson, N. A., Masters, C. L., Anders, R. F., Robinson, C. V., Cappai, R.
and Carver, J. A. (2004). Interaction of the molecular chaperone αB-crystallin
with α-synuclein: Effects on amyloid fibril formation and chaperone activity.
Journal of Molecular Biology 340(5): 1167-1183.
Ribeiro, M., Rosenstock, T. R., Cunha-Oliveira, T., Ferreira, I. L., Oliveira, C. R. and
Rego, A. C. (2012). Glutathione redox cycle dysregulation in Huntington’s
disease knock-in striatal cells. Free Radical Biology and Medicine 53(10): 18571867.
Ribiere, C., Bernardin, M., Sacconi, S., Delmont, E., Fournier-Mehouas, M., Rauscent,
H., Benchortane, M., Staccini, P., Lantéri-Minet, M. and Desnuelle, C. (2012).
Pain assessment in Charcot-Marie-Tooth (CMT) disease. Annals of Physical and
Rehabilitation Medicine 55(3): 160-173.
Richter, L., Flodman, P., von-Bischhoffshausen, F. B., Burch, D., Brown, S., Nguyen,
L., Turner, J., Spence, M. A. and Bateman, J. B. (2008). Clinical variability of
autosomal dominant cataract, microcornea and corneal opacity and novel
mutation in the alphaA-crystallin gene (CRYAA). American Journal of Medical
Genetics 146(7): 833-842.
Rietsch, A. and Beckwith, J. (1998). The genetics of disulfide bond metabolism. Annual
Review of Genetics 32(1): 163-184.
Rinaldi, C., Grunseich, C., Sevrioukova, I. F., Schindler, A., Horkayne-Szakaly, I.,
Lamperti, C., Landouré, G., Kennerson, M. L., Burnett, B. G. and Bönnemann,
C. (2012). Cowchock syndrome is associated with a mutation in apoptosisinducing factor. The American Journal of Human Genetics 91(6): 1095-1102.
Rocchi, P., Beraldi, E., Ettinger, S., Fazli, L., Vessella, R. L., Nelson, C. and Gleave, M.
(2005). Increased Hsp27 after androgen ablation facilitates androgenindependent progression in prostate cancer via signal transducers and activators
of transcription 3–mediated suppression of apoptosis. Cancer Research 65(23):
11083-11093.
Rogalla, T., Ehrnsperger, M., Preville, X., Kotlyarov, A., Lutsch, G., Ducasse, C., Paul,
C., Wieske, M., Arrigo, A. P. and Buchner, J. (1999). Regulation of Hsp27
oligomerization, chaperone function, and protective activity against oxidative
stress/tumor necrosis factor α by phosphorylation. Journal of Biological
Chemistry 274(27): 18947-18956.
Rogers, M. and Strittmatter, P. (1975). The interaction of NADH-cytochrome b5
reductase and cytochrome b5 bound to egg lecithin liposomes. Journal of
Biological Chemistry 250(14): 5713-5718.
Ron, D. and Walter, P. (2007). Signal integration in the endoplasmic reticulum unfolded
protein response. Nature Reviews Molecular Cell Biology 8(7): 519.
Rosales, J. L., Sarker, K., Ho, N., Broniewska, M., Wong, P., Cheng, M., van der
Hoorn, F. A. and Lee, K. Y. (2007). ODF1 phosphorylation by Cdk5/p35
enhances ODF1-OIP1 interaction. Cellular Physiology and Biochemistry 20(5):
311-318.
Rossier, M. F. (2006). T channels and steroid biosynthesis: in search of a link with
mitochondria. Cell Calcium 40(2): 155-164.
231

References

Rossor, A. M., Davidson, G. L., Blake, J., Polke, J. M., Murphy, S. M., Houlden, H.,
Innes, A., Kalmar, B., Greensmith, L. and Reilly, M. M. (2012). A novel p.
Glu175X premature stop mutation in the C‐terminal end of HSP27 is a cause of
CMT2. Journal of the Peripheral Nervous System 17(2): 201-205.
Saad, S., Cereghetti, G., Feng, Y., Picotti, P., Peter, M. and Dechant, R. (2017).
Reversible protein aggregation is a protective mechanism to ensure cell cycle
restart after stress. Nature Cell Biology 19(10): 1202-1213.
Sabourin, L. A., Seale, P., Wagner, J. and Rudnicki, M. A. (2000). Caspase 3 cleavage
of the Ste20-related kinase SLK releases and activates an apoptosis-inducing
kinase domain and an actin-disassembling region. Molecular and Cellular
Biology 20(2): 684-696.
Sacconi, S., Féasson, L., Antoine, J. C., Pécheux, C., Bernard, R., Cobo, A. M., Casarin,
A., Salviati, L., Desnuelle, C. and Urtizberea, A. (2012). A novel CRYAB
mutation resulting in multisystemic disease. Neuromuscular Disorders 22(1):
66-72.
Safka Brozkova, D., Deconinck, T., Beth Griffin, L., Ferbert, A., Haberlova, J.,
Mazanec, R., Lassuthova, P., Roth, C., Pilunthanakul, T. and Rautenstrauss, B.
(2015). Loss of function mutations in HARS cause a spectrum of inherited
peripheral neuropathies. Brain 138(8): 2161-2172.
Saha, S. and Das, K. P. (2007). Unfolding and refolding of bovine α-crystallin in urea
and its chaperone activity. The Protein Journal 26(5): 315-326.
Sahenk, Z., Chen, L. and Mendell, J. R. (1999). Effects of PMP22 duplication and
deletions on the axonal cytoskeleton. Annals of Neurology 45(1): 16-24.
Sakamoto, H., Mashima, T., Yamamoto, K. and Tsuruo, T. (2002). Modulation of heatshock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification.
Journal of Biological Chemistry 277(48): 45770-45775.
San Gil, R., Berg, T. and Ecroyd, H. (2017). Using bicistronic constructs to evaluate the
chaperone activities of heat shock proteins in cells. Scientific Reports 7(1): 1-12.
Sandoval, M. E. (1980). Studies on the relationship between Ca2+ efflux from
mitochondria and the release of amino acid neurotransmitters. Brain Research
181(2): 357-367.
Sas, K., Robotka, H., Toldi, J. and Vécsei, L. (2007). Mitochondria, metabolic
disturbances, oxidative stress and the kynurenine system, with focus on
neurodegenerative disorders. Journal of the Neurological Sciences 257(1-2):
221-239.
Saxton, W. M. and Hollenbeck, P. J. (2012). The axonal transport of mitochondria.
Journal of Cell Science 125(9): 2095-2104.
Scarlato, M., Viganò, F., Carrera, P., Previtali, S. C. and Bolino, A. (2015). A novel
heat shock protein 27 homozygous mutation: widening of the continuum
between MND/dHMN/CMT2. Journal of the Peripheral Nervous System 20(4):
419-421.
Schafer, F. Q. and Buettner, G. R. (2001). Redox environment of the cell as viewed
through the redox state of the glutathione disulfide/glutathione couple. Free
Radical Biology and Medicine 30(11): 1191-1212.
Scherer, S. S. (2006). Finding the causes of inherited neuropathies. Archives of
Neurology 63(6): 812-816.
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T.,
232

References

Preibisch, S., Rueden, C., Saalfeld, S. and Schmid, B. (2012). Fiji: an opensource platform for biological-image analysis. Nature Methods 9(7): 676.
Schmidt, T., Bartelt-Kirbach, B. and Golenhofen, N. (2012). Phosphorylationdependent subcellular localization of the small heat shock proteins
HspB1/Hsp25 and HspB5/αB-crystallin in cultured hippocampal neurons.
Histochemistry and Cell Biology 138(3): 407-418.
Schnelldorfer, T., Gansauge, S., Gansauge, F., Schlosser, S., Beger, H. G. and Nussler,
A. K. (2000). Glutathione depletion causes cell growth inhibition and enhanced
apoptosis in pancreatic cancer cells. Cancer: Interdisciplinary International
Journal of the American Cancer Society 89(7): 1440-1447.
Scholler, J. K. and Kanner, S. B. (1997). The human p167 gene encodes a unique
structural protein that contains centrosomin A homology and associates with a
multicomponent complex. DNA and Cell Biology 16(4): 515-531.
Schreij, A. M., Fon, E. A. and McPherson, P. S. (2016). Endocytic membrane
trafficking and neurodegenerative disease. Cellular and Molecular Life Sciences
73(8): 1529-1545.
Schwartz, N. U., Linzer, R. W., Truman, J. P., Gurevich, M., Hannun, Y. A., Senkal, C.
E. and Obeid, L. M. (2018). Decreased ceramide underlies mitochondrial
dysfunction in Charcot‐Marie‐Tooth 2F. The Federation of American Societies
for Experimental Biology Journal 32(3): 1716-1728.
Seetharaman, S. V., Winkler, D. D., Taylor, A. B., Cao, X., Whitson, L. J., Doucette, P.
A., Valentine, J. S., Schirf, V., Demeler, B. and Carroll, M. C. (2010). Disrupted
zinc-binding sites in structures of pathogenic SOD1 variants D124V and H80R.
Biochemistry 49(27): 5714-5725.
Segal, N. a. and Shapira, M. (2015). HSP 33 in eukaryotes–an evolutionary tale of a
chaperone adapted to photosynthetic organisms. The Plant Journal 82(5): 850860.
Shemesh, N., Jubran, J., Dror, S., Simonovsky, E., Basha, O., Argov, C., Hekselman, I.,
Abu-Qarn, M., Vinogradov, E. and Mauer, O. (2021). The landscape of
molecular chaperones across human tissues reveals a layered architecture of core
and variable chaperones. Nature Communications 12(1): 1-16.
Seidel, K., J., V., den Dunnen, W. F. A., Brunt, E. R., Meister, M., Boncoraglio, A.,
Zijlstra, M. P., Boddeke, H. W. G. M., Rüb, U., Kampinga, H. H. and Carra, S.
(2012). The HSPB8-BAG3 chaperone complex is upregulated in astrocytes in
the human brain affected by protein aggregation diseases. Neuropathology and
Applied Neurobiology 38: 39-53.
Seminotti, B., Leipnitz, G., Karunanidhi, A., Kochersperger, C., Roginskaya, V. Y.,
Basu, S., Wang, Y., Wipf, P., Van Houten, B. and Mohsen, A.-W. (2019).
Mitochondrial energetics is impaired in very long-chain acyl-CoA
dehydrogenase deficiency and can be rescued by treatment with mitochondriatargeted electron scavengers. Human Molecular Genetics 28(6): 928-941.
Senderek, J., Bergmann, C., Ramaekers, V. T., Nelis, E., Bernert, G., Makowski, A.,
Züchner, S., De Jonghe, P., Rudnik‐Schöneborn, S. and Zerres, K. (2003a).
Mutations in the ganglioside‐induced differentiation‐associated protein‐1
(GDAP1) gene in intermediate type autosomal recessive Charcot–Marie–Tooth
neuropathy. Brain 126(3): 642-649.
Senderek, J., Bergmann, C., Weber, S., Ketelsen, U.-P., Schorle, H., Rudnik233

References

Schöneborn, S., Büttner, R., Buchheim, E. and Zerres, K. (2003b). Mutation of
the SBF2 gene, encoding a novel member of the myotubularin family, in
Charcot–Marie–Tooth neuropathy type 4B2/11p15. Human Molecular Genetics
12(3): 349-356.
Seo, S., Baye, L. M., Schulz, N. P., Beck, J. S., Zhang, Q., Slusarski, D. C. and
Sheffield, V. C. (2010). BBS6, BBS10, and BBS12 form a complex with
CCT/TRiC family chaperonins and mediate BBSome assembly. Proceedings of
the National Academy of Sciences 107(4): 1488-1493.
Sevilla, T., Lupo, V., Martínez-Rubio, D., Sancho, P., Sivera, R., Chumillas, M. J.,
García-Romero, M., Pascual-Pascual, S. I., Muelas, N. and Dopazo, J. (2015).
Mutations in the MORC2 gene cause axonal Charcot–Marie–Tooth disease.
Brain 139(1): 62-72.
Sharma, K. K., Kaur, H. and Kester, K. (1997). Functional elements in molecular
chaperone α-crystallin: identification of binding sites in αB-crystallin.
Biochemical and Biophysical Research Communications 239(1): 217-222.
Shashidharamurthy, R., Koteiche, H. A., Dong, J. and Mchaourab, H. S. (2005).
Mechanism of chaperone function in small heat shock proteins: dissociation of
the Hsp27 oligomer is required for recognition and binding of destabilized T4
lysozyme. Journal of Biological Chemistry 280(7): 5281-5289.
Shemetov, A. A., Seit-Nebi, A. S., Bukach, O. V. and Gusev, N. B. (2008).
Phosphorylation by cyclic AMP-dependent protein kinase inhibits chaperonelike activity of human HSP22 in vitro. Biochemistry 73(2): 200-208.
Shendelman, S., Jonason, A., Martinat, C., Leete, T. and Abeliovich, A. (2004). DJ-1 is
a redox-dependent molecular chaperone that inhibits α-synuclein aggregate
formation. Proceedings of the National Academy of Sciences 2(11): e362.
Sheng, Z.-H. and Cai, Q. (2012). Mitochondrial transport in neurons: impact on
synaptic homeostasis and neurodegeneration. Nature Reviews Neuroscience
13(2): 77.
Shepherd, D. L., Croston, T. L., Lewis, S. E., Nichols, C. E., Thapa, D., Jagannathan, R.
and Hollander, J. M. (2013). Heat Shock Protein 27 (hsp27) Translocation to the
Mitochondria is Associated with Protection Against Diabetic Cardiomyopathy.
The Federation of American Societies for Experimental Biology Journal 27(1):
1209.1203-1209.1203.
Shi, G.-X., Jin, L. and Andres, D. A. (2008). Pituitary adenylate cyclase-activating
polypeptide 38-mediated Rin activation requires Src and contributes to the
regulation of HSP27 signaling during neuronal differentiation. Molecular and
Cellular Biology 28(16): 4940-4951.
Shin, E.K., Lee, D. and Jeung, E.B., 2014. The acyl-CoA dehydrogenase, very long
chain (ACADVL) expression under hypoxic condition in human placental cell
line (BeWo). Reproduction Abstracts, 1.
Shroff, N. P., Cherian-Shaw, M., Bera, S. and Abraham, E. C. (2000). Mutation of
R116C results in highly oligomerized alphaA-crystallin with modified structure
and defective chaperone-like function. Biochemistry 39: 1420-1426.
Shy, M., Rebelo, A. P., Feely, S. M., Abreu, L. A., Tao, F., Swenson, A., Bacon, C. and
Zuchner, S. (2018). Mutations in BAG3 cause adult-onset Charcot-Marie-Tooth
disease. Journal of Neurology Neurosurgery and Psychiatry 89(3): 313-315.
Singh, B. N., Rao, K. S. and Rao, C. M. (2010). Ubiquitin–proteasome-mediated
234

References

degradation and synthesis of MyoD is modulated by αB-crystallin, a small heat
shock protein, during muscle differentiation. Biochimica et Biophysica Acta Molecular Cell Research 1803(2): 288-299.
Singh, M., Brooks, G. C. and Srere, P. A. (1970). Subunit structure and chemical
characteristics of pig heart citrate synthase. Journal of Biological Chemistry
245(18): 4636-4640.
Skre, H. (1974). Genetic and clinical aspects of Charcot-Marie-Tooth's disease. Clinical
Genetics 6(2): 98-118.
Smith, J. B., Sun, Y., Smith, D. L. and Green, B. (1992). Identification of the
posttranslational modifications of bovine lens alphaB-crystallins by mass
spectrometry. Protein Science 1(5): 601-608.
Solla, P., Vannelli, A., Bolino, A., Marrosu, G., Coviello, S., Murru, M. R., Tranquilli,
S., Corongiu, D., Benedetti, S. and Marrosu, M. G. (2010). Heat shock protein
27 R127W mutation: evidence of a continuum between axonal Charcot–Marie–
Tooth and distal hereditary motor neuropathy. Journal of Neurology
Neurosurgery and Psychiatry 81(9): 958-962.
Song, J. l. and Wang, C. c. (1995). Chaperone‐like activity of protein disulfide‐
isomerase in the refolding of rhodanese. European Journal of Biochemistry
231(2): 312-316.
Soong, B.-W., Huang, Y.-H., Tsai, P.-C., Huang, C.-C., Pan, H.-C., Lu, Y.-C., Chien,
H.-J., Liu, T.-T., Chang, M.-H. and Lin, K.-P. (2013). Exome sequencing
identifies GNB4 mutations as a cause of dominant intermediate Charcot-MarieTooth disease. The American Journal of Human Genetics 92(3): 422-430.
Sreerama, N. and Woody, R. W. (2000). Estimation of protein secondary structure from
circular dichroism spectra: comparison of CONTIN, SELCON, and CDSSTR
methods with an expanded reference set. Analytical Biochemistry 287(2): 252260.
Srinivasan, S., Stevens, M. and Wiley, J. W. (2000). Diabetic peripheral neuropathy:
evidence for apoptosis and associated mitochondrial dysfunction. Diabetes
49(11): 1932-1938.
Srivastava, A. K., Renusch, S. R., Naiman, N. E., Gu, S., Sneh, A., Arnold, W. D.,
Sahenk, Z. and Kolb, S. J. (2012). Mutant HhpB1 overexpression in neurons is
sufficient to cause age-related motor neuronopathy in mice. Neurobiology of
Disease 47(2): 163-173.
Stadtman, E. R. (1992). Protein oxidation and aging. Science 257(5074): 1220-1224.
Stancanelli, C., Fabrizi, G. M., Ferrarini, M., Cavallaro, T., Taioli, F., Di Leo, R.,
Russo, M., Gentile, L., Toscano, A. and Vita, G. (2015). Charcot–Marie–Tooth
2F: phenotypic presentation of the Arg136Leu HSP27 mutation in a
multigenerational family. Neurological Sciences 36(6): 1003-1006.
Stege, G., Li, G., Li, L., Kampinga, H. and Konings, A. (1994). On the role of hsp72 in
heat-induced intranuclear protein aggregation. International Journal of
Hyperthermia 10(5): 659-674.
Stendel, C., Roos, A., Deconinck, T., Pereira, J., Castagner, F., Niemann, A., Kirschner,
J., Korinthenberg, R., Ketelsen, U.-P. and Battaloglu, E. (2007). Peripheral
nerve demyelination caused by a mutant Rho GTPase guanine nucleotide
exchange factor, frabin/FGD4. The American Journal of Human Genetics 81(1):
158-164.
235

References

Stothard, P. (2000). The sequence manipulation suite: JavaScript programs for
analyzing and formatting protein and DNA sequences. Biotechniques 28(6):
1102, 1104.
Street, V., Bennett, C., Goldy, J., Shirk, A., Kleopa, K., Tempel, B., Lipe, H., Scherer,
S., Bird, T. and Chance, P. (2003). Mutation of a putative protein degradation
gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 60(1): 2226.
Stroud, D. A., Surgenor, E. E., Formosa, L. E., Reljic, B., Frazier, A. E., Dibley, M. G.,
Osellame, L. D., Stait, T., Beilharz, T. H. and Thorburn, D. R. (2016).
Accessory subunits are integral for assembly and function of human
mitochondrial complex I. Nature 538(7623): 123-126.
Sun, X., Fontaine, J.-M., Rest, J. S., Shelden, E. A., Welsh, M. J. and Benndorf, R.
(2004). Interaction of human HSP22 (HSPB8) with other small heat shock
proteins. Journal of Biological Chemistry 279(4): 2394-2402.
Supek, F., Bošnjak, M., Škunca, N. and Šmuc, T. (2011). REVIGO summarizes and
visualizes long lists of gene ontology terms. Public Library of Science One 6(7):
e21800.
Suter, U. and Scherer, S. S. (2003). Disease mechanisms in inherited neuropathies.
Nature Reviews Neuroscience 4(9): 714-726.
Sweeney, P., Park, H., Baumann, M., Dunlop, J., Frydman, J., Kopito, R., McCampbell,
A., Leblanc, G., Venkateswaran, A. and Nurmi, A. (2017). Protein misfolding in
neurodegenerative diseases: implications and strategies. Translational
Neurodegeneration 6(1): 1-13.
Szabo, A., Langer, T., Schröder, H., Flanagan, J., Bukau, B. and Hartl, F. U. (1994).
The ATP hydrolysis-dependent reaction cycle of the Escherichia coli Hsp70
system DnaK, DnaJ, and GrpE. Proceedings of the National Academy of
Sciences 91(22): 10345-10349.
Tamiya, G., Makino, S., Hayashi, M., Abe, A., Numakura, C., Ueki, M., Tanaka, A.,
Ito, C., Toshimori, K. and Ogawa, N. (2014). A mutation of COX6A1 causes a
recessive axonal or mixed form of Charcot-Marie-Tooth disease. The American
Journal of Human Genetics 95(3): 294-300.
Tan, C. Y., Ban, H., Kim, Y.-H. and Lee, S.-K. (2009). The heat shock protein 27
(Hsp27) operates predominantly by blocking the mitochondrialindependent/extrinsic pathway of cellular apoptosis. Molecules and Cells 27(5):
533-538.
Tanabe, H., Higuchi, Y., Yuan, J. H., Hashiguchi, A., Yoshimura, A., Ishihara, S.,
Nozuma, S., Okamoto, Y., Matsuura, E. and Ishiura, H. (2018). Clinical and
genetic features of Charcot‐Marie‐Tooth disease 2F and hereditary motor
neuropathy 2B in Japan. Journal of the Peripheral Nervous System 23(1): 40-48.
Tang, B., Liu, X., Zhao, G., Luo, W., Xia, K., Pan, Q., Cai, F., Hu, Z., Zhang, C. and
Chen, B. (2005a). Mutation analysis of the small heat shock protein 27 gene in
chinese patients with Charcot-Marie-Tooth disease. Archives of Neurology
62(8): 1201-1207.
Tang, B., Zhao, G., Luo, W., Xia, K., Cai, F., Pan, Q., Zhang, R., Zhang, F., Jiang, H.,
Long, Z. and Dai, H. (2005b). Small heat-shock protein 22 mutated in autosomal
dominant Charcot-Marie-Tooth disease type 2L. Human Genetics 116(3): 222224.
236

References

Tang, B. S., Luo, W., Xia, K., Xiao, J. F., Jiang, H., Shen, L., Tang, J. G., Zhao, G. H.,
Cai, F. and Pan, Q. (2004). A new locus for autosomal dominant Charcot-MarieTooth disease type 2 (CMT2L) maps to chromosome 12q24. Human Genetics
114(6): 527-533.
Tang, D., Kang, R., Livesey, K. M., Cheh, C.-W., Farkas, A., Loughran, P., Hoppe, G.,
Bianchi, M. E., Tracey, K. J. and Zeh, H. J. (2010). Endogenous HMGB1
regulates autophagy. The Journal of Cell Biology 190(5): 881-892.
Tang, D., Kang, R., Livesey, K. M., Kroemer, G., Billiar, T. R., Van Houten, B., Zeh,
H. J. and Lotze, M. T. (2011). High-mobility group box 1 is essential for
mitochondrial quality control. Cell Metabolism 13(6): 701-711.
Tetin, S. Y., Prendergast, F. G. and Venyaminov, S. Y. (2003). Accuracy of protein
secondary structure determination from circular dichroism spectra based on
immunoglobulin examples. Analytical biochemistry 321(2): 183-187.
Tétreault, M., Gonzalez, M., Dicaire, M.-J., Allard, P., Gehring, K., Leblanc, D.,
Leclerc, N., Schondorf, R., Mathieu, J. and Zuchner, S. (2015). Adult-onset
painful axonal polyneuropathy caused by a dominant NAGLU mutation. Brain
138(6): 1477-1483.
Thériault, J. R., Lambert, H., Chávez-Zobel, A. T., Charest, G., Lavigne, P. and Landry,
J. (2004). Essential role of the NH2-terminal WD/EPF motif in the
phosphorylation-activated protective function of mammalian Hsp27. Journal of
Biological Chemistry 279(22): 23463-23471.
Thulasiraman, V., Yang, C. F. and Frydman, J. (1999). In vivo newly translated
polypeptides are sequestered in a protected folding environment. European
Molecular Biology Organization Journal 18(1): 85-95.
Tooth, H. (1886). The peroneal type of progressive muscular atrophy [Thesis]. Doctor
of Medicine, University of Cambridge.
Towbin, H., Staehelin, T. and Gordon, J. (1979). Electrophoretic transfer of proteins
from polyacrylamide gels to nitrocellulose sheets: procedure and some
applications. Proceedings of the National Academy of Sciences 76(9): 43504354.
Treweek, T. M., Meehan, S., Ecroyd, H. and Carver, J. A. (2015). Small heat-shock
proteins: important players in regulating cellular proteostasis. Cellular and
Molecular Life Sciences 72(3): 429-451.
Treweek, T. M., Rekas, A., Lindner, R. A., Walker, M. J., Aquilina, J. A., Robinson, C.
V., Horwitz, J., Der Perng, M., Quinlan, R. A. and Carver, J. A. (2005). R120G
αB‐crystallin promotes the unfolding of reduced α‐lactalbumin and is inherently
unstable. Federation of European Biochemical Societies Journal 272(3): 711724.
Tsai, P.-C., Soong, B.-W., Mademan, I., Huang, Y.-H., Liu, C.-R., Hsiao, C.-T., Wu,
H.-T., Liu, T.-T., Liu, Y.-T. and Tseng, Y.-T. (2017). A recurrent WARS
mutation is a novel cause of autosomal dominant distal hereditary motor
neuropathy. Brain 140(5): 1252-1266.
Tu, B. P. and Weissman, J. S. (2004). Oxidative protein folding in eukaryotes:
mechanisms and consequences. The Journal of Cell Biology 164(3): 341-346.
Tzima, E., Reader, J., Irani-Tehrani, M., Ewalt, K., Schwartz, M. and Schimmel, P.
(2003). Biologically active fragment of a human tRNA synthetase inhibits fluid
shear stress-activated responses of endothelial cells. Proceedings of the National
237

References

Academy of Sciences 100(25): 14903-14907.
Uehara, T., Nakamura, T., Yao, D., Shi, Z.-Q., Gu, Z., Ma, Y., Masliah, E., Nomura, Y.
and Lipton, S. A. (2006). S-nitrosylated protein-disulphide isomerase links
protein misfolding to neurodegeneration. Nature 441(7092): 513.
UniProt-Consortium (2019). UniProt: a worldwide hub of protein knowledge. Nucleic
Acids Research 47(D1): D506-D515.
V Sudnitsyna, M., V Mymrikov, E., S Seit-Nebi, A. and B Gusev, N. (2012). The role
of intrinsically disordered regions in the structure and functioning of small heat
shock proteins. Current Protein and Peptide Science 13(1): 76-85.
Vaeth, S., Vaeth, M., Andersen, H., Christensen, R. and Jensen, U. B. (2017). CharcotMarie-Tooth disease in Denmark: a nationwide register-based study of
mortality, prevalence and incidence. British Medical Journal 7(11): e018048.
Valente, A. J., Maddalena, L. A., Robb, E. L., Moradi, F. and Stuart, J. A. (2017). A
simple ImageJ macro tool for analyzing mitochondrial network morphology in
mammalian cell culture. Acta Histochemica 119(3): 315-326.
Valentijn, L. J., Baas, F., Wolterman, R. A., Hoogendijk, J. E., van den Bosch, N. H.,
Zorn, I., Gabreëls-Festen, A. A., de Visser, M. and Bolhuis, P. A. (1992).
Identical point mutations of PMP–22 in Trembler–J mouse and Charcot–Marie–
Tooth disease type 1A. Nature Genetics 2(4): 288.
Vallat, J.-M., Mathis, S. and Funalot, B. (2013). The various Charcot–Marie–Tooth
diseases. Current Opinion in Neurology 26(5): 473-480.
van Montfort, R. L., Basha, E., Friedrich, K. L., Slingsby, C. and Vierling, E. (2001).
Crystal structure and assembly of a eukaryotic small heat shock protein. Nature
Structural and Molecular Biology 8(12): 1025-1030.
Vasak, M., Nagayama, K., Wuethrich, K., Mertens, M. L. and Kaegi, J. H. (1979).
Creatine kinase. Nuclear magnetic resonance and fluorescence evidence for
interaction of adenosine 5'-diphosphate with aromatic residue (s). Biochemistry
18(23): 5050-5055.
Verhoeven, K., De Jonghe, P., Coen, K., Verpoorten, N., Auer-Grumbach, M., Kwon, J.
M., FitzPatrick, D., Schmedding, E., De Vriendt, E. and Jacobs, A. (2003).
Mutations in the small GTP-ase late endosomal protein RAB7 cause CharcotMarie-Tooth type 2B neuropathy. The American Journal of Human Genetics
72(3): 722-727.
Vicart, P., Caron, A., Guicheney, P., Li, Z., Prevost, M.-C., Faure, A., Chateau, D.,
Chapon, F., Tome, F., Dupret, J.-M., Paulin, D. and Fardeau, M. (1998). A
missense mutation in the alphaB-crystallin chaperone gene causes desminrelated myopathy. Nature Genetics 20(1): 92-95.
Voges, D., Zwickl, P. and Baumeister, W. (1999). The 26S proteasome: a molecular
machine designed for controlled proteolysis. Annual Review of Biochemistry
68(1): 1015-1068.
Voorter, C. E., de Haard-Hoekman, W. A., Roersma, E. S., Meyer, H. E., Bloemendal,
H. and de Jong, W. W. (1989). The in vivo phosphorylation sites of bovine
alphaB-crystallin. Federation of European Biochemical Societies Letters 259(1):
50-52.
Wagner, B. A., Buettner, G. R., Oberley, L. W., Darby, C. J. and Burns, C. P. (2000).
Myeloperoxidase is involved in H2O2-induced apoptosis of HL-60 human
leukemia cells. Journal of Biological Chemistry 275(29): 22461-22469.
238

References

Wagner, S., Flood, T. A., O'Reilly, P., Hume, K. and Sabourin, L. A. (2002).
Association of the Ste20-like Kinase (SLK) with the Microtubule: role in Rac1mediated regulation of actin dynamics during cell adhesion and spreading.
Journal of Biological Chemistry 277(40): 37685-37692.
Wali, A. (2010). FHIT Doubts are Clear Now. The Scientific World Journal 10: 11421151.
Wang, G., Klostergaard, J., Khodadadian, M., Wu, J., Wu, T.-W., Fung, K., Carper, S.
W. and Tomasovic, S. P. (1996). Murine cells transfected with human Hsp27
cDNA resist TNF-induced cytotoxicity. Journal of Immunotherapy with
Emphasis on Tumor Immunology 19(1): 9-20.
Wang, K. and Spector, A. (2000). α‐Crystallin prevents irreversible protein denaturation
and acts cooperatively with other heat‐shock proteins to renature the stabilized
partially denatured protein in an ATP‐dependent manner. European Journal of
Biochemistry 267(15): 4705-4712.
Wang, S., Li, W., Liu, S. and Xu, J. (2016). RaptorX-Property: a web server for protein
structure property prediction. Nucleic Acids Research 44(W1): W430-W435.
Warner, L. E., Mancias, P., Butler, I. J., McDonald, C. M., Keppen, L., Koob, K. G. and
Lupski, J. R. (1998). Mutations in the early growth response 2 (EGR2) gene are
associated with hereditary myelinopathies. Nature Genetics 18(4): 382.
Weber, K. and Osborn, M. (1969). The reliability of molecular weight determinations
by dodecyl sulfate-polyacrylamide gel electrophoresis. Journal of Biological
Chemistry 244(16): 4406-4412.
Webster, J. M., Darling, A. L., Uversky, V. N. and Blair, L. J. (2019). Small heat shock
proteins, big impact on protein aggregation in neurodegenerative disease.
Frontiers in Pharmacology 10.
Wedi, B., Straede, J., Wieland, B. and Kapp, A. (1999). Eosinophil apoptosis is
mediated by stimulators of cellular oxidative metabolisms and inhibited by
antioxidants: involvement of a thiol-sensitive redox regulation in eosinophil cell
death. Blood 94(7): 2365-2373.
Weedon, M. N., Hastings, R., Caswell, R., Xie, W., Paszkiewicz, K., Antoniadi, T.,
Williams, M., King, C., Greenhalgh, L. and Newbury-Ecob, R. (2011). Exome
sequencing identifies a DYNC1H1 mutation in a large pedigree with dominant
axonal Charcot-Marie-Tooth disease. The American Journal of Human Genetics
89(2): 308-312.
Weeks, S. D., Muranova, L. K., Heirbaut, M., Beelen, S., Strelkov, S. V. and Gusev, N.
B. (2018). Characterization of human small heat shock protein HSPB1 αcrystallin domain localized mutants associated with hereditary motor neuron
diseases. Scientific Reports 8(1): 688.
Weiduschat, N., Mao, X., Hupf, J., Armstrong, N., Kang, G., Lange, D., Mitsumoto, H.
and Shungu, D. (2014). Motor cortex glutathione deficit in ALS measured in
vivo with the J-editing technique. Neuroscience Letters 570: 102-107.
Wielen, M. and Van Gelder, J. H. (2021). Management of gait impairments in people
with Charcot-Marie-Tooth disease: A treatment algorithm. Management 500:
33.
Weissman, A. M. (2001). Ubiquitin and proteasomes: themes and variations on
ubiquitylation. Nature Reviews Molecular Cell Biology 2(3): 169.
Wettstein, G., Bellaye, P.-S., Kolb, M., Hammann, A., Crestani, B., Soler, P., Marchal239

References

Somme, J., Hazoume, A., Gauldie, J. and Gunther, A. (2013). Inhibition of
HSP27 blocks fibrosis development and EMT features by promoting Snail
degradation. The Federation of American Societies for Experimental Biology
Journal 27(4): 1549-1560.
Whitmore, L. and Wallace, B. (2004). DICHROWEB, an online server for protein
secondary structure analyses from circular dichroism spectroscopic data. Nucleic
Acids Research 32(suppl_2): W668-W673.
Whitmore, L. and Wallace, B. A. (2008). Protein secondary structure analyses from
circular dichroism spectroscopy: methods and reference databases. Biopolymers:
Original Research on Biomolecules 89(5): 392-400.
Willems, P. H., Rossignol, R., Dieteren, C. E., Murphy, M. P. and Koopman, W. J.
(2015). Redox homeostasis and mitochondrial dynamics. Cell Metabolism 22(2):
207-218.
Williams, K. L. and Mearow, K. M. (2011). Phosphorylation status of heat shock
protein 27 influences neurite growth in adult dorsal root ganglion sensory
neurons in vitro. Journal of Neuroscience Research 89(8): 1160-1172.
Williams, K. L., Rahimtula, M. and Mearow, K. M. (2005). Hsp27 and axonal growth
in adult sensory neurons in vitro. BioMed Central Neuroscience 6(1): 24.
Williams, K. L., Rahimtula, M. and Mearow, K. M. (2006). Heat shock protein 27 is
involved in neurite extension and branching of dorsal root ganglion neurons in
vitro. Journal of Neuroscience Research 84(4): 716-723.
Williamson, T. L. and Cleveland, D. W. (1999). Slowing of axonal transport is a very
early event in the toxicity of ALS–linked SOD1 mutants to motor neurons.
Nature Neuroscience 2(1): 50.
Wingfield, J. L., Lechtreck, K.-F. and Lorentzen, E. (2018). Trafficking of ciliary
membrane proteins by the intraflagellar transport/BBSome machinery. Essays in
Biochemistry 62(6): 753-763.
Wistow, G. (1985). Domain structure and evolution in α-crystallins and small heatshock proteins. Federation of European Biochemical Societies Letters 181(1): 16.
Wong, P. C., Pardo, C. A., Borchelt, D. R., Lee, M. K., Copeland, N. G., Jenkins, N. A.,
Sisodia, S. S., Cleveland, D. W. and Price, D. L. (1995). An adverse property of
a familial ALS-linked SOD1 mutation causes motor neuron disease
characterized by vacuolar degeneration of mitochondria. Neuron 14(6): 11051116.
Wu, J. T., Tu, M. C. and Zhung, P. (1996). Advanced glycation end product (AGE):
Characterization of the products from the reaction between D‐glucose and serum
albumin. Journal of Clinical Laboratory Analysis 10(1): 21-34.
Wyatt, A. R., Kumita, J. R., Mifsud, R. W., Gooden, C. A., Wilson, M. R. and Dobson,
C. M. (2014). Hypochlorite-induced structural modifications enhance the
chaperone activity of human α2-macroglobulin. Proceedings of the National
Academy of Sciences 111(20): E2081-E2090.
Xu, W.-y., Gu, M.-m., Sun, L.-h., Guo, W.-t., Zhu, H.-b., Ma, J.-f., Yuan, W.-t., Kuang,
Y., Ji, B.-j. and Wu, X.-l. (2012). A nonsense mutation in DHTKD1 causes
Charcot-Marie-Tooth disease type 2 in a large Chinese pedigree. The American
Journal of Human Genetics 91(6): 1088-1094.
Yan, L. J., Christians, E. S., Liu, L., Xiao, X., Sohal, R. S. and Benjamin, I. J. (2002).
240

References

Mouse heat shock transcription factor 1 deficiency alters cardiac redox
homeostasis and increases mitochondrial oxidative damage. The European
Molecular Biology Organization Journal 21(19): 5164-5172.
Yavarna, T., Al-Dewik, N., Al-Mureikhi, M., Ali, R., Al-Mesaifri, F., Mahmoud, L.,
Shahbeck, N., Lakhani, S., AlMulla, M. and Nawaz, Z. (2015). High diagnostic
yield of clinical exome sequencing in Middle Eastern patients with Mendelian
disorders. Human Genetics 134(9): 967-980.
Yerbury, J. J., Gower, D., Vanags, L., Roberts, K., Lee, J. A. and Ecroyd, H. (2013).
The small heat shock proteins αB-crystallin and Hsp27 suppress SOD1
aggregation in vitro. Cell Stress and Chaperones 18(2): 251-257.
Ylikallio, E., Johari, M., Konovalova, S., Moilanen, J. S., Kiuru-Enari, S., Auranen, M.,
Pajunen, L. and Tyynismaa, H. (2014). Targeted next-generation sequencing
reveals further genetic heterogeneity in axonal Charcot–Marie–Tooth
neuropathy and a mutation in HSPB1. European Journal of Human Genetics
22(4): 522-527.
Ylikallio, E., Konovalova, S., Dhungana, Y., Hilander, T., Junna, N., Partanen, J. V.,
Toppila, J. P., Auranen, M. and Tyynismaa, H. (2015). Truncated HSPB1 causes
axonal neuropathy and impairs tolerance to unfolded protein stress. Biochimica
et Biophysica Acta - Clinical 3: 233-242.
Ylikallio, E., Pöyhönen, R., Zimon, M., De Vriendt, E., Hilander, T., Paetau, A.,
Jordanova, A., Lönnqvist, T. and Tyynismaa, H. (2013). Deficiency of the E3
ubiquitin ligase TRIM2 in early-onset axonal neuropathy. Human Molecular
Genetics 22(15): 2975-2983.
Ylikallio, E., Woldegebriel, R., Tumiati, M., Isohanni, P., Ryan, M. M., Stark, Z.,
Walsh, M., Sawyer, S. L., Bell, K. M. and Oshlack, A. (2017). MCM3AP in
recessive Charcot-Marie-Tooth neuropathy and mild intellectual disability.
Brain 140(8): 2093-2103.
Yoshimura, A., Yuan, J.-H., Hashiguchi, A., Ando, M., Higuchi, Y., Nakamura, T.,
Okamoto, Y., Nakagawa, M. and Takashima, H. (2019). Genetic profile and
onset features of 1005 patients with Charcot-Marie-Tooth disease in Japan.
Journal of Neurology Neurosurgery and Psychiatry 90(2): 195-202.
Young, I. and Harper, P. (1980). Hereditary distal spinal muscular atrophy with vocal
cord paralysis. Journal of Neurology, Neurosurgery and Psychiatry 43(5): 413418.
Yu, C., Yu, L. and King, T. E. (1977). The existence of an ubiquinone binding protein
in the reconstitutively active cytochrome b-c1 complex. Biochemical and
Biophysical Research Communications 78(1): 259-265.
Zhai, J., Lin, H., Julien, J. P. and Schlaepfer, W. W. (2007). Disruption of neurofilament
network with aggregation of light neurofilament protein: a common pathway
leading to motor neuron degeneration due to Charcot-Marie-Tooth diseaselinked mutations in NFL and HspB1. Human Molecular Genetics 16(24): 31033116.
Zhao, C., Takita, J., Tanaka, Y., Setou, M., Nakagawa, T., Takeda, S., Yang, H. W.,
Terada, S., Nakata, T. and Takei, Y. (2001). Charcot-Marie-Tooth disease type
2A caused by mutation in a microtubule motor KIF1Bβ. Cell 105(5): 587-597.
Zhao, H., Race, V., Matthijs, G., De Jonghe, P., Robberecht, W., Lambrechts, D. and
Van Damme, P. (2014). Exome sequencing reveals HINT1 mutations as a cause
241

References

of distal hereditary motor neuropathy. European Journal of Human Genetics
22(6): 847.
Zhou, S., Shi, D., Liu, X., Yao, X., Da, L.T. and Liu, H., 2019. pH-induced misfolding
mechanism of prion protein: Insights from microsecond-accelerated molecular
dynamics simulations. ACS chemical neuroscience, 10(6), pp.2718-2729.
Zhu, Z. and Reiser, G. (2018). The small heat shock proteins, especially HspB4 and
HspB5 are promising protectants in neurodegenerative diseases. Neurochemistry
International 115: 69-79.
Züchner, S., Mersiyanova, I. V., Muglia, M., Bissar-Tadmouri, N., Rochelle, J., Dadali,
E. L., Zappia, M., Nelis, E., Patitucci, A. and Senderek, J. (2004). Mutations in
the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy
type 2A. Nature Genetics 36(5): 449.
Züchner, S. and Vance, J. M. (2006a). Mechanisms of disease: a molecular genetic
update on hereditary axonal neuropathies. Nature Clinical Practice Neurology
2(1): 45-53.
Züchner, S. and Vance, J. M. (2006b). Molecular genetics of autosomal-dominant
axonal Charcot-Marie-Tooth disease. Neuromolecular Medicine 8(1-2): 63-74.
Żwirowski, S., Kłosowska, A., Obuchowski, I., Nillegoda, N. B., Piróg, A., Ziętkiewicz,
S., Bukau, B., Mogk, A. and Liberek, K. (2017). Hsp70 displaces small heat
shock proteins from aggregates to initiate protein refolding. The European
Molecular
Biology
Organization
Journal
36(6):
783-796.

242

Appendices

Chapter 9: Appendices

243

Appendices

9 Appendices
9.1
9.1.1

Appendix I: Chapter 4 supplementary material
Hsp27X disulfide bond strength supplementary material

Figure 9.1. Disease-causing mutations in Hsp27 alter the strength of the disulfide bond
across the dimer interface (supplementary data to Figure 4.4). Non-reducing SDS-PAGE of
purified Hsp27P39L (A), Hsp27G84R (B), Hsp27R127W (C), Hsp27S135F (D), Hsp27R136W (E), Hsp27R140G (F),
and Hsp27T151I (G) mutant isoforms after incubation for 1 h at 37°C in varying ratios of GSH and GSSG,
such that the total glutathione (GSH molar equivalent) concentration remained the same (12 mM). The
percent GSH of each sample is indicated above the lanes and the positions of molecular weight markers
are shown to the left of the gels.
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9.1.2

Sequence alignment of human Hsp27 and the redox-modulating E. coli
Hsp33

Figure 9.2 Human Hsp27 C137 aligns with the redox-controlled E. coli Hsp33 C139. Amino
acid sequences were aligned using the Clustal Omega sequence alignment tool (Madeira et al., 2019). The
Hsp27 C137 and Hsp33 C139 are marked in green. ‘*’ indicates a fully conserved residue, ‘.’ indicates
conservation between groups of strongly similar properties, and ‘:’ indicates conservation between groups
of weakly similar properties.
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9.2 Appendix II: Chapter 6 supplementary material
9.2.1

Principle component analysis of Hsp27 binding partner proteomic data

Figure 9.3: Global comparison of the protein interactomes of Hsp27WT, Hsp27R136W and
Hsp27T151I by principle component analysis. Cells were transfected with plasmids encoding Myctagged isoforms of Hsp27 and allowed to express for 48 h. Cells were then lysed, and each isoform of
Hsp27 was precipitated using an anti-Myc antibody and magnetic protein A/G beads. Data obtained from
MS analysis of co-IP samples were pre-filtered to identify positive interactions (based on the
untransfected sample as representing false interactions) and subjected to Perseus (Tyanova and Cox,
2018) normalisation and principle component analysis to explore the similarities between replicates, and
the overall relationships between Hsp27WT ( ), Hsp27R136W ( ) and Hsp27T151I ( ). Proteomic
identification, abundance determination, and PCA analyses were performed in collaboration with Dr.
Matt Dun (University of Newcastle, Australia). The red squares represent a sample not pertinent to this
thesis.
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9.2.2

Hsp27 binding partner details

Table 9.1 Binding partners of Hsp27WT. Each identified binding partner of Hsp27WT after filtering based on untransfected samples is listed in order of most to least abundance. The

GRAVY, protein stats (aromatic, sulfur, basic, acidic), pI, molecular weight (mW), theoretical disorder and redox-sensitive disorder, proportion of secondary structures (α-helix, β-sheet,
coiled-coil), the log2, normalised abundance (averaged from three replicates), and the accession number of the human ortholog are given for each protein.
GRAVY

Aliphatic

Aromatic

Sulfur

Basic

Acidic

pI (pH)

MW
(kDa)

Disorder
(%)

Redox
disorder
(%)

Helix %

Beta %

Coil %

Abundance

Human ortholog

12.13483

47.86517

0.428118

C9IY40

31.6568

51.47929

0.358199

A0A384P622

13.95973

67.11409

0.356391

Q1KMD3

Q9D773; 39S ribosomal protein L2, mitochondrial; Mrpl2
-0.325

40.85

4.9

3.92

18.3

14.05

11.65

33.35

16.01307

0

40

Q8K2T1; NmrA-like family domain-containing protein 1; Nmral1
-0.349

39.16

8.41

3.24

14.89

21.36

6.86

34.38

5.501618

0

16.86391

Q00PI9; Heterogeneous nuclear ribonucleoprotein U-like protein 2; Hnrnpul2
-1.092

28.86

9.26

3.09

15.17

28.99

4.54

84.95

42.95302

0

18.92617

P70349.3; Histidine triad nucleotide-binding protein 1; Hint1
-0.154

42.86

5.56

4.76

16.67

19.05

6.88

13.78

0

0

33.78747

14.16894

52.0436

0.338723

A0A384NPU2

0

9.274194

37.09677

53.62903

0.334835

E9PID1

59.38776

1.428571

39.18367

0.325771

A0A087WUW5

21.35642

46.60895

0.325377

A0A024R4U3

12.37624

52.47525

0.3162

A0A087WUL9

P08882; Granzyme C; Gzmc
-0.273

37.1

7.26

4.84

16.53

16.53

9.68

27.31

5.241935

Q922I7; Polypyrimidine tract binding protein 1; Ptbp1
-0.123

39.64

6.67

2.88

11.89

19.1

9.67

59.33

12.25225

0

Q3UDE2; Tubulin--tyrosine ligase-like protein 12; Ttll12
-0.376

31.14

11.42

4.54

13.93

22.38

5.39

74.06

5.477308

0

32.03463

Q9WVJ2; 26S proteasome non-ATPase regulatory subunit 13; Psmd13
-0.139

37.77

7.71

4.52

13.3

23.14

5.45

42.82

0

0

35.14851

F2Z456; NADH-cytochrome b5 reductase; Cyb5r3
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GRAVY

Aliphatic

Aromatic

Sulfur

Basic

Acidic

pI (pH)

MW
(kDa)

Disorder
(%)

Redox
disorder
(%)

Helix %

Beta %

Coil %

Abundance

Human ortholog

-0.265

37.7

8.31

3.19

15.34

17.25

9.50

34.94

7.348243

0

20.44728

27.79553

51.75719

0.28288

B1AHF3

26.14379

66.66667

0.264097

A0A0S2Z4Q2

3.088803

74.51737

0.254972

J3QKU9

22.40117

46.5593

0.239042

P62318

3.723404

26.06383

0.233125

F8W079

13.40839

52.81474

0.232769

A0A024R7P2

68.98876

2.696629

28.31461

0.229159

Q9H1B7

40.45307

15.85761

43.68932

0.223277

A0A024R3P1

41.29353

9.950249

48.75622

0.211171

Q0VDF9

38.81674

1.731602

59.45166

0.20822

E9PJD9

1.701702

2.402402

95.8959

0.196906

A0A0C4DH09

P82198; Transforming growth factor-beta-induced protein ig-h3; Tgfbi
-0.066

40.85

5.27

4.69

12.3

19.77

7.07

74.61

2.781845

3.513909

7.189542

P50544; Very long-chain specific acyl-CoA dehydrogenase, mitochondrial; Acadvl
-0.082

41.92

6.86

4.12

12.8

18.45

9.07

70.89

8.231707

0

22.39382

P62320; Small nuclear ribonucleoprotein Sm D3; Snrpd3
-0.434

40.48

3.97

7.14

19.05

19.05

10.98

13.92

18.25397

0

31.03953

P56480; ATP synthase subunit beta, mitochondrial; Atp5b
0.033

46.31

5.29

2.46

10.96

18.71

4.99

56.31

3.213611

0

70.21277

O35465; Full=Peptidyl-prolyl cis-trans isomerase; Fkbp8
-0.239

41.04

4.73

4.23

11.94

20.9

4.81

43.54

27.61194

0

33.77687

Q8K3X4; Probable E3 ubiquitin-protein ligase; Irf2bpl
-0.451

36.39

4.77

4.26

11.35

16.26

8.30

80.58

60.77419

14.45161

O09005; Sphingolipid delta(4)-desaturase; Degs1
-0.021

33.44

17.34

4.02

14.86

14.86

7.89

38.24

1.547988

0

Q99M31; Heat shock 70 kDa protein 14; Hspa14
-0.091

41.06

5.11

4.13

12.77

20.04

5.71

54.66

1.178782

0

P14115; 60S ribosomal protein L27a; Rpl27a
-0.651

37.84

7.43

3.38

29.05

10.14

11.73

16.61

28.37838

0

E9QAT4; Protein transport protein Sec16A; Sec16a
-0.69

30.25

6.92

2.42

10.56

21.04

5.64

254.26

73.69538

0
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GRAVY

Aliphatic

Aromatic

Sulfur

Basic

Acidic

pI (pH)

MW
(kDa)

Disorder
(%)

Redox
disorder
(%)

Helix %

Beta %

Coil %

Abundance

Human ortholog

40.82569

41.74312

0.186474

A0A3B3IT07

27.67857

56.25

0.185009

A0A087WVI0

1.253482

57.52089

0.181843

A0A024RBE7

Q9WU78; Programmed cell death 6-interacting protein; Pdcd6ip
-0.456

34.41

7.59

2.76

12.31

23.01

6.46

96.05

20.48331

0

17.43119

Q9Z160; Conserved oligomeric Golgi complex subunit 1; Cog1
-0.205

35.82

6.12

4.9

12.86

20.31

7.19

109.07

12.34694

2.755102

16.07143

Q61033; Lamina-associated polypeptide 2, isoforms alpha/zeta; Tmpo
-0.594

32.76

4.76

2.31

14.86

20.06

8.15

75.18

52.52525

0

41.22563

Q8BMF4; Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial; Dlat
-0.033

42.37

5.14

3.74

12.15

14.95

8.78

67.95

19.4704

0

41.42012

18.93491

39.64497

0.16074

E9PEJ4

O08911; Mitogen-activated protein kinase 12; Mapk12
-0.394

34.33

9.54

4.36

15.26

21.25

6.20

42.05

8.446866

0

54.26829

7.164634

38.56707

0.159445

A8MY48

7.520891

56.73188

0.460299

42.80783

0.15515

J3QSF7

11.14058

49.60212

0.153384

A0A024R8M0

21.54839

3.096774

75.35484

0.146473

O43143

14.28571

33.33333

52.38095

0.143101

A6NHK2

21.75926

49.53704

0.139044

A0A0R4J2F4

P11247; Myeloperoxidase; Mpo
-0.311

34.12

8.64

4.87

13.37

19.92

9.98

81.20

2.089136

P27601; Guanine nucleotide-binding protein subunit alpha-13; Gna13
-0.416

32.36

9.55

3.98

16.98

24.14

8.35

44.06

1.355932

0

39.25729

O35286; Pre-mRNA-splicing factor ATP-dependent RNA helicase; Dhx15
-0.52

32.08

7.55

4.78

16.73

21.38

7.48

91.02

17.61006

0

P62305; Small nuclear ribonucleoprotein E; Snrpe
-0.351

35.87

7.61

6.52

15.22

26.09

9.86

10.81

0

0

Q8R4K2; Interleukin-1 receptor-associated kinase 4; Irak4
-0.349

34.2

6.1

4.79

13.07

22.44

5.06

50.88

18.95425

0

28.7037

Q9R0Y5; Adenylate kinase isoenzyme 1; Ak1
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GRAVY

Aliphatic

Aromatic

Sulfur

Basic

Acidic

pI (pH)

MW
(kDa)

Disorder
(%)

Redox
disorder
(%)

Helix %

Beta %

Coil %

Abundance

Human ortholog

-0.446

37.11

6.7

3.61

15.46

21.13

5.48

21.54

11.34021

0

39.2936

16.99779

43.70861

0.137511

F8VRY5

30.84479

35.36346

33.79175

0.135879

A0A024R4K3

0

48.76957

51.23043

0.122983

A0A024R6K8

59.95116

0.610501

39.43834

0.115423

E5RGA2

0

35.71429

64.28571

0.115126

H7BYH4

12.8866

32.47423

0.114588

B7Z6P0

52.45902

0

47.54098

0.104045

H3BP04

31.56997

11.77474

56.65529

0.101816

A0A3B3IUD2

12.42775

16.76301

70.80925

0.101752

A0A024QZK8

15.73209

26.16822

58.09969

0.09868

O14950

14.81481

65.06507

0.096514

G3V4C6

P08249; Malate dehydrogenase, mitochondrial; Mdh2
0.118

44.08

5.03

4.44

12.13

15.68

8.90

35.62

0.295858

0

P32921; Tryptophan--tRNA ligase, cytoplasmic; Wars
-0.37

30.56

10.81

4.99

14.35

20.58

6.89

54.37

7.900208

0

P60229; Eukaryotic translation initiation factor 3 subunit E; Eif3e
-0.327

31.69

11.46

4.72

13.71

24.72

5.89

52.23

2.47191

0

P08228; Superoxide dismutase [Cu-Zn]; Sod1
-0.455

42.21

2.6

3.9

14.94

20.78

6.50

15.95

64.93506

0

Q9R061; Cytosolic Fe-S cluster assembly factor NUBP2; Nubp2
0.037

42.18

5.45

5.09

12

16.73

6.50

29.52

4.727273

7.272727

54.63918

Q9DB77; Cytochrome b-c1 complex subunit 2, mitochondrial; Uqcrc2
-0.057

43.27

7.28

2.21

12.14

17.66

9.71

48.24

0.662252

0

D3YX87; Protein misato homolog 1; Msto1
-0.367

37.71

7.51

3.07

14.51

17.24

8.11

64.24

27.13311

0

D3Z3N4; Heterogeneous nuclear ribonucleoprotein H3; Hnrnph3
-0.719

39.88

11.85

5.2

13.29

17.92

6.87

36.87

18.20809

0

Q3THE2; Myosin regulatory light chain 12B; Myl12b
-0.778

26.16

9.88

5.81

14.53

29.07

4.44

19.78

14.53488

0

Q9CQE8; RNA transcription, translation and transport factor protein; Rtraf
-0.497

37.7

7.38

2.05

17.62

27.46

6.89

28.16

7.786885

0

20.12012
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GRAVY

Aliphatic

Aromatic

Sulfur

Basic

Acidic

pI (pH)

MW
(kDa)

Disorder
(%)

Redox
disorder
(%)

Helix %

Beta %

Coil %

Abundance

Human ortholog

41.46868

0.09281

A0A590UJJ1

44.11765

0.089968

A0A0U1RQF8

20.97027

52.73865

0.088284

A0A087WUN7

20

20.36036

59.63964

0.088143

F6V6Z1

29.65517

23.44828

46.89655

0.069985

H3BM93

37.05104

15.50095

47.44802

0.067366

K7EIZ6

45.11435

6.444906

48.44075

0.06116

A0A024R5Z8

8.695652

48.91304

42.3913

0.049682

P62310

2.480916

67.74809

0.040228

A0A024R4U0

17.81818

48.36364

0.036225

E9PMA0

Q6P1F6; Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform; Ppp2r2a
-0.611

27.74

10.07

4.25

15.66

24.38

6.11

51.70

4.474273

0

38.87689

19.65443

Q9Z2I9; Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial; Sucla2
-0.023

44.06

5.62

4.54

12.74

21.38

7.01

50.12

0.215983

0

7.843137

48.03922

Q9D8T7; SRA stem-loop-interacting RNA-binding protein, mitochondrial; Slirp
-0.448

36.61

8.04

2.68

19.64

18.75

10.59

12.61

4.464286

0

26.29108

Q922Q1; Mitochondrial amidoxime reducing component 2; Mtarc2
-0.23

34.91

7.99

6.21

14.79

16.86

8.83

38.20

0

5.91716

Q8BJ71; Nuclear pore complex protein Nup93; Nup93
-0.356

34.31

8.42

3.66

13.55

23.69

5.43

93.30

9.64591

0

P13864; DNA (cytosine-5)-methyltransferase 1; Dnmt1
-0.746

29.44

7.72

4.38

17.16

22.1

7.78

183.22

30.55556

6.975309

P62492; Ras-related protein Rab-11A; Rab11a
-0.421

34.72

7.87

2.78

14.35

23.15

6.53

24.40

15.27778

6.018519

P62311; U6 snRNA-associated Sm-like protein; Lsm3
-0.488

35.29

4.9

3.92

13.73

28.43

4.32

11.85

13.72549

0

A0A0R4J0T8; ADP-ribosylation factor GTPase-activating protein 3; Arfgap3
-0.78

28.44

7.63

3.44

15.08

20.8

8.67

57.55

52.67176

0

29.77099

Q9Z0X1; Apoptosis-inducing factor 1, mitochondrial; Aifm1
-0.24

41.01

7.03

2.78

14.22

18.63

9.68

66.78

13.23529

0

33.81818

Q3THK7; GMP synthase; Gmps
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GRAVY

Aliphatic

Aromatic

Sulfur

Basic

Acidic

pI (pH)

MW
(kDa)

Disorder
(%)

Redox
disorder
(%)

Helix %

Beta %

Coil %

Abundance

Human ortholog

-0.162

37.66

6.49

3.9

14.29

19.77

6.72

76.73

5.483405

0

54.06977

2.325581

43.60465

0.02975

P49915

12.83784

75

0.028575

A0A087WVM4

38.86792

14.46541

46.66667

0.027269

I3L102

55.72755

0.619195

43.65325

0.023105

Q13885

0

37.2549

8.932462

53.81264

0.008874

J3KS10

0

22.38562

20.75163

56.86275

0.005412

F8WEQ1

Q3V3R1; Monofunctional C1-tetrahydrofolate synthase, mitochondrial; Mthfd1l
-0.099

42.07

4.91

3.38

13.2

19.14

7.02

105.75

7.062436

0

12.16216

Q922E4; Ethanolamine-phosphate cytidylyltransferase; Pcyt2
-0.522

34.65

8.17

3.71

15.59

21.53

6.56

45.24

16.83168

0

Q7TMM9.1; Tubulin beta-2A chain; Tubb2a
-0.408

32.13

9.66

5.84

10.56

24.04

4.52

49.92

9.213483

0

P61255; 60S ribosomal protein L26; Rpl26
-1.107

27.59

6.21

2.76

31.03

19.31

11.24

17.26

51.03448

O08579; Emerin; Emd
-0.572

28.57

12.74

1.54

11.2

20.85

4.62

29.44

8.880309

Table 9.2 Binding partners of Hsp27R136W. Each identified binding partner of Hsp27R136W after filtering based on untransfected samples is listed in order of most to least abundance. The

GRAVY, protein stats (aromatic, sulphur, basic, acidic), pI, molecular weight (mW), theoretical disorder and redox-sensitive disorder, proportion of secondary structures (α-helix, β-sheet,
coiled-coil), the log2, normalised abundance (averaged from three replicates), and the accession number of the human ortholog are given for each protein.
GRAVY

Aliphatic

Aromatic

Sulphur

Basic

Acidic

pI

MW

Disorder

Redox
disorder

H%

E%

C%

Abundance

37.2549

8.932462

53.81264

0.508758

P50990

75.5237

0

24.4763

0.445827

C9JLV5

14.08451

57.74648

0.431779

E9PER6

P42932; T-complex protein 1 subunit theta; Cct8
-0.077

41.42

5.84

4.93

12.77

20.62

5.31

59.56

4.19708

0

O88543; COP9 signalosome complex subunit 3; Cops3
-0.193

34.04

8.51

6.62

12.06

22.93

6.64

47.84

9.692671

0

Q9Z2A0; 3-phosphoinositide-dependent protein kinase 1;Pdpk1
-0.503

30.77

10.2

3.22

14.67

21.11

7.40

63.77

16.98113

0

28.16901
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GRAVY

Aliphatic

Aromatic

Sulphur

Basic

Acidic

pI

MW

Disorder

Redox
disorder

H%

E%

C%

Abundance

12.45675

35.29412

0.424773

A0A024R5K6

67.61229

2.364066

30.02364

0.326627

A0A384MTT2

27.34375

32.29167

40.36458

0.321664

F5H0Y3

26.78571

1.785714

71.42857

0.297173

A0A023T787

5.338809

61.60164

0.285141

J3QLC1

2.824859

62.71186

0.274686

K7EKP8

0.460299

42.80783

0.261724

A0A494C0D1

39.43944

7.407407

53.15315

0.224809

E5RGA2

37.37374

13.80471

48.82155

0.214787

C9J5N1

29.83425

41.62063

0.201478

J3KQ48

Q9CQ54; NADH dehydrogenase [ubiquinone] 1 subunit C2; Ndufc2
-0.388

30.83

13.33

7.5

18.33

15.83

9.55

14.17

80.10336

0

52.24913

A0A0R4J0G0; Phosphoenolpyruvate carboxykinase [GTP], mitochondrial; Pck2
-0.227

37.93

8.55

5.4

12.74

16.79

7.80

73.43

3.898051

2.998501

Q99KX1.1; Myeloid leukemia factor 2; Mlf2
-0.88

26.72

8.1

8.1

16.19

21.46

6.97

28.06

42.95302

0

Q9CWZ3; RNA-binding protein 8A; Rbm8a
-1.153

31.61

7.47

3.45

20.69

25.86

5.43

19.89

53.44828

0

Q8VE22; 28S ribosomal protein S23, mitochondrial; Mrps23
-0.711

31.64

10.17

1.69

16.95

23.16

8.95

20.35

19.77401

0

33.05955

E9PYH2; Cytosolic acyl coenzyme A thioester hydrolase; Acot7
-0.349

35.42

5.47

5.99

16.41

19.27

8.88

42.83

24.7482

0

34.46328

Q9WUM5; Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial; Suclg1
-0.012

45.09

4.91

3.76

13.58

14.16

9.94

36.16

3.757225

0

56.73188

P60229; Eukaryotic translation initiation factor 3 subunit E; Eif3e
-0.327

31.69

11.46

4.72

13.71

24.72

5.89

52.23

2.47191

0

A2A4P4; Predicted gene, 27029; Gm27029
-0.439

36.65

6.08

2.76

15.29

22.84

5.55

60.52

10.49724

0

Q8R2Y8; Peptidyl-tRNA hydrolase 2, mitochondrial; Ptrh2
-0.091

41.44

4.97

5.52

12.71

16.02

7.50

19.53

11.60221

0

28.54512
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Aliphatic

Aromatic

Sulphur

Basic

Acidic

pI

MW

Disorder

Redox
disorder

H%

E%

C%

Abundance

0

36.99732

11.52815

51.47453

0.200257

A0A087X211

0

22.33883

19.1904

58.47076

0.198859

A0A2R8Y4A2

21.18863

6.976744

71.83463

0.190678

Q14152

0

68.98876

2.696629

28.31461

0.176731

A0A024R366

14.78439

40.44044

0

59.55956

0.16795

A0A0S2Z665

55

0

45

0.156578

Q9Y3Q8

26.07004

17.50973

56.42023

0.150322

H3BS70

0

38.43931

16.47399

45.08671

0.129033

Q9H2G2

0

22.00358

15.7424

62.25403

0.123809

P03928

D3Z7B5; Protein CIP2A; Cip2a
-0.172

36.16

4.63

4.41

13.89

23.48

6.35

102.16

12.78942

P47962; 60S ribosomal protein L5; Rpl5
-0.755

32.66

10.77

5.05

21.55

20.2

10.27

34.41

19.19192

P23116; Eukaryotic translation initiation factor 3 subunit A; Eif3a
-1.454

24.63

5.58

2.38

23.96

30.65

6.73

161.96

41.44345

0

E9PZ91; Bis(5'-adenosyl)-triphosphatase; Fhit
-0.306

32.86

10.33

3.76

15.96

20.19

7.35

24.52

11.73709

Q8C966; PHD finger protein 21B; Phf21b
-0.547

32.85

2.87

3.08

14.58

19.3

9.78

53.01

57.28953

Q9EQN3; TSC22 domain family protein 4; Tsc22d4
-0.506

38.5

3.36

1.55

11.11

16.02

8.46

39.99

80.10336

0

P42125; Enoyl-CoA delta isomerase 1, mitochondrial; Eci1
-0.148

39.79

6.92

5.19

15.22

18.34

9.33

32.25

0.346021

0

O54988; STE20-like serine/threonine-protein kinase; Slk
-1.02

28.22

4.14

2.51

16.79

32.28

4.80

141.49

60.42174

P03930; ATP synthase protein 8; mt-Atp8
0.139

26.87

11.94

4.48

10.45

10.45

10.58

7.77

0

Q99M04; Lipoyl synthase, mitochondrial; Lias
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Aliphatic

Aromatic

Sulphur

Basic

Acidic

pI

MW

Disorder

Redox
disorder

H%

E%

C%

Abundance

-0.48

35.12

7.77

4.29

17.43

19.03

9.17

41.88

3.44086

12.47312

29.77099

2.480916

67.74809

0.115174

A0A024R9W0

67.76777

1.201201

31.03103

0.100251

Q5JTZ9

39.59184

16.12245

44.28571

0.097094

A6NCQ0

20.88235

22.05882

57.05882

0.070001

P50991

15.51724

19.54023

64.94253

0.057946

P68032

46.89781

14.41606

38.68613

0.050714

A0A1B0GX60

16.19433

23.48178

60.32389

0.05019

A0A024R4U0

35.8209

0

64.1791

0.047759

A0A0U1RQI6

45.16484

7.912088

46.92308

0.035346

A0A0K0K1K7

23.34218

43.23607

0.0342

Q9NSD9

Q14CH7; Alanine--tRNA ligase, mitochondrial; Aars2
-0.169

41.33

6.12

3.67

12.35

19.08

6.11

106.81

9.081633

0

Q9JKX6; ADP-sugar pyrophosphatase;Nudt5
-0.372

33.94

6.88

4.59

14.22

18.81

5.18

23.99

24.77064

9.174312

P80315; T-complex protein 1 subunit delta; Cct4
0.009

42.3

2.6

4.64

13.36

18.74

8.14

58.08

9.833024

0

P68033; Actin, alpha cardiac muscle 1; Actc1
-0.228

35.81

8.49

5.84

12.2

19.36

5.05

42.02

3.713528

2.917772

Q9QYJ3; DnaJ homolog subfamily B member 1; Dnajb1
-0.718

30.88

8.82

3.24

17.65

20.29

8.98

38.17

34.70588

0

A0A0R4J0T8; ADP-ribosylation factor GTPase-activating protein 3; Arfgap3
-0.78

28.44

7.63

3.44

15.08

20.8

8.67

57.55

52.67176

0

F7DCH5; CLIP-associating protein 2; Clasp2
-0.45

33.89

5.36

3.29

14.92

19.05

8.89

142.87

40.90408

0

Q9CQ60; 6-phosphogluconolactonase; Pgls
0.149

45.14

5.84

2.33

10.51

15.18

5.64

27.26

5.836576

0

Q9WUA2; Phenylalanine--tRNA ligase beta subunit; Farsb
-0.094

38.03

7.64

4.24

14.26

19.35

7.13

65.71

0.169779

0

33.42175
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Sulphur
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Disorder

Redox
disorder

H%

E%

C%

Abundance

42.74809

11.83206

45.41985

0.025215

A0A087WTT6

13.25967

47.51381

0.022747

A0A0A0MTL6

40.82569

41.74312

0.012144

A0A3B3IT07

7.307307

67.06707

0.011936

A0A0R4J2F4

26.99491

25.63667

47.36842

0.003475

F2Z2K7

48.60853

13.72913

37.66234

4.27E-05

F5H2V6

P62274; 40S ribosomal protein S29; Rps29
-0.773

26.79

12.5

10.71

25

16.07

10.63

6.68

0

69.64286

Q68FE6.; Rho family-interacting cell polarization regulator 1; Ripor1
-0.384

32.46

5.4

3.11

11.45

18.07

5.73

132.38

46.11611

4.742437

39.22652

Q9WU78; Programmed cell death 6-interacting protein; Pdcd6ip
-0.456

34.41

7.59

2.76

12.31

23.01

6.46

96.05

20.48331

0

17.43119

Q8R4K2; Interleukin-1 receptor-associated kinase 4; Irak4
-0.349

34.2

6.1

4.79

13.07

22.44

5.06

50.88

18.95425

0

25.62563

Q3TBW2, 39S ribosomal protein L10, mitochondrial;Mrpl10
-0.17

39.31

5.34

3.82

16.41

17.94

10.28

29.40

17.77778

0

E9QB02; Methionine-tRNA ligase, cytoplasmic; Mars1
-0.242

37.25

8.68

3.85

13.08

20.55

6.91

102.39

T151I

8.241758

7.142857

WT

Table 9.3 Binding partners of Hsp27
. Each identified binding partner of Hsp27 after filtering based on untransfected samples is listed in order of most to least abundance. The
GRAVY, protein stats (aromatic, sulphur, basic, acidic), pI, molecular weight (mW), theoretical disorder and redox-sensitive disorder, proportion of secondary structures (α-helix, β-sheet,
coiled-coil), the log2, normalised abundance (averaged from three replicates), and the accession number of the human ortholog are given for each protein.
GRAVY

Aliphatic

Aromatic

Sulphur

Basic

Acidic

pI

MW

Disorder

Redox
disorder

H%

E%

C%

Abundance

Human

32.19178

20.54795

47.26027

0.799664

M0QX76

26.78571

1.785714

71.42857

0.573179

A0A087WTT6

P14131; 40S ribosomal protein S16; Rps16
-0.445

40.41

7.53

2.74

21.92

15.07

10.81

16.45

3.125

0

P62274; 40S ribosomal protein S29; Rps29
-0.773

26.79

12.5

10.71

25

16.07

10.63

6.68

0

69.64286
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Redox
disorder

H%

E%

C%

Abundance

Human

6.962025

31.64557

61.39241

0.538717

M0QZ90

19.1904

58.47076

0.36931

A0A384MTT2

0

45

0.360157

A0A024R5K6

68.98876

2.696629

2.696629

0.329909

E5RGA2

67.8487

2.364066

29.78723

0.300782

C9JLV5

15.7424

62.25403

0.295906

E9PER6

2.824859

62.71186

0.240873

J3QLC1

52.60417

0.892857

46.50298

0.227288

Q14152

28.54512

29.83425

41.62063

0.215108

C9J5N1

46.89781

14.41606

38.68613

0.20683

P50990

32.29167

40.36458

0.193887

K7EKP8

P62281; 40S ribosomal protein S11; Rps11
-0.607

31.01

9.49

4.43

24.05

16.46

10.96

18.43

0

0

A0A0R4J0G0; Phosphoenolpyruvate carboxykinase [GTP], mitochondrial; Pck2
-0.227

37.93

8.55

5.4

12.74

16.79

7.80

73.43

3.898051

2.998501

22.33883

Q9CQ54; NADH dehydrogenase [ubiquinone] 1 subunit C2; Ndufc2
-0.388

30.83

13.33

7.5

18.33

15.83

9.55

14.17

80.10336

0

55

P60229; Eukaryotic translation initiation factor 3 subunit E; Eif3e
-0.327

31.69

11.46

4.72

13.71

24.72

5.89

52.23

2.47191

0

O88543; COP9 signalosome complex subunit 3; Cops3
-0.193

34.04

8.51

6.62

12.06

22.93

6.64

47.84

9.692671

0

Q9Z2A0; 3-phosphoinositide-dependent protein kinase 1;Pdpk1
-0.503

30.77

10.2

3.22

14.67

21.11

7.40

63.77

16.98113

0

22.00358

Q8VE22; 28S ribosomal protein S23, mitochondrial; Mrps23
-0.711

31.64

10.17

1.69

16.95

23.16

8.95

20.35

19.77401

0

34.46328

P23116; Eukaryotic translation initiation factor 3 subunit A; Eif3a
-1.454

24.63

5.58

2.38

23.96

30.65

6.73

161.96

41.44345

0

A2A4P4; Predicted gene, 27029; Gm27029
-0.439

36.65

6.08

2.76

15.29

22.84

5.55

60.52

10.49724

0

P42932; T-complex protein 1 subunit theta; Cct8
-0.077

41.42

5.84

4.93

12.77

20.62

5.31

59.56

4.19708

0

E9PYH2; Cytosolic acyl coenzyme A thioester hydrolase; Acot7
-0.349

35.42

5.47

5.99

16.41

19.27

8.88

42.83

24.7482

0

27.34375
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Sulphur
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Redox
disorder

H%

E%

C%

Abundance

Human

33.05955

5.338809

61.60164

0.192834

A0A0S2Z665

15.51724

19.54023

64.94253

0.150323

A0A023T787

Q8C966; PHD finger protein 21B; Phf21b
-0.547

32.85

2.87

3.08

14.58

19.3

9.78

53.01

57.28953

14.78439

Q9CWZ3; RNA-binding protein 8A; Rbm8a
-1.153

31.61

7.47

3.45

20.69

25.86

5.43

19.89

53.44828

0

Q9WUM5; Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial; Suclg1
-0.012

45.09

4.91

3.76

13.58

14.16

9.94

36.16

3.757225

0

38.43931

16.47399

45.08671

0.136857

A0A494C0D1

16.19433

23.48178

60.32389

0.136132

F5H0Y3

36.99732

11.52815

51.47453

0.115828

A0A024R9W0

0

37.37374

13.80471

48.82155

0.10831

A0A2R8Y4A2

0

75.5237

0

24.4763

0.089616

A0A087X211

42.74809

11.83206

45.41985

0.07887

F2Z2K7

44.37643

0

55.62357

0.074859

A0A0U1RQI6

39.59184

16.12245

44.28571

0.067046

Q5JTZ9

35.58484

28.83031

35.58484

0.062109

A0A024R494

Q99KX1.1; Myeloid leukemia factor 2; Mlf2
-0.88

26.72

8.1

8.1

16.19

21.46

6.97

28.06

62.75304

0

Q99M04; Lipoyl synthase, mitochondrial; Lias
-0.48

35.12

7.77

4.29

17.43

19.03

9.17

41.88

3.44086

12.47312

P47962; 60S ribosomal protein L5; Rpl5
-0.755

32.66

10.77

5.05

21.55

20.2

10.27

34.41

19.19192

D3Z7B5; Protein CIP2A; Cip2a
-0.172

36.16

4.63

4.41

13.89

23.48

6.35

102.16

14.06061

Q3TBW2; 39S ribosomal protein L10, mitochondrial; Mrpl10
-0.17

39.31

5.34

3.82

16.41

17.94

10.28

29.40

12.21374

0

F7DCH5; CLIP-associating protein 2; Clasp2
-0.45

33.89

5.36

3.29

14.92

19.05

8.89

142.87

40.90408

0

Q14CH7; Alanine--tRNA ligase, mitochondrial; Aars2
-0.169

41.33

6.12

3.67

12.35

19.08

6.11

106.81

9.081633

0

Q8C0J2; Autophagy-related protein 16-1; Atg16l1
-0.512

34.6

5.93

2.97

15.98

23.23

6.32

68.18

27.04762

0
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H%

E%

C%

Abundance

Human

33.62069

18.10345

48.27586

0.057137

A0A0S2Z4T1

22.05882

57.05882

0.053519

A0A1B0GX60

6.001622

46.30981

0.051662

Q9H2G2

45.16484

7.912088

46.92308

0.051197

F5H2V6

45.11435

6.444906

48.44075

0.042288

A0A024R6K8

36.84211

11.24402

51.91388

0.039444

H3BMQ8

49.26471

14.15441

36.58088

0.030452

A0A0D9SG95

0

34.34343

65.65657

0.029125

A0A024R9G0

48.60853

13.72913

37.66234

0.028265

P50991

13.25967

47.51381

0.02517

J3KQ48

2.480916

67.74809

0.022097

A0A024R4U0

P25206; DNA replication licensing factor; Mcm3
-0.557

32.88

6.16

3.94

15.89

24.14

5.22

91.56

28.76712

0

Q9QYJ3; DnaJ homolog subfamily B member 1; Dnajb1
-0.718

30.88

8.82

3.24

17.65

20.29

8.98

38.17

34.70588

0

20.88235

O54988; STE20-like serine/threonine-protein kinase; Slk
-1.02

28.22

4.14

2.51

16.79

32.28

4.80

141.49

60.42174

0

47.68856

E9QB02; Methionine--tRNA ligase, cytoplasmic; Mars1
-0.242

37.25

8.68

3.85

13.08

20.55

6.91

102.39

8.241758

7.142857

P32921; Tryptophan--tRNA ligase, cytoplasmic; Wars
-0.37

30.56

10.81

4.99

14.35

20.58

6.89

54.37

7.900208

0

A6ZI44; Fructose-bisphosphate aldolase ; Aldoa
-0.315

38.76

6.22

3.35

13.16

19.14

8.01

45.13

22.02381

0

P80313; T-complex protein 1 subunit eta; Cct7
-0.09

41.54

5.7

4.96

13.79

20.59

7.95

59.66

4.761905

0

Q8BFX0; Adult male small intestine cDNA, RIKEN full-length; Polr2k
-0.592

31.31

7.07

8.08

19.19

22.22

8.97

11.66

5.050505

37.37374

P80315; T-complex protein 1 subunit delta; Cct4
0.009

42.3

2.6

4.64

13.36

18.74

8.14

58.08

9.833024

0

Q8R2Y8; Full=Peptidyl-tRNA hydrolase 2, mitochondrial; Ptrh2
-0.091

41.44

4.97

5.52

12.71

16.02

7.50

19.53

11.60221

0

39.22652

A0A0R4J0T8; ADP-ribosylation factor GTPase-activating protein 3; Arfgap3
-0.78

28.44

7.63

3.44

15.08

20.8

8.67

57.55

52.67176

0

29.77099
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Redox
disorder

H%

E%

C%

Abundance

Human

11.14058

49.60212

0.021153

A0A024R8M0

3.723404

26.06383

0.015858

A0A087WUL9

0

47.54098

0.001661

G3V4C6

P27601; Guanine nucleotide-binding protein subunit alpha-13; Gna13
-0.416

32.36

9.55

3.98

16.98

24.14

8.35

44.06

1.355932

0

39.25729

Q9WVJ2; 26S proteasome non-ATPase regulatory subunit 13; Psmd13
-0.139

37.77

7.71

4.52

13.3

23.14

5.45

42.82

0

0

70.21277

Q9CQE8; RNA transcription, translation and transport factor protein; Rtraf
-0.497

9.2.3

37.7

7.38

2.05

17.62

27.46

6.89

28.16

7.786885

0

52.45902

Activities of interactors

Table 9.4 Activities of Hsp27WT binding partners. The functional information for each binding partner were obtained from the UniProt Knowledgebase (UniProt-Consortium, 2019).
Acadvl

Very long-chain specific acyl-CoA dehydrogenase, mitochondrial; Active toward esters of long-chain and very long chain fatty acids such as palmitoyl-CoA, mysritoyl-CoA and stearoyl-Co
family (656 aa)

Aifm1

Functions both as NADH oxidoreductase and as regulator of apoptosis (By similarity). In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into th
independent fragmentation of chromosomal DNA (PubMed:9989411). Binds to DNA in a sequence-independent manner. Interacts with EIF3G, and thereby inhibits the EIF3 machinery and
participates in normal mitochondrial metabolism. Plays an important role in the regulation of respiratory chain biogenesis by interacting with CHCHD4 and controlling CHCHD4 mitochondr

Ak1

Adenylate kinase isoenzyme 1; Catalyzes the reversible transfer of the terminal phosphate group between ATP and AMP. Also possesses broad nucleoside diphosphate kinase activity. Plays
aa)

Atp5b

Mitochondrial membrane ATP synthase (F1F0 ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by ele
proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F1 is coupled via a rotary mechanism of the central stalk
three separate catalytic sites on the beta subunits. (529 aa)

Cog1

Conserved oligomeric Golgi complex subunit 1; Required for normal Golgi function (980 aa)

Cyb5r3

NADH-cytochrome b5 reductase 3; Desaturation and elongation of fatty acids, cholesterol biosynthesis, drug metabolism, and, in erythrocyte, methemoglobin reduction (301 aa)

Degs1

Sphingolipid delta(4)-desaturase DES1; Has sphingolipid-delta-4-desaturase activity. Converts D-erythro-sphinganine to D-erythro-sphingosine (E-sphing-4-enine) (323 aa)

Dhx15

Pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15; Pre-mRNA processing factor involved in disassembly of spliceosomes after the release of mature mRNA. In cooperation
introns (By similarity); Belongs to the DEAD box helicase family. DEAH subfamily. DDX15/PRP43 sub-subfamily (795 aa)
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Dlat

Dihydrolipoamide S-acetyltransferase (E2 component of pyruvate dehydrogenase complex); The pyruvate dehydrogenase complex catalyzes the overall conversion of pyruvate to acetyl-CoA

Dnmt1

Methylates CpG residues. Preferentially methylates hemimethylated DNA. Associates with DNA replication sites in S phase maintaining the methylation pattern in the newly synthesized str
methylation patterns established in development. DNA methylation is coordinated with methylation of histones. Mediates transcriptional repression by direct binding to HDAC2. In assoc
Probably forms a corepressor complex required for activated KRAS-mediated promoter hypermethylation and transcriptional silencing of tumor suppressor genes (TSGs) or other tumor-rela
Associates at promoter regions of tumor suppressor genes (TSGs) leading to their gene silencing (By similarity). Promotes tumor growth (By similarity).

Eif3e

Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein synthesis. The eIF-3 complex associates with the
recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recycling of post-termination ribosomal complexes
involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert either translational activation or repression.
regulate the proteasome-mediated degradation of these proteins. (445 aa)

Emd

Emerin; Stabilizes and promotes the formation of a nuclear actin cortical network. Stimulates actin polymerization in vitro by binding and stabilizing the pointed end of growing filaments
centrosomes to the nuclear envelope via a microtubule association. Required for proper localization of non-farnesylated prelamin-A/C (By similarity) (259 aa)

Fkbp8

Peptidyl-prolyl cis-trans isomerase FKBP8; Constitutively inactive PPiase, which becomes active when bound to calmodulin and calcium. Seems to act as a chaperone for BCL2, targets i
FKBP8 may therefore play a role in the regulation of apoptosis (By similarity). Required for normal embryonic development (403 aa)

Gmps

GMP synthase [glutamine-hydrolyzing]; Involved in the de novo synthesis of guanine nucleotides which are not only essential for DNA and RNA synthesis, but also provide GTP, which is i

Gna13

Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems (PubMed:21212405, PubMed:19151758, PubMed
signaling subsequently regulates transcription factor AP-1 (activating protein-1). Promotes tumor cell invasion and metastasis by activating Rho/ROCK signaling pathway (By similarity). Inh

Gzmc

Granzyme C; This enzyme is probably necessary for target cell lysis in cell-mediated immune responses (248 aa)

Hint1

Hydrolyzes purine nucleotide phosphoramidates with a single phosphate group, including adenosine 5'monophosphoramidate (AMP-NH2), adenosine 5'monophosphomorpholidate (AMP-m
as well as Met-AMP, His-AMP and Asp-AMP, lysyl-GMP (GMP-N-epsilon-(N-alpha-acetyl lysine methyl ester)) and AMP-N-alanine methyl ester. Can also convert adenosine 5'-O-phos
that modulates transcriptional activation by the LEF1/TCF1-CTNNB1 complex and by the complex formed with MITF and CTNNB1. Modulates p53/TP53 levels and p53/TP53-mediated ap

Hnrnph3

Heterogeneous nuclear ribonucleoprotein H3; Involved in the splicing process and participates in early heat shock-induced splicing arrest. Due to their great structural variations the different

Hnrnpul
2

Heterogeneous nuclear ribonucleoprotein U-like 2 (745 aa)

Hspa14

Heat shock 70 kDa protein 14; Component of the ribosome-associated complex (RAC), a complex involved in folding or maintaining nascent polypeptides in a folding-competent state. In th

Irak4

Interleukin-1 receptor-associated kinase 4; Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like recep
initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to prom
TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and acti
suggesting a similar mechanism during microbial infections (By similarity). (459 aa)
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Irf2bpl

Interferon regulatory factor 2-binding protein-like; May contribute to the control of female reproductive function. May play a role in gene transcription by transactivating GNRH1 promoter a

Lsm3

U6 snRNA-associated Sm-like protein LSm3; Binds specifically to the 3’-terminal U-tract of U6 snRNA (102 aa)

Mapk12

Serine/threonine kinase which acts as an essential component of the MAP kinase signal transduction pathway. MAPK12 is one of the four p38 MAPKs which play an important role in the c
Accordingly, p38 MAPKs phosphorylate a broad range of proteins and it has been estimated that they may have approximately 200 to 300 substrates each. Some of the targets are downs
regulation of cyclin D1 in response to hypoxia in adrenal cells suggesting MAPK12 may inhibit cell proliferation while promoting differentiation. Phosphorylates DLG1. Following osmotic
and could affect mRNA processing and/or gene transcription to aid cell adaptation to osmolarity changes in the environment. Regulates UV-induced checkpoint signaling and repair of UV
regulates SLC2A4 expression and contraction-mediated glucose uptake in adult skeletal muscle. C-Jun (JUN) phosphorylation is stimulated by MAPK14 and inhibited by MAPK12, leading
also positively regulating the expansion of transient amplifying myogenic precursor cells during muscle growth and regeneration.3 Publications (367 aa)

Marc2

Mitochondrial amidoxime reducing component 2; As a component of the benzamidoxime prodrug-converting complex required to reduce N-hydroxylated prodrugs, such as benzamidoxim
similarity) (338 aa)

Mdh2

Malate dehydrogenase 2, NAD (mitochondrial) (338 aa)

Mpo

Myeloperoxidase; Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MP
the peroxidase family. XPO subfamily (718 aa)

Mrpl2

Mitochondrial ribosomal protein L2; Belongs to the universal ribosomal protein uL2 family (306 aa)

Msto1

Protein misato homolog 1; Involved in the regulation of mitochondrial distribution and morphology. Required for mitochondrial fusion and mitochondrial network formation (556 aa)

Mthfd1l

Monofunctional C1-tetrahydrofolate synthase, mitochondrial; May provide the missing metabolic reaction required to link the mitochondria and the cytoplasm in the mammalian mode
dehydrogenase/cyclohydrolase family (977 aa)

Myl12b

Myosin regulatory light chain 12B; Myosin regulatory subunit that plays an important role in regulation of both smooth muscle and nonmuscle cell contractile activity via its phosphorylation

Nmral1

Redox sensor protein. Undergoes restructuring and subcellular redistribution in response to changes in intracellular NADPH/NADP+ levels. At low NADPH concentrations the protein is fou
nitric oxide, which subsecuently prevents apoptosis. Under normal NADPH concentrations, the protein is found as a dimer and hides the binding site for ASS1. The homodimer binds one mo

Nubp2

Cytosolic Fe-S cluster assembly factor NUBP2; Component of the cytosolic iron-sulfur (Fe/S) protein assembly (CIA) machinery. Required for maturation of extramitochondrial Fe-S prot
formation and structure; Belongs to the Mrp/NBP35 ATP-binding proteins family. NUBP2/CFD1 subfamily (275 aa)

Nup93

Nuclear pore complex protein Nup93; Plays a role in the nuclear pore complex (NPC) assembly and/or maintenance. May anchor nucleoporins, but not NUP153 and TPR, to the NPC (By si
(819 aa)

Pcyt2

Ethanolamine-phosphate cytidylyltransferase; Plays an important role in the biosynthesis of the phospholipid phosphatidylethanolamine. Catalyzes the formation of CDP-ethanolamine (By s

Pdcd6ip

Multifunctional protein involved in endocytosis, multivesicular body biogenesis, membrane repair, cytokinesis, apoptosis and maintenance of tight junction integrity. Class E VPS protein in
the limiting membrane of the endosome. Binds to the phospholipid lysobisphosphatidic acid (LBPA) which is abundant in MVBs internal membranes. The MVB pathway requires the seq
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Adapter for a subset of ESCRT-III proteins, such as CHMP4, to function at distinct membranes. Required for completion of cytokinesis. May play a role in the regulation of both apopto
positioning of actomyosin-tight junction complex at the apical sides of adjacent epithelial cells that defines a spatial membrane domain essential for the maintenance of epithelial cell polarity
Ppp2r2a

Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform; The B regulatory subunit might modulate substrate selectivity and catalytic activity, and also might dire

Psmd13

26S proteasome non-ATPase regulatory subunit 13; Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. Th
functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair (376 aa)

Ptbp1

Polypyrimidine tract-binding protein 1; Plays a role in pre-mRNA splicing and in the regulation of alternative splicing events. Activates exon skipping of its own pre-mRNA during muscle c
of U2 snRNP to pre-mRNA. Cooperates with RAVER1 to modulate switching between mutually exclusive exons during maturation of the TPM1 pre-mRNA. Represses the splicing of MAP

Rab11a

The small GTPases Rab areR key regulators of intracellular membrane trafficking, from the formation of transport vesicles to their fusion with membranes. Rabs cycle between an inactive
fusion. The small Rab GTPase RAB11A regulates endocytic recycling. Acts as a major regulator of membrane delivery during cytokinesis. Together with MYO5B and RAB8A participates
initiation sites (AMIS), apical surface formation and lumenogenesis. Together with MYO5B participates in CFTR trafficking to the plasma membrane and TF (Transferrin) recycling in non
the Golgi apparatus to the plasma membrane. Regulates the recycling of FCGRT (receptor of Fc region of monomeric Ig G) to basolateral membranes (By similarity). May also play a role in

Rpl26

Ribosomal protein L26 (145 aa)

Rpl27a

Ribosomal protein L27A (148 aa)

Rtraf

RNA transcription, translation and transport factor protein; RNA-binding protein involved in modulation of mRNA transcription by Polymerase II. Component of the tRNA-splicing ligase co

Sec16a

Protein transport protein sec16; Required for secretory cargo traffic from the endoplasmic reticulum to the Golgi apparatus and for normal transitional endoplasmic reticulum (tER) organizat

Slirp

SRA stem-loop-interacting RNA-binding protein, mitochondrial; RNA-binding protein that acts as a nuclear receptor corepressor. Probably acts by binding the SRA RNA, and repressing th
(By similarity) (112 aa)

Snrpd3

Small nuclear ribonucleoprotein Sm D3; Core component of the spliceosomal U1, U2, U4 and U5 small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. Ther
and SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. As part of the U7 snRNP it is involved in histone 3’-end processing

Snrpe

Small nuclear ribonucleoprotein E; Core component of the spliceosomal U1, U2, U4 and U5 small nuclear ribonucleoproteins (snRNPs), the building blocks of the spliceosome. Thereby, p
SNRPG that assemble in a heptameric protein ring on the Sm site of the small nuclear RNA to form the core snRNP. As part of the U7 snRNP it is involved in histone 3’-end processing. Ma

Sod1

Superoxide dismutase [Cu-Zn]; Destroys radicals which are normally produced within the cells and which are toxic to biological systems; Belongs to the Cu-Zn superoxide dismutase family

Sucla2

Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial; ATP-specific succinyl-CoA synthetase functions in the citric acid cycle (TCA), coupling the hydrolysis of succinyl-CoA
succinate, while the binding sites for coenzyme A and phosphate are found in the alpha subunit (463 aa)

Tgfbi

Transforming growth factor-beta-induced protein ig-h3; Plays a role in cell adhesion. May play a role in cell-collagen interactions (By similarity) (683 aa)

Tmpo

Lamina-associated polypeptide 2, isoforms alpha/zeta; May be involved in the structural organization of the nucleus and in the post-mitotic nuclear assembly. Plays an important role, togethe

263

Appendices
Ttll12

Tubulin tyrosine ligase-like family, member 12 (639 aa)

Tubb2a

Tubulin beta-2A chain; Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the a

Uqcrc2

Cytochrome b-c1 complex subunit 2, mitochondrial; This is a component of the ubiquinol-cytochrome c reductase complex (complex III or cytochrome b-c1 complex), which is part of the m

Wars

Tryptophan--tRNA ligase, cytoplasmic; T1-TrpRS has aminoacylation activity while T2-TrpRS lacks it. T1-TrpRS and T2-TrpRS possess angiostatic activity. T2- TrpRS inhibits fluid s
responsive gene expression (By similarity) (481 aa)

Table 9.5 Activities of Hsp27R136W binding partners. The functional information for each binding partner were obtained from the UniProt Knowledgebase (UniProt-Consortium, 2019).
Aars2

Alanine--tRNA ligase, mitochondrial; Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction- alanine is first activated by ATP to form Ala- AMP and then transferred to the

Acot7

Cytosolic acyl coenzyme A thioester hydrolase: Acyl-CoA thioesterases are a group of enzymes that catalyze the hydrolysis of acyl-CoAs to the free fatty acid and coenzyme A (CoASH),
broad specificity acting on other fatty acyl-CoAs with chain-lengths of C8-C18 (Probable). May play an important physiological function in brain. (379 aa)

Actc1

Actin, alpha cardiac muscle 1; Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells (377 aa)

Cct4

T-complex protein 1 subunit delta; Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the BBS/CCT complex may play a role in the assembly of BBSome,
family (539 aa)

Cct8

T-complex protein 1 subunit theta; Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the BBS/CCT complex may play a role in the assembly of BBSome,

Clasp2

CLIP-associating protein 2; Microtubule plus-end tracking protein that promotes the stabilization of dynamic microtubules. Involved in the nucleation of noncentrosomal microtubules origin
to enhance the frequency of rescue of depolymerizing microtubules by attaching their plus-ends to cortical platforms composed of ERC1 and PHLDB2. This cortical microtubule stabilizin
chromosomes on the mitotic spindle. Acts as a mediator of ERBB2-dependent stabilization of microtubules at the cell cortex. (1307 aa)

Cops3

COP9 signalosome complex subunit 3; Component of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes (By similarity). The CSN
ligase activity of SCF-type complexes such as SCF, CSA or DDB2 (By similarity). The complex is also involved in phosphorylation of p53/TP53, c-jun/JUN, IkappaBalpha/NFKBIA, ITP
system, respectively (By similarity). Essential to maintain the survival of epiblast cells and thus the development of the postimplantation embryo. (423 aa)

Dnajb1

DnaJ homolog subfamily B member 1; Interacts with HSP70 and can stimulate its ATPase activity. Stimulates the association between HSC70 and HIP. Negatively regulates heat shock-in
HSPA1A/B (in vitro) (340 aa)

Eci1

Enoyl-CoA delta isomerase 1, mitochondrial; Able to isomerize both 3-cis and 3-trans double bonds into the 2-trans form in a range of enoyl-CoA species (289 aa)

Eif3a

Eukaryotic translation initiation factor 3 subunit A; RNA-binding component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the init
initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for d
specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-lo

Eif3e

Eukaryotic translation initiation factor 3 subunit E; Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein
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(43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recyc
initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert e
May interact with MCM7 and EPAS1 and regulate the proteasome-mediated degradation of these proteins. (445 aa)
Fam65a

Rho family-interacting cell polarization regulator 1; Downstream effector protein for Rho-type small GTPases that plays a role in cell polarity and directional migration. Acts as an adapter p
relocation of STK26 from the Golgi to cytoplasm punctae in a Rho- and PDCD10-dependent manner upon serum stimulation; Belongs to the RIPOR family (1223 aa)

Farsb

phenylalanyl-tRNA synthetase, beta subunit (589 aa)

Fhit

Bis(5’-adenosyl)-triphosphatase; Cleaves P1-P3-bis(5'-adenosyl) triphosphate (Ap3A) to yield AMP and ADP. Can also hydrolyze P1-P4-bis(5'-adenosyl) tetraphosphate (Ap4A), but has ex
CCND1 and BIRC5. Plays a role in the induction of apoptosis via SRC and AKT1 signaling pathways. Inhibits MDM2-mediated proteasomal degradation of p53/TP53 and thereby plays a
activity (By similarity). Functions as tumor suppressor. (213 aa)

Gm2702
9

Predicted gene, 27029 (543 aa)

Irak4

Interleukin-1 receptor-associated kinase 4; Serine/threonine-protein kinase that plays a critical role in initiating innate immune response against foreign pathogens. Involved in Toll-like recep
initially IRAK1, thus stimulating the kinase activity and intensive autophosphorylation of IRAK1. Phosphorylates E3 ubiquitin ligases Pellino proteins (PELI1, PELI2 and PELI3) to prom
TRAF6 complex and the NEMO-IKKA-IKKB complex. In turn, MAP3K7/TAK1 activates IKKs (CHUK/IKKA and IKBKB/IKKB) leading to NF-kappa-B nuclear translocation and acti
suggesting a similar mechanism during microbial infections (By similarity). (459 aa)

Kiaa152
4

Protein CIP2A; Promotes anchorage-independent cell growth and tumor formation (907 aa)

Lias

Lipoyl synthase, mitochondrial; Catalyzes the radical-mediated insertion of two sulfur atoms into the C-6 and C-8 positions of the octanoyl moiety bound to the lipoyl domains of lipoate-dep

Mars

Methionine--tRNA ligase, cytoplasmic; Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction- the amino acid (AA) is first activated by ATP to form AA

Mlf2

Myeloid leukemia factor 2 (247 aa)

Mrpl10

Mitochondrial ribosomal protein L10; Belongs to the universal ribosomal protein uL10 family (262 aa)

Mrps23

Mitochondrial ribosomal protein S23; Belongs to the mitochondrion-specific ribosomal protein mS23 family (177 aa)

mt-Atp8

ATP synthase protein 8; Mitochondrial membrane ATP synthase (F1F0 ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane
containing the membrane proton channel, linked together by a central stalk and a peripheral stalk. During catalysis, ATP synthesis in the catalytic domain of F1 is coupled via a rotary mechan

Ndufc2

NADH dehydrogenase [ubiquinone] 1 subunit C2; Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved

Nudt5

ADP-sugar pyrophosphatase; Enzyme that can either act as an ADP-sugar pyrophosphatase in absence of diphosphate or catalyze the synthesis of ATP in presence of diphosphate (By simila
Can also hydrolyze other nucleotide sugars with low activity. In presence of diphosphate, mediates the synthesis of ATP in the nucleus by catalyzing the conversion of ADP-ribose to AT

265

Appendices
remodeling events that are energy-consuming (By similarity). Does not play a role in U8 snoRNA decapping activity. Binds U8 snoRNA. (218 aa)
Pdcd6ip

Programmed cell death 6-interacting protein; Multifunctional protein involved in endocytosis, multivesicular body biogenesis, membrane repair, cytokinesis, apoptosis and maintenance of ti
generated by invagination and scission from the limiting membrane of the endosome. Binds to the phospholipid lysobisphosphatidic acid (LBPA) which is abundant in MVBs internal mem
such as the terminal stages of cytokinesis. Adapter for a subset of ESCRT-III proteins, such as CHMP4, to function at distinct membranes. Required for completion of cytokinesis. May pla
TJP1 secures the proper assembly and positioning of actomyosin-tight junction complex at the apical sides of adjacent epithelial cells that defines a spatial membrane domain essential for the

Pdpk1

3-phosphoinositide-dependent protein kinase 1; Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. Its ta
cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated kinase-1 (P
signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. Negatively regulates the TGF-beta-induced signaling by: modu
and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta. Activates PPARG transcriptional activity and promotes adipocyte differentiation. Activates th
growth of developing pancreatic cells. Participates in the regulation of Ca2+ entry and Ca2+-activated K+ channels of mast cells. Essential for the motility of vascular endothelial cells (ECs)
role during thymocyte development by regulating the expression of key nutrient receptors on the surface of pre-T cells and mediating Notch-induced cell growth and proliferative responses. P

Pgls

6-phosphogluconolactonase; Hydrolysis of 6-phosphogluconolactone to 6- phosphogluconate; Belongs to the glucosamine/galactosamine-6-phosphate isomerase family. 6-phosphogluconola

Phf21b

PHD finger protein 21B (487 aa)

Ptrh2

Peptidyl-tRNA hydrolase 2, mitochondrial; The natural substrate for this enzyme may be peptidyl- tRNAs which drop off the ribosome during protein synthesis (181 aa)

Rbm8a

RNA-binding protein 8A; Required for pre-mRNA splicing as component of the spliceosome (By similarity). Core component of the splicing-dependent multiprotein exon junction comp
complex only transiently either during EJC assembly or during subsequent mRNA metabolism. The EJC marks the position of the exon-exon junction in the mature mRNA for the gene exp
export, subcellular mRNA localization, translation efficiency and nonsense-mediated mRNA decay (NMD). Its removal from cytoplasmic mRNAs requires translation initiation from EJC-b
both nuclear mRNAs and newly exported cytoplasmic mRNAs (By similarity) (174 aa)

Rpl5

60S ribosomal protein L5; Component of the ribosome, a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. The small ribosomal subunit (SSU) binds m
termed the peptidyl transferase center (PTC), which catalyzes the formation of peptide bonds, thereby polymerizing the amino acids delivered by tRNAs into a polypeptide chain. The nascen
the exit of the ribosomal tunnel. As part of the 5S RNP/5S ribonucleoprotein particle it is an essential component of the LSU, required for its formation and the maturation of rRNAs. It a
stabilization and the activation of TP53. Interacts with RRP1B. (297 aa)

Rps29

Ribosomal protein S29 (56 aa)

Slk

STE20-like serine/threonine-protein kinase; Mediates apoptosis and actin stress fiber dissolution; Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. STE20 subfam

Suclg1

Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial; Succinyl-CoA synthetase functions in the citric acid cycle (TCA), coupling the hydrolysis of succinyl-CoA to
phosphate, while succinate binding and specificity for either ATP or GTP is provided by different beta subunits (346 aa)

Tsc22d4

TSC22 domain family protein 4; Transcriptional repressor; Belongs to the TSC-22/Dip/Bun family (387 aa)

266

Appendices
Table 9.6 Activities of Hsp27WT binding partners. The functional information for each binding partner were obtained from the UniProt Knowledgebase (UniProt-Consortium, 2019).
Aars2

Alanine--tRNA ligase, mitochondrial; Catalyzes the attachment of alanine to tRNA(Ala) in a two-step reaction- alanine is first activated by ATP to form Ala- AMP and then transferred to the

Acot7

Cytosolic acyl coenzyme A thioester hydrolase: Acyl-CoA thioesterases are a group of enzymes that catalyze the hydrolysis of acyl-CoAs to the free fatty acid and coenzyme A (CoASH),
broad specificity acting on other fatty acyl-CoAs with chain-lengths of C8-C18 (Probable). May play an important physiological function in brain. (379 aa)

Aldoa

Fructose-bisphosphate aldolase A; Plays a key role in glycolysis and gluconeogenesis. In addition, may also function as scaffolding protein (By similarity); Belongs to the class I fructose-bis

Atg16l1

Autophagy-related protein 16-1; Plays an essential role in autophagy: interacts with ATG12-ATG5 to mediate the conjugation of phosphatidylethanolamine (PE) to LC3 (MAP1LC3A,
mitochondrial antiviral signaling (MAVS)-dependent type I interferon (IFN-I) production (By similarity). Negatively regulates NOD1- and NOD2-driven inflammatory cytokine response. In

Cct4

T-complex protein 1 subunit delta; Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the BBS/CCT complex may play a role in the assembly of BBSome,
family (539 aa)

Cct7

T-complex protein 1 subunit eta; Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. Known to play a role, in vitro, in the folding of actin and tubulin; Belongs to the T

Cct8

T-complex protein 1 subunit theta; Molecular chaperone; assists the folding of proteins upon ATP hydrolysis. As part of the BBS/CCT complex may play a role in the assembly of BBSome,

Clasp2

CLIP-associating protein 2; Microtubule plus-end tracking protein that promotes the stabilization of dynamic microtubules. Involved in the nucleation of noncentrosomal microtubules origin
to enhance the frequency of rescue of depolymerizing microtubules by attaching their plus-ends to cortical platforms composed of ERC1 and PHLDB2. This cortical microtubule stabilizin
chromosomes on the mitotic spindle. Acts as a mediator of ERBB2-dependent stabilization of microtubules at the cell cortex. (1307 aa)

Cops3

COP9 signalosome complex subunit 3; Component of the COP9 signalosome complex (CSN), a complex involved in various cellular and developmental processes (By similarity). The CSN
ligase activity of SCF-type complexes such as SCF, CSA or DDB2 (By similarity). The complex is also involved in phosphorylation of p53/TP53, c-jun/JUN, IkappaBalpha/NFKBIA, ITP
system, respectively (By similarity). Essential to maintain the survival of epiblast cells and thus the development of the postimplantation embryo. (423 aa)

Dnajb1

DnaJ homolog subfamily B member 1; Interacts with HSP70 and can stimulate its ATPase activity. Stimulates the association between HSC70 and HIP. Negatively regulates heat shock-in
HSPA1A/B (in vitro) (340 aa)

Eif3a

Eukaryotic translation initiation factor 3 subunit A; RNA-binding component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the init
initiation complex (43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for d
specifically targets and initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-lo

Eif3e

Eukaryotic translation initiation factor 3 subunit E; Component of the eukaryotic translation initiation factor 3 (eIF-3) complex, which is required for several steps in the initiation of protein
(43S PIC). The eIF-3 complex stimulates mRNA recruitment to the 43S PIC and scanning of the mRNA for AUG recognition. The eIF-3 complex is also required for disassembly and recyc
initiates translation of a subset of mRNAs involved in cell proliferation, including cell cycling, differentiation and apoptosis, and uses different modes of RNA stem-loop binding to exert e
May interact with MCM7 and EPAS1 and regulate the proteasome-mediated degradation of these proteins. (445 aa)

Gm2702
9

Predicted gene, 27029 (543 aa)
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Gna13

Guanine nucleotide-binding protein subunit alpha-13; Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling syste
subsequently regulates transcription factor AP-1 (activating protein-1). Promotes tumor cell invasion and metastasis by activating Rho/ROCK signaling pathway (By similarity). Inhibits CDH

Kiaa152
4

Protein CIP2A; Promotes anchorage-independent cell growth and tumor formation (907 aa)

Lias

Lipoyl synthase, mitochondrial; Catalyzes the radical-mediated insertion of two sulfur atoms into the C-6 and C-8 positions of the octanoyl moiety bound to the lipoyl domains of lipoate-dep

Mars

Methionine--tRNA ligase, cytoplasmic; Catalyzes the specific attachment of an amino acid to its cognate tRNA in a 2 step reaction- the amino acid (AA) is first activated by ATP to form AA

Mcm3

DNA replication licensing factor MCM3; Acts as component of the MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for 'once per cell cycle' DNA re
structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likel

Mlf2

Myeloid leukemia factor 2 (247 aa)

Mrpl10

Mitochondrial ribosomal protein L10; Belongs to the universal ribosomal protein uL10 family (262 aa)

Mrps23

Mitochondrial ribosomal protein S23; Belongs to the mitochondrion-specific ribosomal protein mS23 family (177 aa)

Ndufc2

NADH dehydrogenase [ubiquinone] 1 subunit C2; Accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I), that is believed not to be involved

Pdpk1

3-phosphoinositide-dependent protein kinase 1; Serine/threonine kinase which acts as a master kinase, phosphorylating and activating a subgroup of the AGC family of protein kinases. Its ta
cyclic AMP-dependent protein kinase (PRKACA), protein kinase C (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase (SGK1, SGK2 and SGK3), p21-activated kinase-1 (P
signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. Negatively regulates the TGF-beta-induced signaling by: modu
and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta. Activates PPARG transcriptional activity and promotes adipocyte differentiation. Activates th
growth of developing pancreatic cells. Participates in the regulation of Ca2+ entry and Ca2+-activated K+ channels of mast cells. Essential for the motility of vascular endothelial cells (ECs)
role during thymocyte development by regulating the expression of key nutrient receptors on the surface of pre-T cells and mediating Notch-induced cell growth and proliferative responses. P

Phf21b

PHD finger protein 21B (487 aa)

Polr2k

DNA-directed RNA polymerases I, II, and III subunit RPABC4; DNA-dependent RNA polymerase catalyzes the transcription of DNA into RNA using the four ribonucleoside triphospha
RNAs, such as 5S rRNA and tRNAs, respectively (By similarity); Belongs to the archaeal RpoP/eukaryotic RPC10 RNA polymerase subunit family (99 aa)

Psmd13

26S proteasome non-ATPase regulatory subunit 13; Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. Th
functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair (376 aa)

Ptrh2

Peptidyl-tRNA hydrolase 2, mitochondrial; The natural substrate for this enzyme may be peptidyl- tRNAs which drop off the ribosome during protein synthesis (181 aa)

Rbm8a

RNA-binding protein 8A; Required for pre-mRNA splicing as component of the spliceosome (By similarity). Core component of the splicing-dependent multiprotein exon junction comp
complex only transiently either during EJC assembly or during subsequent mRNA metabolism. The EJC marks the position of the exon-exon junction in the mature mRNA for the gene exp
export, subcellular mRNA localization, translation efficiency and nonsense-mediated mRNA decay (NMD). Its removal from cytoplasmic mRNAs requires translation initiation from EJC-b
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both nuclear mRNAs and newly exported cytoplasmic mRNAs (By similarity) (174 aa)
Rpl5

60S ribosomal protein L5; Component of the ribosome, a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell. The small ribosomal subunit (SSU) binds m
termed the peptidyl transferase center (PTC), which catalyzes the formation of peptide bonds, thereby polymerizing the amino acids delivered by tRNAs into a polypeptide chain. The nascen
the exit of the ribosomal tunnel. As part of the 5S RNP/5S ribonucleoprotein particle it is an essential component of the LSU, required for its formation and the maturation of rRNAs. It a
stabilization and the activation of TP53. Interacts with RRP1B. (297 aa)

Rps11

Ribosomal protein S11 (158 aa)

Rps16

Ribosomal protein S16; Belongs to the universal ribosomal protein uS9 family (146 aa)

Rps29

Ribosomal protein S29 (56 aa)

RTRAF

RNA transcription, translation and transport factor protein; RNA-binding protein involved in modulation of mRNA transcription by Polymerase II. Component of the tRNA-splicing ligase co

Slk

STE20-like serine/threonine-protein kinase; Mediates apoptosis and actin stress fiber dissolution; Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. STE20 subfam

Suclg1

Succinate--CoA ligase [ADP/GDP-forming] subunit alpha, mitochondrial; Succinyl-CoA synthetase functions in the citric acid cycle (TCA), coupling the hydrolysis of succinyl-CoA to
phosphate, while succinate binding and specificity for either ATP or GTP is provided by different beta subunits (346 aa)

Wars

Tryptophan--tRNA ligase, cytoplasmic; T1-TrpRS has aminoacylation activity while T2-TrpRS lacks it. T1-TrpRS and T2-TrpRS possess angiostatic activity. T2- TrpRS inhibits fluid s
responsive gene expression (By similarity) (481 aa)

9.2.4

Randomly selected control proteins
Table 9.7. The 100 randomly selected mouse cellular proteins used
as a control for analyses of binding partner properties in Chapter
6.

ACCESSION

GENE

PROTEIN NAME

Q9Z0K7.1

SLUR1

Secreted Ly-6/uPAR-related protein 1

Q9JLM8.1

DCLK1

Serine/threonine-protein kinase DCLK1

Q9QYJ7.1

DS13B

Dual specificity protein phosphatase 13 isoform B

Q9R000.1

ITBP2

Integrin beta-1-binding protein 2

Q9QY53.1

NPHP1

Nephrocystin-1

Q9JK53.2

PRELP

Prolargin

ACCESSION

GENE

PROTEIN NAME

Q9WV54.1

ASAH1

Acid ceramidase

Q9WVL0.1

MAAI

Maleylacetoacetate isomerase

Q9WUA3.1

PFKAP

ATP-dependent 6-phosphofructokinase, platelet
type

Q9D110.2

MTHFS

5-formyltetrahydrofolate cyclo-ligase

Q9D2R8.1

RT33

28S ribosomal protein S33, mitochondrial

Q9Z0J0.1

NPC2

NPC intracellular cholesterol transporter 2

Q9ER58.1

TICN2

Testican-2
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ACCESSION

GENE

PROTEIN NAME

ACCESSION

GENE

PROTEIN NAME

Q9R1Z7.2

PTPS

6-pyruvoyl tetrahydrobiopterin synthase

Q9JHK0.1

PR2A1

Prolactin-2A1

Q9DAN6.1

GTSF1

Gametocyte-specific factor 1

Q9DBI2.2

BBS10

Bardet-Biedl syndrome 10 protein homolog

Q9WTJ8.1

FA50B

Protein FAM50B

Q9DA03.2

LYRM7

Complex III assembly factor LYRM7

Q9QZN0.2

FBX15

F-box only protein 15

Q9Z2H5.2

E41L1

Band 4.1-like protein 1

Q9ES17.1

IL21

Interleukin-21

Q9QXN0.2

SHRM3

Protein Shroom3

Q9R0X2.1

ADEC1

ADAM DEC1

Q9Z223.3

MOC2B

Molybdopterin synthase catalytic subunit

Q9QWG7.2

ST1B1

Sulfotransferase family cytosolic 1B member 1

Q9JJF6.2

EFCC1

Q9Z331.3

K2C6B

Keratin, type II cytoskeletal 6B

EF-hand
protein 1

Q9JHH6.1

CBPB2

Carboxypeptidase B2

Q9WV04.2

KIF9

Kinesin-like protein KIF9

Q9JLI7.1

SPAG6

Sperm-associated antigen 6

Q9JJL8.2

SYSM

Serine--tRNA ligase, mitochondrial

Q9ERQ8.2

CAH7

Carbonic anhydrase 7

Q9QYZ8.2

DKK2

Dickkopf-related protein 2

Q9JMB7.1

PIWL1

Piwi-like protein 1

Q9R059.2

FHL3

Four and a half LIM domains protein 3

Q9D1U0.1

GRIFN

Grifin

Q9ESY9.3

GILT

Gamma-interferon-inducible
reductase

Q9D7V1.1

SH24A

SH2 domain-containing protein 4A

Q9QX60.3

DGUOK

Deoxyguanosine kinase, mitochondrial

Q9JI83.1

PLAC1

Placenta-specific protein 1

S4R1M9.1

OSB10

Oxysterol-binding protein-related protein 10

Q9Z179.1

SHCBP

SHC SH2 domain-binding protein 1

Q9DCB3.2

RN227

RING finger protein 227

Q9D4C1.1

LMTD1

Lamin tail domain-containing protein 1

P03953.1

CFAD

Complement factor D

Q9D5U5.1

HDHD1

Pseudouridine-5'-phosphatase

P21952.1

PO3F1

POU domain, class 3, transcription factor 1

Q9D735.1

TRIR

Telomerase RNA component interacting RNase

P26369.3

U2AF2

Splicing factor U2AF 65 kDa subunit

Q9D8P4.1

RM17

39S ribosomal protein L17, mitochondrial

P21300.4

ALD1

Aldo-keto reductase family 1 member B7

Q9D9C7.1

CC062

Uncharacterized protein C3orf62 homolog

P21275.2

BMP4

Bone morphogenetic protein 4

Q9EPL4.1

METL9

Methyltransferase-like protein 9

P00493.3

HPRT

Hypoxanthine-guanine phosphoribosyltransferase

and

coiled-coil

domain-containing

lysosomal

thiol
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ACCESSION

GENE

PROTEIN NAME

ACCESSION

GENE

PROTEIN NAME

Q60662.1

AKAP4

A-kinase anchor protein 4

Q8VBU8.1

BANP

Protein BANP

P56394.2

COX17

Cytochrome c oxidase copper chaperone

Q9D0F1.1

NDC80

Kinetochore protein NDC80 homolog

O08796.1

EF2K

Eukaryotic elongation factor 2 kinase

Q9QYP6.1

AZI2

5-azacytidine-induced protein 2

P70351.1

EZH1

Histone-lysine N-methyltransferase EZH1

Q8BSP2.1

CNDH2

Condensin-2 complex subunit H2

Q05722.2

CO9A1

Collagen alpha-1(IX) chain

Q8CHV6.1

TAD2A

Transcriptional adapter 2-alpha

Q62227.1

NR0B2

Nuclear receptor subfamily 0 group B member 2

Q8K3J5.1

ZN131

Zinc finger protein 131

P70390.1

SHOX2

Short stature homeobox protein 2

Q61699.2

HS105

Heat shock protein 105 kDa

O54754.2

AOXA

Aldehyde oxidase 1

Q3TSG4.2

ALKB5

RNA demethylase ALKBH5

Q9ERA6.1

TFP11

Tuftelin-interacting protein 11

Q8VE73.2

CUL7

Cullin-7

Q8BUK6.2

HOOK3

Protein Hook homolog 3

Q9R229.2

BMP10

Bone morphogenetic protein 10

Q8BML1.1

MICA2

[F-actin]-monooxygenase MICAL2

Q6ZPS2.2

CRNS1

Carnosine synthase 1

P61969.1

LMO4

LIM domain transcription factor LMO4

Q8BG87.3

TET3

Methylcytosine dioxygenase TET3

Q61474.1

MSI1H

RNA-binding protein Musashi homolog 1

O08686.2

BARX2

Homeobox protein BarH-like 2

Q6PGN3.1

DCLK2

Serine/threonine-protein kinase DCLK2

D0QMC3.1

MNDAL

Q6PCN7.1

HLTF

Helicase-like transcription factor

Myeloid cell nuclear differentiation antigen-like
protein

Q68ED3.2

PAPD5

Terminal nucleotidyltransferase 4A

Q7M6Y6.2

MRO2B

Maestro heat-like
family member 2B

O35310.1

HS3S1

Heparan sulfate glucosamine 3-O-sulfotransferase
1

Q8BM75.3

ARI5B

AT-rich interactive domain-containing protein 5B

Q9DBQ7.3

PACE1

Protein-associating with the carboxyl-terminal
domain of ezrin

Q8CJG0.3

AGO2

Protein argonaute-2

Q3U0V1.2

FUBP2

Far upstream element-binding protein 2

repeat-containing

O70326.1

GREM1

Gremlin-1

Q9R1E0.2

FOXO1

Forkhead box protein O1

Q5SWU9.1

ACACA

Acetyl-CoA carboxylase 1

Q9WV56.2

GDF2

Growth/differentiation factor 2

Q80UF7.1

TCAM1

TIR domain-containing adapter molecule 1

P26928.2

HGFL

Hepatocyte growth factor-like protein

protein
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ACCESSION

GENE

PROTEIN NAME

O54804.3

CHKA

Choline kinase alpha

Q9R016.3

BIR1E

Baculoviral IAP repeat-containing protein 1 e
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